Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof

FIELD OF THE INVENTION

The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.

BACKGROUND OF THE INVENTION

Stem Cells

Stem cells are undifferentiated cells which can give rise to a succession of mature functional cells. For example, a hematopoictic stem cell may give rise to any of the different types of terminally differentiated blood cells. Embryonic stem (ES) cells are derived from the embryo and are pluripotent, thus possessing the capability of developing into any organ or tissue type or, at least potentially, into a complete embryo.

The first evidence for the existence of stem cells came from studies of embryonic carcinoma (EC) cells, the undifferentiated stem cells of teratocarcinomas, which are tumors derived from germ cells. These cells were found to be pluripotent and immortal, but possess limited developmental potential and abnormal karyotypes (Rossant and Papaioannou, Cell Differ 15,155-161, 1984). ES cells, on the other hand, are thought to retain greater developmental potential because they are derived from normal embryonic cells, without the selective pressures of the teratocarcinoma environment.

Pluripotent embryonic stem cells have traditionally been derived principally from two embryonic sources. One type can be isolated in culture from cells of the inner cell mass of a pre-implantation embryo and are termed embryonic stem (ES) cells (Evans and Kaufman, Nature 292,154-156, 1981; U.S. Pat. No. 6,200,806). A second type of pluripotent stem cell can be isolated from primordial germ cells (PGCS) in the mesenteric or genital ridges of embryos and has been termed embryonic germ cell (EG) (U.S. Pat. No. 5,453,357, U.S. Pat. No. 6,245,566). Both human ES and EG cells are pluripotent. This has been shown by differentiating cells in vitro and by injecting human cells into immunocompromised (SCUM) mice and analyzing resulting teratomas (U.S. Pat. No.6,200,806). The term “stem cell” as used herein means stem cells including embryonic stem cells or embryonic type stem cells and stem cells diffentiated thereof to more tissue specific stem cells, adults stem cells including mesenchymal stem cells and blood stem cells such as stem cells obtained from bone marrow or cord blood.

The present invention provides novel markers and target structures and binders to these for especially embryonic and adult stem cells, when these cells are not heamtopoietic stem cells. From hematopoietic CD34+ cells certain terminal structures such as terminal sialylated type two N-acetyllactosamines such as NeuNAcα3Galβ4GlcNAc (Magnani J. U.S. Pat. No. 6,362,010 ) has been suggested and there is indications for low expression of Slex type structures NeuNAcα3Galβ4(Fucα3)GlcNAc (Xia L et al Blood (2004) 104 (10) 3091-6). The invention is also directed to the NeuNAcα3Galβ4GlcNAc non-polylactosamine variants separately from specific characteristic O-glycans and N-glycans. The invention further provides novel markers for CD133+ cells and novel hematopoietic stem cell markers according to the invention, especially when the structures does not include NeuNAcα3Galβ4(Fucα3)_0-1GlcNAc. Preferably the hematopoictic stem cell structures are non-sialylated, fucosylated structures Galβ1-3-structures according to the invention and even more preferably type 1 N-acetyllactosamine structures Galβ3GlcNAc or separately preferred Galβ3GalNAc based structures.

Human ES, EG and EC cells, as well as primate ES cells, express alkaline phosphatase, the stage-specific embryonic antigens SSEA-3 and SSEA-4, and surface proteoglycans that are recognized by the TRA-1-60; and TRA-1-81 antibodies. All these markers typically stain these cells, but are not entirely specific to stem cells, and thus cannot be used to isolate stem cells from organs or peripheral blood.

The SSEA-3 and SSEA4 structures are known as galactosylgloboside and sialylgalactosylgloboside, which are among the few suggested structures on embryonal stem cells, though the nature of the structures in not ambigious. An antibody called K21 has been suggested to bind a sulfated polysaccharide on embryonal carcinoma cells (Badcock G et al Cancer Res (1999) 4715-19. Due to cell type, species, tissue and other specificity aspects of glycosylation (Furukawa, K., and Kobata, A. (1992) Curr. Opin. Struct. Biol. 3, 554-559, Gagncux, and Varki, A. (1999) Glycobiology 9, 747-755;Gawlitzek, M. et al. (1995), J. Biotechnol. 42, 117-131; Goelz, S., Kumar, R., Potvin, B., Sundaram, S., Brickelmaier, M., and Stanley, P. (1994) J. Biol. Chem. 269,1033-1040; Kobata, A (1992) Eur. J. Biochem. 209 (2) 483-501.) This result does not indicate the presence of the structure on native embryonal stem cells. The present invention is directed to human stem cells.

Some low specificity plant lectin reagents have been reported in binding of embryonal stem cell like materials. Venable et al 2005, (Dev. Biol. 5:15) measured lectins the binding of SSEA-4 antibod positive subpopulation of embryonal stem cells. This approach suffers obvious problems. It does not tell the expression of the structures in native non-selected embryonal strem cells. The SSEA-4 was chosen select especially pluripotent stem cells. The scientists of the same Bresagen company have further revealed that actual role of SSEA-4 with the specific stem cell lines is not relevant for the pluripotency.

The work does not reveal: 1) The actual amount of molecules binding to the lectins or 2) presence of any molecules due to defects caused by the cell sorting and experimental problems such as tyypsination of the cells. It is really alerting that the cells were trypsinized, which removes protein and then enriched by possible glycolipid binding SSEA-4 antibody and secondary antimouse antibody, fixed with paraformaldehyde without removing the antibodies, and labelled by simultaneous with lectin and the same antibody and then the observed glycan profile is the similar as revealed by lectin analysis by same scientist for antibody glycosylation (M. Pierce US2005 ) or 3) the actual structures, which are bound by the lectins. To reveal the possible residual binding to the cells would require analysis of of the glycosylations of the antibodies used (sources and lots not revealed).

The purity of the SSEA-4 positive cells was reported to be 98-99%, which is unusually high. The quantitation of the binding is not clear as FIG. 3 shows about 10% binding by lectins LTL and DBA, which are not bound to hESC-cells 3^rdpage, column 2, paragraph 2 and by immunocytochemistry 4the page last line.

It appears that skilled artisan would consider the results of Venable et al such convenient colocalization of SSEA-4 and the lectin binding by binding of the lectins to the anti-SSEA-4 antibody. It appears that the more rare binding would reflect lower proportion of the terminal epitope per antibody molecule leading to lower density of the labellable antibodies. It is also realized that the non-controlled cell culture process with animal derived material would lead to contamination of the cells by N-glycolyl-neuraminic acid, which may be recognized by anti-mouse antibodies used as secondary antibody (not defined what kind of anti-mouse) used in purification and analysis of purity, which could lead to convieniently high cell purity. The work is directed only to the “pluripotent” embryonal stem cells associated with SSEA-4 labelling and not to differentiated variants thereof as the present invention. The results indicated possible binding (likely on the antibodies) to certain potential monosaccharide epitopes (6^thpage, Table 1, and column 2 ) such Gal and Galactosamine for RCA (ricin, inhitable by Gal or lactose), GlcNAc for TL (tomato lcctin), Man or Glc for ConA, Sialic acid/Sialic acid α6GalNAc for SNA, Manα for HHL; lectins with partial binding not correlating with SSEA4: GalNAc/GalNAcβ4Gal(in text) WFA, Gal for PNA, and Sialic acid/Sialic acid α6GalNAc for SNA; and lectins associated by part of SSEA-4 cells were indicated to bind Gal by PHA-L and PHA-E, GalNAc by VVA and Fuc by UEA, and Gal by MAA (inhibited by lactose). UEA binding was discussed with reference as endothelial marker and O-linked fucose which is directly bound to Ser (Thr) on protein. The background has indicated a H type 2 specificity for the endothelial UEA receptor. The specificities of the lectins are somewhat unusual, but the product codes or isolectin numbers/names of the lectins were not indicated (except for PHA-E and PHA-L) and it is known that plants contain numerous isolectins with varying specificities.

The present invention revealed specific structures by mass spectrometric profiling, NMR spectrometry and binding reagents including glycan modifying enzymes. The lectins are in general low specificity molecules. The present invention revealed binding epitopes larger than the previously described monosaccharide epitopes. The larger epitopes allowed us to design more specific binding substances with typical binding specificities of at least disaccharides. The invention also revealed lectin reagents with specified with useful specificities for analysis of native embryonal stem cells without selection against an uncontrolled marker and/or coating with an antibody or two from different species. Clearly the binding to native embryonal stem cells is different as the binding with MAA was clear to most of cells, there was differences between cell line so that RCA, LTA and UEA was clearly binding a hESC cell line but not another.

Methods for separation and use of stem cells are known in the art.

Characterizations and isolation of hematopoietic stem cells are reported in U.S. Pat. No. 5,061,620. The hematopoietic CD34 marker is the most common marker known to identify specifically blood stem cells, and CD34 antibodies are used to isolate stem cells from blood for transplantation purposes. However, CD34+ cells can differentiate only or mainly to blood cells and differ from embryonic stem cells which have the capability of developing into different body cells. Moreover, expansion of CD34+ cells is limited as compared to embryonic stem cells which are immortal. U.S. Pat. No. 5,677,136 discloses a method for obtaining human hematopoietic stem cells by enrichment for stem cells using an antibody which is specific for the CD59 stem cell marker. The CD59 epitope is highly accessible on stem cells and less accessible or absent on mature cells. U.S. Pat. No. 6,127,135 provides an antibody specific for a unique cell marker (EM10) that is expressed on stem cells, and methods of determining hematopoictic stem cell content in a sample of hematopoietic cells. These disclosures are specific for hematopoietic cells and the markers used for selection are not absolutely absent on more mature cells.

There have been great efforts toward isolating pluripotent or multipotent stem cells, in earlier differentiation stages than hematopoictic stem cells, in substantially pure or pure form for diagnosis, replacement treatment and gene therapy purposes. Stem cells are important targets for gene therapy, where the inserted genes are intended to promote the health of the individual into whom the stem cells are transplanted. In addition, the ability to isolate stem cells may serve in the treatment of lymphomas and leukemias, as well as other neoplastic conditions where the stem cells are purified from tumor cells in the bone marrow or peripheral blood, and reinfused into a patient after myelosuppressive or mycloablative chemotherapy.

Multiple adult stem cell populations have been discovered from various adult tissues. In addition to hematopoictic stem cells, neural stem cells were identified in adult mammalian central nervous system (Ourednik et al. Clin. Genet. 56, 267, 1999). Adult stem cells have also been identified from epithelial and adipose tissues (Zuk et al. Tissue Engineering 7, 211, 2001). Mesenchymal stem cells (MSCs) have been cultured from many sources, including liver and pancreas (Hu et al. J. Lab Clin Med. 141, 342-349, 2003). Recent studies have demonstrated that certain somatic stem cells appear to have the ability to differentiate into cells of a completely different lineage (Pfendler K C and Kawase E, Obstet Gynecol Surv 58, 197-208, 2003). Monocyte derived (Zhao et al. Proc. Natl. Acad. Sci. USA 100, 2426-2431, 2003) and mesodermal derived (Schwartz et al. J. Clin. Invest 109, 1291-1301, 2002) cells that possess some multipotent characteristics were identified. The presence of multipotent “embryonic-like” progenitor cells in blood was suggested also by in-vivo experiments following bone marrow transplantations (Zhao et al. Brain Res Protoc 11, 3845, 2003). However, such multipotent “embryonic-like” stem cells cannot be identified and isolated using the known markers.

The possibility of recovering fetal cells from the maternal circulation has generated interest as a possible means, non-invasive to the fetus, of diagnosing fetal anomalies (Simpson and Elias, J. Am. Med. Assoc. 270, 2357-2361, 1993). Prenatal diagnosis is carried out widely in hospitals throughout the world. Existing procedures such as fetal, hepatic or chorionic biopsy for diagnosis of chromosomal disorders including Down's syndrome, as well as single gene defects including cystic fibrosis are very invasive and carry a considerable risk to the fetus. Amniocentesis, for example, involves a needle being inserted into the womb to collect cells from the embryonic tissue or amniotic fluid. The test, which can detect Down's syndrome and other chromosomal abnormalities, carries a miscarriage risk estimated at 1%. Fetal therapy is in its very early stages and the possibility of early tests for a wide range of disorders would undoubtedly greatly increase the pace of research in this area. Thus, relatively non-invasive methods of prenatal diagnosis are an attractive alternative to the very invasive existing procedures. A method based on maternal blood should make earlier and easier diagnosis more widely available in the first trimester, increasing options to parents and obstetricians and allowing for the eventual development of specific fetal therapy.

The present invention provides methods of identifying, characterizing and separating stem cells having characteristics of embryonic stem (ES) cells for diagnostic, therapy and tissue engineering. In particular, the present invention provides methods of identifying, selecting and separating embryonic stem cells or fetal cells from maternal blood and to reagents for use in prenatal diagnosis and tissue engineering methods. The present invention provides for the first time a specific marker/binder/binding agent that can be used for identification, separation and characterization of valuable stem cells from tissues and organs, overcoming the ethical and logistical difficulties in the currently available methods for obtaining embryonic stem cells.

The present invention overcomes the limitations of known binders/markers for identification and separation of embryonic or fetal stem cells by disclosing a very specific type of marker/binder, which does not react with differentiated somatic maternal cell types. In other aspect of the invention, a specific binder/marker/binding agent is provided which does not react, i.e. is not expressed on feeder cells, thus enabling positive selection of feeder cells and negative selection of stem cells.

By way of exemplification, the binder to Formula (I) are now disclosed as useful for identifying, selecting and isolating pluripotent or multipotent stem cells including embryonic stem cells, which have the capability of differentiating into varied cell lineages.

According to one aspect of the present invention a novel method for identifying pluripotent or multipotent stem cells in peripheral blood and other organs is disclosed. According to this aspect an embryonic stem cell binder/marker is selected based on its selective expression in stem cells and/or germ stem cells and its absence in differentiated somatic cells and/or feeder cells. Thus, glycan structures expressed in stem cells are used according to the present invention as selective binders/markers for isolation of pluripotent or multipotent stem cells from blood, tissue and organs. Preferably the blood cells and tissue samples are of mammalian origin, more preferably human origin.

According to a specific embodiment the present invention provides a method for identifying a selective embryonic stem cell binder/marker comprising the steps of:

A method for identifying a selective stem cell binder to a glycan structure of Formula (I) which comprises:

i. selecting a glycan structure exhibiting specific expression in/on stem cells and absence of expression in/on feeder cells and/or differentiated somatic cells; ii. and confirming the binding of binder to the glycan structure in/on stem cells.

By way of a non-limiting example, adult, mesenchymal, embryonal type, or hematopoictic stem cells selected using the binder may be used in regenerating the hematopoictic or ther tissue system of a host deficient in any class of stem cells. A host that is diseased can be treated by removal of bone marrow, isolation of stem cells and treatment with drugs or irradiation prior to re-engraftment of stem cells. The novel markers of the present invention may be used for identifying and isolating various stem cells; detecting and evaluating growth factors relevant to stem cell self-regeneration; the development of stem cell lineages; and assaying for factors associated with stem cell development.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. FACS analysis of seven cord blood mononuclear cell samples (parallel columns) by FITC-labelled lectins. The percentages refer to proportion of cells binding to lectin. For abbreviations of FITC-labelled lectins see text.

FIG. 2. Lectin staining of hESC colonies grown on mouse feeder cell layers, with (A) Maackia amuriensis agglutinin (MAA) that recognizes α2,3-sialylated glycans, and with (B) Pisum sativum agglutinin (PSA) that recognizes α-mannosylated glycans. Lectin binding to HESC was inhibited by α3′-sialyllactose and D-mannose for MAA and PSA, respectively, and PSA recognized hESC only after cell permeabilization (data not shown). Mouse fibroblasts had complementary staining patterns with both lectins, indicating that their surface glycans differed from hESC. C. The results indicate that mannosylated N-glycans are localized in the intracellular compartments in HESC, whereas α2,3-sialylated glycans occur on the cell surface.

FIG. 3. Implications of hESC fucosyltransferase gene expression profile. A. hESC express three fucosyltransferase genes: FUT1, FUT4, and FUT8. B. The expression levels of FUT1 and FUT4 are increased in hESC compared to EB, which potentially leads to more complex fucosylation in hESC. Known fucosyltransferase glycan products are shown. Arrows indicate sites of glycan chain elongation. Asn indicates linkage to glycoprotein.

FIG. 4. Portrait of the hESC N-glycome. MALDI-TOF mass spectrometric profiling of the most abundant 50 neutral N-glycans (A.) and 50 sialylated N-glycans (B.) of the four hESC lines FES 21, 22, 29, and 30 (black columns), four EB samples (gray columns), and four st.3 differentiated cell samples (white columns) derived from the four hESC lines, respectively. The columns indicate the mean abundance of each glycan signal (% of the total glycan signals). The observed m/z values for either [M+Na]+ or [M−H]− ions for the neutral and sialylated N-glycan fractions, respectively, are indicated on the x-axis.

FIG. 5. Detection of hESC glycans by structure-specific reagents. To study the localization of the detected glycan components in hESC, stem cell colonies grown on mouse feeder cell layers were labeled by fluoresceinated glycan-specific reagents selected based on the analysis results. A. The hESC surfaces were stained by Maackia amurensis agglutinin (MAA), indicating that α2,3-sialylated glycans are abundant on hESC but not on feeder cells (MEF, mouse feeder cells). B. In contrast, the hESC cell surfaces were not stained by Pisum sativum agglutinin (PSA) that recognized mouse feeder cells, indicating that α-mannosylated glycans are not abundant on hESC surfaces but are present on mouse feeder cells. C. Addition of 3′-sialyllactose blocks MAA binding, and D. addition of D-mannose blocks PSA binding.

FIG. 6. hESC-associated glycan signals selected from the 50 most abundant sialylated N-glycan signals of the analyzed hESC, EB, and st.3 samples (data taken from FIG. 4.B).

FIG. 7. Differentiated cell associated glycan signals selected from the 50 most abundant sialylated N-glycan signals of the analyzed hESC, EB, and st3 samples (data taken from FIG. 4.B).

FIG. 8. Schematic representation of the N-glycan change during differentiation (details do not necessarily refer to actual structures). According to characterization of the Finish hESC lines FES 21, 22, 29, and 30, hESC differentiation leads to a major change in hESC surface molecules. St.3 means differentiation stage after EB stage.

FIG. 9. Stem cell nomenclature used to describe the present invention.

FIG. 10. MALDI-TOF mass spectrometric profile of isolated human stem cell neutral glycosphingolipid glycans. x-axis: approximate m/z values of [M+Na]⁺ ions as described in Table. y-axis: relative molar abundance of each glycan component in the profile. hESC, BM MSC, CB MSC, CB MNC: stem cell samples as described in the text.

FIG. 11. MALDI-TOF mass spectrometric profile of isolated human stem cell acidic glycosphingolipid glycans. x-axis: approximate m/z values of [M−H]⁻ ions as described in Table. y-axis: relative molar abundance of each glycan component in the profile. hESC, BM MSC, CB MSC, CB MNC: stem cell samples as described in the text.

FIG. 12. Mass spectrometric profiling of human embryonic stem cell and differentiated cell N-glycans. a Neutral N-glycans and b 50 most abundant acidic N-glycans of the four hESC lines (white columns), embryoid bodies derived from FES 29 and FES 30 hESC lines (EB, light columns), and stage 3 differentiated cells derived from FES 29 (st.3, black colunmns). The columns indicate the mean abundance of each glycan signal (% of the total detected glycan signals). Error bars indicate the range of detected signal intensities. Proposed monosaccharide compositions are indicated on the x-axis. H: hexose, N: N-acetylhexosamine, F: deoxyhexose, S: N-acetylneuraminic acid, G: N-glycolylneuraminic acid, P: sulphate/phosphate ester.

FIG. 13. A) Baboon polyclonal antiGalα3Gal antibody staining of mouse fibroblast feeder cells (left) showing absence of staining in hESC colony (right). B) UEA (Ulex Europaeus) lectin staining of stage 3 human embryonic stem cells. FES 30 line.

FIG. 14. A) UEA lectin staining of FES22 human embryonic stem cells (pluripotent, undifferentiated). B) UEA staining of FES30 human embryonic stem cells (pluripotent, undifferentiated).

FIG. 15. A) RCA lectin staining of FES22 human embryonic stem cells (pluripotent, undifferentiated). B) WFA lectin staining of FES30 human embryonic stem cells (pluripotent, undifferentiated).

FIG. 16. A) PWA lectin staining of FES30 human embryonic stem cells (pluripotent, undifferentiated). B) PNA lectin staining of FES30 human embryonic stem cells (pluripotent, undifferentiated).

FIG. 17. A) GF 284 immunostaining of FES30 human embryonic stem cell line. Immunostaining is seen in the edges of colonies in cells of early differentiation (lox magnification). Mouse feeder cells do not stain. B) Detail of GF284 as seen in 40× magnification. This antibody is suitable for detecting a subset of hESC lineage.

FIG. 18. A) GF 287 immunostaining of FES30 human embryonic stem cell line. Immunostaining is seen throughout the colonies (10× magnification). Mouse feeder cells do not stain. B) Detail of GF287 as seen in 40× magnification. This antibody is suitable for detecting undifferentiated, pluripotent stem cells.

FIG. 19. A) GF 288 immunostaining of FES30 human embryonic stem cells. Immunostaining is seen mostly in the edges of colonies in cells of early differentiation (10× magnification). Mouse feeder cells do not stain. B) Detail of GF288 as seen in 40× magnification. This antibody is suitable for detecting a subset of hESC lineage.

SUMMARY OF THE INVENTION

The present invention is directed to analysis of broad glycan mixtures from stem cell samples by specific binder (binding) molecules.

The present invention is specifically directed to glycomes of stem cells according to the invention comprising glycan material with monosaccharide composition for each of glycan mass components according to the Formula I:

R₁Hexβz{R₃}_n1HexNAcXyR₂ (I),

wherein X is nothing or a glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein

n is 0 or 1;

Hex is Gal or Man or GlcA;

HexNAc is GlcNAc or GalNAc;

y is anomeric linkage structure α and/or β or a linkage from a derivatized anomeric carbon,

z is linkage position 3 or 4, with the provision that when z is 4, then HexNAc is GlcNAc and

Hex is Man or Hex is Gal or Hex is GlcA, and

when z is 3, then Hex is Glcα or Gal and HexNAc is GlcNAc or GalNAc;

R₁indicates 1-4 natural type carbohydrate substituents linked to the core structures,

R₂is reducing end hydroxyl, a chemical reducing end derivative or a natural asparagine linked N-glycoside derivative including asparagines, N-glycoside aminoacids and/or peptides derived from proteins, or a natural serine or threonine linked O-glycoside derivative including asparagines, N-glycoside aminoacids and/or peptides derived from proteins;

R3 is nothing or a branching structure representing GlcNAcβ6 or an oligosaccharide with GlcNAcβ6 at its reducing end linked to GalNAc, when HexNAc is GalNAc, or R3 is nothing or Fucα4, when Hex is Gal, HexNAc is GlcNAc, and z is 3, or R3 is nothing or Fucα3, when

z is 4.

Typical glycomes comprise of subgroups of glycans, including N-glycans, O-glycans, glycolipid glycans, and neutral and acidic subglycomes.

The invention is directed to diagnosis of clinical state of stem cell samples, based on analysis of glycans present in the samples. The invention is especially directed to diagnosing cancer and the clinical state of cancer, preferentially to differentiation between stem cells and cancerous cells and detection of cancerous changes in stem cell lines and preparations.

The invention is further directed to structural analysis of glycan mixtures present in stem cell samples.

DESCRIPTION OF THE INVENTION

Glycomes—Novel Glycan Mixtures From Stem Cells

The present invention revealed novel glycans of different sizes from stem cells. The stem cells contain glycans ranging from small oligosaccharides to large complex structures. The analysis reveals compositions with substantial amounts of numerous components and structural types. Previously the total glycomes from these rare materials has not been available and nature of the releasable glycan mixtures, the glycomes, of stem cells has been unknown.

The invention revealed that the glycan structures on cell surfaces vary between the various populations of the early human cells, the preferred target cell populations according to the invention. It was revealed that the cell populations contained specifically increased “reporter structures”.

The glycan structures on cell surfaces in general have been known to have numerous biological roles. Thus the knowledge about exact glycan mixtures from cell surfaces is important for knowledge about the status of cells. The invention revealed that multiple conditions affect the cells and cause changes in their glycomes. The present invention revealed novel glycome components and structures from human stem cells. The invention revealed especially specific terminal Glycan epitopes, which can be analyzed by specific binder molecules.

Recognition of Structures From Glycome Materials and On Cell Surfaces By Binding Methods

The present invention revealed that beside the physicochemical analysis by NMR and/or mass spectrometry several methods are useful for the analysis of the structures. The invention is especially directed to a method:

- i) Recognition by molecules binding glycans referred as the binders
- These molecules bind glycans and include property allowing observation of the binding such as a label linked to the binder. The preferred binders include
  - a) Proteins such as antibodies, lectins and enzymes
  - b) Peptides such as binding domains and sites of proteins, and synthetic library derived analogs such as phage display peptides
  - c) Other polymers or organic scaffold molecules mimicking the peptide materials

The peptides and proteins are preferably recombinant proteins or corresponding carbohydrate recognition domains derived thereof, when the proteins are selected from the group of monoclonal antibody, glycosidase, glycosyl transferring enzyme, plant lectin, animal lectin or a peptide mimetic thereof, and wherein the binder may include a detectable label structure.

The genus of enzymes in carbohydrate recognition is continuous to the genus of lectins (carbohydrate binding proteins without enzymatic activity).

a) Native glycosyltransferases (Rauvala et al. (1983) PNAS (USA) 3991-3995) and glycosidases (Rauvala and Hakomori (1981) J. Cell Biol. 88, 149-159) have lectin activities.

b) The carbohydrate binding enzymes can be modified to lectins by mutating the catalytic amino acid residues (see WO9842864; Aalto J. et al. Glycoconjugate J. (2001, 18(10); 751-8; Mega and Hase (1994) BBA 1200 (3) 331-3).

c) Natural lectins, which are structurally homologous to glycosidases are also known indicating the continuity of the genus enzymes and lectins (Sun, Y-J. et al. J. Biol. Chem. (2001) 276 (20) 17507-14).

The genus of the antibodies as carbohydrate binding proteins without enzymatic activity is also very close to the concept of lectins, but antibodies are usually not classified as lectins.

Obviousness of the Peptide Concept and Continuity With the Carbohydrate Binding Protein Concept

It is further realized that proteins consist of peptide chains and thus the recognition of carbohydrates by peptides is obvious. E.g. it is known in the art that peptides derived from active sites of carbohydrate binding proteins can recognize carbohydrates (e.g. Geng J-G. et al (1992) J. Biol. Chem. 19846-53).

As described above antibody fragment are included in description and genetically engineered variants of the binding proteins. The obvious genetically engineered variants would included truncated or fragment peptides of the enzymes, antibodies and lectins.

Revealing Cell or Differentiation and Individual Specific Terminal Variants of Structures

The invention is directed use the glycomics profiling methods for the revealing structural features with on-off changes as markers of specific differentiation stage or quantitative difference based on quantitative comparison of glycomes. The individual specific variants are based on genetic variations of glycosyltransferases and/or other components of the glycosylation machinery preventing or causing synthesis of individual specific structure.

Terminal Structural Epitopes

We have previously revealed glycome compositions of human glycomes, here we provide structural terminal epitopes useful for the characterization of stem cell glycomes, especially by specific binders.

The examples of characteristic altering terminal structures includes expression of competing terminal epitopes created as modification of key homologous core Galβ-epitopes, with either the same monosaccharides with difference in linkage position Galβ3GlcNAc, and analogue with either the same monosaccharides with difference in linkage position Galβ4GlcNAc; or the with the same linkage but 4-position epimeric backbone Galβ3GalNAc. These can be presented by specific core structures modifying the biological recognition and function of the structures. Another common feature is that the similar Galβ-structures are expressed both as protein linked (O- and N-glycan) and lipid linked (glycolipid structures). As an alternative for α2-fucosylation the terminal Gal may comprise NAc group on the same 2 position as the fucose. This leads to homologous epitopes GalNAcβ4GlcNAc and yet related GalNAcβ3Gal-structure on characteristic special glycolipid according to the invention.

The invention is directed to novel terminal disaccharide and derivative epitopes from human stem cells, preferably from human embryonal stem cells or adult stem cells, when these are not hematopoictic stem cells, which are preferably mesenchymal stem cells. It should realized that glycosylations are species, cell and tissue specific and results from cancer cells usually differ dramatically from normal cells, thus the vast and varying glycosylation data obtained from human embryonal carcinomas are not actually relevant or obvious to human embryonal stem cells (unless accidentally appeared similar). Additionally the exact differentiation level of teratocarcinomas cannot be known, so comparison of terminal epitope under specific modification machinery cannot be known. The terminal structures by specific binding molecules including glycosidases and antibodies and chemical analysis of the structures.

The present invention reveals group of terminal Gal(NAc)β1-3/4Hex(NAc) structures, which carry similar modifications by specific fucosylation/NAc-modification, and sialylation on corresponding positions of the terminal disaccharide epitopes. It is realized that the terminal structures are regulated by genetically controlled homologous family of fucosyltransferases and sialyltransferases. The regulation creates a characteristic structural patterns for communication between cells and recognition by other specific binder to be used for analysis of the cells. The key epitopes are presented in the TABLE 37. The data reveals characteristic patterns of the terminal epitopes for each types of cells, such as for example expression on hESC-cells generally much Fucα-structures such as Fucα2-structures on type 1 lactosamine (Galβ3GlcNAc), similarily β3-linked core I Galβ3GlcNAcα, and type 4 structure which is present on specific type of glycolipids and expression of α3-fucosylated structures, while α6-sialic on type II N-acetylalactosamine appear on N-glycans of embryoid bodies and st3 embryonal stem cells. E.g. terminal type lactosamine and poly-lactosamines differentiate mesenchymal stem cells from other types. The terminal Galb-information is preferably combined with information about

The invention is directed especially to high specificity binding molecules such as monoclonal antibodies for the recognition of the structures.

The structures can be presented by Formula T1. the formula describes first monosaccharide residue on left, which is a β-D-galactopyranosyl structure linked to either 3 or 4-position of the α- or β-D-(2-deoxy-2-acetamido)galactopyranosyl structure, when R₅is OH, or β-D-(2-deoxy-2-acetamido)glucopyranosyl, when R₄comprises O—. The unspecified stereochemistry of the reducing end in formulas T1 and T2 is indicated additionally (in claims) with curved line. The sialic acid residues can be linked to 3 or 6-position of Gal or 6-position of GlcNAc and fucose residues to position 2 of Gal or 3- or 4-position of GlcNAc or position 3 of Glc.

The invention is directed to Galactosyl-globoside type structures comprising terminal Fucα2-revealed as novel terminal epitope Fucα2Galβ3GalNAcβ or Galβ3GalNAcβGalα3-comprising isoglobotructures revealed from the embryonal type cells.

wherein

X is linkage position

R₁, R₂, and R₆are OH or glycosidically linked monosaccharide residue Sialic acid, preferably Neu5Acα2 or Neu5Gc α2, most preferably Neu5Acα2 or

R₃, is OH or glycosidically linked monosaccharide residue Fucα1 (L-fucose) or N-acetyl (N-acetamido, NCOCH₃);

R₄, is H, OH or glycosidically linked monosaccharide residue Fucα1 (L-fucose),

R₅is OH, when R₄is H, and R₅is H, when R₄is not H;

R7 is N-acetyl or OH

X is natural oligosaccharide backbone structure from the cells, preferably N-glycan, O-glycan or glycolipid structure; or X is nothing, when n is 0,

Y is linker group preferably oxygen for O-glycans and O-linked terminal oligosaccharides and glycolipids and N for N-glycans or nothing when n is 0;

Z is the carrier structure, preferably natural carrier produced by the cells, such as protein or lipid, which is preferably a ceramide or branched glycan core structure on the carrier or H;

The arch indicates that the linkage from the galactopyranosyl is either to position 3 or to position 4 of the residue on the left and that the R4 structure is in the other position 4 or 3;

n is an integer 0 or 1, and m is an integer from 1 to 1000, preferably 1 to 100, and most preferably 1 to 10 (the number of the glycans on the carrier),

With the provisions that one of R2 and R3 is OH or R3 is N-acetyl,

R6 is OH, when the first residue on left is linked to position 4 of the residue on right:

X is not Galα4Galβ4Glc, (the core structure of SSEA-3 or 4) or R3 is Fucosyl

R7 is preferably N-acetyl, when the first residue on left is linked to position 3 of the residue on right:

Preferred terminal β3-linked subgroup is represented

by Formula T2 indicating the situation, when the first residue on the left is linked to the 3 position with backbone structures Gal(NAc)β3Gal/GlcNAc.

Wherein the variables including R₁to R₇

are as described for T1

Preferred terminal β4-linked subgroup is represented by the Formula 3

Wherein the variables including R₁to R₄and R7

are as described for T1 with the provision that

R₄, is OH or glycosidically linked monosaccharide residue Fucα1 (L-fucose),

Alternatively the epitope of the terminal structure can be represented by Formulas T4 and T5 Core Galepitopes formula T4:

Galβ1-xHex(NAc)_p,

x is linkage position 3 or 4,

and Hex is Gal or Glc

with provision

p is 0 or 1

when x is linkage position 3, p is 1 and HexNAc is GlcNAc or GalNAc,

and when x is linkage position 4, Hex is Glc.

The core Galβ1-3/4 epitope is optionally substituted to hydroxyl

by one or two structures SAα or Fucα, preferably selected from the group

Gal linked SAα3 or SAα6 or Fucα2, and

Glc linked Fucα3 or GlcNAc linked Fucα3/4.

[Mα]_mGalβ1-x[Nα]_nHex(NAc)_p, Formula T5

wherein m, n and p are integers 0, or 1, independently

Hex is Gal or Glc,

X is linkage position

M and N are monosaccharide residues being either

SA which is Sialic acid linked to 3-position of Gal or/and 6-position of HexNAc and/or

Fuc (L-fucose) residue linked to 2-position of Gal

and/or 3 or 4 position of HexNAc, when Gal is linked to the other position (4 or 3),

and HexNAc is GlcNAc, or 3-position of Glc when Gal is linked to the other position (3),

with the provision that sum of m and n is 2

preferably m and n are 0 or 1, independently,

The exact structural details are essential for optimal recognition by specific binding molecules designed for the analysis and/or manipulation of the cells.

The terminal key Galβ-epitopes are modified by the same modification monosaccharides NeuX (X is 5 position modification Ac or Gc of sialic acid) or Fuc, with the same linkage type alfa( modifying the same hydroxyl-positions in both structures.

NeuXα3, Fucα2 on the terminal Galβ of all the epitopes and

NeuXα6 modifying the terminal Galβ of Galβ4GlcNAc, or HexNAc, when linkage is 6 competing

or Fucα modifying the free axial primary hydroxyl left in GlcNAc (there is no free axial hydroxyl in GalNAc-residue).

The preferred structures can be divided to preferred Galβ1-3 structures analogously to T2,

[Mα]_mGalβ1-3[Nα]_nHexNAc, Formula T6:

Wherein the variables are as described for T5.

The preferred structures can be divided to preferred Galβ1-4 structures analogously to T4,

[Mα]_mGalβ1-4[Nα]_nGlc(NAc)_p, Formula T7:

Wherein the variables are as described for T5.

Fucosylated and Non-Modified Structures

The invention is further directed to the core disaccharide epitope structures when the structures are not modified by sialic acid (none of the R-groups according to the Formulas T1-T3 or M or N in formulas T4-T7 is not sialic acid.

The invention is in a preferred embodiment directed to structures, which comprise at least one fucose residue according to the invention. These structures are novel specific fucosylated terminal epitopes, useful for the analysis of stem cells according to the invention. Preferably native stem cells are analyzed.

The preferred fucosylated structures include novel α3/4fucosylated markers of human stem cells such as (SAα3)_0or1Galβ3/4(Fucα4/3)GlcNAc including Lewis x and and sialylated variants thereof.

Among the structures comprising terminal Fucα1-2 the invention revealed especially useful novel marker structures comprising Fucα2Galβ3GalNAcα/β and

Fucα2Galβ3(Fucα4)_0or1GlcNAcβ, these were found useful studying embryonal stem cells. A especially preferred antibody/binder group among this group is antibodies specific for Fucα2Galβ3GlcNAcβ, preferred for high stem cell specificity. Another preferred structural group includes Fucα2Gal comprising glycolipids revealed to form specific structural group, especially interesting structure is globo-H-type structure and glycolipids with terminal Fucα2Galβ3GalNAcβ, preferred with interesting biosynthetic context to earlier speculated stem cell markers.

Among the antibodies recognizing Fucα2Galβ4GlcNAcβ substantial variation in binding was revealed likely based on the carrier structures, the invention is especially directed to antibodies recognizing this type of structures, when the specificity of the antibody is similar to the ones binding to the embryonal stem cells as shown in Example 18 with fucose recognizing antibodies. The invention is preferably directed to antibodies recognizing Fucα2Galβ4GlcNAcβ on N-glycans, revealed as common structural type in terminal epitope Table 37. In a separate embodiment the antibody of the non-binding clone is directed to the recognition of the feeder cells.

The preferred non-modified structures includes Galβ4Glc, Galβ3GlcNAc, Galβ3GalNAc, Galβ4GlcNAc, Galβ3GlcNAcβ, Galβ3GalNAcβ/α, and Galβ4GlcNAcβ. These are preferred novel core markers characteristics for the various stem cells. The structure Galβ3GlcNAc is especially preferred as novel marker observable in hESC cells. Preferably the structure is carried by a glycolipid core structure according to the invention or it is present on an O-glycan. The non-modified markers are preferred for the use in combination with at least one fucosylated or/and sialylated structure for analysis of cell status.

Additional preferred non-modified structures includes GalNAcβ-structures includes terminal LacdiNAc, GalNAcβ4GlcNAc, preferred on N-glycans and GalNAcβ3Gal GalNAcβ3Gal present in globoseries glycolipids as terminal of globotetraose structures. Among these characteristic subgroup of Gal(NAc)β3-comprising Galβ3GlcNAc, Galβ3GalNAc, Galβ3GlcNAcβ, Galβ3GalNAcβ/α, and GalNAcβ3Gal GalNAcβ3Gal and the characteristic subgroup of Gal(NAc)β4-comprising Galβ4Glc, Galβ4GlcNAc, and Galβ4GlcNAc are separately preferred.

Preferred sialylated structures

The preferred sialylated structures includes characteristic SAα3Gal-structures SAα3Galβ4Glc, SAα3Galβ3GlcNAc, SAα3Galβ3GalNAc, SAα3Galβ4GlcNAc, SAα3Galβ3GlcNAcβ, SAα3Galβ3GalNAcβ/α, and SAα3Galβ4GlcNAcβ; and biosynthetically partially competing SAα6Galβ-structures SAα6Galβ4Glc, SAα6Galβ4Glcβ; SAα6Galβ4GlcNAc and SAα6Galβ4GlcNAcβ; and disialo structures SAα3Galβ3(SAα6)GalNAcβ/α,

The invention is preferably directed to specific subgroup of Gal(NAc)β3-comprising SAα3Galβ3GlcNAc, SAα3Galβ3GalNAc, SAα3Galβ4GlcNAc, SAα3Galβ3GlcNAcβ, SAα3Galβ3GalNAcβ/α and SAα3Galβ3(SAα6)GalNAcβ/α, and Gal(NAc)β34-comprising sialylated structures. SAα3Galβ4Glc, and SAα3Galβ4GlcNAcβ; and SAα6Galβ4Glc, SAα6Galβ4Glcβ; SAα6Galβ4GlcNAc and SAα6Galβ4GlcNAcβ These are preferred novel regulated markers characteristics for the various stem cells.

Use Together With a Terminal ManαMan-Structure

The terminal non-modified or modified epitopes are in preferred embodiment used together with at least one ManαMan-structure. This is preferred because the structure is in different N-glycan or glycan subgroup than the other epitopes.

Preferred Structural Groups for Hematopoietic Stem Cells.

Preferred Binder Molecules

The present invention revealed various types of binder molecules useful for characterization of cells according to the invention and more specifically the preferred cell groups and cell types according to the invention. The preferred binder molecules are classified based on the binding specificity with regard to specific structures or structural features on carbohydrates of cell surface. The preferred binders recognize specifically more than single monosaccharide residue.

It is realized that most of the current binder molecules such as all or most of the plant lectins are not optimal in their specificity and usually recognize roughly one or several monosaccharides with various linkages. Furthermore the specificities of the lectins are usually not well characterized with several glycans of human types.

The preferred high specificity binders recognize

- A) at least one monosaccharide residue and a specific bond structure between those to another monosaccharides next monosaccharide residue referred as MS1B1-binder,
- B) more preferably recognizing at least part of the second monosaccharide residue referred as MS2B1-binder,
- C) even more preferably recognizing second bond structure and or at least part of third mono saccharide residue, referred as MS3B2-binder, preferably the MS3B2 recognizes a specific complete trisaccharide structure.
- D) most preferably the binding structure recognizes at least partially a tetrasaccharide with three bond structures, referred as MS4B3-binder, preferably the binder recognizes complete tetrasaccharide sequences.

The preferred binders includes natural human and or animal, or other proteins developed for specific recognition of glycans. The preferred high specificity binder proteins are specific antibodies preferably monoclonal antibodies; lectins, preferably mammalian or animal lectins; or specific glycosyltransferring enzymes more preferably glycosidase type enzymes, glycosyltransferases or transglycosylating enzymes.

Modulation of Cells By the Binders

The invention revealed that the specific binders directed to a cell type can be used to modulate cells. In a preferred embodiment the (stem) cells are modulated with regard to carbohydrate mediated interactions. The invention revealed specific binders, which change the glycan structures and thus the receptor structure and function for the glycan, these are especially glycosidases and glycosyltransferring enzymes such as glycosyltransferases and/or transglycosylating enzymes. It is further realized that the binding of a non-enzymatic binder as such select and/or manipulate the cells. The manipulation typically depend on clustering of glycan receptors or affect of the interactions of the glycan receptors with counter receptors such as lectins present in a biological system or model in context of the cells. The invention further reveled that the modulation by the binder in context of cell culture has effect about the growth velocity of the cells.

Preferred Combinations of the Binders

The invention revealed useful combination of specific terminal structures for the analysis of status of a cells. In a preferred embodiment the invention is directed to measuring the level of two different terminal structures according to the invention, preferably by specific binding molecules, preferably at least by two different binders. In a preferred embodiment the binder molecules are directed to structures indicating modification of a terminal receptor glycan structures, preferably the structures represent sequential (substrate structure and modification thereof, such as terminal Gal-structure and corresponding sialylated structure) or competing biosynthetic steps (such as fucosylation and sialylation of terminal Galβ or terminal Galβ3GlcNAc and Galβ4GlcNAc). In another embodiment the binders are directed to three different structures representing sequential and competing steps such as such as terminal Gal-structure and corresponding sialylated structure and corresponding sialylated structure.

The invention is further directed to recognition of at least two different structures according to the invention selected from the groups of non-modified (non-sialylated or non-fucosylated) Gal(NAc)β3/4-core structures according to the invention, preferred fucosylated structures and preferred sialylated structures according to the invention. It is realized that it is useful to recognize even 3, and more preferably 4 and even more preferably five different structures, preferably within a preferred structure group.

Target Structures for Specific Binders and Examples of the Binding Molecules

Combination of Terminal Structures with Specific Glycan Core Structures

It is realized that part of the structural elements are specifically associated with specific glycan core structure. The recognition of terminal structures linked to specific core structures are especially preferred, such high specificity reagents have capacity of recognition almost complete individual glycans to the level of physicochemical characterization according to the invention. For example many specific mannose structures according to the invention are in general quite characteristic for N-glycan glycomes according to the invention. The present invention is especially directed to recognition terminal epitopes.

Common Terminal Structures on Several Glycan Core Structures

The present invention revealed that there are certain common structural features on several glycan types and that it is possible to recognize certain common epitopes on different glycan structures by specific reagents when specificity of the reagent is limited to the terminal without specificity for the core structure. The invention especially revealed characteristic terminal features for specific cell types according to the invention. The invention realized that the common epitopes increase the effect of the recognition. The common terminal structures are especially useful for recognition in the context with possible other cell types or material, which do not contain the common terminal structure in substantial amount.

The invention revealed the presence of the terminal structures on specific core structures such as N-glycan, O-glycan and/or glycolipids. The invention is preferably directed to the selection of specific binders for the structures including recognition of specific glycan core types.

The invention is further directed to glycome compositions of protein linked glycomes such as N-glycans and O-glycans and glycolipids each composition comprising specific amounts of glycan subgroups. The invention is further directed to the compositions when these comprise specific amount of Defined terminal structures.

Specific Preferred Structural Groups

The present invention is directed to recognition of oligosaccharide sequences comprising specific terminal monosaccharide types, optionally further including a specific core structure. The preferred oligosaccharide sequences are in a preferred embodiment classified based on the terminal monosaccharide structures.

The invention further revealed a family of terminal (non-reducing end terminal) disaccharide epitopes based on β-linked galactopyranosylstructures, which may be further modified by fucose and/or sialic acid residues or by N-acetylgroup, changing the terminal Gal residue to GalNAc. Such structures are present in N-glycan, O-glycan and glycolipid subglycomes.

Furthermore the invention is directed to terminal disaccharide epitopes of N-glycans comprising terminal ManαMan.

The structures were derived by mass spectrometric and optionally NMR analysis and by high specificity binders according to the invention, for the analysis of glycolipid structures permethylation and fragmentation mass spectrometry was used. Biosynthetic analysis including known biosynthetic routes to N-glycans, O-glycans and glycolipids was additionally used for the analysis of the glycan compositions and additional support, though not direct evidence due to various regulation levels after mRNA, for it was obtained from gene expression profiling data of Example 24 and Skotttman, H. et al. (2005) Stem cells and similar data obtained from the mRNA profiling for cord blood cells and used to support the biosynthetic analysis using the data of Jaatinen T et al. Stem Cells (2006) 24 (3) 631-41.

1. Structures With Terminal Mannose Monosaccharide

Preferred mannose-type target structures have been specifically classified by the invention. These include various types of high and low-mannose structures and hybrid type structures according to the invention.

The Preferred Terminal Manα-Target Structure Epitopes

The invention revealed the presence of Manα on low mannose N-glycans and high mannose N-glycans. Based on the biosynthetic knowledge and supporting this view by analysis of mRNAs of biosynthetic enzymes and by NMR-analysis the structures and terminal epitopes could be revealed:

Manα2Man, Manα3Man, Manα6Man and Manα3(Manα6)Man, wherein the reducing end Man is preferably either α- or β-linked glycoside and α-linked glycoside in case of Manα2Man:

The general structure of terminal Manα-structures is

Manαx(Manαy)_zManα/β

Wherein x is linkage position 2, 3 or 6, and y is linkage position 3 or 6,

z is integer 0 or 1, indicating the presence or the absence of the branch,

with the provision that x and y are not the same position and

when x is 2, the z is 0 and reducing end Man is preferably α-linked;

The low_mannose structures includes preferably non-reducing end terminal epitopes with structures with α3- and/or α6- mannose linked to another mannose residue

Manαx(Manαy)_zManα/β

wherein x and y are linkage positions being either 3 or 6,

z is integer 0 or 1, indicating the presence or the absence of the branch,

The high mannose structure includes terminal α2-linked Mannose:

Manα2Man(α) and optionally on or several of the terminal α3- and/or α6-mannose-structures as above.

The presence of terminal Manα-structures is regulated in stem cells and the proportion of the high-Man-structures with terminal Manα2-structures in relation to the low Man structures with Manα3/6- and/or to complex type N-glycans with Gal-backbone epitopes varies cell type specifically.

The data indicated that binder revealing specific terminal Manα2Man and/or Manα3/6Man is very useful in characterization of stem cells. The prior science has not characterized the epitopes as specific signals of cell types or status.

The invention is especially directed to the measuring the levels of both low-Man and high-Man structures, preferably by quantifying two structure type the Manα2Man-structures and the Manα3/6Man-structures from the same sample.

The invention is especially directed to high specificity binders such as enzymes or monoclonal antibodies for the recognition of the terminal Manα-structures from the preferred stem cells according to the invention, more preferably from differentiated embryonal type cells, more preferably differentiated beyond embryoid bodies such as stage 3 differentiated cells, most preferably the structures are recognized from stage 3 differentiated cells. The invention is especially preferably directed to detection of the structures from adult stem cells more preferably mesenchymal stem cells, especially from the surface of mesenchymal stem cells and in separate embodiment from blood derived stem cells, with separately preferred groups of cord blood and bone marrow stem cells. In a preferred embodiment the cord blood and/or peripheral blood stem cell is not hematopoietic stem cell.

Low or Uncharacterised Specificity Binders

preferred for recognition of terminal mannose structures includes mannose-monosaccharide binding plant lectins. The invention is in preferred embodiment directed to the recognition of stem cells such as embryonal type stem cells by a Manα-recognizing lectin such as lectin PSA. In a preferred embodiment the recognition is directed to the intracellular glycans in permebilized cells. In another embodiment the Manα-binding lectin is used for intact non-permeabilized cells to recognize terminal Manα-from contaminating cell population such as fibroblast type cells or feeder cells as shown in corresponding Example 6.

Preferred High Specific High Specificity Binders

include

i) Specific mannose residue releasing enzymes such as linkage specific mannosidases, more preferably an α-mannosidase or β-mannosidase.

Preferred α-mannosidases includes linkage specific α-mannosidases such as α-Mannosidases cleaving preferably non-reducing end terminal, an example of preferred mannosidascs is jack bean α-mannosidase (Canavalia ensiformis; Sigma, USA) and homologous α-mannosidases

α2-linked mannose residues specifically or more effectively than other linkages, more preferably cleaving specifically Manα2-structures; or

α3-linked mannose residues specifically or more effectively than other linkages, more preferably cleaving specifically Manα3-structures; or

α6-linked mannose residues specifically or more effectively than other linkages, more preferably cleaving specifically Manα6-structures;

Preferred β-mannosidases includes β-mannosidases capable of cleaving β4-linked mannose from non-reducing end terminal of N-glycan core Manβ4GlcNAc-structure without cleaving other β-linked monosaccharides in the glycomes.

ii) Specific binding proteins recognizing preferred mannose structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins. The invention is directed to antibodies recognizing MS2B1 and more preferably MS3B2-structures.

Mannosidase analyses of neutral N-glycans Examples of detection of mannosylated by α-mannosidase binder and mass spectrometric profiling of the glycans cord blood and peripheral blood mesenchymal cells in Example 1; for cord blood cells in example 19, hESC EB and stage 3 cells in Example 10, in Example 22 and 2 for embryonal stem cells and differentiated cells;, and, and indicates presence of all types of Manβ4, Manα3/6 terminal structures of Man_1-4GlcNAcβ4(Fucα6)_0-1GlcNAc-comprising low Mannose glycans as described by the invention.

Lectin Binding

α-linked mannose was demonstrated in Example 7 for human mesenchymal cell by lectins Hippeastrum hybrid (HUA) and Pisum sativum (PSA) lectins suggests that they express mannose, more specifically α-linked mannose residues on their surface glycoconjugates such as N-glycans. Possible α-mannose linkages include α1→2, α1→3, and α1→6. The lower binding of Galanthus nivalis (GNA) lectin suggests that some α-mannose linkages on the cell surface are more prevalent than others. The combination of the terminal Manα-recognizing low affinity reagents appears to be useful and correspond to results obtained by mannosidase screening; NMR and mass spectrometric results. Lectin binding of cord blood cells is in example 8.

Mannose-binding lectin labeling. Labelling of the mesenchymal cells in Example 7 was also detected with human serum mannose-binding lectin (MBL) coupled to fluorescein label. This indicate that ligands for this innate immunity system component may be expressed on in vitro cultured BM MSC cell surface.

The present invention is especially directed to analysis of terminal Manα-on cell surfaces as the structure is ligand for MBL and other lectins of innate immunity. It is further realized that terminal Manα-structures would direct cells in blood circulation to mannose receptor comprising tissues such as Kupfer cells of liver. The invention is especially directed to control of the amount of the structure by binding with a binder recognizing terminal Manα-structure.

In a preferred embodiment the present invention is directed to the testing of presence of ligands of lectins present in human, such as lectins of innate immunity and/or lectins of tissues or leukocytes, on stem cells by testing of the binding of the lectin (purified or preferably a recombinant form of the lectin, preferably in labeled form) to the stem cells. It is realized that such lectins includes especially lectins binding Manα and Galβ/GalNAcβ-structures (terminal non-reducing end or even α6-sialylated forms according to the invention.

Mannose Binding Antibodies

A high-mannose binding antibody has been described for example in Wang LX et al (2004) 11 (1) 127-34. Specific antibodies for short mannosylated structures such as the trimannosyl core structure have been also published.

2. Structures With Terminal Gal-Monosaccharide

Preferred galactose-type target structures have been specifically classified by the invention. These include various types of N-acetyllactosamine structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal Gal

Preferred for recognition of terminal galactose structures includes plant lectins such as ricin lectin (ricinus communis agglutinin RCA), and peanut lectin(/agglutinin PNA). The low resolution binders have different and broad specificities.

Preferred High Specific High Specificity Binders Include

i) Specific galactose residue releasing enzymes such as linkage specific galactosidases, more preferably α-galactosidase or β-galactosidase.

Preferred α-galactosidases include linkage galactosidases capable of cleaving Galα3Gal-structures revealed from specific cell preparations

Preferred β-galactosidases includes β-galactosidases capable of cleaving

β4-linked galactose from non-reducing end terminal Galβ4GlcNAc-structure without cleaving other β-linked monosaccharides in the glycomes and

β3-linked galactose from non-reducing end terminal Galβ3GlcNAc-structure without cleaving other β-linked monosaccharides in the glycomes

ii) Specific binding proteins recognizing preferred galactose structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins and animal lectins such as galectins.

Specific Binder Experiments and Examples for Galβ-Structures

Specific exoglycosidase and glycosyltransferase analysis for the structures are included in Example 22 and 2 for embryonal stem cells and differentiated cells; Example 1 mesenchymal cells, for cord blood cells in example 19 and in example 20 on cell surface and including glycosyltransferases, for glycolipids in Example 15. Sialylation level analysis related to terminal Galβ and Sialic acid expression is in Example 9.

Preferred enzyme binders for the binding of the Galβ-epitopes according to the invention includes β1,4-galactosidase e.g from S. pneumoniae (rec. in E. coli, Calbiochem, USA), β1,3-galactosidase (e.g rec. in E. coli, Calbiochem ); glycosyltransferases: α2,3-(N)-sialyltransferase (rat, recombinant in S. frugiperda, Calbiochem), α1,3-fucosyltransferase VI (human, recombinant in S. frugiperda, Calbiochem), which are known to recognize specific N-acetyllactosamine epitopes, Fuc-TVI especially Galβ4GlcNAc.

Plant low specificity lectin, such as RCA, PNA, ECA, STA, and

PWA, data is in Example 6 for hESC, Example 7 for MSCs, Example 8 for cord blood, effects of the lectin binders for the cell proliferation is in Example 14, cord blood cell selection is in Example 16.

Human lectin analysis by various galectin expression is Example 17 from cord blood and embryonal cells,

In example 18 there is antibody labeling of especially fucosylated and galactosylated structures.

Poly-N-acetyllactosamine sequences. Labelling of the cells by pokeweed (PWA) and less intense labelling by Solanum tuberosum (STA) lectins suggests that the cells express poly-N-acetyllactosamine sequences on their surface glycoconjugates such as N- and/or O-glycans and/or glycolipids. The results further suggest that cell surface poly-N-acetyllactosamine chains contain both linear and branched sequences.

3. Structures With Terminal GalNAc-Monosaccharide

Preferred GalNAc-type target structures have been specifically revealed by the invention. These include especially LacdiNAc, GalNAcβGlcNAc-type structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal GalNAc

Several plant lectins has been reported for recognition of terminal GalNAc. It is realized that some GalNAc-recognizing lectins may be selected for low specificity recognition of the preferred LacdiNAc-structures.

β-linked N-acetylgalactosamine. Abundant labelling of hESC by Wisteria floribunda lectin (WFA) suggests that hESC express β-linked non-reducing terminal N-acetylgalactosamine residues on their surface glycoconjugates such as N- and/or O-glycans. The absence of specific binding of WFA to mEF suggests that the lectin ligand epitopes are less abundant in mEF.

The low specificity binder plant lectins such as Wisteria floribunda agglutinin and Lotus tetragonolobus agglutinin bind to oligosaccharide sequences Srivatsan J. et al. Glycobiology (1992) 2 (5) 445-52: Do, K Y et al. Glycobiology (1997) 7 (2) 183-94; Yan, L., et al (1997) Glycoconjugate J. 14 (1) 45-55. The article also shows that the lectins are useful for recognition of the structures, when the cells are verified not to contain other structures recognized by the lectins.

In a preferred embodiment a low specificity lectin reagent is used in combination with another reagent verifying the binding.

Preferred High Specific High Specificity Binders Include

i) The invention revealed that β-linked GalNAc can be recognized by specific β-N-acetylhexosaminidase enzyme in combination with β-N-acetylhexosaminidase enzyme. This combination indicates the terminal monosaccharide and at least part of the linkage structure.

Preferred β-N-acetylehexosaminidase, includes enzyme capable of cleaving β-linked GalNAc from non-reducing end terminal GalNAcβ4/3-structures without cleaving α-linked HexNAc in the glycomes; preferred N-acetylglucosaminidases include enzyme capable of cleaving β-linked GlcNAc but not GalNAc.

Specific binding proteins recognizing preferred GalNAcβ4, more preferably GalNAcβ4GlcNAc, structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins.

Examples antibodies recognizing LacdiNAc-structures includes publications of Nyame A. K. et al. (1999) Glycobiology 9 (10) 1029-35; van Remoortere A. et al (2000) Glycobiology 10 (6) 601-609; and van Remoortere A. et al (2001) Infect Immun. 69 (4) 2396-2401. The antibodies were characterized in context of parasite (Schistosoma) infection of mice and humans, but according to the present invention these antibodies can also be used in screening stem cells. The present invention is especially directed to selection of specific clones of LacdiNac recognizing antibodies specific for the subglycomes and glycan structures present in N-glycomes of the invention.

The articles disclose antibody binding specificities similar to the invention and methods for producing such antibodies, therefore the antibody binders are obvious for person skilled in the art. The immunogenicity of certain LacdiNAc-structures are demonstrated in human and mice.

The use of glycosidase in recognition of the structures in known in the prior art similarity as in the present invention for example in Srivatsan J. et al. (1992) 2 (5) 445-52.

4. Structures With Terminal GlcNAc-Monosaccharide

Preferred GlcNAc-type target structures have been specifically revealed by the invention. These include especially GlcNAcβ-type structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal GlcNAc

Several plant lectins has been reported for recognition of terminal GlcNAc. It is realized that some GlcNAc-recognizing lectins may be selected for low specificity recognition of the preferred GlcNAc-structures.

Preferred High Specific High Specificity Binders Include

- i) The invention revealed that β-linked GlcNAc can be recognized by specific β-N-acetylglucosaminidase enzyme.

Preferred β-N-acetylglucosaminidase includes enzyme capable of cleaving β-linked GlcNAc from non-reducing end terminal GlcNAcβ2/3/6-structures without cleaving β-linked GalNAc or α-linked HexNAc in the glycomes;

ii) Specific binding proteins recognizing preferred GlcNAcβ2/3/6, more preferably GlcNAcβ32Manα, structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins.

Specific Binder Experiments and Examples for Terminal HexNAc(GalNAc/GlcNAc and GlcNAc Structures

Plant low specificity lectin, such as WFA and GNAII, and data is in Example 6 for hESC, Example 7 for MSCs, Example 8 for cord blood, effects of the lectin binders for the cell proliferation is in Example 14, cord blood cell selection is in Example 16.

Preferred enzymes for the recognition of the structures includes general hexosaminidase β-hexosaminidase from Jack beans (C. ensiformis, Sigma, USA) and and specific N-acetylglucosaminidases or N-acetylgalactosaminidases such as β-glucosaminidase from S. pneumoniae (rec. in E. coli, Calbiochem, USA). Combination of these allows determination of LacdiNAc on Verification of the target structures includes NMR analysis as exemplified in Example 21

The invention is further directed to analysis of the structures by specific monoclonal antibodies recognizing terminal GlcNAcα-structures such as described in Holmes and Greene (1991) 288 (1) 87-96, with specificity for several terminal GlcNAc structures.

The invention is specifically directed to the use of the terminal structures according to the invention for selection and production of antibodies for the structures.

Verification of the target structures includes mass spectrometry and permethylation/fragmentation analysis for glycolipid structures

5. Structures With Terminal Fucose-Monosaccharide

Preferred fucose-type target structures have been specifically classified by the invention. These include various types of N-acetyllactosamine structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal Fuc

Preferred for recognition of terminal fucose structures includes fucose monosaccharide binding plant lectins. Lectins of Ulex europeaus and Lotus tetragonolobus has been reported to recognize for example terminal Fucoses with some specificity binding for α2-linked structures, and branching α3-fucose, respectively. Data is in Example 6 for hESC, Example 7 for MSCs, Example 8 for cord blood, effects of the lectin binders for the cell proliferation is in Example 14, cord blood cell selection is in Example 16.

Preferred High Specific High Specificity Binders Include

i) Specific fucose residue releasing enzymes such as linkage fucosidases, more preferably α-fucosidase.

Preferred α-fucosidases include linkage fucosidases capable of cleaving Fucα2Gal-, and Galβ4/3(Fucα3/4)GlcNAc-structures revealed from specific cell preparations.

Specific exoglycosidase and for the structures are included in Example 22 and 2 for embryonal stem cells and differentiated cells; Example 1 for mesenchymal cells, for cord blood cells in example 19 and in example 20 on cell surface for glycolipids in Example 15. Preferred fucosidases includes α1,3/4-fucosidase e.g. α1,3/4-fucosidase from Xanthomonas sp. (Calbiochem, USA), and α1,2-fucosidase e.g α1,2-fucosidase from X. manihotis (Glyko),

ii)Specific binding proteins recognizing preferred fucose structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins and animal lectins such as selectins recognizing especially Lewis type structures such as Lewis x, Galβ4(Fucα3)GlcNAc, and sialyl-Lewis x, SAcα3Galβ4(Fucα3)GlcNAc.

The preferred antibodies includes antibodies recognizing specifically Lewis type structures such as Lewis x, and sialyl-Lewis x. More preferably the Lewis x-antibody is not classic SSEA-1 antibody, but the antibody recognizes specific protein linked Lewis x structures such as Galβ4(Fucα3)GlcNAcβ2Manα-linked to N-glycan core.

Specific Binder Experiments and Examples for Terminal HexNAc Structures

Verification of the target structures includes mass spectrometry and permethylation/fragmentation analysis for glycolipid structures

6. Structures With Terminal Sialic Acid-Monosaccharide

Preferred sialic acid-type target structures have been specifically classified by the invention.

Low or Uncharacterised Specificity Binders for Terminal Sialic Acid

Preferred for recognition of terminal sialic acid structures includes sialic acid monosaccharide binding plant lectins.

Preferred High Specific High Specificity Binders Include

i) Specific sialic acid residue releasing enzymes such as linkage sialidases, more preferably α-sialidases.

Preferred α-sialidases include linkage sialidases capable of cleaving SAα3Gal- and SAα6Gal-structures revealed from specific cell preparations by the invention.

Preferred low specificity lectins, with linkage specificity include the lectins, that are specific for SAα3Gal-structures, preferably being Maackia amurensis lectin and/or lectins specific for SAα6Gal-structures, preferably being Sambucus nigra agglutinin.

ii) Specific binding proteins recognizing preferred sialic acid oligosaccharide sequence structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins and animal lectins such as selectins recognizing especially Lewis type structures such as sialyl-Lewis x, SAα3Galβ4(Fucα3)GlcNAc or sialic acid recognizing Siglec-proteins. The preferred antibodies includes antibodies recognizing specifically sialyl-N-acetyllactosamines, and sialyl-Lewis x.

Preferred antibodies for NeuGc-structures includes antibodies recognizes a structure NeuGcα3Galβ4Glc(NAc)_{0 or 1}and/or GalNAcβ4[NeuGcα3]Galβ4Glc(NAc)_{0 or 1}, wherein [ ] indicates branch in the structure and ( )_{0 or 1}a structure being either present or absent. In a preferred embodiment the invention is directed recognition of the N-glycolyl-Neuraminic acid structures by antibody, preferably by a monoclonal antibody or human/humanized monoclonal antibody. A preferred antibody contains the variable domains of P3-antibody.

Specific Binder Experiments and Examples for α3/6 Sialylated Structures

Specific exoglycosidase analysis for the structures are included in Example 22 and 2 for embryonal stem cells and differentiated cells; Example 1 for mesenchymal cells, for cord blood cells in example 19 and in example 20 on cell surface and including glycosyltransferases, for glycolipids in Example 15. Sialylation level analysis related to terminal Galβ and Sialic acid expression is in Example 9.

Preferred enzyme binders for the binding of the Sialic acid epitopes according to the invention includes: sialidases such as general sialidase α2,3/6/8/9-sialidase from A. ureafaciens (Glyko), and α2,3-Sialidases such as: α2,3-sialidase from S. pneumoniae (Calbiochem, USA). Other useful sialidases are known from E. coli, and Vibrio cholerae.

α1,3-facosyltransferase VI (human, recombinant in S. frugiperda, Calbiochem), which are known to recognize specific N-acetyllactosamine epitopes, Fuc-TVI especially including SAα3Galβ4GlcNAc.

Plant low specificity lectin, such as MAA and SNA, and data is in Example 6 for hESC, Example 7 for MSCs, Example 8 for cord blood, effects of the lectin binders for the cell proliferation is in Example 14, cord blood cell selection is in Example 16.

In example 18 there is antibody labeling of sialylstructures.

Preferred Uses For Stem Cell Type Specific Galectins and/or Galectin Ligands

As described in the Examples, the inventors also found that different stem cells have distinct galectin expression profiles and also distinct galectin (glycan) ligand expression profiles. The present invention is further directed to using galactose-binding reagents, preferentially galactose-binding lectins, more preferentially specific galectins; in a stem cell type specific fashion to modulate or bind to certain stem cells as described in the present invention to the uses described. In a further preferred embodiment, the present invention is directed to using galectin ligand structures, derivatives thereof, or ligand-mimicking reagents to uses described in the present invention in stem cell type specific fashion. The preferred galectins are listed in Example 17—

The invention is in a preferred embodiment directed to the recognition of terminal N-acetyllactosamines from cells by galectins as described above for recognition of Galβ4GlNAc and Galβ3GlcNAc structures: The results indicate that both CB CD34+/CD133+ stem cell populations and hESC have an interesting and distinct galectin expression profiles, leading to different galectin ligand affinity profiles (Hirabayashi et al., 2002). The results further correlate with the glycan analysis results showing abundant galectin ligand expression in these stem cells, especially non-reducing terminal β-Gal and type II LacNAc, poly-LacNAc, β1,6-branched poly-LacNAc, and complex-type N-glycan expression.

Specific Technical Aspects of Stem Cell Glycome Analysis

Isolation of Glycans and Glycan Fractions

Glycans of the present invention can be isolated by the methods known in the art. A preferred glycan preparation process consists of the following steps:

1° isolating a glycan-containing fraction from the sample,

2° . . . Optionally purification the fraction to useful purity for glycome analysis

The preferred isolation method is chosen according to the desired glycan fraction to be analyzed. The isolation method may be either one or a combination of the following methods, or other fractionation methods that yield fractions of the original sample:

1° extraction with water or other hydrophilic solvent, yielding water-soluble glycans or glycoconjugates such as free oligosaccharides or glycopeptides,

2° extraction with hydrophobic solvent, yielding hydrophilic glycoconjugates such as glycolipids,

3° N-glycosidase treatment, especially Flavobacterium meningosepticum N-glycosidase F treatment, yielding N-glycans,

4° alkaline treatment, such as mild (e.g. 0.1 M) sodium hydroxide or concentrated ammonia treatment, either with or without a reductive agent such as borohydride, in the former case in the presence of a protecting agent such as carbonate, yielding β-elimination products such as O-glycans and/or other elimination products such as N-glycans,

5° endoglycosidase treatment, such as endo-β-galactosidase treatment, especially Escherichia freundii endo-β-galactosidase treatment, yielding fragments from poly-N-acetyllactosamine glycan chains, or similar products according to the enzyme specificity, and/or

6° protease treatment, such as broad-range or specific protease treatment, especially trypsin treatment, yielding proteolytic fragments such as glycopeptides.

The released glycans are optionally divided into sialylated and non-sialylated subfractions and analyzed separately. According to the present invention, this is preferred for improved detection of neutral glycan components, especially when they are rare in the sample to be analyzed, and/or the amount or quality of the sample is low. Preferably, this glycan fractionation is accomplished by graphite chromatography.

According to the present invention, sialylated glycans are optionally modified in such manner that they are isolated together with the non-sialylated glycan fraction in the non-sialylated glycan specific isolation procedure described above, resulting in improved detection simultaneously to both non-sialylated and sialylated glycan components. Preferably, the modification is done before the non-sialylated glycan specific isolation procedure. Preferred modification processes include neuraminidase treatment and derivatization of the sialic acid carboxyl group, while preferred derivatization processes include amidation and esterification of the carboxyl group.

Glycan Release Methods

The preferred glycan release methods include, but are not limited to, the following methods:

Free glycans—extraction of free glycans with for example water or suitable water-solvent mixtures.

Protein-linked glycans including O- and N-linked glycans—alkaline elimination of protein-linked glycans, optionally with subsequent reduction of the liberated glycans.

Mucin-type and other Ser/Thr O-linked glycans—alkaline β-elimination of glycans, optionally with subsequent reduction of the liberated glycans.

N-glycans—enzymatic liberation, optionally with N-glycosidase enzymes including for example N-glycosidase F from C. meningosepticum, Endoglycosidase H from Streptomyces, or N-glycosidase A from almonds.

Lipid-linked glycans including glycosphingolipids—enzymatic liberation with endoglycoceramidase enzyme; chemical liberation; ozonolytic liberation.

Glycosaminoglycans—treatment with endo-glycosidase cleaving glycosaminoglycans such as chondroinases, chondroitin lyases, hyalurondases, heparanases, beparatinases, or keratanases/endo-beta-galactosidases; or use of O-glycan release methods for O-glycosidic Glycosaminoglycans; or N-glycan release methods for N-glycosidic glycosaminoglycans or use of enzymes cleaving specific glycosaminoglycan core structures; or specific chemical nitrous acid cleavage methods especially for amine/N-sulphate comprising glycosaminoglycans

Glycan fragments—specific exo- or endoglycosidase enzymes including for example keratanase, endo-β-galactosidase, hyaluronidase, sialidase, or other exo- and endoglycosidase enzyme; chemical cleavage methods; physical methods

Preferred Target Cell Populations and Types for Analysis According to the Invention

Early Human Cell Populations

Human Stem Cells and Multipotent Cells

Under broadest embodiment the present invention is directed to all types of human stem cells, meaning fresh and cultured human stem cells. The stem cells according to the invention do not include traditional cancer cell lines, which may differentiate to resemble natural cells, but represent non-natural development, which is typically due to chromosomal alteration or viral transfection. Stem cells include all types of non-malignant multipotent cells capable of differentiating to other cell types. The stem cells have special capacity stay as stem cells after cell division, the self-renewal capacity.

Under the broadest embodiment for the human stem cells, the present invention describes novel special glycan profiles and novel analytics, reagents and other methods directed to the glycan profiles. The invention shows special differences in cell populations with regard to the novel glycan profiles of human stem cells.

The present invention is further directed to the novel structures and related inventions with regard to the preferred cell populations according to the invention. The present invention is further directed to specific glycan structures, especially terminal epitopes, with regard to specific preferred cell population for which the structures are new.

Preferred Types of Early Human Cells

The invention is directed to specific types of early human cells based on the tissue origin of the cells and/or their differentiation status.

The present invention is specifically directed to early human cell populations meaning multipotent cells and cell populations derived thereof based on origins of the cells including the age of donor individual and tissue type from which the cells are derived, including preferred cord blood as well as bone marrow from older individuals or adults. Preferred differentiation status based classification includes preferably “solid tissue progenitor” cells, more preferably “mesenchymal-stem cells”, or cells differentiating to solid tissues or capable of differentiating to cells of either ectodermal, mesodermal, or endodermal, more preferentially to mesenchymal stem cells.

The invention is further directed to classification of the early human cells based on the status with regard to cell culture and to two major types of cell material. The present invention is preferably directed to two major cell material types of early human cells including fresh, frozen and cultured cells.

Cord Blood Cells, Embryonal-Type Cells and Bone Marrow Cells

The present invention is specifically directed to early human cell populations meaning multipotent cells and cell populations derived thereof based on the origin of the cells including the age of donor individual and tissue type from which the cells are derived.

- a) from early age-cells such 1) as neonatal human, directed preferably to cord blood and related material, and 2) embryonal cell-type material
- b) from stem and progenitor cells from older individuals (non-neonatal, preferably adult), preferably derived from human “blood related tissues” comprising, preferably bone marrow cells.

Cells Differentiating to Solid Tissues, Preferably to Mesenchymal Stem Cells

The invention is specifically under a preferred embodiment directed to cells, which are capable of differentiating to non-hematopoietic tissues, referred as “solid tissue progenitors”, meaning to cells differentiating to cells other than blood cells. More preferably the cell population produced for differentiation to solid tissue are “mesenchymal-type cells”, which are multipotent cells capable of effectively differentiating to cells of mesodermal origin, more preferably mesenchymal stem cells.

Most of the prior art is directed to hematopoietic cells with characteristics quite different from the mesenchymal-type cells and mesenchymal stem cells according to the invention.

Preferred solid tissue progenitors according to the invention includes selected multipotent cell populations of cord blood, mesenchymal stem cells cultured from cord blood, mesenchymal stem cells cultured/obtained from bone marrow and embryonal-type cells. In a more specific embodiment the preferred solid tissue progenitor cells are mesenchymal stem cells, more preferably “blood related mesenchymal cells”, even more preferably mesenchymal stem cells derived from bone marrow or cord blood.

Under a specific embodiment CD34+ cells as a more hematopoietic stem cell type of cord blood or CD34+ cells in general are excluded from the solid tissue progenitor cells.

Early Blood Cell Populations and Corresponding Mesenchymal Stem Cells

Cord Blood

The early blood cell populations include blood cell materials enriched with multipotent cells. The preferred early blood cell populations include peripheral blood cells enriched with regard to multipotent cells, bone marrow blood cells, and cord blood cells. In a preferred embodiment the present invention is directed to mesenchymal stem cells derived from early blood or early blood derived cell populations, preferably to the analysis of the cell populations.

Bone Marrow

Another separately preferred group of early blood cells is bone marrow blood cells. These cell do also comprise multipotent cells. In a preferred embodiment the present invention is directed to directed to mesenchymal stem cells derived from bone marrow cell populations, preferably to the analysis of the cell populations.

Preferred Subpopulations of Early Human Blood Cells

The present invention is specifically directed to subpopulations of early human cells. In a preferred embodiment the subpopulations are produced by selection by an antibody and in another embodiment by cell culture favouring a specific cell type. In a preferred embodiment the cells are produced by an antibody selection method preferably from early blood cells. Preferably the early human blood cells are cord blood cells.

The CD34 positive cell population is relatively large and heterogenous. It is not optimal for several applications aiming to produce specific cell products. The present invention is preferably directed to specifically selected non-CD34 populations meaning cells not selected for binding to the CD34-marker, called homogenous cell populations. The homogenous cell populations may be of smaller size mononuclear cell populations for example with size corresponding to CD133+ cell populations and being smaller than specifically selected CD34+ cell populations. It is further realized that preferred homogenous subpopulations of early human cells may be larger than CD34+ cell populations.

The homogenous cell population may a subpopulation of CD34+ cell population, in preferred embodiment it is specifically a CD133+ cell population or CD133-type cell population. The “CD133-type cell populations” according to the invention are similar to the CD133+ cell populations, but preferably selected with regard to another marker than CD133. The marker is preferably a CD133-coexpressed marker. In a preferred embodiment the invention is directed to CD133+ cell population or CD133+ subpopulation as CD133-type cell populations. It is realized that the preferred homogeneous cell populations further includes other cell populations than which can be defined as special CD133-type cells.

Preferably the homogenous cell populations are selected by binding a specific binder to a cell surface marker of the cell population. In a preferred embodiment the homogenous cells are selected by a cell surface marker having lower correlation with CD34-marker and higher correlation with CD133 on cell surfaces. Preferred cell surface markers include α3-sialylated structures according to the present invention enriched in CD133-type cells. Pure, preferably complete, CD133+ cell population are preferred for the analysis according to the present invention.

The present invention is directed to essential mRNA-expression markers, which would allow analysis or recognition of the cell populations from pure cord blood derived material. The present invention is specifically directed to markers specifically expressed on early human cord blood cells.

The present invention is in a preferred embodiment directed to native cells, meaning non-genetically modified cells. Genetic modifications are known to alter cells and background from modified cells. The present invention further directed in a preferred embodiment to fresh non-cultivated cells.

The invention is directed to use of the markers for analysis of cells of special differentiation capacity, the cells being preferably human blood cells or more preferably human cord blood cells.

Preferred Purity of Reproducibly Highly Purified Mononuclear Complete Cell Populations from Human Cord Blood

The present invention is specifically directed to production of purified cell populations from human cord blood. As described above, production of highly purified complete cell preparations from human cord blood has been a problem in the field. In the broadest embodiment the invention is directed to biological equivalents of human cord blood according to the invention, when these would comprise similar markers and which would yield similar cell populations when separated similarly as the CD133+ cell population and equivalents according to the invention or when cells equivalent to the cord blood is contained in a sample further comprising other cell types. It is realized that characteristics similar to the cord blood can be at least partially present before the birth of a human. The inventors found out that it is possible to produce highly purified cell populations from early human cells with purity useful for exact analysis of sialylated glycans and related markers.

Preferred Bone Marrow Cells

The present invention is directed to multipotent cell populations or early human blood cells from human bone marrow. Most preferred arc bone marrow derived mesenchymal stem cells. In a preferred embodiment the invention is directed to mesenchymal stem cells differentiating to cells of structural support function such as bone and/or cartilage.

Embryonal-Type Cell Populations

The present invention is specifically directed to methods directed to embryonal-type cell populations, preferably when the use does not involve commercial or industrial use of human embryos nor involve destruction of human embryos. The invention is under a specific embodiment directed to use of embryonal cells and embryo derived materials such as embryonal stem cells, whenever or wherever it is legally acceptable. It is realized that the legislation varies between countries and regions.

The present invention is further directed to use of embryonal-related, discarded or spontaneously damaged material, which would not be viable as human embryo and cannot be considered as a human embryo. In yet another embodiment the present invention is directed to use of accidentally damaged embryonal material, which would not be viable as human embryo and cannot be considered as human embryo.

It is further realized that early human blood derived from human cord or placenta after birth and removal of the cord during normal delivery process is ethically uncontroversial discarded material, forming no part of human being.

The invention is further directed to cell materials equivalent to the cell materials according to the invention. It is further realized that functionally and even biologically similar cells may be obtained by artificial methods including cloning technologies.

Mesenchymal Multipotent Cells

The present invention is further directed to mesenchymal stem cells or multipotent cells as preferred cell population according to the invention. The preferred mesencymal stem cells include cells derived from early human cells, preferably human cord blood or from human bone marrow. In a preferred embodiment the invention is directed to mesenchymal stem cells differentiating to cells of structural support function such as bone and/or cartilage, or to cells forming soft tissues such as adipose tissue.

Control of Cell Status and Potential Contaminations by Glycosylation Analysis

Control of Cell Status

Control of Raw Material Cell Population

The present invention is directed to control of glycosylation of cell populations to be used in therapy.

The present invention is specifically directed to control of glycosylation of cell materials, preferably when

- 1) there is difference between the origin of the cell material and the potential recipient of transplanted material. In a preferred embodiment there are potential inter-individual specific differences between the donor of cell material and the recipient of the cell material. In a preferred embodiment the invention is directed to animal or human, more preferably human specific, individual person specific glycosylation differences. The individual specific differences are preferably present in mononuclear cell populations of early human cells, early human blood cells and embryonal type cells. The invention is preferably not directed to observation of known individual specific differences such as blood group antigens changes on erythrocytes.
- 2) There is possibility in variation due to disease specific variation in the materials. The present invention is specifically directed to search of glycosylation differences in the early cell populations according to the present invention associated with infectious disease, inflammatory disease, or malignant disease. Part of the inventors have analysed numerous cancers and tumors and observed similar types glycosylations as certain glycosylation types in the early cells.
- 3) There is for a possibility of specific inter-individual biological differences in the animals, preferably humans, from which the cell are derived for example in relation to species, strain, population, isolated population, or race specific differences in the cell materials.
- 4) When it has been established that a certain cell population can be used for a cell therapy application, glycan analysis can be used to control that the cell population has the same characteristics as a cell population known to be useful in a clinical setting.

Time Dependent Changes During Cultivation of Cells

Furthermore during long term cultivation of cells spontaneous mutations may be caused in cultivated cell materials. It is noted that mutations in cultivated cell lines often cause harmful defects on glycosylation level.

It is further noticed that cultivation of cells may cause changes in glycosylation. It is realized that minor changes in any parameter of cell cultivation including quality and concentrations of various biological, organic and inorganic molecules, any physical condition such as temperature, cell density, or level of mixing may cause difference in cell materials and glycosylation. The present invention is directed to monitoring glycosylation changes according to the present invention in order to observe change of cell status caused by any cell culture parameter affecting the cells.

The present invention is in a preferred embodiment directed to analysis of glycosylation changes when the density of cells is altered. The inventors noticed that this has a major impact of the glycosylation during cell culture.

It is further realized that if there is limitations in genetic or differentiation stability of cells, these would increase probability for changes in glycan structures. Cell populations in early stage of differentiation have potential to produce different cell populations. The present inventors were able to discover glycosylation changes in early human cell populations.

Differentiation of Cell Lines

The present invention is specifically directed to observe glycosylation changes according to the present invention when differentiation of a cell line is observed. In a preferred embodiment the invention is directed to methods for observation of differentiation from early human cell or another preferred cell type according to the present invention to mesodermal types of stem cell

In case there is heterogeneity in cell material this may cause observable changes or harmful effects in glycosylation.

Furthermore, the changes in carbohydrate structures, even non-harmful or functionally unknown, can be used to obtain information about the exact genetic status of the cells.

The present invention is specifically directed to the analysis of changes of glycosylation, preferably changes in glycan profiles, individual glycan signals, and/or relative abundancies of individual glycans or glycan groups according to the present invention in order to observe changes of cell status during cell cultivation.

Analysis of Supporting/Feeder Cell Lines

The present invention is specifically directed to observe glycosylation differences according to the present invention, on supporting/feeder cells used in cultivation of stem cells and early human cells or other preferred cell type. It is known in the art that some cells have superior activities to act as a support/feeder cells than other cells. In a preferred embodiment the invention is directed to methods for observation of differences on glycosylation on these supporting/feeder cells. This information can be used in design of novel reagents to support the growth of the stem cells and early human cells or other preferred cell type.

Contaminations or Alterations in Cells Due to Process Conditions

Conditions and Reagents Inducing Harmful Glycosylation or Harmful Glycosylation Related Effects to Cells During Cell Handling

The inventors further revealed conditions and reagents inducing harmful glycans to be expressed by cells with same associated problems as the contaminating glycans. The inventors found out that several reagents used in a regular cell purification processes caused changes in early human cell materials.

It is realized, that the materials during cell handling may affect the glycosylation of cell materials. This may be based on the adhesion, adsorption, or metabolic accumulation of the structure in cells under processing.

In a preferred embodiment the cell handling reagents are tested with regard to the presence glycan component being antigenic or harmful structure such as cell surface NcuGc, Ncu-O-Ac or mannose structure. The testing is especially preferred for human early cell populations and preferred subpopulations thereof.

The inventors note effects of various effector molecules in cell culture on the glycans expressed by the cells if absortion or metabolic transfer of the carbohydrate structures have not been performed. The effectors typically mediate a signal to cell for example through binding a cell surface receptor.

The effector molecules include various cytokines, growth factors, and their signalling molecules and co-receptors. The effector molecules may be also carbohydrates or carbohydrate binding proteins such as lectins.

Controlled Cell Isolation/Purification and Culture Conditions to Avoid Contaminations with Harmful Glycans or Other Alteration in Glycome Level

Stress Caused by Cell Handling

It is realized that cell handling including isolation/purification, and handling in context of cell storage and cell culture processes are not natural conditions for cells and cause physical and chemical stress for cells. The present invention allows control of potential changes caused by the stress. The control may be combined by regular methods may be combined with regular checking of cell viability or the intactness of cell structures by other means.

Examples of Physical and/or Chemical Stress in Cell Handling Step

Washing and centrifuging cells cause physical stress which may break or harm cell membrane structures. Cell purifications and separations or analysis under non-physiological flow conditions also expose cells to certain non-physiological stress. Cell storage processes and cell preservation and handling at lower temperatures affects the membrane structure. All handling steps involving change of composition of media or other solution, especially washing solutions around the cells affect the cells for example by altered water and salt balance or by altering concentrations of other molecules effecting biochemical and physiological control of cells.

Observation and Control of Glycome Changes by Stress in Cell Handling Processes

The inventors revealed that the method according to the invention is useful for observing changes in cell membranes which usually effectively alter at least part of the glycome observed according to the invention. It is realized that this related to exact organization and intact structures cell membranes and specific glycan structures being part of the organization.

The present invention is specifically directed to observation of total glycome and/or cell surface glycomes, these methods are further aimed for the use in the analysis of intactness of cells especially in context of stressful condition for the cells, especially when the cells are exposed to physical and/or chemical stress. It is realized that each new cell handling step and/or new condition for a cell handling step is useful to be controlled by the methods according to the invention. It is further realized that the analysis of glycome is useful for search of most effectively altering glycan structures for analysis by other methods such as binding by specific carbohydrate binding agents including especially carbohydrate binding proteins (lectins, antibodies, enzymes and engineered proteins with carbohydrate binding activity).

Controlled Cell Preparation (Isolation or Purification) with Regard to Reagents

The inventors analysed process steps of common cell preparation methods. Multiple sources of potential contamination by animal materials were discovered.

The present invention is specifically directed to carbohydrate analysis methods to control of cell preparation processes. The present invention is specifically directed to the process of controlling the potential contaminations with animal type glycans, preferably N-glycolylneuraminic acid at various steps of the process.

The invention is further directed to specific glycan controlled reagents to be used in cell isolation

The glycan-controlled reagents may be controlled on three levels:

- 1. Reagents controlled not to contain observable levels of harmful glycan structure, preferably N-glycolylneuraminic acid or structures related to it
- 2. Reagents controlled not to contain observable levels of glycan structures similar to the ones in the cell preparation
- 3. Reagent controlled not to contain observable levels of any glycan structures.

The control levels 2 and 3 are useful especially when cell status is controlled by glycan analysis and/or profiling methods. In case reagents in cell preparation would contain the indicated glycan structures this would make the control more difficult or prevent it. It is further noticed that glycan structures may represent biological activity modifying the cell status.

Cell Preparation Methods Including Glycan-Controlled Reagents

The present invention is further directed to specific cell purification methods including glycan-controlled reagents.

Preferred Controlled Cell Purification Process

When the binders are used for cell purification or other process after which cells are used in method where the glycans of the binder may have biological effect the binders are preferably glycan controlled or glycan neutralized proteins.

The present invention is especially directed to controlled production of human early cells containing one or several following steps. It was realized that on each step using regular reagents in following process there is risk of contamination by extragenous glycan material. The process is directed to the use of controlled reagents and materials according to the invention in the steps of the process.

Preferred purification of cells includes at least one of the steps including the use of controlled reagent, more preferably at least two steps are included, more preferably at least 3 steps and most preferably at least steps 1, 2, 3, 4, and 6.

- 1. Washing cell material with controlled reagent.
- 2. When antibody based process is used cell material is in a preferred embodiment blocked with controlled Fc-receptor blocking reagent. It is further realized that part of glycosylation may be needed in a antibody preparation, in a preferred embodiment a terminally depleted glycan is used.
- 3. Contacting cells with immobilized cell binder material including controlled blocking material and controlled cell binder material. In a more preferred the cell binder material comprises magnetic beads and controlled gelatin material according the invention. In a preferred embodiment the cell binder material is controlled, preferably a cell binder antibody material is controlled. Otherwise the cell binder antibodies may contain even N-glycolylneuraminic acid, especially when the antibody is produced by a cell line producing N-glycolylneuraminic acid and contaminate the product.
- 4. Washing immobilized cells with controlled protein preparation or non-protein preparation.
- In a preferred process magnetic beads are washed with controlled protein preparation, more preferably with controlled albumin preparation.
- 5. Optional release of cells from immobilization.
- 6. Washing purified cells with controlled protein preparation or non-protein preparation.

In a preferred embodiment the preferred process is a method using immunomagnetic beads for purification of early human cells, preferably purification of cord blood cells.

The present invention is further directed to cell purification kit, preferably an immunomagnetic cell purification kit comprising at least one controlled reagent, more preferably at least two controlled reagents, even more preferably three controlled reagents, even preferably four reagents and most preferably the preferred controlled reagents are selected from the group: albumin, gelatin, antibody for cell purification and Fc-receptor blocking reagent, which may be an antibody.

Contaminations with Harmful Glycans Such as Antigenic Animal Type Glycans

Several glycans structures contaminating cell products may weaken the biological activity of the product.

The harmful glycans can affect the viability during handling of cells, or viability and/or desired bioactivity and/or safety in therapeutic use of cells.

The harmful glycan structures may reduce the in vitro or in vivo viability of the cells by causing or increasing binding of destructive lectins or antibodies to the cells. Such protein material may be included e.g. in protein preparations used in cell handling materials. Carbohydrate targeting lectins are also present on human tissues and cells, especially in blood and endothelial surfaces. Carbohydrate binding antibodies in human blood can activate complement and cause other immune responses in vivo. Furthermore immune defence lectins in blood or leukocytes may direct immune defence against unusual glycan structures.

Additionally harmful glycans may cause harmful aggregation of cells in vivo or in vitro. The glycans may cause unwanted changes in developmental status of cells by aggregation and/or changes in cell surface lectin mediated biological regulation.

Additional problems include allergenic nature of harmful glycans and misdirected targeting of cells by endothelial/cellular carbohydrate receptors in vivo.

Common Structural Features of all Glycomes and Preferred Common Subfeatures

The present invention reveals useful glycan markers for stem cells and combinations thereof and glycome compositions comprising specific amounts of key glycan structures. The invention is furthermore directed to specific terminal and core structures and to the combinations thereof.

The preferred glycome glycan structure(s) and/or glycomes from cells according to the invention comprise structure(s) according to the formula C0:

R₁Hexβz{R₃}_n1Hex(NAc)_n2XyR₂,

Wherein X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and

Hex is Gal or Man or GlcA,

HexNAc is GlcNAc or GalNAc,

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon,

z is linkage position 3 or 4, with the provision that when z is 4 then HexNAc is GlcNAc and then Hex is Man or Hex is Gal or Hex is GlcA, and

when z is 3 then Hex is GlcA or Gal and HexNAc is GlcNAc or GalNAc;

n1 is 0 or 1 indicating presence or absence of R3;

n2 is 0 or 1, indicating the presence or absence of NAc, with the proviso that n2 can be 0 only when Hexβz is Galβ4, and n2 is preferably 0, n2 structures are preferably derived from glycolipids;

R₁indicates 1-4, preferably 1-3, natural type carbohydrate substituents linked to the core structures or nothing;

R₂is reducing end hydroxyl, chemical reducing end derivative or natural asparagine N-glycoside derivative such as asparagine N-glycosides including asparagine N-glycoside aminoacids and/or peptides derived from protein, or natural serine or threonine linked O-glycoside derivative such as serine or threonine linked O-glycosides including asparagine N-glycoside aminoacids and/or peptides derived from protein, or when n2 is 1 R2 is nothing or a ceramide structure or a derivative of a ceramide structure, such as lysolipid and amide derivatives thereof;

R3 is nothing or a branching structure representing a GlcNAcβ6 or an oligosaccharide with GlcNAcβ6 at its reducing end linked to GalNAc (when HexNAc is GalNAc); or when Hex is Gal and HexNAc is GlcNAc, and when z is 3 then R3 is Fucα4 or nothing, and when z is 4 R3 is Fucα3 or nothing.

The preferred disaccharide epitopes in the glycan structures and glycomes according to the invention include structures Galβ4GlcNAc, Manβ4GlcNAc, GlcAβ4GlcNAc, Galβ3GlcNAc, Galβ3GalNAc, GlcAβ3GlcNAc, GlcAβ3GalNAc, and Galβ4Glc, which may be further derivatized from reducing end carbon atom and non-reducing monosaccharide residues and is in a separate embodiment branched from the reducing end residue. Preferred branched epitopes include Galβ4(Fucα3)GlcNAc, Galβ3(Fucα4)GlcNAc, and Galβ3(GlcNAcβ6)GalNAc, which may be further derivatized from reducing end carbon atom and non-reducing monosaccharide residues.

Preferred Epitopes for Methods According to the Invention

N-Acetyllactosamine Galβ3/4GlcNAc Terminal Epitopes

The two N-acetyllactosamine epitopes Galβ4GlcNAc and/or Galβ3GlcNAc represent preferred terminal epitopes present on stem cells or backbone structures of the preferred terminal epitopes for example further comprising sialic acid or fucose derivatisations according to the invention. In a preferred embodiment the invention is directed to fucosylated and/or non-substituted glycan non-reducing end forms of the terminal epitopes, more preferably to fucosylated and non-substituted forms. The invention is especially directed to non-reducing end terminal (non-substituted) natural Galβ4GlcNAc and/or Galβ3GlcNAc-structures from human stem cell glycomes. The invention is in a specific embodiment directed to non-reducing end terminal fucosylated natural Galβ4GlcNAc and/or Galβ3GlcNAc-structures from human stem cell glycomes.

Preferred Fucosylated N-Acetyllactosamines

The preferred fucosylated epitopes are according to the Formula TF:

(Fucα2)_n1Galβ3/4(Fucα4/3)GlcNAcβ-R

Wherein

n1 is 0 or 1 indicating presence or absence of Fucα2;

n2 is 0 or 1, indicating the presence or absence of Fucα4/3 (branch), and

R is the reducing end core structure of N-glycan, O-glycan and/or glycolipid.

The preferred structures thus include type 1 lactosamines (Galβ3GlcNAc based):

Galβ3(Fucα4)GlcNAc (Lewis a), Fucα2Galβ3GlcNAc H-type 1, structure and, Fucα2Galβ3(Fucα4)GlcNAc (Lewis b) and

type 2 lactosamines (Galβ4GlcNAc based):

Galβ4(Fucα3)GlcNAc (Lewis x), Fucα2Galβ4GlcNAc H-type 2, structure and, Fucα2Galβ4(Fucα3)GlcNAc (Lewis y).

The type 2 lactosamines (fucosylated and/or terminal non-substituted) form an especially preferred group in context of adult stem cells and differentiated cells derived directly from these. Type 1 lactosamines (Galβ3GlcNAc-structures) arc especially preferred in context of embryonal-type stem cells.

Lactosamines Galβ3/4GlcNAc and Glycolipid Structures Comprising Lactose Structures (Galβ4 Glc)

The lactosamines form a preferred structure group with lactose-based glycolipids. The structures share similar features as products of β3/4Gal-transferases. The β3/4 galactose based structures were observed to produce characteristic features of protein linked and glycolipid glycomes.

The invention revealed that furthermore Galβ3/4GlcNAc-structures are a key feature of differentiation related structures on glycolipids of various stem cell types. Such glycolipids comprise two preferred structural epitopes according to the invention. The most preferred glycolipid types include thus lactosylceramide based glycosphingolipids and especially lacto-(Galβ3GlcNAc), such as

lactotetraosylceramide Galβ3GlcNAcβ3Galβ4GlcβCer, preferred structures further including its non-reducing terminal structures selected from the group: Galβ3(Fucα4)GlcNAc (Lewis a), Fucα2Galβ3GlcNAc (H-type 1), structure and, Fucα2Galβ3(Fucα4)GlcNAc (Lewis b) or sialylated structure SAα3Galβ3GlcNAc or SAα3Galβ3(Fucα4)GlcNAc, wherein SA is a sialic acid, preferably Neu5Ac preferably replacing Galβ3GlcNAc of lactotetraosylceramide and its fucosylated and/or elogated variants such as preferably according to the Formula:

(Sacα3)_n5(Fucα2)_n1Galβ3(Fucα4)_n3GlcNAcβ3[Galβ3/4(Fucα4/3)GlcNAcβ3]_n4Galβ4GlcβCer

wherein

n1 is 0 or 1, indicating presence or absence of Fucα2;

n2 is 0 or 1, indicating the presence or absence of Fucα4/3 (branch),

n3 is 0 or 1, indicating the presence or absence of Fucα4 (branch)

n4 is 0 or 1, indicating the presence or absence of (fucosylated) N-acetyllactosamine elongation;

n5 is 0 or 1, indicating the presence or absence of Sacα3 elongation;

Sac is terminal structure, preferably sialic acid, with α3-linkage, with the proviso that when Sac is present, n5 is 1, then n1 is 0

and

neolacto (Galβ4GlcNAc)-comprising glycolipids such as

neolactotetraosylceramide Galβ4GlcNAcβ3Galβ4GlcβCer, preferred structures further including its non-reducing terminal Galβ4(Fucα3)GlcNAc (Lewis x), Fucα2Galβ4GlcNAc H-type 2, structure and, Fucα2Galβ4(Fucα3)GlcNAc (Lewis y)

and

its fucosylated and/or elogated variants such as preferably (Sacα3/6)_n5(Fucα2)_n1Galβ4(Fucα3)_n3GlcNAcβ3[Galβ4(Fucα3)_n2GlcNAcβ3]_n4Galβ4GlcβCer

n1 is 0 or 1 indicating presence or absence of Fucα2;

n2 is 0 or 1, indicating the presence or absence of Fucα3 (branch),

n3 is 0 or 1, indicating the presence or absence of Fucα3 (branch)

n4 is 0 or 1, indicating the presence or absence of (fucosylated) N-acetyllactosamine elongation,

n5 is 0 or 1, indicating the presence or absence of Sacα3/6 elongation;

Sac is terminal structure, preferably sialic acid (SA) with α3-linkage, or sialic acid with α6-linkage, with the proviso that when Sac is present, n5 is 1, then n1 is 0, and when sialic acid is bound by α6-linkage preferably also n3 is 0.

Preferred Stem Cell Glycosphingolipid Glycan Profiles, Compositions, and Marker Structures

The inventors were able to describe stem cell glycolipid glycomes by mass spectrometric profiling of liberated free glycans, revealing about 80 glycan signals from different stem cell types. The proposed monosaccharide compositions of the neutral glycans were composed of 2-7 Hex, 0-5 HexNAc, and 0-4 dHex. The proposed monosaccharide compositions of the acidic glycan signals were composed of 0-2 NeuAc, 2-9 Hex, 0-6 HexNAc, 0-3 dHex, and/or 0-1 sulphate or phosphate esters. The present invention is especially directed to analysis and targeting of such stem cell glycan profiles and/or structures for the uses described in the present invention with respect to stem cells.

The present invention is further specifically directed to glycosphingolipid glycan signals specific tostem cell types as described in the Examples. In a preferred embodiment, glycan signals typical to hESC, preferentially including 876 and 892 are used in their analysis, more preferentially FucHexHexNAcLac, wherein α1,2-Fuc is preferential to α1,3/4-Fuc, and Hex₂HexNAc₁Lac, and more preferentially to Galβ3[Hex₁HexNAc₁]Lac. In another preferred embodiment, glycan signals typical to MSC, especially CB MSC, preferentially including 1460 and 1298, as well as large neutral glycolipids, especially Hex_2-3HexNAc₃Lac, more preferentially poly-N-acetyllactosamine chains, even more preferentially β1,6-branched, and preferentially terminated with type II LacNAc epitopes as described above, are used in context of MSC according to the uses described in the present invention.

Terminal glycan epitopes that were demonstrated in the present experiments in stem cell glycosphingolipid glycans are useful in recognizing stem cells or specifically binding to the stem cells via glycans, and other uses according to the present invention, including terminal epitopes: Gal, Galβ4Glc (Lac), Galβ4GlcNAc (LacNAc type 2), Galβ3, Non-reducing terminal HexNAc, Fuc, α1,2-Fuc, α1,3-Fuc, Fucα2Gal, Fucα2Galβ4GlcNAc (H type 2), Fucα2Galβ4Glc (2′-fucosyllactose), Fucα3GlcNAc, Galβ4(Fucα3)GlcNAc (Lex), Fucα3Glc, Galβ4(Fucα3)Glc (3-fucosyllactose), Neu5Ac, Neu5Acα2,3, and Neu5Acα2,6. The present invention is further directed to the total terminal epitope profiles within the total stem cell glycosphingolipid glycomes and/or glycomes.

The inventors were further able to characterize in hESC the corresponding glycan signals to SSEA-3 and SSEA-4 developmental related antigens, as well as their molar proportions within the stem cell glycome. The invention is further directed to quantitative analysis of such stem cell epitopes within the total glycomes or subglycomes, which is useful as a more efficient alternative with respect to antibodies that recognize only surface antigens. In a further embodiment, the present invention is directed to finding and characterizing the expression of cryptic developmental and/or stem cell antigens within the total glycome profiles by studying total glycan profiles, as demonstrated in the Examples for α1,2-fucosylated antigen expression in hESC in contrast to SSEA-1 expression in mouse ES cells.

The present invention revealed characteristic variations (increased or decreased expression in comparison to similar control cell or a contaminating cell or like) of both structure types in various cell materials according to the invention. The structures were revealed with characteristic and varying expression in three different glycome types: N-glycans, O-glycans, and glycolipids. The invention revealed that the glycan structures are a characteristic feature of stem cells and are useful for various analysis methods according to the invention. Amounts of these and relative amounts of the epitopes and/or derivatives varies between cell lines or between cells exposed to different conditions during growing, storage, or induction with effector molecules such as cytokines and/or hormones.

The preferred glycome glycan structure(s) and/or glycomes from cells according to the invention comprise structure(s) according to the formula C1:

R₁Hexβz{R₃}_n1HexNAcXyR₂,

Wherein X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and

Hex is Gal or Man or GlcA,

HexNAc is GlcNAc or GalNAc,

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon,

z is linkage position 3 or 4, with the provision that when z is 4 then HexNAc is GlcNAc and then Hex is Man or Hex is Gal or Hex is GlcA, and

when z is 3 then Hex is GlcA or Gal and HexNAc is GlcNAc or GalNAc,

R₁indicates 1-4, preferably 1-3, natural type carbohydrate substituents linked to the core structures,

R₂is reducing end hydroxyl, chemical reducing end derivative or natural asparagine N-glycoside derivative such as asparagine N-glycosides including asparagines N-glycoside aminoacids and/or peptides derived from protein, or natural serine or threonine linked O-glycoside derivative such as serine or threonine linked O-glycosides including asparagines N-glycoside aminoacids and/or peptides derived from protein.

R3 is nothing or a branching structure representing a GlcNAcβ6 or an oligosaccharide with GlcNAcβ6 at its reducing end linked to GalNAc (when HexNAc is GalNAc) or when Hex is Gal and HexNAc is GlcNAc the then when z is 3 R3 is Fucα4 or nothing and when z is 4 R3 is Fucα3 or nothing.

The preferred disaccharide epitopes in the glycan structures and glycomes according to the invention include structures Galβ4GlcNAc, Manβ4GlcNAc, GlcAβ4GlcNAc, Galβ3GlcNAc, Galβ3GalNAc, GlcAβ3GlcNAc and GlcAβ3GalNAc, which may be further derivatized from reducing end carbon atom and non-reducing monosaccharide residues and is separate embodiment branched from the reducing end residue. Preferred branched epitopes include Galβ4(Fucα3)GlcNAc, Galβ3(Fucα4)GlcNAc, Galβ3(GlcNAcβ6)GalNAc, which may be further derivatized from reducing end carbon atom and non-reducing monosaccharide residues.

The preferred disaccharide epitopes of glycoprotein or glycolipid structures present on glycans of human cells according to the invention comprise structures based on the formula C2:

R₁Hexβ4GlcNAcXyR₂,

Wherein Hex is Gal OR Man and when Hex is Man then X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and when Hex is Gal then X is β3GalNAc of O-glycan core or β2/4/6Manα3/6 terminal of N-glycan core (as in formula NC3)

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon,

R₁indicates 1-4, preferably 1-3, natural type carbohydrate substituents linked to the core structures,

when Hex is Gal preferred R1 groups include structures SAα3/6, SAα3/6Galβ4GlcNAcβ3/6,

when Hex is Man preferred R1 groups include Manα3, Manα6, branched structure

Manα3 {Manα6} and elongated variants thereof as described for low mannose, high-mannose and complex type N-glycans below,

Structures of N-Linked Glycomes

The Minimum Formula

The present invention is directed to glycomes derived from stem cells and comprising a common N-glycosidic core structures. The invention is specifically directed to minimum formulas covering both GN₁-glycomes and GN₂-glycomes with difference in reducing end structures.

The minimum core structure includes glycans from which reducing end GlcNAc or Fucα6GlcNAc has been released. These are referred as GN₁-glycomes and the components thereof as GN₁-glycans. The present invention is specifically directed to natural N-glycomes from human stem cells comprising GN₁-glycans. In a preferred embodiment the invention is directed to purified or isolated practically pure natural GN₁-glycome from human stem cells. The release of the reducing end GlcNAc-unit completely or partially may be included in the production of the N-glycome or N-glycans from stem cells for analysis.

The glycomes including the reducing end GlcNAc or Fucα6GlcNAc are referred as GN₂-glycomes and the components thereof as GN₂-glycans. The present invention is also specifically directed to natural N-glycomes from human stem cells comprising GN₂-glycans. In a preferred embodiment the invention is directed to purified or isolated practically pure natural GN₂-glycome from human stem cells.

The preferred N-glycan core structure(s) and/or N-glycomes from stem cells according to the invention comprise structure(s) according to the formula NC1:

R₁Mβ4GNXyR₂,

Wherein X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon, and

R₁indicates 1-4, preferably 1-3, natural type carbohydrate substituents linked to the core structures,

It is realized that when the invention is directed to a glycome, the formula indicates mixture of several or typically more than ten or even higher number of different structures according to the Formulas describing the glycomes according to the invention.

The possible carbohydrate substituents R₁comprise at least one mannose (Man) residue, and optionally one or several GlcNAc, Gal, Fuc, SA and/GalNAc residues, with possible sulphate and or phosphate modifications.

When the glycome is released by N-glycosidase the free N-glycome saccharides comprise in a preferred embodiment reducing end hydroxyl with anomeric linkage A having structure α and/or β, preferably both α and β. In another embodiment the glycome is derivatized by a molecular structure which can be reacted with the free reducing end of a released glycome, such as amine, aminooxy or hydrazine or thiol structures. The derivatizing groups comprise typically 3 to 30 atoms in aliphatic or aromatic structures or can form terminal group spacers and link the glycomes to carriers such as solid phases or microparticels, polymeric carries such as oligosaccharides and/or polysaccharide, peptides, dendrimer, proteins, organic polymers such as plastics, polyethyleneglycol and derivatives, polyamines such as polylysines.

When the glycome comprises asparagine N-glycosides, A is preferably beta and R is linked asparagine or asparagine peptide. The peptide part may comprise multiple different aminoacid residues and typically multiple forms of peptide with different sequences derived from natural proteins carrying the N-glycans in cell materials according to the invention. It is realized that for example proteolytic release of glycans may produce mixture of glycopeptides. Preferably the peptide parts of the glycopeptides comprises mainly a low number of amino acid residues, preferably two to ten residues, more preferably two to seven amino acid residues and even more preferably two to five aminoacid residues and most preferably two to four amino acid residues when “mainly” indicates preferably at least 60% of the peptide part, more preferably at least 75% and most preferably at least 90% of the peptide part comprising the peptide of desired low number of aminoacid residues.

The Preferred GN₂- N-Glycan Core Structures

The preferred GN₂- N-glycan core structure(s) and/or N-glycomes from stem cells according to the invention comprise structure(s) according to the formula NC2:

R₁Mβ4GNβ4(Fucα6)_nGNyR₂,

wherein n is 0 or 1 and

wherein y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon and

R₁indicates 1-4, preferably 1-3, natural type carbohydrate substituents linked to the core structures,

The preferred compositions thus include one or several of the following structures

NC2a: Mα3 {Mα6}Mβ4GNβ4{Fucα6}_n1GNyR₂

NC2b: Mα6Mβ4GNβ4{Fucα6}_n1GNyR₂

NC2c: Mα3Mβ4GNβ4{Fucα6}_n1GNyR₂

More preferably compositions comprise at least 3 of the structures or most preferably both structures according to the formula NC2a and at least both fucosylated and non-fucosylated with core structure(s) NC2b and/or NC2c.

The Preferred GN₁- N-Glycan Core Structure(s)

The preferred GN₁- N-glycan core structure(s) and/or N-glycomes from stem cells according to the invention comprise structure(s) according to the formula NC3:

R₁Mβ4GNyR₂,

wherein y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon and

R₁indicates 1-4, preferably 1-3, natural type carbohydrate substituents linked to the core structures,

Multi-Mannose GN₁- N-Glycan Core Structure(s)

The invention is specifically directed glycans and/or glycomes derived from preferred cells according to the present invention when the natural glycome or glycan comprises Multi-mannose GN₁- N-glycan core structure(s) structure(s) according to the formula NC4:

[R₁Mα3]_n3{R₃Mα6}_n2Mβ4GNXyR₂,

R₁and R3 indicate nothing or one or two, natural type carbohydrate substituents linked to the core structures, when the substituents are α-linked mannose monosaccharide and/or oligosaccharides and the other variables are as described above.

Furthermore common elongated GN₂- N-glycan core structures are preferred types of glycomes according to the invention

The preferred N-glycan core structures further include differently elongated GN₂- N-glycan core structures according to the formula NC5:

[R₁Mα3]_n3{R₃Mα6}_n2Mβ4GNβ4{Fucα6}_n1GNyR₂,

wherein n1, n2 and n3 are either 0 or 1 and

wherein y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon and

R₁and R₃indicate nothing or 1-4, preferably 1-3, most preferably one or two, natural type carbohydrate substituents linked to the core structures,

GN is GlcNAc, M is mannosyl-, [ ] indicate groups either present or absent in a linear sequence.

{ }indicates branching which may be also present or absent.

with the provision that at least n2 or n3 is 1. Preferably the invention is directed to compositions comprising with all possible values of n2 and n3 and all saccharide types when R1 and/or are R3 are oligosaccharide sequences or nothing.

Preferred N-Glycan Types in Glycomes Comprising N-Glycans

The present invention is preferably directed to N-glycan glycomes comprising one or several of the preferred N-glycan core types according to the invention. The present invention is specifically directed to specific N-glycan core types when the compositions comprise N-glycan or N-glycans from one or several of the groups Low mannose glycans, High mannose glycans, Hybrid glycans, and Complex glycans, in a preferred embodiment the glycome comprise substantial amounts of glycans from at least three groups, more preferably from all four groups.

Major Subtypes of N-Glycans in N-Linked Glycomes

The invention revealed certain structural groups present in N-linked glycomes. The grouping is based on structural features of glycan groups obtained by classification based on the monosaccharide compositions and structural analysis of the structurel groups. The glycans were analysed by NMR, specific binding reagents including lectins and antibodies and specific glycosidases releasing monosaccharide residues from glycans. The glycomes are preferably analysed as neutral and acidic glycomes

The Major Neutral Glycan Tapes

The neutral glycomes mean glycomes comprising no acidic monosaccharide residues such as sialic acids (especially NcuNAc and NcuGc), HexA (cspecially GlcA, glucuronic acid) and acid modification groups such as phosphate and/or sulphate esters. There are four major types of neutral N-linked glycomes which all share the common N-glycan core structure: High-mannose N-glycans, low-mannose N-glycans, hydrid type and complex type N-glycans. These have characteristic monosaccharide compositions and specific substructures. The complex and hybrid type glycans may include certain glycans comprising monoantennary glycans.

The groups of complex and hybrid type glycans can be further analysed with regard to the presence of one or more fucose residues. Glycans containing at least one fucose units are classified as fucosylated. Glycans containing at least two fucose residues are considered as glycans with complex fucosylation indicating that other fucose linkages, in addition to the α1,6-linkage in the N-glycan core, arc present in the structure. Such linkages include α1,2-, α1,3-, and α1,4-linkage.

Furthermore the complex type N-glycans may be classified based on the relations of HexNAc (typically GlcNAc or GalNAc) and Hex residues (typically Man, Gal). Terminal HexNAc glycans comprise at least three HexNAc units and at least two Hexose units so that the number of Hex Nac residues is at least larger or equal to the number of hexose units, with the provision that for non branched, monoantennary glycans the number of HexNAcs is larger than number of hexoses.

This consideration is based on presence of two GlcNAc units in the core of N-glycan and need of at least two Mannose units to for a single complex type N-glycan branch and three mannose to form a trimannosyl core structure for most complex type structures. A specific group of HexNAc N-Glycans contains the same number of HexNAcs and Hex units, when the number is at least 5.

Preferred Mannose Type Structures

The invention is further directed to glycans comprising terminal Mannose such as Mα6-residue or both Manα6- and Manα3-residues, respectively, can additionally substitute other Mα2/3/6 units to form a Mannose-type structures including hydrid, low-Man and High-Man structures according to the invention.

Preferred high- and low mannose type structures with GN2-core structure are according to the Formula M2:

[Mα2]_n1[Mα3]_n2{[Mα2]_n3[Mα6)]_n4}[Mα6]_n5{[Mα2]_n6[Mα2]_n7[Mα3]_n8}Mβ4GNβ4[{Fucα6}]_mGNyR₂

wherein p, n1, n2, n3, n4, n5, n6, n7, n8, and m are either independently 0 or 1; with the proviso that when n2 is 0, also n1 is 0; when n4 is 0, also n3 is 0; when n5 is 0, also n1, n2, n3, and n4 are 0; when n7 is 0, also n6 is 0; when n8 is 0, also n6 and n7 are 0;

y is anomeric linkage structure (x and/or 0 or linkage from derivatized anomeric carbon, and

[ ] indicates determinant either being present or absent depending on the value of n1, n2, n3, n4, n5, n6, n7, n8, and m; and

{ } indicates a branch in the structure.

Preferred yR₂-structures include [β-N-Asn]_p, wherein p is either 0 or 1.

Preferred Mannose Type Glycomes Comprising GN1-Core Structures

As described above a preferred variant of N-glycomes comprising only single GlcNAc-residue in the core. Such structures are especially preferred as glycomes produced by endo-N-acetylglucosaminidase enzymes and Soluble glycomes. Preferred Mannose type glycomesnclude structures according to the Formula M2

[Mα2]_n1[Mα3]_n2{[Mα2]_n3[Mα6)]_n4}[Mα6]_n5{[Mα2]_n6[Mα2]_n7[Mα3]_n8}Mβ4GNyR₂

Fucosylated high-mannose N-glycans according to the invention have molecular compositions Man_5-9GlcNAc₂Fuc₁. For the fucosylated high-mannose glycans according to the formula, the sum of n1, n2, n3, n4, n5, n6, n7, and n8 is an integer from 4 to 8 and m is 0.

The low-mannose structures have molecular compositions Man_1-4GlcNAc₂Fuc_0-1. They consist of two subgroups based on the number of Fuc residues: 1) nonfucosylated low-mannose structures have molecular compositions Man_1-4GlcNAc₂and 2) fucosylated low-mannose structures have molecular compositions Man_1-4GlcNAc₂Fuc₁. For the low mannose glycans the sum of n1, n2, n3, n4, n5, n6, n7, and n8 is less than or equal to (m+3); and preferably n1, n3, n6, and n7 are 0 when m is 0.

Low Mannose Glycans

The invention revealed a very unusual group of glycans in N-glycomes of the invention defined here as low mannose N-glycans. These are not clearly linked to regular biosynthesis of N-glycans, but may represent unusual biosynthetic midproducts or degradation products. The low mannose glycans are especially characteristics changing during the changes of cell status, the differentiation and other changes according to the invention, for examples changes associated with differentiation status of embryonal-type stem cells and their differentiated products and control cell materials. The invention is especially directed to recognizing low amounts of low-mannose type glycans in cell types, such as stem cells, preferably embryonal type stem cells with low degree of differentiation.

The invention revealed large differences between the low mannose glycan expression in the early human blood cell glycomes, especially in different preferred cell populations from human cord blood.

The invention is especially directed to the use of specific low mannose glycan comprising glycomes for analysis of early human blood glycomes especially glycomes from cord blood.

The invention further revealed specific mannose directed recognition methods useful for recognizing the preferred glycomes according to the invention. The invention is especially directed to combination of glycome analysis and recognition by specific binding agents, most preferred binding agent include enzymes and theis derivatives. The invention further revealed that specific low mannose glycans of the low mannose part of the glycomes can be recognized by degradation by specific α-mannosidase (Man_2-4GlcNAc₂Fuc_0-1) or β-mannosidase (Man₁GlcNAc₂Fuc_0-1) enzymes and optionally further recognition of small low mannose structures, even more preferably low mannose structures comprising terminal Manβ4-structures according to the invention.

The low mannose N-glycans, and preferred subgroups and individual structures thereof, are especially preferred as markers of the novel glycome compositions of the cells according to the invention useful for characterization of the cell types.

The low-mannose type glycans includes a specific group of α3- and/or α6-linked mannose type structures according to the invention including a preferred terminal and core structure types according to the invention.

The inventions further revealed that low mannose N-glycans comprise a unique individual structural markers useful for characterization of the cells according to the invention by specific binding agents according to the invention or by combinations of specific binding agents according to the invention.

Neutral low-mannose type N-glycans comprise one to four or five terminal Man-residues, preferentially Manα structures; for example Man_0-3Manβ4GlcNAcβ4GlcNAc(β-N-Asn) or Manα_0-4Manβ4GlcNAcβ4(Fucα6)GlcNAc(β-N-Asn).

Low-mannose N-glycans are smaller and more rare than the common high-mannose N-glycans (Man_5-9GlcNAc₂). The low-mannose N-glycans detected in cell samples fall into two subgroups: 1) non-fucosylated, with composition Man_nGlcNAc₂, where 1≦n≦4, and 2) core-fucosylated, with composition Man_nGlcNAc₂Fuc₁, where 1≦n≦5. The largest of the detected low-mannose structure structures is Man₅GlcNAc₂Fuc₁(m/z 1403 for the sodium adduct ion), which due to biosynthetic reasons most likely includes the structure below (in the figure the glycan is free oligosaccharide and β-anomer; in glycoproteins in tissues the glycan is N-glycan and β-anomer):

Preferred general molecular structural features of low Man glycans According to the present invention, low-mannose structures arc preferentially identified by mass spectrometry, preferentially based on characteristic Hex_1-4HexNAc₂dHex_0-1monosaccharide composition. The low-mannose structures are further preferentially identified by sensitivity to exoglycosidase digestion, preferentially α-mannosidase (Hex_2-4HexNAc₂dHexc_0-1) or β-mannosidase (Hex₁HexNAc₂dHex_0-1) enzymes, and/or to endoglycosidase digestion, preferentially N-glycosidase F detachment from glycoproteins, Endoglycosidase H detachment from glycoproteins (only Hex_1-4HexNAc₂liberated as Hex_1-4HexNAc₁), and/or Endoglycosidase F2 digestion (only Hex_1-4HexNAc₂dHex₁digested to Hex_1-4HexNAc₁). The low-mannose structures are further preferentially identified in NMR spectroscopy based on characteristic resonances of the Manβ4GlcNAcβ4GlcNAc N-glycan core structure and Manα residues attached to the Manβ4 residue.

Several preferred low Man glycans described above can be presented in a single Formula:

[Mα3]_n2{[Mα6)]_n4}[Mα6]_n5{[Mα3]_n8}Mβ4GNβ4[{Fucα6}]_mGNyR₂

wherein p, n2, n4, n5, n8, and m arc either independently 0 or 1; with the proviso that when n2 is 0, also n1 is 0; when n4 is 0, also n3 is 0; when n5 is 0, also n1, n2, n3, and n4 are 0; when n7 is 0, also n6 is 0; when n8 is 0, also n6 and n7 are 0; the sum of n1, n2, n3, n4, n5, n6, n7, and n8 is less than or equal to (m+3); [ ] indicates determinant either being present or absent depending on the value of n2, n4, n5, n8, and m; and

{ } indicates a branch in the structure;

y and R2 are as indicated above.

Preferred non-fucosylated low-mannose glycans are according to the formula:

[Mα3]_n2([Mα6)]_n4)[Mα6]_n5{[Mα3]_n8}Mβ4GNβ4GNyR₂

wherein p, n2, n4, n5, n8, and m are either independently 0 or 1,

with the provisio that when n5 is 0, also n2 and n4 are 0, and preferably either n2 or n4 is 0,

[ ] indicates determinant either being present or absent depending on the value of, n2, n4, n5, n8,

{ } and ( ) indicates a branch in the structure,

y and R2 are as indicated above.

Preferred Individual Structures of Non-Fucosylated Low-Mannose Glycans

Special Small Structures

Small non-fucosylated low-mannose structures are especially unusual among known N-linked glycans and characteristic glycans group useful for separation of cells according to the present invention. These include:

Mβ4GNβ4GNyR₂

Mα6Mβ4GNβ4GNyR₂

Mα3Mβ4GNβ4GNyR₂and

Mα6{Mα3}Mβ4GNβ4GNyR₂.

Mβ4GNβ4GNyR₂trisaccharide epitope is a preferred common structure alone and together with its mono-mannose derivatives Mα6Mβ4GNβ4GNyR₂and/or Mα3Mβ4GNβ4GNyR₂, because these are characteristic structures commonly present in glycomes according to the invention. The invention is specifically directed to the glycomes comprising one or several of the small non-fucosylated low-mannose structures. The tetrasaccharides are in a specific embodiment preferred for specific recognition directed to α-linked, preferably α3/6-linked Mannoses as preferred terminal recognition element.

Special Large Structures

The invention further revealed large non-fucosylated low-mannose structures that are unusual among known N-linked glycans and have special characteristic expression features among the preferred cells according to the invention. The preferred large structures include [Mα3]_n2([Mα6]_n4)Mα6{Mα3}Mβ4GNβ4GNyR₂

more specifically

Mα6Mα6{Mα3}Mβ4GNβ4GNyR₂

Mα3Mα6{Mα3}Mβ4GNβ4GNyR₂and

Mα3(Mα6)Mα6{Mα3}Mβ4GNβ4GNyR₂.

The hexasaccharide epitopes are preferred in a specific embodiment as rare and characteristic structures in preferred cell types and as structures with preferred terminal epitopes. The heptasaccharide is also preferred as structure comprising a preferred unusual terminal epitope Mα3(Mα6)Mα useful for analysis of cells according to the invention.

Preferred fucosylated low-mannose glycans are derived according to the formula:

[Mα3]_n2{[Mα6]_n4}[Mα6]_n5{[Mα3]_n8}Mβ4GNβ4(Fucα6)GNyR₂

wherein p, n2, n4, n5, n8, and m are either independently 0 or 1, with the provisio that when n5 is 0, also n2 and n4 are 0, [ ] indicates determinant either being present or absent depending on the value of n1, n2, n3, n4, ( ) indicates a branch in the structure;

and wherein n1, n2, n3, n4 and m are either independently 0 or 1,

with the provisio that when n3 is 0, also n1 and n2 are 0,

[ ] indicates determinant either being present or absent

depending on the value of n1, n2, n3, n4 and m,

{ } and ( ) indicate a branch in the structure.

Preferred Individual Structures of Fucosylated Low-Mannose Glycans

Small fucosylated low-mannose structures are especially unusual among known N-linked glycans and form a characteristic glycan group useful for separation of cells according to the present invention. These include:

Mβ4GNβ4(Fucα6)GNyR₂

Mα6Mβ4GNβ4(Fucα6)GNyR₂

Mα3Mβ4GNβ4(Fucα6)GNyR₂and

Mα6{Mα3}Mβ4GNβ4(Fucα6)GNyR₂.

Mβ4GNβ4(Fucα6)GNyR₂tetrasaccharide epitope is a preferred common structure alone and together with its mono-mannose derivatives Mα6Mβ4GNβ4(Fucα6)GNyR₂and/or Mα3Mβ4GNβ4(Fucα6)GNyR₂, because these are commonly present characteristics structures in glycomes according to the invention. The invention is specifically directed to the glycomes comprising one or several of the small non-fucosylated low-mannose structures. The tetrasaccharides are in a specific embodiment preferred for specific recognition directed to α-linked, preferably α3/6-linked Mannoses as preferred terminal recognition element.

Special Large Structures

The invention further revealed large fucosylated low-mannose structures are unusual among known N-linked glycans and have special characteristic expression features among the preferred cells according to the invention. The preferred large structure includes

[Mα3]_n2([Mα6]_n4)Mα6{Mα3}Mβ4GNβ4(Fucα6)GNyR₂

more specifically

Mα6Mα6{Mα3}Mβ4GNβ4(Fucα6)GNyR₂

Mα3Mα6{Mα3}Mβ4GNβ4(Fucα6)GNyR₂and

Mα3(Mα6)Mα6{Mα3}Mβ4GNβ4(Fucα6)GNyR₂.

The heptasaccharide epitopes are preferred in a specific embodiment as rare and characteristic structures in preferred cell types and as structures with preferred terminal epitopes. The octasaccharide is also preferred as structure comprising a preferred unusual terminal epitope Mα3(Mα6)Mα useful for analysis of cells according to the invention.

Preferred Non-Reducing End Terminal Mannose-Epitopes

The inventors revealed that mannose-structures can be labeled and/or otherwise specifically recognized on cell surfaces or cell derived fractions/materials of specific cell types. The present invention is directed to the recognition of specific mannose epitopes on cell surfaces by reagents binding to specific mannose structures from cell surfaces.

The preferred reagents for recognition of any structures according to the invention include specific antibodies and other carbohydrate recognizing binding molecules. It is known that antibodies can be produced for the specific structures by various immunization and/or library technologies such as phage display methods representing variable domains of antibodies. Similarily with antibody library technologies, including aptamer technologies and including phage display for peptides, exist for synthesis of library molecules such as polyamide molecules including peptides, especially cyclic peptides, or nucleotide type molecules such as aptamer molecules.

The invention is specifically directed to specific recognition high-mannose and low-mannose structures according to the invention. The invention is specifically directed to recognition of non-reducing end terminal Manα-epitopes, preferably at least disaccharide epitopes, according to the formula:

[Mα2]_m1[Mαx]_m2[Mα6]_m3{{[Mα2]_m9[Mα2]_m8[Mα3]_m7}_m10(Mβ4[GN]_m4)_m5}_m6yR₂

wherein m1, m2, m3, m4, m5, m6, m7, m8, m9 and m10 are independently either 0 or 1; with the proviso that when m3 is 0, then m1 is 0 and, when m7 is 0 then either m1-5 are 0 and m8 and m9 are 1 forming Mα2Mα2-disaccharide or both m8 and m9 are 0

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon, and

R₂is reducing end hydroxyl, chemical reducing end derivative

and x is linkage position 3 or 6 or both 3 and 6 forming branched structure,

{ } indicates a branch in the structure.

The invention is further directed to terminal Mα2-containing glycans containing at least one Mα2-group and preferably Mα2-group on each, branch so that m1 and at least one of m8 or m9 is 1. The invention is further directed to terminal Mα3 and/or Mα6-epitopes without terminal Mα2-groups, when all m1, m8 and m9 are 1.

The invention is further directed in a preferred embodiment to the terminal epitopes linked to a Mβ-residue and for application directed to larger epitopes. The invention is especially directed to Mβ4GN-comprising reducing end terminal epitopes.

The preferred terminal epitopes comprise typically 2-5 monosaccharide residues in a linear chain. According to the invention short epitopes comprising at least 2 monosaccharide residues can be recognized under suitable background conditions and the invention is specifically directed to epitopes comprising 2 to 4 monosaccharide units and more preferably 2-3 monosaccharide units, even more preferred epitopes include linear disaccharide units and/or branched trisaccharide non-reducing residue with natural anomeric linkage structures at reducing end. The shorter epitopes may be preferred for specific applications due to practical reasons including effective production of control molecules for potential binding reagents aimed for recognition of the structures.

The shorter epitopes such as Mα2M-may is often more abundant on target cell surface as it is present on multiple arms of several common structures according to the invention.

Preferred Disaccharide Epitopes Includes

Manα2Man, Manα3Man, Manα6Man, and more preferred anomeric forms Manα2Manα, Manα3Manβ, Manα6Manβ, Manα3Manα and Manα6Manα.

Preferred branched trisaccharides includes Manα3(Manα6)Man, Manα3(Manα6)Manβ, and Manα3(Manα6)Manα.

The invention is specifically directed to the specific recognition of non-reducing terminal Manα2-structures especially in context of high-mannose structures.

The invention is specifically directed to following linear terminal mannose epitopes:

a) preferred terminal Manα2-epitopes including following oligosaccharide sequences:

Manα2Man,

Manα2Manα,

Manα2Manα2Man, Manα2Manα3Man, Manα2Manα6Man,

Manα2Manα2Manα, Manα2Manα3Manβ, Manα2Manα6Manα,

Manα2Manα2Manα3Man, Manα2Manα3Manα6Man, Manα2Manα6Manα6Man

Manα2Manα2Manα3Manβ, Manα2Manα3Manα6Manβ, Manα2Manα6Manα6Manβ;

The invention is further directed to recognition of and methods directed to non-reducing end terminal Manα3- and/or Manα6-comprising target structures, which arc characteristic features of specifically important low-mannose glycans according to the invention. The preferred structural groups includes linear epitopes according to b) and branched epitopes according to the c3) especially depending on the status of the target material.

b) preferred terminal Manα3- and/or Manα6-epitopes including following oligosaccharide sequences:

Manα3Man, Manα6Man, Manα3Manβ, Manα6Manβ, Manα3Manα, Manα6Manα,

Manα3Manα6Man, Manα6Manα6Man, Manα3Manα6Manβ, Manα6Manα6Manβ

and to following

c) branched terminal mannose epitopes, are preferred as characteristic structures of especially high-mannose structures (c1 and c2) and low-mannose structures (c3), the preferred branched epitopes include:

c1) branched terminal Manα2-epitopes

Manα2Manα3(Manα2Manα6)Man, Manα2Manα3(Manα2Manα6)Manα,

Manα2Manα3(Manα2Manα6)Manα6Man, Manα2Manα3(Manα2Manα6)Manα6Manβ,

Manα2Manα3(Manα2Manα6)Manα6(Manα2Manα3)Man,

Manα2Manα3(Manα2Manα6)Manα6(Manα2Manα2Manα3)Man,

Manα2Manα3(Manα2Manα6)Manα6(Manα2Manα3)Manβ

Manα2Manα3(Manα2Manα6)Manα6(ManαManα2Manα3 )Manβ

c2) branched terminal Manα2- and Manα3 or Manα6-epitopes

according to formula when m1 and/or m8 and/m9 is 1 and the molecule comprise at least one nonreducing end terminal Manα3 or Manα6-epitope

c3) branched terminal Manα3 or Manα6-epitopes

Manα3(Manα6)Man, Manα3(Manα6)Manβ, Manα3(Manα6)Manα,

Manα3(Manα6)Manα6Man, Manα3(Manα6)Manα6Manβ,

Manα3(Manα6)Manα6(Manα3)Man, Manα3(Manα6)Manα6(Manα3)Manβ

The present invention is further directed to increase of selectivity and sensitivity in recognition of target glycans by combining recognition methods for terminal Manα2 and Manα3 and/or Manα6-comprising structures. Such methods would be especially useful in context of cell material according to the invention comprising both high-mannose and low-mannose glycans.

Complex Type N-Glycans

According to the present invention, complex-type structures are preferentially identified by mass spectrometry, preferentially based on characteristic monosaccharide compositions, wherein HexNAc≧4 and Hex≧3. In a more preferred embodiment of the present invention, 4≦HexNAc≦20 and 3≦Hex≦21, and in an even more preferred embodiment of the present invention, 4≦HexNAc≦10 and 3≦Hex≦11. The complex-type structures are further preferentially identified by sensitivity to endoglycosidase digestion, preferentially N-glycosidase F detachment from glycoproteins. The complex-type structures are further preferentially identified in NMR spectroscopy based on characteristic resonances of the Manα3(Manα6)Manβ4GlcNAcβ4GlcNAc N-glycan core structure and GlcNAc residues attached to the Manα3 and/or Manα6 residues.

Beside Mannose-type glycans the preferred N-linked glycomes include GlcNAcβ2-type glycans including Complex type glycans comprising only GlcNAcβ2-branches and Hydrid type glycan comprising both Mannose-type branch and GlcNAcβ2-branch.

GlcNAcβ2-Type Glycans

The invention revealed GlcNAcβ2Man structures in the glycomes according to the invention. Preferably GlcNAcβ2Man-structures comprise one or several of GlcNAcβ2Manα-structures, more preferably GlcNAcβ2Manα3 or GlcNAcβ2Manα6-structure.

The Complex type glycans of the invention comprise preferably two GlcNAcβ2Manα structures, which are preferably GlcNAcβ2Manα3 and GlcNAcβ2Manα6-.

The Hybrid type glycans comprise preferably GlcNAcβ2Manα3-structure.

The present invention is directed to at least one of natural oligosaccharide sequence structures and structures truncated from the reducing end of the N-glycan according to the Formula GNβ2

[R₁GNβ2]_n1[Mα3]_n2{[R₃]_n3[GNβ2]_n4Mα6}_n5Mβ4GNXyR₂,

with optionally one or two or three additional branches according to formula [R_xGNβz]_nxlinked to Mα6-, Mα3-, or Mβ4 and R_xmay be different in each branch

wherein n1, n2, n3, n4, n5 and nx, are either 0 or 1, independently,

with the proviso that when n2 is 0 then n1 is 0 and when n3 is 1 or/and n4 is 1 then n5 is also 1, and at least n1 or n4 is 1, or n3 is 1,

when n4 is 0 and n3 is 1 then R₃is a mannose type substituent or nothing and

wherein X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon, and

R₁, R_xand R₃indicate independently one, two or three, natural substituents linked to the core structure,

[ ] indicate groups either present or absent in a linear sequence. { } indicates branching which may be also present or absent.

Elongation of GlcNAcβ2-Type Structures, Complex/Hydrid Type Structures

The substituents R₁, R_xand R₃may form elongated structures. In the elongated structures R₁, and R_xrepresent substituents of GlcNAc (GN) and R₃is either substituent of GlcNAc or when n4 is 0 and n3 is 1 then R3 is a mannose type substituent linked to mannosea6-branch forming a Hybrid type structure. The substituents of GN are monosaccharide Gal, GalNAc, or Fuc or and acidic residue such as sialic acid or sulfate or fosfate ester.

GlcNAc or GN may be elongated to N-acetyllactosaminyl also marked as GalβGN or di-N-acetyllactosdiaminyl GalNAcβGlcNAc preferably GalNAcβ4GlcNAc. LNβ2M can be further elongated and/or branched with one or several other monosaccharide residues such as by galactose, fucose, SA or LN-unit(s) which may be further substituted by SAα-structures,

and/or Mα6 residue and/or Mα3 residues can be further substituted one or two β6-, and/or β4-linked additional branches according to the formula,

and/or either of Mα6 residue or Mα3 residue may be absent

and/or Mα6-residue can be additionally substitutes other Manα units to form a hybrid type structures

and/or Manβ4 can be further substituted by GNβ4,

and/or SA may include natural substituents of sialic acid and/or it may be substituted by other SA-residues preferably by α8- or α9-linkages.

Hybrid Type Structures

According to the present invention, hybrid-type or monoantennary structures are preferentially identified by mass spectrometry, preferentially based on characteristic monosaccharide compositions, wherein HexNAc=3 and Hex≧2. In a more preferred embodiment of the present invention 2≦Hex≦11, and in an even more preferred embodiment of the present invention 2≦Hex≦9. The hybrid-type structures are further preferentially identified by sensitivity to exoglycosidase digestion, preferentially a-mannosidase digestion when the structures contain non-reducing terminal α-mannose residues and Hex≧3, or even more preferably when Hex≧4, and to endoglycosidase digestion, preferentially N-glycosidase F detachment from glycoproteins. The hybrid-type structures are further preferentially identified in NMR spectroscopy based on characteristic resonances of the Manα3(Manα6)Manβ4GlcNAcβ4GlcNAc N-glycan core structure, a GlcNAcβ residue attached to a Manα residue in the N-glycan core, and the presence of characteristic resonances of non-reducing terminal α-mannose residue or residues.

The monoantennary structures are further preferentially identified by insensitivity to α-mannosidase digestion and by sensitivity to endoglycosidase digestion, preferentially N-glycosidase F detachment from glycoproteins. The monoantennary structures are further preferentially identified in NMR spectroscopy based on characteristic resonances of the Manα3Manβ4GlcNAcβ4GlcNAc N-glycan core structure, a GlcNAcβ residue attached to a Manα residue in the N-glycan core, and the absence of characteristic resonances of further non-reducing terminal α-mannose residues apart from those arising from a terminal α-mannose residue present in a ManαManβ sequence of the N-glycan core.

The present invention is directed to at least one of natural oligosaccharide sequence structures and structures truncated from the reducing end of the N-glycan according to the Formula HY1

R₁GNβ2Mα3{[R₃]_n3Mα6}Mβ4GNXyR₂,

wherein n3, is either 0 or 1, independently,

AND

wherein X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon, and

R₁indicate nothing or substituent or substituents linked to GlcNAc, R₃indicates nothing or Mannose-substituent(s) linked to mannose residue, so that each of R₁, and R₃may correspond to one, two or three, more preferably one or two, and most preferably at least one natural substituents linked to the core structure,

[ ] indicate groups either present or absent in a linear sequence. { } indicates branching which may be also present or absent.

Preferred Hybrid Type Structures

The preferred hydrid type structures include one or two additional mannose residues on the preferred core structure.

R₁GNβ2Mα3{[Mα3]_m1([Mα6])_m2Mα6}Mβ4GNXyR₂, Formula HY2

wherein n3, is either 0 or 1, and m1 and m2 are either 0 or 1, independently,

{ } and ( ) indicates branching which may be also present or absent,

other variables are as described in Formula HY1 .

Furthermore the invention is directed to structures comprising additional lactosamine type structures on GNβ2-branch. The preferred lactosamine type elongation structures includes N-acetyllactosamines and derivatives, galactose, GalNAc, GlcNAc, sialic acid and fucose.

Preferred structures according to the formula HY2 include:

Structures containing non-reducing end terminal GlcNAc

As a specific preferred group of glycans

GNβ2Mα3{Mα3Mα6}Mβ4GNXyR₂,

GNβ2Mα3{Mα6Mα6}Mβ4GNXyR₂,

GNβ2Mα3{Mα3(Mα6)Mα6}Mβ4GNXyR₂,

and/or elongated variants thereof

R₁GNβ2Mα3{Mα3Mα6}Mβ4GNXyR₂,

R₁GNβ2Mα3{Mα6Mα6}Mβ4GNXyR₂,

R₁GNβ2Mα3{Mα3(Mα6)Mα6}Mβ4GNXyR₂,

[R₁Gal[NAc]_o2βz]_o1GNβ2Mα3{[Mα3]_m1[(Mα6)]_m2Mα6}_n5Mβ4GNXyR₂, Formula HY3

wherein n1, n2, n3, n5, m1, m2, o1 and o2 are either 0 or 1, independently,

z is linkage position to GN being 3 or 4 in a preferred embodiment 4,

R₁indicates on or two a N-acetyllactosamine type elongation groups or nothing,

{ } and ( ) indicates branching which may be also present or absent,

other variables are as described in Formula HY1.

Preferred structures according to the formula HY3 include especially structures containing non-reducing end terminal Galβ, preferably Galβ3/4 forming a terminal N-acetyllactosamine structure. These are preferred as a special group of Hybrid type structures, preferred as a group of specific value in characterization of balance of Complex N-glycan glycome and High mannose glycome:

GalβzGNβ2Mα3{Mα3Mα6}Mβ4GNXyR₂, GalβzGNβ2Mα3{Mα6Mα6}Mβ4GNXyR₂, GalβzGNβ2Mα3{Mα3(Mα6)Mα6}Mβ4GNXyR₂,

and/or elongated variants thereof preferred for carrying additional characteristic terminal structures useful for characterization of glycan materials

R₁GalβzGNβ2Mα3{Mα3Mα6}Mβ4GNXyR₂,

R₁GalβzGNβ2Mα3{Mα6Mα6}Mβ4GNXyR₂,

R₁GalβzGNβ2Mα3{Mα3(Mα6)Mα6}Mβ4GNXyR₂. Preferred elongated materials include structures wherein R₁is a sialic acid, more preferably NeuNAc or NeuGc.

Complex N-Glycan Structures

The present invention is directed to at least one of natural oligosaccharide sequence structures and structures truncated from the reducing end of the N-glycan according to the Formula CO1

[R₁GNβ2]_n1[Mα3]_n2{[R₃GNβ2]_n4Mα6}_n5Mβ4GNXyR₂

with optionally one or two or three additional branches according to formula [R_xGNβz]_nxlinked to Mα6-, Mα3-, or Mβ4 and R_xmay be different in each branch

wherein n1, n2, n4, n5 and nx, are either 0 or 1, independently,

with the proviso that when n2 is 0 then n1 is 0 and when n4 is 1 then n5 is also 1, and at least n1 is 1 or n4 is 1, and at least either of n1 and n4 is 1

and

wherein X is glycosidically linked disaccharide epitope β4(Fucα6)_nGN, wherein n is 0 or 1, or X is nothing and

y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon, and

R₁, R_xand R₃indicate independently one, two or three, natural substituents linked to the core structure,

[ ] indicate groups either present or absent in a linear sequence. { } indicates branching which may be also present or absent.

Preferred Complex Type Structures

Incomplete Monoantennary N-Glycans

The present invention revealed incomplete Complex monoantennary N-glycans, which are unusual and useful for characterization of glycomes according to the invention. The most of the in complete monoantennary structures indicate potential degradation of biantennary N-glycan structures and are thus preferred as indicators of cellular status. The incomplete Complex type monoantennary glycans comprise only one GNβ2-structure.

The invention is specifically directed to structures are according to the Formula CO1 above when only n1 is 1 or n4 is one and mixtures of such structures.

The preferred mixtures comprise at least one monoantennary complex type glycans

A) with single branches from a likely degradative biosynthetic process:

R₁GNβ2Mα3β4GNXyR₂

R₃GNβ2Mα6Mβ4GNXyR₂and

B) with two branches comprising mannose branches

B1) R₁GNβ2Mα3{Mα6}_n5Mβ4GNXyR₂

B2) Mα3{R₃GNβ2Mα6}_n5Mβ4GNXyR₂

The structure B2 is preferred with A structures as product of degradative biosynthesis, it is especially preferred in context of lower degradation of Manα3-structures. The structure B1 is useful for indication of either degradative biosynthesis or delay of biosynthetic process

Biantennary and Multiantennary Structures

The inventors revealed a major group of biantennary and multiantennary N-glycans from cells according to the invention, the preferred biantennary and multiantennary structures comprise two GNβ2 structures.

These are preferred as an additional characteristics group of glycomes according to the invention and are represented according to the Formula CO2:

R₁GNβ2Mα3{R₃GNβ2Mα6}Mβ4GNXyR₂

with optionally one or two or three additional branches according to formula [R_xGNβz]_nxlinked to Mα6-, Mα3-, or Mβ4 and R_xmay be different in each branch

wherein nx is either 0 or 1,

and other variables are according to the Formula CO1.

Preferred Biantennary Structure

A biantennary structure comprising two terminal GNβ-epitopes is preferred as a potential indicator of degradative biosynthesis and/or delay of biosynthetic process. The more preferred structures are according to the Formula CO2 when R₁and R₃are nothing.

Elongated Structures

The invention revealed specific elongated complex type glycans comprising Gal and/or GalNAc-structures and elongated variants thereof. Such structures are especially preferred as informative structures because the terminal epitopes include multiple informative modifications of lactosamine type, which characterize cell types according to the invention. The present invention is directed to at least one of natural oligosaccharide sequence structure or group of structures and corresponding structure(s) truncated from the reducing end of the N-glycan according to the Formula CO3

[R₁Gal[NAc]_o2βz2]_o1GNβ2Mα3{[R₁Gal[NAc]_o4βz2]_o3GNβ2Mα6}Mβ4GNXyR₂,

with optionally one or two or three additional branches according to formula [R_xGNβz1]_nxlinked to Mα6-, Mα3-, or Mβ4 and R_xmay be different in each branch

wherein nx, o1, o2, o3, and o4 are either 0 or 1, independently,

with the provisio that at least o1 or o3 is 1, in a preferred embodiment both are 1

z2 is linkage position to GN being 3 or 4, in a preferred embodiment 4,

z1 is linkage position of the additional branches.

R₁, Rx and R₃indicate on or two a N-acetyllactosamine type elongation groups or nothing,

{ } and ( ) indicates branching which may be also present or absent,

other variables are as described in Formula CO1.

Galactosylated Structures

The inventors characterized especially directed to digalactosylated structure

GalβzGNβ2Mα3{GalβzGNβ2Mα6}Mβ4GNXyR₂,

and monogalactosylated structures:

GalβzGNβ2Mα3{GNβ2Mα6}Mβ4GNXyR₂,

GNβ2Mα3{GalβzGNβ2Mα6}Mβ4GNXyR₂,

and/or elongated variants thereof preferred for carrying additional characteristic terminal structures useful for characterization of glycan materials

R₁GalβzGNβ2Mα3{R₃GalβzGNβ2Mα6}Mβ4GNXyR₂

R₁GalβzGNβ2Mα3{GNβ2Mα6}Mβ4GNXyR₂, and

GNβ2Mα3{R₃GalβzGNβ2Mα6}Mβ4GNXyR₂.

Preferred elongated materials include structures wherein R₁is a sialic acid, more preferably NeuNAc or NeuGc.

LacdiNAc-Structure Comprising N-Glycans

The present invention revealed for the first time LacdiNAc, GalNacbGlcNAc structures from the cell according to the invention. Preferred N-glycan lacdiNAc structures arc included in structures according to the Formula CO1, when at least one the variable o2 and o4 is 1.

The Major Acidic Glycan Types

The acidic glycomes mean glycomes comprising at least one acidic monosaccharide residue such as sialic acids (especially NeuNAc and NeuGc) forming silylated glycome, HexA (especially GlcA, glucuronic acid) and/or acid modification groups such as phosphate and/or sulphate esters.

According to the present invention, presence of phosphate and/or sulphate ester (SP) groups in acidic glycan structures is preferentially indicated by characteristic monosaccharide compositions containing one or more SP groups. The preferred compositions containing SP groups include those formed by adding one or more SP groups into non-SP group containing glycan compositions, while the most preferential compositions containing SP groups according to the present invention arc selected from the compositions described in the acidic N-glycan fraction glycan group tables. The presence of phosphate and/or sulphate ester groups in acidic glycan structures is preferentially further indicated by the characteristic fragments observed in fragmentation mass spectrometry corresponding to loss of one or more SP groups, the insensitivity of the glycans carrying SP groups to sialidase digestion. The presence of phosphate and/or sulphate ester groups in acidic glycan structures is preferentially also indicated in positive ion mode mass spectrometry by the tendency of such glycans to form salts such as sodium salts as described in the Examples of the present invention. Sulphate and phosphate ester groups are further preferentially identified based on their sensitivity to specific sulphatase and phosphatase enzyme treatments, respectively, and/or specific complexes they form with cationic probes in analytical techniques such as mass spectrometry.

Complex N-Glycan Glycomes, Sialylated

The present invention is directed to at least one of natural oligosaccharide sequence structures and structures truncated from the reducing end of the N-glycan according to the Formula

[{SAα3/6}_s1LNβ2]_r1Mα3{({SAα3/6}_s2LNβ2)_r2Mα6}_r8{M[β4GN[β4{Fucα6}_r3GN]_r4]_r5}_r6 (I)

with optionally one or two or three additional branches according to formula

{SAα3/6}_s3LNβ, (IIb)

wherein r1, r2, r3, r4, r5, r6, r7 and r8 are either 0 or 1, independently,

wherein s1, s2 and s3 are either 0 or 1, independently,

with the proviso that at least r1 is 1 or r2 is 1, and at least one of s1, s2 or s3 is 1.

LN is N-acetyllactosaminyl also marked as GalβGN or di-N-acetyllactosdiaminyl GalNAcβGlcNAc preferably GalNAcβ4GlcNAc, GN is GlcNAc, M is mannosyl-,

with the proviso LNβ2M or GNβ2M can be further elongated and/or branched with one or several other monosaccharide residues such as by galactose, fucose, SA or LN-unit(s) which may be further substituted by SAα-structures,

and/or one LNβ can be truncated to GNβ

and/or Mα6 residue and/or Mα3 residues can be further substituted one or two β6-, and/or β4-linked additional branches according to the formula,

and/or either of Mα6 residue or Mα3 residue may be absent

and/or Mα6-residue can be additionally substitutes other Manα units to form a hybrid type structures

and/or Manβ4 can be further substituted by GNβ4,

and/or SA may include natural substituents of sialic acid and/or it may be substituted by other SA-residues preferably by α8- or α9-linkages.

( ), { }, [ ] and [ ] indicate groups either present or absent in a linear sequence. { }indicates branching which may be also present or absent.

The SAα-groups are linked to either 3- or 6-position of neighboring Gal residue or on 6-position of GlcNAc, preferably 3- or 6-position of neighboring Gal residue. In separately preferred embodiments the invention is directed structures comprising solely 3-linked SA or 6-linked SA, or mixtures thereof. In a preferred embodiment the invention is directed to glycans wherein r6 is 1 and r5 is 0, corresponding to N-glycans lacking the reducing end GlcNAc structure.

The LN unit with its various substituents can in a preferred general embodiment represented by the formula:

[Gal(NAc)_n1α3]_n2{Fucα2}_n3Gal(NAc)_n4β3/4{Fucα4/3}_n5GlcNAcβ

wherein n1, n2, n3, n4, and n5 are independently either 1 or 0,

with the provisio that

the substituents defined by n2 and n3 are alternative to presence of SA at the non-reducing end terminal

the reducing end GlcNAc-unit can be further β3- and/or β6-linked to another similar LN-structure forming a poly-N-acetyllactosamine structure

with the provision that for this LN-unit n2, n3 and n4 are 0,

the Gal(NAc)β and GlcNAcβ units can be ester linked a sulphate ester group,

( ), and [ ] indicate groups either present or absent in a linear sequence; { }indicates branching which may be also present or absent.

LN unit is preferably Galβ4GN and/or Galβ3GN. The inventors revealed that early human cells can express both types of N-acetyllactosamine, the invention is especially directed to mixtures of both structures. Furthermore the invention is directed to special relatively rear type 1 N-acetyllactosamines, Galβ3GN, without any non-reducing end/site modification, also called lewis c-structures, and substituted derivatives thereof, as novel markers of early human cells.

Occurrence of Structure Groups in Preferred Cell Types

In the present invention, glycan signals with preferential monosaccharide compositions can be grouped into structure groups based on classification rules described in the present invention. The present invention includes parallel and overlapping classification systems that are used for the classification of the glycan structure groups.

Glycan signals isolated from the N-glycan fractions from the cell types studied in the present invention are grouped into glycan structure groups based on their preferential monosaccharide compositions according to the invention, in Table 29 for neutral N-glycan fractions and Table 30 acidic N-glycan fractions. Taken together, the analyses revealed that all the structure groups according to the invention are present in the studied cell types.

The invention is specifically directed to terminal HexNAc groups and/or other structure groups and/or combinations thereof as shown in the Examples describing and analysis of stem cell including hESC glycan structure classification. Non-reducing terminal HexNAc residues could be liberated from the cell types studied in the present invention by specific combinations of β-hexosaminidase and β-glucosaminidase digestions, confining the structural group classification of the present invention, and identifying terminal HexNAc residues as β-GlcNAc and/or β-GalNAc residues in the studied cell types. According to the present invention, specifically in hESC and cells differentiated therefrom the terminal HexNAc residues preferentially include both β-GlcNAc and β-GalNAc residues, more preferentially terminal β-GlcNAc linkages including bisecting GlcNAc linkages and other hybrid-type and complex-type GlcNAc linkages according to the present invention, and terminal β-GalNAc linkages including β4-linked GalNAc and most preferentially GalNAcβ4GlcNAcβ (LacdiNAc) structures according to the present invention.

Integrated Glycome Analysis Technology

The invention is directed to analysis of present cell materials based on single or several glycans (glycome profile) of cell materials according to the invention. The analysis of multiple glycans is preferably performed by physical analysis methods such as mass spectrometry and/or NMR.

The invention is specifically directed to integrated analysis process for glycomes, such as total glycomes and cell surface glycomes. The integrated process represent various novel aspects in each part of the process. The methods are especially directed to analysis of low amounts of cells. The integrated analysis process includes

A) preferred preparation of substrate cell materials for analysis, including one or several of the methods: use of a chemical buffer solution, use of detergents, chemical reagents and/or enzymes.

B) release of glycome(s), including various subglycome type based on glycan core, charge and other structural features, use of controlled reagents in the process

C) purification of glycomes and various subglycomes from complex mixtures

D) preferred glycome analysis, including profiling methods such as mass spectrometry and/or NMR spectroscopy

E) data processing and analysis, especially comparative methods between different sample types and quantitative analysis of the glycome data.

Low Amounts of Cells for Glycome Analysis from Stem Cells

The invention revealed that its possible to produce glycome from very low amount of cells. The preferred embodiments amount of cells is between 1000 and 10 000 000 cells, more preferably between 10 000 and 1 000 000 cells. The invention is further directed to analysis of released glycomes of amount of at least 0.1 pmol, more preferably of at least to 1 pmol, more preferably at least of 10 pmol.

(a) Total asparagine-linked glycan (N-glycan) pool was enzymatically isolated from about 100 000 cells. (b) The total N-glycan pool (picomole quantities) was purified with microscale solid-phase extraction and divided into neutral and sialylated N-glycan fractions. The N-glycan fractions were analyzed by MALDI-TOF mass spectrometry either in positive ion mode for neutral N-glycans (c) or in negative ion mode for sialylated glycans (d). Over one hundred N-glycan signals were detected from each cell type revealing the surprising complexity of hESC glycosylation. The relative abundances of the observed glycan signals were determined based on relative signal intensities (Saarinen et al., 1999, Eur. J Biochem. 259, 829-840).

Methods for Low Sample Amounts

The present invention is specifically directed to methods for analysis of low amounts of samples.

The invention further revealed that it is possible to use the methods according to the invention for analysis of low sample amounts. It is realized that the cell materials are scarce and difficult to obtain from natural sources. The effective analysis methods would spare important cell materials. Under certain circumstances such as in context of cell culture the materials may be available from large scale. The required sample scale depends on the relative abundancy of the characteristic components of glycome in comparison to total amount of carbohydrates. It is further realized that the amount of glycans to be measured depend on the size and glycan content of the cell type to be measured and analysis including multiple enzymatic digestions of the samples would likely require more material. The present invention revealed especially effective methods for free released glycans.

The picoscale samples comprise preferably at least about 1000 cells, more preferably at least about 50 000 cells, even more more preferably at least 100 000 cells, and most preferably at least about 500 000 cells. The invention is further directed to analysis of about 1 000 000 cells. The preferred picoscale samples contain from at least about 1000 cells to about 10 000 000 cells according to the invention. The useful range of amounts of cells is between 50 000 and 5 000 000, even more preferred range of of cells is between 100 000 and 3 000 000 cells. A preferred practical range for free oligosaccharide glycomes is between about 500 000 and about 2 000 000 cells. It is realized that cell counting may have variation of less than 20%, more preferably 10% and most preferably 5%, depending on cell counting methods and cell sample, these variations may be used instead of term aboul It is further understood that the methods according to the present invention can be upscaled to much larger amounts of material and the pico/nanosoale analysis is a specific application of the technology. The invention is specifically directed to use of microcolumn technologies according to the invention for the analysis of the preferred picoscale and low amount samples according to the invention,

The invention is specifically directed to purification to level, which would allow production of high quality mass spectrum covering the broad size range of glycans of glycome compositions according to the invention.

The Binding Methods for Recognition of Structures from Cell Surfaces

Recognition of Structures from Glycome Materials and on Cell Surfaces by Binding Methods

- ii) Recognition by molecules binding glycans referred as the binders
- These molecules bind glycans and include property allowing observation of the binding such as a label linked to the binder. The preferred binders include
  - a) Proteins such as antibodies, lectins and enzymes
  - b) Peptides such as binding domains and sites of proteins, and synthetic library derived analogs such as phage display peptides
  - c) Other polymers or organic scaffold molecules mimicking the peptide materials

The peptides and proteins are preferably recombinant proteins or corresponding carbohydrate recognition domains derived thereof, when the proteins are selected from the group monoclonal antibody, glycosidase, glycosyl transferring enzyme, plant lectin, animal lectin or a peptide mimetic thereof, and wherein the binder includes a detectable label structure.

Preferred Binder Molecules

The preferred high specificity binders recognize

- E) at least one monosaccharide residue and a specific bond structure between those to another monosaccharides next monosaccharide residue referred as MS1B1-binder,
- F) more preferably recognizing at least part of the second monosaccharide residue referred as MS2B1-binder,
- G) even more preferably recognizing second bond structure and or at least part of third mono saccharide residue, referred as MS3B2-binder, preferably the MS3B2 recognizes a specific complete trisaccharide structure.
- H) most preferably the binding structure recognizes at least partially a tetrasaccharide with three bond structures, referred as MS4B3-binder, preferably the binder recognizes complete tetrasaccharide sequences.

Target Structures for Specific binders and Examples of the Binding Molecules

Combination of Terminal Structures in Combination with Specific Glycan Core Structures

Common Terminal Structures on Several Glycan Core Structures

Specific Preferred Structural Groups

The present invention is directed to recognition of oligosaccharide sequences comprising specific terminal monosaccharide types, optionally further including a specific core structure. The preferred oligosaccharide sequences classified based on the terminal monosaccharide structures.

1. Structures with Terminal Mannose Monosaccharide

Low or Uncharacterised Specificity Binders

preferred for recognition of terminal mannose structures includes mannose-monosaccharide binding plant lectins.

Preferred High Specific High Specificity Binders

include

i) Specific mannose residue releasing enzymes such as linkage specific mannosidases, more preferably an α-mannosidase or β-mannosidase.

Preferred α-mannosidases includes linkage specific α-mannosidases such as α-Mannosidases cleaving preferably non-reducing end terminal

α2-linked mannose residues specifically or more effectively than other linkages, more preferably cleaving specifically Manα2-structures; or

α6-linked mannose residues specifically or more effectively than other linkages, more preferably cleaving specifically Manα6-structures;

2. Structures with Terminal Gal-Monosaccharide

Preferred galactose-type target structures have been specifically classified by the invention. These include various types of N-acetyllactosamine structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal Gal

Preferred for recognition of terminal galactose structures includes plant lectins such as ricin lectin (ricinus communis agglutinin RCA), and peanut lectin(/agglutinin PNA).

Preferred High Specific High Specificity Binders Include

i) Specific galactose residue releasing enzymes such as linkage specific galactosidases, more preferably α-galactosidase or β-galactosidase.

Preferred α-galactosidases include linkage galactosidases capable of cleaving Galα3Gal-structures revealed from specific cell preparations

Preferred β-galactosidases includes β-galactosidases capable of cleaving

β4-linked galactose from non-reducing end terminal Galβ4GlcNAc-structure without cleaving other β-linked monosaccharides in the glycomes and

β3-linked galactose from non-reducing end terminal Galβ3GlcNAc-structure without cleaving other β-linked monosaccharides in the glycomes

3. Structures with Terminal GalNAc-Monosaccharide

Preferred GalNAc-type target structures have been specifically revealed by the invention. These include especially LacdiNAc, GalNAcβGlcNAc-type structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal GalNAc

Preferred High Specific High Specificity binders Include

i) The invention revealed that β-linked GalNAc can be recognized by specific β-N-acetylhexosaminidase enzyme in combination with β-N-acetylhexosaminidase enzyme.

This combination indicates the terminal monosaccharide and at least part of the linkage structure.

ii) Specific binding proteins recognizing preferred GalNAcβ4, more preferably GalNAcβ4GlcNAc, structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins, and a special plant lectin WFA (Wisteria floribunda agglutinin).

4. Structures with Terminal GlcNAc-Monosaccharide

Preferred GlcNAc-type target structures have been specifically revealed by the invention. These include especially GlcNAcβ-type structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal GlcNAc

Preferred High Specific High Specificity Binders Include

i) The invention revealed that C-linked GlcNAc can be recognized by specific β-N-acetyglucosaminidase enzyme.

Preferred β-N-acetyglucosaminidase includes enzyme capable of cleaving β-linked GlcNAc from non-reducing end terminal GlcNAcβ2/3/6-structures without cleaving β-linked GalNAc or α-linked HexNAc in the glycomes;

ii) Specific binding proteins recognizing preferred GlcNAcβ2/3/6, more preferably GlcNAcβ2Manα, structures according to the invention. The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins.

5. Structures with Terminal Fucose-Monosaccharide

Preferred fucose-type target structures have been specifically classified by the invention. These include various types of N-acetyllactosamine structures according to the invention.

Low or Uncharacterised Specificity Binders for Terminal Fuc

Preferred High Specific High Specificity Binders Include

i) Specific fucose residue releasing enzymes such as linkage fucosidases, more preferably α-fucosidase.

Preferred α-fucosidases include linkage fucosidases capable of cleaving Fucα2Gal-, and Galβ4/3(Fucα3/4)GlcNAc-structures revealed from specific cell preparations.

ii) Specific binding proteins recognizing preferred fucose structures according to the invention.

The preferred reagents include antibodies and binding domains of antibodies (Fab-fragments and like), and other engineered carbohydrate binding proteins and animal lectins such as selectins recognizing especially Lewis type structures such as Lewis x, Galβ4(Fucα3)GlcNAc, and sialyl-Lewis x, SAα3Galβ4(Fucα3)GlcNAc.

6. Structures with Terminal Sialic Acid-Monosaccharide

Preferred sialic acid-type target structures have been specifically classified by the invention.

Low or Uncharacterised Specificity Binders for Terminal Fuc

Preferred for recognition of terminal sialic acid structures includes sialic acid monosaccharide binding plant lectins.

Preferred High Specific High Specificity Binders Include

i) Specific sialic acid residue releasing enzymes such as linkage sialidases, more preferably α-sialidases.

Preferred α-sialidases include linkage sialidases capable of cleaving SAα3Gal- and SAα6Gal-structures revealed from specific cell preparations by the invention.

Preferred lectins, with linkage specificity include the lectins, that are specific for SAα3Gal-structures, preferably being Maackia amurensis lectin and/or lectins specific for SAα6Gal-structures, preferably being Sambucus nigra agglutinin.

Preferred antibodies for NeuGc-structures includes antibodies recognizes a structure NeuGcα3Galβ4Glc(NAc)_{0 or 1}and/or GalNAcβ4[NeuGcα3]Galβ4Glc(NAc)_{0 or 1}, wherein wherein [ ] indicates branch in the structure and ( )_{0 or 1}a structure being either present or absent. In a preferred embodiment the invention is directed recognition of the N-glycolyl-Neuraminic acid structures by antibody, preferably by a monoclonal antibody or human/humanized monoclonal antibody. A preferred antibody contains the variable domains of P3-antibody.

Preferred Epitopes and Antibody Binders

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 287 (H type 1). In a preferred embodiment, an antibody binds to Fucα2Galβ3GlcNAc epitope. A more preferred antibody comprises of the antibody of clone 17-206 (ab3355) by Abeam. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 279 (Lewis c, Galβ3GlcNAc). In a preferred embodiment, an antibody binds to Galβ3GlcNAc epitope in glycoconjugates, more preferably in glycoproteins and glycolipids such as lactotetraosylceramide. A more preferred antibody comprises of the antibody of clone K21 (ab3352) by Abeam. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 288 (Globo H). In a preferred embodiment, an antibody binds to Fucα2Galβ3GalNAcβ epitope, more preferably Fucα2Galβ3GalNAcβ3GalαLacCer epitope. A more preferred antibody comprises of the antibody of clone A69-A/E8 (MAB-S206) by Glycotope. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 284 (H type 2). In a preferred embodiment, an antibody binds to Fucα2Galβ4GlcNAc epitope. A more preferred antibody comprises of the antibody of clone B393 (DM3015) by Acris. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 283 (Lewis b). In a preferred embodiment, an antibody binds to Fucα2Galβ3(Fucα4)GlcNAc epitope. A more preferred antibody comprises of the antibody of clone 2-25LE (DM3122) by Acris. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 286 (H type 2). In a preferred embodiment, an antibody binds to Fucα2Galβ4GlcNAc epitope. A more preferred antibody comprises of the antibody of clone B393 (BM258P) by Acris. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other preferred binders and/or antibodies comprise of binders which bind to the same epitope than GF 290 (H type 2). In a preferred embodiment, an antibody binds to Fucα2Galβ4GlcNAc epitope. A more preferred antibody comprises of the antibody of clone A51-B/A6 (MAB-S204) by Glycotope. This epitope is suitable and can be used to detect, isolate and evaluate the differentiation stage, and/or plucipotency of stem cells, preferably human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells, preferably human embryonice stem cells from a mixture of cells comprising feeder and stem cells.

Other binders binding to feeder cells, preferably mouse feeder cells, comprise of binders which bind to the same epitope than GF 285 (H type 2). In a preferred embodiment, an antibody binds to Fucα2Galβ4GlcNAc, Fucα2Galβ3(Fucα4)GlcNAc, Fucα2Galβ4(Fucα3)GlcNAc epitope. A more preferred antibody comprises of the antibody of clone B389 (DM3014) by Acris. This epitope is suitable and can be used to detect, isolate and evaluate of feeder cells, preferably mouse feeder cells in culture with human embryonic stem cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich feeder cells (negatively select stem cells), preferably mouse embryonic feeder cells from a mixture of cells comprising feeder and stem cells.

Other binders binding to stem cells, preferably human stem cells, comprise of binders which bind to the same epitope than GF 289 (Lewis y). In a preferred embodiment, an antibody binds to Fucα2Galβ4(Fucα3)GlcNAc epitope. A more preferred antibody comprises of the antibody of clone A70-C/C8 (MAB-S201) by Glycotope. This epitope is suitable and can be used to detect, isolate and evaluate of stem cells, preferably human stem cells in culture with feeder cells. The detection can be performed in vitro, for FACS purposes and/or for cell lineage specific purposes. This antibody can be used to positively isolate and/or separate and/or enrich stem cells (negatively select feeder cells), preferably human stem cells from a mixture of cells comprising feeder and stem cells.

The staining intensity and cell number of stained stem cells, i.e. glycan structures of the present invention on stem cells indicates suitability and usefulness of the binder for isolation and differentiation marker. For example, low relative number of a glycan structure expressing cells may indicate lineage specificity and usefulness for selection of a subset and when selected/isolated from the colonies and cultured. Low number of expression is less than 5%, less than 10%, less than 15%, less than 20%, less than 30% or less than 40%. Further, low number of expression is contemplated when the expression levels are between 1-10%, 10%-20%, 15-25%, 20-40%, 25-35% or 35-50%. Typically, FACS analysis can be performed to enrich, isolate and/or select subsets of cells expressing a glycan structure(s).

High number of glycan expressing cells may indicate usefullness in pluripotency/multipotency marker and that the binder is useful in identifying, characterizing, selecting or isolating pluripotent or multipotent stem cells in a population of mammalian cells. High number of expression is more than 50%, more preferably more than 60%, even more preferably more than 70%, and most preferably more than 80%, 90 or 95%. Further, high number of expression is contemplated when the expression levels are between 50-60, 55%-65%, 60-70%, 70-80, 80-90%, 90-100 or 95-100%. Typically, FACS analysis can be performed to enrich, isolate and/or select subsets of cells expressing a glycan structure(s).

The epitopes recognized by the binders GF 279, GF 287, and GF 289 and the binders are particularly useful in characterizing pluripotency and multipotency of stem cells in a culture. The epitopes recognized by the binders GF 283, GF 284, GF 286, GF 288, and GF 290 and the binders are particularly useful for selecting or isolating subsets of stem cells. These subset or subpopulations can be further propagated and studied in vitro for their potency to differentiate and for differentiated cells or cell committed to a certain differentiation path.

The percentage as used herein means ratio of how many cells express a glycan structure to all the cells subjected to an analysis or an experiment. For example, 20% stem cells expressing a glycan structure in a stem cell colony means that a binder, eg an antibody staining can be observed in about 20% of cells when assessed visually.

In colonies a glycan structure bearing cells can be distnrbuted in a particular regions or they can be scattered in small patch like colonies. Patch like observed stem cells are useful for cell lineage specific studies, isolation and separation. Patch like characteristics were observed with GF 283, GF 284, GF 286, GF 288, and GF 290.

For positive selection of feeder cells, preferably mouse feeder cells, most preferably embryonic fibroblasts, GF 285 is useful. It stains almost all feeder cells whereas very little if at all staining is found in stem cells. For all percentages of expression, see Table 22.

The term “mainly” indicates preferably at least 60%, more preferably at least 75% and most preferably at least 90%. In the context of stem cells, the term “mainly” indicates preferably at least 60%, more preferably at least 75% and most preferably at least 90% of cells expressing a glycan structure and useful for identifying, characterizing, sclccting or isolating pluripotcnt or multipotent stem cells in a population of mammalian cells.

As used herein, “binder”, “binding agent” and “marker” are used interchangeably.

‘Antibodies

Various procedures known in the art may be used for the production of polyclonal antibodies to peptide motifs and regions or fragments thereof. For the production of antibodies, any suitable host animal (including but not limited to rabbits, mice, rats, or hamsters) are immunized by injection with a peptide (immunogenic fragment). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG {Bacille Calmette-Guerin) and Corynebacterium parvum.

A monoclonal antibody to a peptide motif(s) may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kδhler et al., (Nature, 256: 495-497, 1975), and the more recent human B-cell hybridoma technique (Kosbor et al., Immunology Today, 4: 72, 1983) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R Liss, Inc., pp. 77-96, 1985), all specifically incorporated herein by reference. Antibodies also may be produced in bacteria from cloned immunoglobulin cDNAs. With the use of the recombinant phage antibody system it may be possible to quickly produce and select antibodies in bacterial cultures and to genetically manipulate their structure.

When the hybridoma technique is employed, mycloma cell lines may be used. Such cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and exhibit enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX1 BuI; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 all may be useful in connection with cell fusions.

In addition to the production of monoclonal antibodies, techniques developed for the production of “chimeric antibodies”, the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison et al, Proc Natl Acad Sd 81: 6851-6855, 1984; Neuberger et al, Nature 312: 604-608, 1984; Takeda et al, Nature 314: 452-454; 1985). Alternatively, techniques described for the production of single-chain antibodies (U.S. Pat. No.4,946,778) can be adapted to produce influenza-specific single chain antibodies.

Antibody fragments that contain the idiotype of the molecule may be generated by known techniques. For example, such fragments include, but are not limited to, the F(ab′)2 fragment which may be produced by pepsin digestion of the antibody molecule; the Fab′ fragments which may be generated by reducing the disulfide bridges of the F(ab′)2 fragment, and the two Fab fragments which may be generated by treating the antibody molecule with papain and a reducing agent.

Non-human antibodies may be humanized by any methods known in the art. A preferred “humanized antibody” has a human constant region, while the variable region, or at least a complementarity determining region (CDR), of the antibody is derived from a non-human species. The human light chain constant region may be from either a kappa or lambda light chain, while the human heavy chain constant region may be from either an IgM, an IgG (IgG1, IgG2, IgG3, or IgG4) an IgD, an IgA, or an IgE immunoglobulin.

Methods for humanizing non-human antibodies are well known in the art (see U.S. Pat. Nos. 5,585,089, and 5,693,762). Generally, a humanized antibody has one or more amino acid residues introduced into its framework region from a source which is non-human. Humanization can be performed, for example, using methods described in Jones et al. {Nature 321: 522-525, 1986), Riechmann et al, {Nature, 332: 323-327, 1988) and Verhoeyen et al. Science 239:1534-1536, 1988), by substituting at least a portion of a rodent complementarity-determining region (CDRs) for the corresponding regions of a human antibody. Numerous techniques for preparing engineered antibodies are described, e.g., in Owens and Young, J. Immunol. Meth., 168:149-165, 1994. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.

Likewise, using techniques known in the art to isolate CDRs, compositions comprising CDRs are generated. Complementarity determining regions are characterized by six polypeptide loops, three loops for each of the heavy or light chain variable regions. The amino acid position in a CDR and framework region is set out by Kabat et al., “Sequences of Proteins of Immunological Interest,” U.S. Department of Health and Human Services, (1983), which is incorporated herein by reference. For example, hypervariable regions of human antibodies are roughly defined to be found at residues 28 to 35, from residues 49-59 and from residues 92-103 of the heavy and light chain variable regions (Janeway and Travers, Immunobiology, 2nd Edition, Garland Publishing, New York, 1996). The CDR regions in any given antibody may be found within several amino acids of these approximated residues set forth above. An immunoglobulin variable region also consists of “framework” regions surrounding the CDRs. The sequences of the framework regions of different light or heavy chains are highly conserved within a species, and are also conserved between human and murine sequences.

Compositions comprising one, two, and/or three CDRs of a heavy chain variable region or a light chain variable region of a monoclonal antibody are generated. Polypeptide compositions comprising one, two, three, four, five and/or six complementarity determining regions of a monoclonal antibody secreted by a hybridoma are also contemplated. Using the conserved framework sequences surrounding the CDRs, PCR primers complementary to these consensus sequences are generated to amplify a CDR sequence located between the primer regions. Techniques for cloning and expressing nucleotide and polypeptide sequences are well-established in the art [see e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, New York (1989)]. The amplified CDR sequences are ligated into an appropriate plasmid. The plasmid comprising one, two, three, four, five and/or six cloned CDRs optionally contains additional polypeptide encoding regions linked to the CDR.

Preferably, the antibody is any antibody specific for a glycan structure of Formula (I) or a fragment thereof. The antibody used in the present invention encompasses any antibody or fragment thereof, either native or recombinant, synthetic or naturally-derived, monoclonal or polyclonal which retains sufficient specificity to bind specifically to the glycan structure according to Formula (I) which is indicative of stem cells. As used herein, the terms “antibody” or “antibodies” include the entire antibody and antibody fragments containing functional portions thereof. The term “antibody” includes any monospecific or bispecific compound comprised of a sufficient portion of the light chain variable region and/or the heavy chain variable region to effect binding to the epitope to which the whole antibody has binding specificity. The fragments can include the variable region of at least one heavy or light chain immunoglobulin polypeptide, and include, but are not limited to, Fab fragments, F(ab′).sub.2 fragments, and Fv fragments.

The antibodies can be conjugated to other suitable molecules and compounds including, but not limited to, enzymes, magnetic beads, colloidal magnetic beads, haptens, fluorochromes, metal compounds, radioactive compounds, chromatography resins, solid supports or drugs. The enzymes that can be conjugated to the antibodies include, but are not limited to, alkaline phosphatase, peroxidase, urease and .beta.-galactosidase. The fluorochromes that can be conjugated to the antibodies include, but are not limited to, fluorescein isothiocyanate, tetramethylrhodamine isothiocyanate, phycoerythrin, allophycocyanins and Texas Red. For additional fluorochromes that can be conjugated to antibodies see Haugland, R. P. Molecular Probes: Handbook of Fluorescent Probes and Research Chemicals (1992-1994). The metal compounds that can be conjugated to the antibodies include, but are not limited to, ferritin, colloidal gold, and particularly, colloidal superparamagnetic beads. The haptens that can be conjugated to the antibodies include, but are not limited to, biotin, digoxigenin, oxazalone, and nitrophenol. The radioactive compounds that can be conjugated or incorporated into the antibodies are known to the art, and include but are not limited to technetium 99m, sup.125 I and amino acids comprising any radionuclides, including, but not limited to .sup.14 C, .sup.3 H and .sup.35 S.

Antibodies to glycan structure(s) of Formula (I) may be obtained from any source. They may be commercially available. Effectively, any means which detects the presence of glycan structure(s) on the stem cells is with the scope of the present invention. An example of such an antibody is a H type 1 (clone 17-206; GF 287) antibody from Abeam.

The methods outlined herein are particularly useful for identifying HSCs or progeny thereof from a population of cells. However, additional markers may be used to further distinguish subpopulations within the general HSC, or stem cell, population.

The various sub-populations may be distinguished by levels of binders to glycan structures of Formula (I) on stem cells. This may manifest on the stem cell surface (or on feeder cell if feeder cell specific binder is used) which may be detected by the methods outlined herein. However, the present invention may be used to distinguish between various phenotypes of the stem cell or HSC population including, but not limited to, the CD34.sup.+, CD38.sup.−, CD90.sup.+ (thy1) and Lin.sup.− cells. Preferably the cells identified are selected from the group including, but not limited to, CD34.sup.+, CD38.sup.−, CD90+ (thy 1), or Lin.sup.−.

The present invention thus encompasses methods of enriching a population for stem and/or HSCs or progeny thereof. The methods involve combining a mixture of HSCs or progeny thereof with an antibody or marker or binding protein/agent or binder that recognizes and binds to glycan structure according to Formula (I) on stem cell(s) under conditions which allow the antibody or marker or binder to bind to glycan structure according to Formula (I) on stem cell(s) and separating the cells recognized by the antibody or marker to obtain a population substantially enriched in stem cells or progeny thereof. The methods can be used as a diagnostic assay for the number of HSCs or progeny thereof in a sample. The cells and antibody or marker are combined under conditions sufficient to allow specific binding of the antibody or marker to glycan structure according to Formula (I) on stem cell(s) which are then quantitated. The HSCs or stem cells or progeny thereof can be isolated or further purified.

As discussed above the cell population may be obtained from any source of stem cells or HSCs or progeny thereof including those samples discussed above.

The detection for the presence of glycan structure(s) according to Formula (I) on stem cell(s) may be conducted in any way to identify glycan structure according to Formula (I) on stem cell(s). Preferably the detection is by use of a marker or binding protein for glycan structure according to Formula (I) on stem cell(s). The binder/marker for glycan structure according to Formula (I) on stem cell(s) may be any of the markers discussed above. However, anti-bodies or binding proteins to glycan structure according to Formula (I) on stem cell(s) are particularly useful as a marker for glycan structure according to Formula (I) on stem cell(s). The above method is also suitable for feeder cell specific glycan structures according to Formula (I) which are useful for positive selection of feeder cells.

Various techniques can be employed to separate or enrich the cells by initially removing cells of dedicated lineage. Monoclonal antibodies, binding proteins and lectins are particularly useful for identifying cell lineages and/or stages of differentiation. The antibodies can be attached to a solid support to allow for crude separation. The separation techniques employed should maximize the retention of viability of the fraction to be collected. Various techniques of different efficacy can be employed to obtain “relatively crude” separations. The particular technique employed will depend upon efficiency of separation, associated cytotoxicity, ease and speed of performance, and necessity for sophisticated equipment and/or technical skill.

Procedures for separation or enrichment can include, but are not limited to, magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a monoclonal antibody, including, but not limited to, complement and cytotoxins, and “panning” with antibody attached to a solid matrix, e.g., plate, elutriation or any other convenient technique.

The use of separation or enrichment techniques include, but are not limited to, those based on differences in physical (density gradient centrifugation and counter-flow centrifugal elutriation), cell surface (lectin and antibody affinity), and vital staining properties (mitochondria-binding dye rho123 and DNA-binding dye, Hoescht 33342).

Techniques providing accurate separation include, but are not limited to, FACS, which can have varying degrees of sophistication, e.g., a plurality of color channels, low angle and obtuse light scattering detecting channels, impedence channels, etc. Any method which can isolate and distinguish these cells according to levels of expression of glycan structure according to Formula (I) on stem cell(s) may be used.

In a first separation, typically starting with about 1.times.10.sup.10, preferably at about 5.times.10.sup.8-9 cells, antibodies or binding proteins or lectins to glycan structure according to Formula (I) on stem cell(s) can be labeled with at least one fluorochrome, while the antibodies or binding proteins for the various dedicated lineages, can be conjugated to at least one different fluorochrome. While each of the lineages can be separated in a separate step, desirably the lineages are separated at the same time as one is positively selecting for glycan structure according to Formula (I) on stem cell markers. The cells can be selected against dead cells, by employing dyes associated with dead cells (including but not limited to, propidium iodide (PI)).

To further enrich for any cell population, specific markers for those cell populations may be used. For instance, specific markers for specific cell lineages such as lymphoid, myeloid or erythroid lineages may be used to enrich for or against these cells. These markers may be used to enrich for HSCs or progeny thereof by removing or selecting out mesenchymal or keratinocyte stem cells.

The methods described above can include further enrichment steps for cells by positive selection for other stem cell specific markers. Suitable positive stem cell markers include, but are not limited to, SSEA-3, SSEA4, Tra 1-60, CD34.sup.+, Thy-1.sup.+, and c-kit.sup.+. By appropriate selection with particular factors and the development of bioassays which allow for self-regeneration of HSCs or progeny thereof and screening of the HSCs or progeny thereof as to their markers, a composition enriched for viable HSCs or progeny thereof can be produced for a variety of purposes.

Once the stem cells or HSC or progeny thereof population is isolated, further isolation techniques may be employed to isolate sub-populations within the HSCs or progeny thereof. Specific markers including cell selection systems such as FACS for cell lineages may be used to identify and isolate the various cell lineages.

In yet another aspect of the present invention there is provided a method of measuring the content of stem cells or HSC or their progeny said method comprising

obtaining a cell population comprising stem cells or progeny thereof;

combining the cell population with a binding protein or binder for glycan structure according to Formula (I) on stem cell(s) thereof;

selecting for those cells which are identified by the binding protein for glycan structure according to Formula (I) on stem cell(s) thereof, and

quantifying the amount of selected cells relative to the quantity of cells in the cell population prior to selection with the binding protein.

Binder-Label Conjugates

The present invention is specifically directed to the binding of the structures according to the present invention, when the binder is conjugated with “a label structure”. The label structure means a molecule observable in a assay such as for example a fluorescent molecule, a radioactive molecule, a detectable enzyme such as horse radish peroxidase or biotin/streptavidin/avidin. When the labelled binding molecule is contacted with the cells according to the invention, the cells can be monitored, observed and/or sorted based on the presence of the label on the cell surface. Monitoring and observation may occur by regular methods for observing labels such as fluorescence measuring devices, microscopes, scintillation counters and other devices for measuring radioactivity.

Use of Binder and labelled Binder-Conjugates for Cell Sorting

The invention is specifically directed to use of the binders and their labelled conjugates for sorting or selecting human stem cells from biological materials or samples including cell materials comprising other cell types. The preferred cell types includes cord blood, peripheral blood and embryonal stem cells and associated cells. The labels can be used for sorting cell types according to invention from other similar cells. In another embodiment the cells are sorted from different cell types such as blood cells or in context of cultured cells preferably feeder cells, for example in context of embryonal stem cells corresponding feeder cells such as human or mouse feeder cells. A preferred cell sorting method is FACS sorting. Another sorting methods utilized immobilized binder structures and removal of unbound cells for separation of bound and unbound cells.

Use of Immobilized Binder Structures

In a preferred embodiment the binder structure is conjugated to a solid phase. The cells are contacted with the solid phase, and part of the material is bound to surface. This method may be used to separation of cells and analysis of cell surface structures, or study cell biological changes of cells due to immobilization. In the analytics involving method the cells are preferably tagged with or labelled with a reagent for the detection of the cells bound to the solid phase through a binder structure on the solid phase. The methods preferably further include one or more steps of washing to remove unbound cells.

Preferred solid phases include cell suitable plastic materials used in contacting cells such as cell cultivation bottles, petri dishes and microtiter wells; fermentor surface materials

Specific Recognition between Preferred Stem Cells and Contaminating Cells

The invention is further directed to methods of recognizing stem cells from differentiated cells such as feeder cells, preferably animal feeder cells and more preferably mouse feeder cells. It is further realized, that the present reagents can be used for purification of stem cells by any fractionation method using the specific binding reagents.

Preferred fractionation methods includes fluoresce activated cell sorting (FACS), affinity chromatography methods, and bead methods such as magnetic bead methods.

Preferred reagents for recognition between preferred cells, preferably embryonal type cells, and contaminating cells, such as feeder cells, most preferably mouse feeder cells, include reagents according to the Table 31, more preferably proteins with similar specificity with lectins PSA, MAA, and PNA.

The invention is further directed to positive selection methods including specific binding to the stem cell population but not to contaminating cell population. The invention is further directed to negative selection methods including specific binding to the contaminating cell population but not to the stem cell population. In yet another embodiment of recognition of stem cells the stem cell population is recognized together with a homogenous cell population such as a feeder cell population, preferably when separation of other materials is needed. It is realized that a reagent for positive selection can be selected so that it binds stem cells as in the present invention and not to the contaminating cell population and a reagent for negative selection by selecting opposite specificity. In case of one population of cells according to the invention is to be selected from a novel cell population not studied in the present invention, the binding molecules according to the invention maybe used when verified to have suitable specificity with regard to the novel cell population (binding or not binding). The invention is specifically directed to analysis of such binding specificity for development of a new binding or selection method according to the invention.

The preferred specificities according to the invention include recognition of:

- i) mannose type structures, especially alpha-Man structures like lectin PSA, preferably on the surface of contaminating cells
- ii) α3-sialylated structures similarity as by MAA-lectin, preferably for recognition of embryonal type stem cells
- iii) Gal/GalNAc binding specificity, preferably Gal1-3/GalNAc1-3 binding specificity, more preferably Galβ1-3/GalNAcβ1-3 binding specificity similar to PNA, preferably for recognition of embryonal type stem cells

Manipulation of Cells by Binders

The invention is specifically directed to manipulation of cells by the specific binding proteins. It is realized that the glycans described have important roles in the interactions between cells and thus binders or binding molecules can be used for specific biological manipulation of cells. The manipulation may be performed by free or immobilized binders. In a preferred embodiment cells are used for manipulation of cell under cell culture conditions to affect the growth rate of the cells.

Preferred Cell Population to be Produced by Glycomodification According to the Present Invention

The present invention is directed to specific cell populations comprising in vitro enzymatically altered glycosylations according to the present invention. It is realized that special structures revealed on cell surfaces have specific targeting, and immune recognition properties with regard to cells carrying the structures. It is realized that sialylated and fucosylated terminal structures such as sialyl-lewis x structures target cells to selectins involved in bone marrow homing of cells and invention is directed to methods to produce such structures on cells surfaces. It is further realized that mannose and galactose terminal structures revealed by the invention target cells to liver and/or to immune recognition, which in most cases are harmful for effective cell therapy, unless liver is not targeted by the cells. NeuGc is target for immune recognition and has harmful effects for survival of cells expressing the glycans.

The invention revealed glycosidase methods for removal of the structures from cell surface while keeping the cells intact. The invention is especially directed to sialyltransferase methods for modification of terminal galactoses. The invention further revealed novel method to remove mannose residues from intact cells by alpha-manosidase.

The invention is further directed to metabolic regulation of glycosylation to alter the glycosylation for reduction of potentially harmful structures.

The present invention is directed to specific cell populations comprising in vitro enzymatically altered sialylation according to the present invention. The preferred cell population includes cells with decreased amount of sialic acids on the cell surfaces, preferably decreased from the preferred structures according to the present invention. The altered cell population contains in a preferred embodiment decreased amounts of α3-linked sialic acids. The present invention is preferably directed to the cell populations when the cell populations are produced by the processes according to the present invention.

Cell Populations with Altered Sialylated Structures

The invention is further directed to novel cell populations produced from the preferred cell populations according to the invention when the cell population comprises altered sialylation as described by the invention. The invention is specifically directed to cell populations comprising decreased sialylation as described by the invention. The invention is specifically directed to cell populations comprising increased sialylation of specific glycan structures as described by the invention. Furthermore invention is specifically directed to cell populations of specifically altered α3- and or α6-sialylation as described by the invention These cells are useful for studies of biological functions of the cell populations and role of sialylated, linkage specifically sialylated and non-sialylated structures in the biological activity of the cells.

Preferred Cell Populations with Decreased Sialylation

The preferred cell population includes cells with decreased amount of sialic acids on the cell surfaces, preferably decreased from the preferred structures according to the present invention. The altered cell population contains in a preferred embodiment decreased amounts of α3-linked sialic or α6-linked sialic acid. In a preferred embodiment the cell populations comprise practically only α3-sialic acid, and in another embodiment only α6-linked sialic acids, preferably on the preferred structures according to the invention, most preferably on the preferred N-glycan structures according to the invention. The present invention is preferably directed to the cell populations when the cell populations are produced by the processes according to the present invention. The cell populations with altered sialylation are preferably mesenchymal stem cell, embryonal-type cells or cord blood cell populations according to the invention.

Preferred Cell Populations with Increased Sialylation

The preferred cell population includes cells with increased amount of sialic acids on the cell surfaces, preferably decreased from the preferred structures according to the present invention. The altered cell population contains in preferred embodiments increased amounts of α3-linked sialic or α6-linked sialic acid. In a preferred embodiment the cell populations comprise practically only α3-sialic acid, and in another embodiment only α6-linked sialic acids, preferably on the preferred structures according to the invention, most preferably on the preferred N-glycan structures according to the invention. The present invention is preferably directed to the cell populations when the cell populations are produced by the processes according to the present invention. The cell populations with altered sialylation are preferably mesenchymal stem cells or embryonal-type cells or cord blood cell populations according to the invention.

Preferred Cell Populations with Altered Sialylation

The preferred cell population includes cells with altered linkage structures of sialic acids on the cell surfaces, preferably decreased from the preferred structures according to the present invention. The altered cell population contains in a preferred embodiments altered amount of α3-linked sialic and/or α6-linked sialic acid. The invention is specifically directed to cell populations having a sialylation level similar to the original cells but the linkages of structures are altered to α3-linkages and in another embodiment the linkages of structures are altered to α6-structures. In a preferred embodiment the cell populations comprise practically only α3-sialic acid, and in another embodiment only α6-linked sialic acids, preferably on the preferred structures according to the invention, most preferably on the preferred N-glycan structures according to the invention. The present invention is preferably directed to the cell populations when the cell populations are produced by the processes according to the present invention. The cell populations with altered sialylation are preferably mesenchymal stem cells or embryonal-type cells or cord blood cell populations according to the invention.

Cell Populations Comprising Preferred Cell Populations with Preferred Sialic Acid Types

The preferred cell population includes cells with altered types of sialic acids on the cell surfaces, preferably on the preferred structures according to the present invention. The altered cell population contains in a preferred embodiment altered amounts of NeuAc and/or NeuGc sialic acid. The invention is specifically directed to cell populations having sialylation levels similar to original cells but the sialic acid structures altered to NeuAc and in another embodiment the sialic acid type structures altered to NeuGc. In a preferred embodiment the cell populations comprise practically only NeuAc, and in another embodiment only NeuGc sialic acids, preferably on the preferred structures according to the invention, most preferably on the preferred N-glycan structures according to the invention. The present invention is preferably directed to the cell populations when the cell populations are produced by the processes according to the present invention. The cell populations with altered sialylation are preferably mesenchymal stem cells or embryonal-type cells or cord blood cell populations according to the invention.

Low-Molecular Weight Glycan Marker Structures and Stem Cell Glycome Components

The invention describes novel low-molecular weight acidic glycan components within the acidic N-glycan and/or soluble glycan fractions with characteristic monosaccharide compositions SA_xHex_1-2HexNAc_1-2, wherein x indicates that the corresponding glycans are preferentially sialylated with one or more sialic acid residues. The inventors realized that such glycans are novel and unusual with respect to N-glycan biosynthesis and described mammalian cell glycan components, as reveal also by the fact that they are classified as “other (N-)glycan types” in N-glycan classification scheme of the present invention. The invention is directed to analyzing, isolating, modifying, and/or binding to these novel glycan components according to the methods and uses of the present invention, and further to other uses of specific marker glycans as described here. As demonstrated in the Examples of the present invention, such glycan components were specific parts of total glycomes of certain cell types and preferentially to certain stem cell types, making their analysis and use beneficial with regard to stem cells. The invention is further directed to stem cell glycomes and subglycomes containing these glycan components.

Stem Cell Nomenclature

The present invention is directed to analysis of all stem cell types, preferably human stem cells. A general nomenclature of the stem cells is described in FIG. 9. The alternative nomenclature of the present invention describe early human cells which are in a preferred embodiment equivalent of adult stem cells (including cord blood type materials) as shown in FIG. 9. Adult stem cells in bone marrow and blood is equivalent for stem cells from “blood related tissues”.

Lectins for Manipulation of Stem Cells, Especially Under Cell Culture Conditions

The present invention is especially directed to use of lectins as specific binding proteins for analysis of status of stem cells and/or for the manipulation of stems cells.

The invention is specifically directed to manipulation of stem cells under cell culture conditions growing the stem cells in presence of lectins. The manipulation is preferably performed by immobilized lectins on surface of cell culture vessels. The invention is especially directed to the manipulation of the growth rate of stem cells by growing the cells in the presence of lectins, as show in Table 32.

The invention is in a preferred embodiment directed to manipulation of stem cells by specific lectins recognizing specific glycan marker structures according to invention from the cell surfaces. The invention is in a preferred embodiment directed to use of Gal recognizing lectins such as ECA-lectin or similar human lectins such as galectins for recognition of galectin ligand glycans identified from the cell surfaces. It was further realized that there is specific variations of galectin expression in genomic levels in stem cells, especially for galectins-1, -3, and -8. The present invention is especially directed to methods of testing of these lectins for manipulation of growth rates of embryonal type stem cells and for adult stem cells in bone marrow and blood and differentiating derivatives thereof.

Sorting of Stem Cells by Specific Lectins

The invention revealed use of specific lectin types recognizing cell surface glycan epitopes according to the invention for sorting of stem cells, especially by FACS methods, most preferred cell types to be sorted includes adult stem cells in blood and bone marrow, especially cord blood cells. Preferred lectins for sorting of cord blood cells include GNA, STA, GS-II, PWA, HMA, PSA, RCA, and others as shown in Example 16. The relevance of the lectins for isolating specific stem cell populations was demonstrated by double labeling with known stem cells markers, as described in Example 16.

Preferred Structures of O-Glycan Glycomes of Stem Cells

The present invention is especially directed to following O-glycan marker structures of stem cells:

Core 1 type O-glycan structures following the marker composition NeuAc₂Hex₁HexNAc₁, preferably including structures SAα3Galβ3GalNAc and/or SAα3Galβ3(Saα6)GalNAc; and Core 2 type O-glycan structures following the marker composition NeuAc_0-2Hex₂HexNAc₂dHex_0-1, more preferentially further including the glycan series NeuAc_0-1Hex_2+nHexNAc_2+ndHex_0-1, wherein n is either 1, 2, or 3 and more preferentially n is 1 or 2, and even more preferentially n is 1;

more specifically preferably including R₁Galβ4(R₃)GlcNAcβ6(R₂Galβ3)GalNAc,

wherein R₁and R₂are independently either nothing or sialic acid residue, preferably α2,3-linked sialic acid residue, or an elongation with Hex_nHexNAc_n, wherein n is independently an integer at least 1, preferably between 1-3, most preferably between 1-2, and most preferably 1, and the elongation may terminate in sialic acid residue, preferably α2,3-linked sialic acid residue; and

R₃is independently either nothing or fucose residue, preferably α1,3-linked fucose residue.

It is realized that these structures correlate with expression of β6GlcNAc-transferases synthesizing core 2 structures.

Preferred branched N-Acetyllactosamine Type Glycosphingolipids

The invention further revealed branched, I-type, poly-N-acetyllactosamines with two terminal Galβ4-residues from glycolipids of human stem cells. The structures correlate with expression of β6GlcNAc-transferases capable of branching poly-N-acetyllactosamines and further to binding of lectins specific for branched poly-N-acetyllactosamines. It was further noticed that PWA-lectin had an activity in manipulation of stem cells, especially the growth rate thereof.

Preferred Qualitative and Quantitative Complete N-Glycomes of Stem Cells

High-Mannose Type and Glucosylated N-Glycans

The present invention is especially directed to glycan compositions (structures) and analysis of high-mannose type and glucosylated N-glycans according to the formula:

Hex_n3HexNAc_n4,

wherein n3 is 5, 6, 7, 8, 9, 10, 11, or 12, and n4=2.

According to the present invention, within total N-glycomes of stem cells the major high-mannose type and glucosylated N-glycan signals include the compositions with 5≦n3≦10: Hex5HexNAc2 (1257), Hex6HexNAc2 (1419), Hex7HexNAc2 (1581), Hex8HexNAc2 (1743), Hex9HexNAc2 (1905), and Hex10HexNAc2 (2067);

and more preferably with 5≦n3≦9: Hex5HexNAc2 (1257), Hex6HexNAc2 (1419), Hex7HexNAc2 (1581), Hex8HexNAc2 (1743), and Hex9HexNAc2 (1905).

As demonstrated in the present invention by glycan structure analysis, preferably this glycan group in stem cells includes the molecular structure (Manα)₈Manβ4GlcNAcβ4GlcNAc within the glycan signal Hex9HexNAc2 (1905), and even more preferably Manα2Manα6(Manα2Manα3)Manα6(Manα2Manα2Manα3)Manβ4GlcNAcβ4GlcNAc.

Low-Mannose Type N-Glycans

The present invention is especially directed to glycan compositions (structures) and analysis of low-mannose type N-glycans according to the formula:

Hex_n3HexNAc_n4dHex_n5,

wherein n3 is 1, 2, 3, or 4, n4=2, and n5 is 0 or 1.

According to the present invention, within total N-glycomes of stem cells the major low-mannose type N-glycan signals preferably include the compositions with 2≦n3≦4: Hex2HexNAc2 (771), Hex3HexNAc2 (933), Hex4HexNAc2 (1095), Hex2HexNAc2dHex (917), Hex3HexNAc2dHex (1079), and Hex4HexNAc2dHex (1241); and more preferably when n5 is 0: Hex2HexNAc2 (771), Hex3HexNAc2 (933), and Hex4HexNAc2 (1095).

As demonstrated in the present invention by glycan structure analysis of stem cells, preferably this glycan group in stem cells includes the molecular structures:

(Manα)hd 1-3Manβ4GlcNAcβ4(Fucα6)_0-1GlcNAc within the glycan signals 771, 917, 933, 1079, 1095, and 1095, and

the preferred low-Man structures includes structures common all stem cell types, tri-Man and tetra-Man structures according as indicated in Table 29 (Manα)_0-1Manα6(Manα3)Manβ4GlcNAcβ4(Fucα6)_0-1GlcNAc, more preferably the tri-Man structures:

Manα6(Manα3)Manβ4GlcNAcβ4(Fucα6)_0-1GlcNAc

even more preferably the abundant molecular structure:

Manα6(Manα3)Manβ4GlcNAcβ4GlcNAc within the glycan signal 933.

The invention is further directed to analysis of presence and/or absence of structures varying characteristically between stem cells.

These include fucosylated and nonfucosylated di-Man structures,

specifically associated with certain blood associated stem cells

[Manα6]_0-1(Manα3)_0-1Manβ4GlcNAcβ4(Fucα6)_0-1GlcNAc,

when either of the Manα-residues is present or absent.

The fucosylated structure was observed to be associated with specific blood related adult stem cells while the non-fucosylated structures was observed to have more varying expression in embryonal stem cells, embryoid bodies and more primitive cord blood stem cells (CD133+) and

cord blood mesenchymal cells. It is realized that the both di-Man structures reflect have specific qualitative analytical value with regard to specific cell populations.

Fucosylated High-Mannose Type N-Glycans

The present invention is especially directed to glycan compositions (structures) and analysis of fucosylated high-mannose type N-glycans according to the formula:

Hex_n3HexNAc_n4dHex_n5,

wherein n3 is 5, 6, 7, 8, or 9, n4=2, and n5=1.

According to the present invention, within total N-glycomes of stem cells the major fucosylated high-mannose type N-glycan signal preferentially is the composition Hex5HexNAc2dHex (1403). As demonstrated in the present invention by glycan structure analysis of stem cells, more preferably this glycan signal in stem cells includes the molecular structure (Manα)₄Manβ4GlcNAcβ4(Fucα6)GlcNAc.

Neutral Monoantennary or Hybrid-Type N-Glycans

The present invention is especially directed to glycan compositions (structures) and analysis of neutral monoantennary or hybrid-type N-glycans according to the formula:

Hex_n3HexNAc_n4dHex_n5,

wherein n3 is an integer greater or equal to 2, n4=3, and n5 is an integer greater or equal to 0.

According to the present invention, within total N-glycomes of stem cells the major neutral monoantennary or hybrid-type N-glycan signals preferentially include the compositions with 2≦n3≦8 and 0≦n5≦2, more preferentially compositions with 3≦n3≦6 and 0≦n5≦1, with the proviso that when n3=6 also n5=0: Hex3HexNAc3 (1136), Hex3HexNAc3dHex (1282), Hex4HexNAc3 (1298), Hex4HexNAc3dHex (1444), Hex5HexNAc3 (1460), Hex5HexNAc3dHex (1606), and Hex6HexNAc3 (1622).

According to the present invention, the total N-glycomes of cultured human BM MSC, CB MSC, and cells differentiated from them preferentially additionally include the following structures: Hex2HexNAc3dHex (1120), Hex4HexNAc3dHex2 (1590), Hex 5HexNAc3dHex2 (1752), Hex6HexNAc3dHex (1768), and Hex7HexNAc3 (1784).

In a preferred embodiment of the present invention, the N-glycan signal Hex5HexNAc3 (1460), more preferentially also Hex6HexNAc3 (1622), and even more preferentially also Hex5HexNAc3dHex (1606), contain non-reducing terminal Manα.

Neutral Complex-Type N-Glycans

The present invention is especially directed to glycan compositions (structures) and analysis of neutral complex-type N-glycans according to the formula:

Hex_n3HexNAc_n4dHex_n5,

wherein n3 is an integer greater or equal to 3, n4 is an integer greater or equal to 4, and n5 is an integer greater or equal to 0.

Within the total N-glycomes of stem cells the major neutral complex-type N-glycan signals preferentially include the compositions with 3≦n3≦8, 4≦n4≦7, and 0≦n5≦4, more preferentially the compositions with 3≦n3≦5, n4=4, and 0≦n5≦1, with the proviso that when n3 is 3 or 4, then n5=1: Hex3HexNAc4dHex (1485), Hex4HexNAc4dHex (1647), Hex5HexNAc4 (1663), Hex5HexNAc4dHex (1809); and even more preferentially also including the composition Hex3HexNAc5dHex (1688).

In another embodiment of the present invention, the total N-glycomes of cultured human BM MSC, CB MSC, and cells differentiated from them preferentially include in the major neutral complex-type N-glycan signals the compositions with 3≦n3≦5, n3=4, and 0≦n5≦1, as well as the compositions with 5≦n4≦6, n3=n4+1, and 0≦n5≦1, and even more preferentially also including the composition Hex3HexNAc5dHex: Hex3HexNAc4 (1339), Hex3HexNAc4dHex (1485), Hex4HexNAc4 (1501), Hex4HexNAc4dHex (1647), Hex5HexNAc4 (1663), Hex5HexNAc4dHex (1809), Hex6HexNAc5 (2028), Hex6HexNAc5dHex (2174), Hex7HexNAc6 (2393), Hex7HexNAc6dHex (2539), and Hex3HexNAc5dHex (1688).

In another embodiment of the present invention, the total N-glycomes of cultured hESC and cells differentiated from them preferentially further include in the major neutral complex-type N-glycan signal Hex4HexNAc5dHex (1850).

In another embodiment of the present invention, the N-glycan signal Hex3HexNAc4dHex (1485) contains non-reducing terminal GlcNAcβ, and more preferentially the total N-glycome includes the structure:

GlcNAcβ2Manα3(GlcNAcβ2Manα6)Manβ4GlcNAcβ4(Fucα6)GlcNAc (1485).

In yet another embodiment of the present invention, within the total N-glycome of stem cells, the N-glycan signal Hex5HexNAc4dHex (1809), more preferentially also Hex5HexNAc4 (1663), contain non-reducing terminal β1,4-Gal. Even more preferentially the total N-glycome includes the structure:

Galβ4GlcNAcβ2Manα3(Galβ4GlcNAcβ2Manα6)Manβ4GlcNAcβ4GlcNAc (1663); and in a further preferred embodiment the total N-glycome includes the structure:

Galβ4GlcNAcβ2Manα3(Galβ4GlcNAcβ2Manα6)Manβ4GlcNAcβ4(Fucα)GlcNAc (1809).

Neutral Fucosylated N-glycans

The present invention is especially directed to glycan compositions (structures) and analysis of neutral fucosylated N-glycans according to the formula:

Hex_n3HexNAc_n4dHex_n5,

wherein n5 is an integer greater than or equal to 1.

Within the total N-glycomes of stem cells the major neutral fucosylated N-glycan signals preferentially include glycan compositions wherein 1≦n5≦4, more preferentially 1≦n5≦3, even more preferentially 1≦n5≦2, and further more preferentially compositions Hex3HexNAc2dHex (1079), more preferentially also Hex2HexNAc2dHex (917), and even more preferentially also Hex5HexNAc4dHex (1809).

The inventors further found that within the total N-glycomes of stem cells a major fucosylation form is N-glycan core α1,6-fucosylation. In a preferred embodiment of the present invention, major fucosylated N-glycan signals contain GlcNAcβA(Fucα6)GlcNAc reducing end sequence.

The inventors further found that stem cell total N-glycomes contain α1,2-Fuc, α1,3-Fuc, and/or α1,4-Fuc epitopes in a differentiation stage dependent manner. In a preferred embodiment of the present invention, major fucosylated N-glycan signals of stem cells contain α1,2-Fuc, α1,3-Fuc, and/or α1,4-Fuc epitopes, more preferentially in multifucosylated N-glycans, wherein 2≦n5≦4.

Within the total N-glycomes of BM and CB MSC the major neutral multifucosylated N-glycan signals preferentially include the composition Hex5HexNAc4dHex2 (1955), more preferentially also Hex5HexNAc4dHex3 (2101), even more preferentially also Hex4HexNAc3dHex2 (1590), and further more preferentially also Hex6HexNAc5dHex2 (2320).

Within the total N-glycomes of hESC the major neutral multifucosylated N-glycan signals preferentially include the composition Hex5HexNAc4dHex2 (1955), more preferentially also Hex5HexNAc4dHex3 (2101), even more preferentially also Hex4HexNAc5dHex2 (1996), and further more preferentially also Hex4HexNAc5dHex3 (2142).

Neutral N-glycans with Non-Reducing Terminal HexNAc

The present invention is especially directed to glycan compositions (structures) and analysis of neutral N-glycans with non-reducing terminal HexNAc according to the formula:

Hex_n3HexNAc_n4dHex_n5,

wherein n4≧n3.

Preferably these glycan signals include Hex3HexNAc4dHex (1485) in all stem cell types; additionally preferably including Hex3HexNAc4 (1339), Hex3HexNAc4 (1339), and/or Hex3HexNAc5 (1542) in CB and BM MSC as well as cells differentiated directly from them; additionally preferably including Hex4HexNAx5 (1704), Hex4HexNAc5dHex (1850), and/or Hex4HexNAc5dHex2 (1996) in hESC and cells differentiated directly from them; additionally preferably including Hex5HexNAc5 (1866) and/or Hex5HexNAc5dHex (2012) in EB and st.3 differentiated cells (from hESC), as well as adipocyte and osteoblast differentiated cells (from CB MSC and BM MSC, respectively).

Acidic Hybrid-Type or Monoantennary N-glycans

The present invention is especially directed to glycan compositions (structures) and analysis of acidic hybrid-type or monoantennary N-glycans according to the formula:

NeuAc_n1NeuGc_n2Hex_n3HexNAc_n4dHex_n5SP_n6,

wherein n1 and n2 are either independently 1, 2, or 3; n3 is an integer between 3-9; n4 is 3; n5 is an integer between 0-3; and n6 is an integer between 0-2; with the proviso that the sum n1+n2+n6 is at least 1.

Within the total N-glycomes of stem cells the major acidic hybrid-type or monoantennary N-glycan signals preferentially include glycan compositions wherein 3≦n3≦6, more preferentially 3≦n5≦5, and further more preferentially compositions NeuAcHex4HexNAc3dHex (1711), preferentially also NeuAcHex5HexNAc3dHex (1873).

Acidic Complex-Type N-glycans

The present invention is especially directed to glycan compositions (structures) and analysis of acidic complex-type N-glycans according to the formula:

NeuAc_n1NeuGc_n2Hex_n3HexNAc_n4dHex_n5SP_n6,

wherein n1 and n2 are either independently 1, 2, 3, or 4; n3 is an integer between 3-10; n4 is an integer between 4-9; n5 is an integer between 0-5; and n6 is an integer between 0-2; with the proviso that the sum n1+n2+n6 is at least 1.

Within the total N-glycomes of stem cells the major acidic complex-type N-glycan signals preferentially include glycan compositions wherein 4≦n4≦8, more preferentially 4≦n4≦6, more preferentially 4≦n4≦5, and further more preferentially compositions NeuAcHex5HexNAc4 (1930), NeuAcHex5HexNAc4dHex (2076), NeuAc2Hex5HexNAc4 (2221), NeuAcHex5HexNAc4Hex2 (2222), and NeuAc2Hex5HexNAc4dHex (2367); further more preferentially also NeuAc2Hex6HexNAc5dHex (2732), and more preferentially also NeuAcHex5HexNAc5dHex (2279);

and in BM and CB MSC as well as cells directly differentiated from them, further more preferentially also NeuAc2Hex6HexNAc5 (2586) and more preferentially also NeuAc2Hex7HexNAc6 (2952).

Modified Glycan Types

The inventors found that stem cell total N-glycomes; and soluble+N-glycomes further contain characteristic modified glycan signals, including sialylated fucosylated N-glycans, multifucosylated glycans, sialylated N-glycans with terminal HexNAc (the N>H and N═H subclasses), and sulphated or phosphorylated N-glycans, which are subclasses of the abovementioned glycan classes. According to the present invention, their quantitative proportions in different stem cell types have characteristic values as described in Table 33.

Phosphorylated and Sulphated Glycans

Specifically, major phosphorylated glycans typical to stem cells include Hex5HexNAc2(HPO₃) (1313), Hex6HexNAc2(HPO₃) (1475), and Hex7HexNAc2(HPO₃) (1637);

and major sulphated glycans typical to stem cells include Hex5HexNAc4dHex(SO₃) (1865) and more preferentially also Hex6HexNAc3(SO₃) (1678).

According to the present invention, their quantitative proportions in different stem cell types preferentially have characteristic values as described in Table 33.

Preferred Binders for Stem Cell Sorting and Isolation

As described in the Examples, the inventors found that especially the mannose-specific and especially α1,3-linked mannose-binding lectin GNA was suitable for negative selection enrichment of CD34+ stem cells from CB MNC. In addition, the poly-LacNAc specific lectin STA and the fucose-specific and especially α1,2-linked fucose-specific lectin UEA were suitable for positive selection enrichment of CD34+ stem cells from CB MNC.

The present invention is specifically directed to stem cell binding reagents, preferentially proteins, preferentially mannose-binding or α1,3-linked mannose-binding, poly-LacNAc binding, LacNAc-binding, and/or fucose- or preferentially α1,2-linked fucose-binding; in a preferred embodiment stem cell binding or nonbinding lectins, more preferentially GNA, STA, and/or UEA; and in a further preferred embodiment combinations thereof; to uses described in the present invention taking advantage of glycan-binding reagents that selectively either bind to or do not bind to stem cells.

Preferred Uses for Stem Cell Type Specific Galectins and/or Galectin Ligands

Examples
Example 1
MALDI-TOF Mass Spectrometric N-glycan Profiling, Glycosidase and Lectin Profiling of Cord Blood Derived and Bone Marrow Derived Mesenchymal Stem Cell Lines

Examples of Cell Sample Production

Cord Blood Derived Mesenchymal Stem Cell Lines

Collection of umbilical cord blood. Human term umbilical cord blood (UCB) units were collected after delivery with informed consent of the mothers and the UCB was processed within 24 hours of the collection. The mononuclear cells (MNCs) were isolated from each UCB unit diluting the UCB 1:1 with phosphate-buffered saline (PBS) followed by Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden) density gradient centrifugation (400 g/40 min). The mononuclear cell fragment was collected from the gradient and washed twice with PBS.

Umbilical cord blood cell isolation and culture. CD45/Glycophorin A (GlyA) negative cell selection was performed using immunolabeled magnetic beads (Miltenyi Biotec). MNCs were incubated simultaneously with both CD45 and GlyA magnetic microbeads for 30 minutes and negatively selected using LD columns following the manufacturer's instructions (Miltenyi Biotec). Both CD45/GlyA negative elution fraction and positive fraction were collected, suspended in culture media and counted. CD45/GlyA positive cells were plated on fibronectin (FN) coated six-well plates at the density of 1×10⁶/cm². CD45/GlyA negative cells were plated on FN coated 96-well plates (Nunc) about 1×10⁴cells/well. Most of the non-adherent cells were removed as the medium was replaced next day. The rest of the non-adherent cells were removed during subsequent twice weekly medium replacements.

The cells were initially cultured in media consisting of 56% DMEM low glucose (DMEM-LG, Gibco, http://www.invitrogen.com) 40% MCDB-201 (Sigma-Aldrich) 2% fetal calf serum (FCS), 1×penicillin-streptomycin (both form Gibco), 1×ITS liquid media supplement (insulin-transferrin-selenium), 1×linoleic acid-BSA, 5×10⁻⁸M dexamethasone, 0.1 mM L-ascorbic acid-2-phosphate (all three from Sigma-Aldrich), 10 nM PDGF (R&D systems, http://www.RnDSystems.com) and 10 nM EGF (Sigma-Aldrich). In later passages (after passage 7) the cells were also cultured in the same proliferation medium except the FCS concentration was increased to 10%.

Plates were screened for colonies and when the cells in the colonies were 80-90% confluent the cells were subcultured. At the first passages when the cell number was still low the cells were detached with minimal amount of trypsin/EDTA (0.25%/1 mM, Gibco) at room temperature and trypsin was inhibited with FCS. Cells were flushed with serum free culture medium and suspended in normal culture medium adjusting the serum concentration to 2 %. The cells were plated about 2000-3000/cm². In later passages the cells were detached with trypsin/EDTA from defined area at defined time points, counted with hematocytometer and replated at density of 2000-3000 cells/cm².

Bone Marrow Derived Mesenchymal Stem Cell Lines

Isolation and culture of bone marrow derived stem cells. Bone marrow (BM)-derived MSCs were obtained as described by Leskelä et al. (2003). Briefly, bone marrow obtained during orthopedic surgery was cultured in Minimum Essential Alpha-Medium (α-MEM), supplemented with 20 mM HEPES, 10% FCS, 1×penicillin-streptomycin and 2 mM L-glutamine (all from Gibco). After a cell attachment period of 2 days the cells were washed with Ca²⁺ and Mg²⁺ free PBS (Gibco), subcultured further by plating the cells at a density of 2000-3000 cells/cm2 in the same media and removing half of the media and replacing it with fresh media twice a week until near confluence.

Experimental Procedures

Flow cytometric analysis of mesenchymal stem cell phenotype. Both UBC and BM derived mesenchymal stem cells were phenotyped by flow cytometry (FACSCalibur, Becton Dickinson). Fluorescein isothicyanate (FITC) or phycoerythrin (PE) conjugated antibodies against CD13, CD14, CD29, CD34, CD44, CD45, CD49e, CD73 and HLA-ABC (all from BD Biosciences, San Jose, Calif., http://www.bdbiosciences.com), CD105 (Abeam Ltd., Cambridge, UK, http://www.abcam.com) and CD133 (Miltenyi Biotec) were used for direct labeling. Appropriate FITC- and PE-conjugated isotypic controls (BD Biosciences) were used. Unconjugated antibodies against CD90 and HLA-DR (both from BD Biosciences) were used for indirect labeling. For indirect labeling FITC-conjugated goat anti-mouse IgG antibody (Sigma-aldrich) was used as a secondary antibody.

The UBC derived cells were negative for the hematopoietic markers CD34, CD45, CD14 and CD133. The cells stained positively for the CD13 (aminopeptidase N), CD29 (β1-integrin), CD44 (hyaluronate receptor), CD73 (SH3), CD90 (Thy1), CD105 (SH2/endoglin) and CD 49e. The cells stained also positively for HLA-ABC but were negative for HLA-DR. BM-derived cells showed to have similar phenotype. They were negative for CD14, CD34, CD45 and HLA-DR and positive for CD13, CD29, CD44, CD90, CD105 and HLA-ABC.

Adipogenic differentiation. To assess the adipogenic potential of the UCB-derived MSCs the cells were seeded at the density of 3×10³/cm²in 24-well plates (Nunc) in three replicate wells. UCB-derived MSCs were cultured for five weeks in adipogenic inducing medium which consisted of DMEM low glucose, 2% FCS (both from Gibco), 10 μg/ml insulin, 0.1 mM indomethacin, 0.1 μM dexamethasone (Sigma-Aldrich) and penicillin-streptomycin (Gibco) before samples were prepared for glycome analysis. The medium was changed twice a week during differentiation culture.

Osteogenic differentiation. To induce the osteogenic differentiation of the BM-derived MSCs the cells were seeded in their normal proliferation medium at a density of 3×10³/cm²on 24-well plates (Nunc). The next day the medium was changed to osteogenic induction medium which consisted of α-MEM (Gibco) supplemented with 10% FBS (Gibco), 0.1 μM dexamethasone, 10 mM β-glycerophosphate, 0.05 mM L-ascorbic acid-2-phosphate (Sigma-Aldrich) and penicillin-streptomycin (Gibco). BM-derived MSCs were cultured for three weeks changing the medium twice a week before preparing samples for glycome analysis.

Cell harvesting for glycome analysis. 1 ml of cell culture medium was saved for glycome analysis and the rest of the medium removed by aspiration. Cell culture plates were washed with PBS buffer pH 7.2. PBS was aspirated and cells scraped and collected with 5 ml of PBS (repeated two times). At this point small cell fraction (10 μl) was taken for cell-counting and the rest of the sample centrifuged for 5 minutes at 400 g. The supernatant was aspirated and the pellet washed in PBS for an additional 2 times.

The cells were collected with 1.5 ml of PBS, transferred from 50 ml tube into 1.5 ml collection tube and centrifuged for 7 minutes at 5400 rpm. The supernatant was aspirated and washing repeated one more time. Cell pellet was stored at −70° C. and used for glycome analysis.

Lectin stainings. FITC-labeled Maackia amurensis agglutinin (MAA) was purchased from EY Laboratories (USA) and FITC-labeled Sambucus nigra agglutinin (SNA) was purchased from Vector Laboratories (UK). Bone marrow derived mesenchymal stem cell lines were cultured as described above. After culturing, cells were rinsed 5 times with PBS (10 mM sodium phosphate, pH 7.2, 140 mM NaCl) and fixed with 4% PBS-buffered paraformaldehyde pH 7.2 at room temperature (RT) for 10 minutes. After fixation, cells were washed 3 times with PBS and non-specific binding sites were blocked with 3% HSA-PBS (FRC Blood Service, Finland) or 3% BSA-PBS (>99% pure BSA, Sigma) for 30 minutes at RT. According to manufacturers' instructions cells were washed twice with PBS, TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM CaCl₂) or HEPES-buffer (10 mM HEPES, pH 7.5, 150 mM NaCl) before lectin incubation. FITC-labeled lectins were diluted in 1% HSA or 1% BSA in buffer and incubated with the cells for 60 minutes at RT in the dark. Furthermore, cells were washed 3 times 10 minutes with PBS/TBS/HEPES and mounted in Vectashield mounting medium containing DAPI-stain (Vector laboratories, UK). Lectin stainings were observed with Zeiss Axioskop 2 plus-fluorescence microscope (Carl Zeiss Vision GmbH, Germany) with FITC and DAPI filters. Images were taken with Zeiss AxioCam MRc-camera and with AxioVision Software 3.1/4.0 (Carl Zeiss) with the 400× magnification.

Results

Glycan isolation from mesenchymal stem cell populations. The present results are produced from two cord blood derived mesenchymal stem cell lines and cells induced to differentiate into adipogenic direction, and two marrow derived mesenchymal stem cell lines and cells induced to differentiate into osteogenic direction. The caharacterization of the cell lines and differentiated cells derived from them are described above. N-glycans were isolated from the samples, and glycan profiles were generated from MALDI-TOF mass spectrometry data of isolated neutral and sialylated N-glycan fractions as described in the preceding examples.

Cord Blood Derived Mesenchymal Stem cell (CB MSC) Lines

Neutral N-glycan structural features. Neutral N-glycan groupings proposed for the two CB MSC lines resemble each other closely, indicating that there are no major differences in their neutral N-glycan structural features. However, CB MSCs differ from the CB mononuclear cell populations, and they have for example relatively high amounts of neutral complex-type N-glycans, as well as hybrid-type or monoantennary neutral N-glycans, compared to other structural groups in the profiles.

Identification of soluble glycan components. Similarly to CB mononuclear cell populations, in the present analysis neutral glycan components were identified in all the cell types that were assigned as soluble glycans based on their proposed monosaccharide compositions including components from the glycan group Hex_2-12HexNAc₁(see Figures). The abundancies of these glycan components in relation to each other and in relation to the other glycan signals vary between individual samples and cell types.

Sialylated N-glycan profiles. Sialylated N-glycan profiles obtained from two CB MSC lines resemble closely each other with respect to their overall sialylated N-glycan profiles. However, minor differences between the profiles are observed, and some glycan signals can only be observed in one cell line, indicating that the two cell lines have glycan structures that differ them from each other. The analysis revealed in each cell type the relative proportions of about 50-70 glycan signals that were assigned as acidic N-glycan components. Typically, significant differences in the glycan profiles between cell populations are consistent throughout multiple experiments.

Differentiation-associated changes in glycan profiles. Neutral N-glycan profiles of CB MSCs change upon differentation in adipogenic cell culture medium. The present results indicate that relative abundancies of several individual glycan signals as well as glycan signal groups change due to cell culture in differentiation medium. The major change in glycan structural groups associated with differentation is increase in amounts of neutral complex-type N-glycans, such as signals at m/z 1663 and m/z 1809, corresponding to the Hex₅HexNAc₄and Hex₅HexNAc₄dHex₁monosaccharide compositions, respectively. Changes were also observed in sialylated glycan profiles.

Glycosidase analyses of neutral N-glycans. Specific exoglycosidase digestions were performed on isolated neutral N-glycan fractions from CB MSC lines as described in Examples. The results of α-mannosidase analysis show in detail which of the neutral N-glycan signals in the neutral N-glycan profiles of CB MSC lines are susceptible to α-mannosidase digestion, indicating for the presence of non-reducing terminal α-mannose residues in the corresponding glycan structures. As an example, the major neutral N-glycan signals at m/z 1257, 1419, 1581, 1743, and 1905, which were preliminarily assigned as high-mannose type N-glycans according to their proposed monosaccharide compositions Hex_5-9HexNAc₂, were shown to contain terminal α-mannose residues thus confirming the preliminary assignment. The results indicate for the presence of non-reducing terminal β1,4-galactose residues in the corresponding glycan structures. As an example, the major neutral complex-type N-glycan signals at m/z 1663 and m/z 1809 were shown to contain terminal β1,4linked galactose residues.

Bone Marrow Derived Mesenchymal Stem Cell (BM MSC) Lines

Neutral N-glycan profiles and differentiation-associated changes in glycan profiles. Neutral N-glycan profiles obtained from a BM MSC line, grown in proliferation medium and in osteogenic medium resemble CB MSC lines with respect to their overall neutral N-glycan profiles. However, differences between cell lines derived from the two sources are observed, and some glycan signals can only be observed in one cell line, indicating that the cell lines have glycan structures that differ them from each other. The major characteristic structural feature of BM MSCs is even more abundant neutral complex-type N-glycans compared to CB MSC lines. Similarly to CB MSCs, these glycans were also the major increased glycan signal group upon differentiation of BM MSCs. The analysis revealed in each cell type the relative proportions of about 50-70 glycan signals that were assigned as non-sialylated N-glycan components. Typically, significant differences in the glycan profiles between cell populations are consistent throughout multiple experiments.

Sialylated N-glycan profiles. Sialylated N-glycan profiles obtained from a BM MSC line, grown in proliferation medium and in osteogenic medium. The undifferentiated and differentiated cells resemble closely each other with respect to their overall sialylated N-glycan profiles. However, minor differences between the profiles are observed, and some glycan signals can only be observed in one cell line, indicating that the two cell types have glycan structures that differ them from each other. The analysis revealed in each cell type the relative proportions of about 50 glycan signals that were assigned as acidic N-glycan components. Typically, significant differences in the glycan profiles between cell populations are consistent throughout multiple experiments.

Sialidase analysis. The sialylated N-glycan fraction isolated from BM MSCs was digested with broad-range sialidase as described in the preceding Examples. After the reaction, it was observed by MALDI-TOF mass spectrometry that the vast majority of the sialylated N-glycans were desialylated and transformed into corresponding neutral N-glycans, indicating that they had contained sialic acid residues (NeuAc and/or NeuGc) as suggested by the proposed mono saccharide compositions. Glycan profiles of combined neutral and desialylated (originally sialylated) N-glycan fractions of BM MSCs grown in proliferation medium and in osteogenic medium correspond to total N-glycan profiles isolated from the cell samples (in desialylated form). It is calculated that in undifferentiated BM MSCs (grown in osteogenic medium), approximately 53% of the N-glycan signals correspond to high-mannosc type N-glycan monosaccharide compositions, 8% to low-mannose type N-glycans, 31% to complex-type N-glycans, and 7% to hybrid-type or monoantennary N-glycan monosaccharide compositions. In differentiated BM MSCs (grown in osteogenic medium), approximately 28% of the N-glycan signals correspond to high-mannose type N-glycan monosaccharide compositions, 9% to low-mannose type N-glycans, 50% to complex-type N-glycans, and 11% to hybrid-type or monoantennary N-glycan monosaccharide compositions.

Lectin binding analysis of mesenchymal stem cells. As described under Experimental procedures, bone marrow derived mesenchymal stem cells were analyzed for the presence of ligands of α2,3-linked sialic acid specific (MAA) and α2,6-linked sialic acid specific (SNA) lectins on their surface. It was revealed that MAA bound strongly to the cells whereas SNA bound weakly, indicating that in the cell culture conditions, the cells had significantly more α2,3-linked than α2,6-linked sialic acids on their surface glycoconjugates. The present results suggest that lectin staining can be used as a further means to distinguish different cell types and complements mass spectrometric profiling results.

Detection of Potential Glycan Contaminations from Cell Culture Reagents

In the sialylated N-glycan profiles of MSC lines, specific N-glycan signals were observed that indicated contamination of mesenchymal stem cell glycoconjugates by abnormal sialic acid residues. First, when the cells were cultured in cell culture media with added animal sera, such as bovine of equine sera, potential contamination by N-glycolylneuraminic acid (Neu5Gc) was detected. The glycan signals at m/z 1946, corresponding to the [M−H]⁻ ion of NeuGc₁Hex₅HexNAc₄, as well as m/z 2237 and m/z 2253, corresponding to the [M−H]⁻ ions of NeuGc₁NeuAc₁Hex₅HexNAc₄and NeuGc₂Hex₅HexNAc₄, respectively, were indicative of the presence of Neu5Gc, i.e. a sialic acid residue with 16 Da larger mass than N-acetylneuraminic acid (Neu5Ac). Moreover, when the cells were cultured in cell culture media with added horse serum, potential contamination by O-acetylated sialic acids was detected. Diagnostic signals used for detection of O-acetylated sialic acid containing sialylated N-glycans included [M−H]⁻ ions of Ac₁NeuAc₁Hex₅HexNAc₄, Ac₁NeuAc₂Hex₅HexNAc₄, and Ac₂NeuAc₂Hex₅HexNAc₄, at calculated m/z 1972.7, 2263.8, and 2305.8, respectively.

Conclusions

Uses of the glycan profiling method. The results indicate that the present glycan profiling method can be used to differentiate CB MSC lines and BM MSC lines from each other, as well as from other cell types such as cord blood mononuclear cell populations. Differentation-induced changes as well as potential glycan contaminations from e.g. cell culture media can also be detected in the glycan profiles, indicating that changes in cell status can be detected by the present method. The method can also be used to detect MSC-specific glycosylation features including those discussed below.

Differences in glycosylation between cultured cells and native human cells. The present results indicate that BM MSC lines have more high-mannose type N-glycans and less low-mannose type N-glycans compared to the other N-glycan structural groups than mononuclear cells isolated from cord blood. Taken together with the results obtained from cultured human embryonal stem cells in the following Examples, it is indicated that this is a general tendency of cultured stem cells compared to native isolated stem cells. However, differentiation of BM MSCs in osteogenic medium results in significantly increased amounts of complex-type N-glycans and reduction in the amounts of high-mannose type N-glycans.

Mesenchymal stem cell line specific glycosylation features. The present results indicate that mesenchymal stem cell lines differ from the other cell types studied in the present study with regard to specific features of their glycosylation, such as:

- 1) Both CB MSC lines and BM MSC lines have unique neutral and sialylated N-glycan profiles;
- 2) The major characteristic structural feature of both CB and BM MSC lines is abundant neutral complex-type N-glycans;
- 3) An additional characteristic feature is low sialylation level of complex-type N-glycans.

Example 2
MALDI-TOF Mass Spectrometric N-glycan Profiling of Human Embryonic Stem Cell Lines

Examples of Cell Material Production

Human Embryonic Stem Cell Lines (hESC)

Undifferentiated hESC. Processes for generation of hESC lines from blastocyst stage in vitro fertilized excess human embryos have been described previously (e.g. Thomson et al., 1998). Two of the analysed cell lines in the present work were initially derived and cultured on mouse embryonic fibroblasts feeders (MEF; 12-13 pc fetuses of the ICR strain), and two on human foreskin fibroblast feeder cells (HFF; CRL-2429 ATCC, Mananas, USA). For the present studies all the lines were transferred on HFF feeder cells treated with mitomycin-C (1 μg/ml; Sigma-Aldrich) and cultured in serum-free medium (Knockout™ D-MEM; Gibco® Cell culture systems, Invitrogen, Paisley, UK) supplemented with 2 mM L-Glutamin/Penicillin streptomycin (Sigma-Aldrich), 20% Knockout Serum Replacement (Gibco), 1×non-essential amino acids (Gibco), 0.1 mM β-mercaptoethanol (Gibco), 1×ITSF (Sigma-Aldrich) and 4 ng/ml bFGF (Sigma/Invitrogen).

Stage 2 differentiated hESC (embryoid bodies). To induce the formation of embryoid bodies (EB) the hESC colonies were first allowed to grow for 10-14 days whereafer the colonies were cut in small pieces and transferred on non-adherent Petri dishes to form suspension cultures. The formed EBs were cultured in suspension for the next 10 days in standard culture medium (see above) without bFGF.

Stage 3 differentiated hESC. For further differentiation EBs were transferred onto gelatin-coated (Sigma-Aldrich) adherent culture dishes in media consisting of DMEM/F12 mixture (Gibco) supplemented with ITS, Fibronectin (Sigma), L-glutamine and antibiotics. The attached cells were cultured for 10 days whereafter they were harvested.

Sample preparation. The cells were collected mechanically, washed, and stored frozen prior to glycan analysis.

Results

Neutral N-glycan profiles—effect of differentiation status. Neutral N-glycan profiles obtained from a human embryonal stem cell (hESC) line, its embryoid body (EB) differentiated form, and its stage 3 (st.3) differentiated form. Although the cell types resemble each other with respect to the major neutral N-glycan signals, the neutral N-glycan profiles of the two differentiated cell forms differ significantly from the undifferentiated hESC profile. In fact, the farther differentiated the cell type is, the more its neutral N-glycan profile differs from the undifferentiated hESC profile. Multiple differences between the profiles are observed, and many glycan signals can only be observed in one or two out of three cell types, indicating that differentiation induces the appearance of new glycan types. The analysis revealed in each cell type the relative proportions of about 40-55 glycan signals that were assigned as non-sialylated N-glycan components. Typically, significant differences in the glycan profiles between cell populations arc consistent throughout multiple experiments.

Neutral N-glycan profiles—comparison of hESC lines. Neutral N-glycan profiles obtained from four hESC lines closely resemble each other. Individual profile characteristics and cell line specific glycan signals are present in the glycan profiles, but it is concluded that hESC lines resemble more each other with respect to their neutral N-glycan profiles and are different from differentiated EB and st.3 cell types. hESC lines 3 and 4 are derived from sibling embryos, and their neutral N-glycan profiles resemble more each other and are different from the two other cell lines, i.e. they contain common glycan signals. The analysis revealed in each cell type the relative proportions of about 40-55 glycan signals that were assigned as non-sialylated N-glycan components. Typically, significant differences in the glycan profiles between cell populations are consistent throughout multiple experiments.

Neutral N-glycan structural features. Neutral N-glycan groupings proposed for analysed cell types are presented in Table 7. Again, the analysed three major cell types, namely undifferentiated hESCs, differentiated cells, and human fibroblast feeder cells, differ from each other significantly. Within each cell type, however, there are minor differences between individual cell lines. Moreover, differentiation-associated neutral N-glycan structural features are expressed more strongly in st.3 differentiated cells than in EB cells. Cell-type specific glycosylation features are discussed below in Conclusions.

Glycosidase analysis of neutral N-glycan fractions. Specific exoglycosidase digestions were performed on isolated neutral N-glycan fractions from hESC lines as described in the preceding Examples. In α-mannosidase analysis, several neutral glycan signals were shown to be susceptible to α-mannosidase digestion, indicating for potential presence of non-reducing terminal α-mannose residues in the corresponding glycan structures. In hESC and EB cells, these signals included m/z 917, 1079, 1095, 1241, 1257, 1378, 1393, 1403, 1444, 1555, 1540, 1565, 1581, 1606, 1622, 1688, 1743, 1768, 1905, 1996, 2041, 2067, 2158, and 2320. In β1,4-galactosidase analysis, several neutral glycan signals were shown to be susceptible to β1,4-galactosidase digestion, indicating for potential presence of non-reducing terminal β1,4-galactose residues in the corresponding glycan structures. In hESC and EB cells, these signals included m/z 609, 771, 892, 917, 1241, 1378, 1393, 1555, 1565, 1606, 1622, 1647, 1663, 1704, 1809, 1850, 1866, 1955, 1971, 1996, 2012, 2028, 2041, 2142, 2174, and 2320. In α1,3/4-fucosidase analysis, several neutral glycan signals were shown to be susceptible to α1,3/4-fucosidase digestion, indicating for potential presence of non-reducing terminal α1,3- and/or α1,4-fucose residues in the corresponding glycan structures. In hESC and EB cells, these signals included m/z 1120, 1590, 1784, 1793, 1955, 1996, 2101, 2117, 2142, 2158, 2190, 2215, 2247, 2263, 2304, 2320, 2393, and 2466.

Identification of soluble glycan components. Similarly to the cell types described in the preceding examples, in the present analysis neutral glycan components were identified in all the cell types that were assigned as soluble glycans based on their proposed monosaccharide compositions including components from the glycan group Hex_2-12HexNAc₁(see Figures). The abundancies of these glycan components in relation to each other and in relation to the other glycan signals vary between individual samples and cell types.

Sialylated N-glycan profiles—effect of differentiation status. Sialylated N-glycan profiles obtained from a human embryonal stem cell (hESC) line, its embryoid body (EB) differentiated form, and its stage 3 (st.3) differentiated form. Although the cell types resemble each other with respect to the major sialylated N-glycan signals, the sialylated N-glycan profiles of the two differentiated cell forms differ significantly from the undifferentiated hESC profile. In fact, the farther differentiated the cell type is, the more its sialylated N-glycan profile differs from the undifferentiated hESC profile. Multiple differences between the profiles are observed, and many glycan signals can only be observed in one or two out of three cell types, indicating that differentiation induces the appearance of new glycan types as well as decrease in amounts of stem cell specific glycan types. For example, there is significant differentation-associated deercase in relative amounts of glycan signals at m/z 1946 and 2222, corresponding to monosaccharide compositions NeuGc₁Hex₅HexNAc₄and NeuAc₁Hex₅HexNAc₄dHex₂, respectively. The analysis revealed in each cell type the relative proportions of about 50-70 glycan signals that were assigned as acidic N-glycan components. Typically, significant differences in the glycan profiles between cell populations are consistent throughout multiple experiments.

Sialylated N-glycan profiles—comparison of hESC lines. Sialylated N-glycan profiles obtained from four hESC lines closely resemble each other. Individual profile characteristics and cell line specific glycan signals are present in the glycan profiles, but it is concluded that hESC lines resemble more each other with respect to their sialylated N-glycan profiles and are different from differentiated EB and st.3 cell types. The analysis revealed in each cell type the relative proportions of about 50-70 glycan signals that were assigned as acidic N-glycan components. Typically, significant differences in the glycan profiles between cell populations are consistent throughout multiple experiments.

Human fibroblast feeder cell lines. Sialylated N-glycan profiles obtained from human fibroblast feeder cell lines differ from hESC, EB, and st.3 differentiated cells, and that feeder cells grown separately and with hESC cells differ from each other.

Sialylated N-glycan structural features. Sialylated N-glycan groupings proposed for analysed cell types are presented in Table 8. Again, the analysed three major cell types, namely undifferentiated hESCs, differentiated cells, and human fibroblast feeder cells, differ from each other significantly. Within each cell type, however, there are minor differences between individual cell lines. Moreover, differentiation-associated sialylated N-glycan structural features are expressed more strongly in st.3 differentiated cells than in EB cells. Cell-type specific glycosylation features are discussed below in Conclusions.

Conclusions

Comparison of glycan profiles. Differences in the glycan profiles between cell types were consistent throughout multiple samples and experiments, indicating that the present method of glycan profiling and the differences in the present glycan profiles can be used to identify hESCs or cells differentiated therefrom, or other cells such as feeder cells, or to determine their purity, or to identify cell types present in a sample. The present method and the present results can also be used to identify cell-type specific glycan structural features or cell-type specific glycan profiles. The method proved especially useful in determination of differentiation stage, as demonstrated by comparing analysis results between hESC, EB, and st.3 differentiated cells. Furthermore, hESCs were shown to have unique glycosylation profiles, which can be differentiated from differentiated cell types as well as from other stem cell types such as MSCs, indicating that stem cells in general and also specific stem cell types can be identified by the present method. The present method could also detect glycan structures common to hESC lines derived from sibling embryos, indicating that related structural features can be identified in different cell lines or their similarity be estimated by the present method.

Comparison of neutral N-glycan structural features. Differences in glycosylation profiles between analyzed cell types were identified based on proposed structural features, which can be used to identify cell-type specific glycan structural features. Identified cell-type specific features of neutral N-glycan profiles are concluded below:

hESC lines:

- 1) Increased amounts of fucosylated neutral N-glycans, especially glycans with two or more deoxyhexose residues per chain, indicating increased expression of neutral N-glycans containing α1,2-, α1,3-, or α1,4-linked fucose residues; and
- 2) Increased amounts of larger neutral N-glycans.

EBs and st.3 differentiated cells (st.3 cells expressing the features more strongly):

- 1) Lower amounts of neutral N-glycans containing two or more deoxyhexose residues per chain, indicating reduced expression of neutral N-glycans containing α1,2-, α1,3-, or α1,4-linked fucose residues;
- 2) Increased amounts of hybrid-type, monoantennary, and complex-type neutral N-glycans.
- 3) Increased amounts of terminal HexNAc residues; and
- 4) Potentially increased amounts of bisecting GlcNAc structures.

Human fibroblast feeder cells:

- 1) Increased amounts of larger neutral N-glycans;
- 2) Lower amounts of neutral N-glycans containing two or more deoxyhexose residues per chain, indicating reduced expression of neutral N-glycans containing α1,2-, α1,3-, or α1,4-linked fucose residues;
- 3) Increased amounts of terminal HexNAc residues; and
- 4) Potentially no bisecting GlcNAc structures.

Comparison of sialylated N-glycan structural features. Differences in glycosylation profiles between analyzed cell types were identified based on proposed structural features, which can be used to identify cell-type specific glycan structural features. Identified cell-type specific features of sialylated N-glycan profiles are concluded below:

hESC lines:

- 1) Increased amounts of fucosylated sialylated N-glycans, especially glycans with two or more deoxyhexose residues per chain, indicating increased expression of sialylated N-glycans containing α1,2-, α1,3-, or α1,4-linked fucose residues;
- 2) Increased amounts of terminal HexNAc residues; and
- 3) Increased amounts of Neu5Gc containing sialylated N-glycans.

EBs and st.3 differentiated cells (st.3 cells expressing the features more strongly):

- 1) Lower amounts of sialylated N-glycans containing two or more deoxyhexose residues per chain, indicating reduced expression of sialylated N-glycans containing α1,2-, α1,3-, or α1,4-linked fucose residues;
- 2) Increased amounts of hybrid-type or monoantennary sialylated N-glycans; and
- 3) Potentially increased amounts of bisecting GlcNAc structures.

Human fibroblast feeder cells:

- 1) Increased amounts of larger sialylated N-glycans;
- 2) Lower amounts of terminal HexNAc residues; and
- 3) Potentially lower amounts of bisecting GlcNAc structures.

Example 3
Comparison of Human and Murine Fibroblast Feeder Cell N-glycan Profiles

Results

N-glycans were isolated, divided into sialylated and neutral fractions, and analysed by MALDI-TOF mass spectrometry as described in the preceding Examples. Comparison of sialylated N-glycan profiles of human fibroblast feeder cells and mouse fibroblast feeder cells. There are numerous differences in the glycan profiles and it is concluded that human and murine feeder cells differ from each other significantly with respect to their overall glycan profiles as well as many individual glycan signals. The major differences are 2092 and 2238, corresponding to the monosaccharide compositions NeuAc₁Hex₆HexNAc₄and NeuAc₁Hex₆HexNAc₄dHex₁, respectively. These signals correspond to the major sialylated N-glycans that human embryonal stem cells interact with on the cell surfaces of their feeder cells. The present results indicate that the glycan analysis method can be used to study species-specific differences in stem cell to feeder cell interactions.

Example 4
O-glycan Profiling of Human Stem Cells

Methods

Reductive β-elimination. The procedure has been described (Nyman et al., 1998). Briefly, glycoproteins were dissolved in 1 M NaBH₄in 0.1 M NaOH and incubated at 37° C. for two days. Borohydride was destroyed by repeated evaporation from mild acetic acid in methanol. The resulting glycan alditols were purified by solid-phase extraction methods as described above.

Non-reductive β-elimination. The procedure has been described (Huang et al., 2001). Briefly, glycoproteins were dissolved in ammonium carbonate in concentrated ammonia and incubated at 60° C. for two days. The reagents were removed by evaporation and glycosylamines by brief incubation and evaporation from mild aqueous acetic acid. The resulting reducing glycans were purified by solid-phase extraction methods as described above.

Mass spectrometry and data analysis were performed as described in the preceding Examples.

Results and Discussion

O-glycans in cord blood mononuclear cells. O-glycan fraction was isolated by reductive β-elimination from total glycoprotein fractions of cord blood mononuclear cells. The glycan alditols were divided into neutral and acidic fractions and analyzed by MALDI-TOF mass spectrometry as described above. The glycan signals in the present example include both N- and O-glycan alditol signals.

O-glycans in human embryonic stem cells. O-glycans were isolated by non-reductive β-elimination from total glycoprotein fractions of human embryonic stem cells (hESC) grown on mouse feeder cell layers. The glycans were divided into neutral and acidic fractions and analyzed by MALDI-TOF mass spectrometry as described above. The most abundant potential O-glycan signals were Hex₁HexNAc₂, Hex₂HexNAc₂, Hex₂HexNAc₂dHex₁, Hex₃HexNAc₃, Hex₃HexNAc₃dHex₁, NeuAc₂Hex₁HexNAc₁, NeuAc₁Hex₂HexNAc₂, NeuAc₁Hex₂HexNAc₂dHex₁, NeuAc₂Hex₂HexNAc₂, NeuAc₁Hex₃HexNAc₃, NeuAc₂Hex₂HexNAc₂dHex₁, NeuAc₁Hex₃HexNAc₃, Hex₃HexNAc₃SP, Hex₄HexNAc₄SP, and Hex₄HexNAc₄dHex₁SP, wherein SP corresponds to a charged group with a mass of sulphate or phosphate such as sulphate ester linked to an N-acetyllactosamine structure.

Example 5
Glycosaminoglycan Fragment Analyses from Human Stem Cells

N-glycan and soluble glycan fractions were prepared from human cord blood cell populations as described in the preceding Examples. In cord blood mononuclear cells as well as affinity-purified cord blood CD34+, CD34−, CD133−, and LIN+ cell populations, following glycan fragments were identified (approximate experimental m/z for [M−H]⁻ ions in parenthesis): R¹(816), R¹HexNAc₁(1019), R²(1058), R¹HexNAc₁HexA₁(1195), R²HexA₁(1234), R¹HexNAc₂HexA₁(1398), R²HexNAc₁HexA₁(1437), R¹HexNAc₂HexA₂(1574), R²HexNAc₁HexA₂(1613), R¹HexNAc₃HexA₂(1777), R²HexNAc₂HexA₂(1816), R²HexNAc₂HexA₃(1992), and R²HexNAc₃HexA₃(2195), wherein R¹is preferentially HexA₁Hex₂Pen₁R³, R²is preferentially HexA₁Hex₃Pen₁R⁴, R³is preferentially SO₃Ser₁or HPO₃Ser₁, R⁴is preferentially (SO₃)₂Ser₁, SO₃HPO₃Ser₁, or (HPO₃)₂Ser₁. The identified glycans are indicated as being glycosaminoglycan fragments present in stem cell and mononuclear cell populations in human cord blood.

Example 6
Lectin and Antibody Profiling of Human Embryonic Stem Cells

Experimental Procedures

Cell samples. Human embryonic stem cell (hESC) lines FES 22 and FES 30 (Family Federation of Finland) were propagated on mouse feeder cell (mEF) layers as described above.

FITC-labeled lectins. Fluorescein isotiocyanate (FITC) labeled lectins were purchased from several manufacturers: FITC-GNA, -HHA, -MAA, -PWA, -STA and -LTA were from EY Laboratories (USA); FITC-PSA and -UEA and biotin-labelled WFA were from Sigma (USA); and FITC-RCA, -PNA and -SNA were from Vector Laboratories (UK).

Fluorescence microscopy labeling experiments were conducted essentially as described in the preceding Examples. Biotin label was visualized by fluorescein-conjugated streptavidin.

Results

Table 22 shows the tested FITC-labelled lectins and antibodies, examples of their target saccharide sequences, and the graded lectin binding intensities as described in the Table legend, in fluorescence microscopy of fixed cells grown on microscopy slides. Multiple binding specificities for the used lectins are described in the art and in general the binding of a lectin in the present experiments means that the cells express specific ligands for the lectin on their surface, but does not exclude the presence of also other ligands that are recognized by the lectin. See Example 18 for specificities for GF antibodies.

α-linked mannose. Abundant labelling of mEF by Pisum sativum (PSA) lectins suggests that they express mannose, more specifically α-linked mannose residues on their surface glycoconjugates such as N-glycans. The results further suggest that the both hESC lines do not express these ligands at as high concentrations as mEF on their surface.

β-linked galactose. Abundant labelling of hESC by peanut lectin (PNA) and less intense labelling by Ricinus communis lectin I (RCA-I) suggests that hESC express β-linked non-reducing terminal galactose residues on their surface glycoconjugates such as N- and/or O-glycans. More specifically, RCA-I binding suggests that the cells contain high amounts of unsubstituted Galβ epitopes on their surface. PNA binding suggests for the presence of unsubstituted Galβ, and the absence of specific binding of PNA to mEF suggests that the binding epitopes for this lectin are less abundant in mEF.

Sialic acids. Specific labelling of hESC by both Maackia amurensis (MAA) and Sambucus nigra (SNA) lectins suggests that the cells express sialic acid residues on their surface glycoconjugates such as N- and/or O-glycans and/or glycolipids. More specifically, the specific MAA binding of hESC suggests that the cells contain high amounts of α2,3-linked sialic acid residues. In contrast, the results suggest that these epitopes are less abundant in mEF. SNA binding in both cell types suggests for the presence of also α2,6-linkages in the sialic acid residues on the cell surface.

Fucosylation. Labelling of the cells by Ulex europaeus (UEA) and less intense labelling by Lotus tetragonolobus (LTA) lectins suggests that the cells express fucose residues on their surface glycoconjugates such as N- and/or O-glycans and/or glycolipids. More specifically, the UEA binding suggests that the cells contain α-linked fucose residues including α1,2-linked fucose residues. LTA binding suggests for the presence of α-linked fucose residues including α1,3- or α1,4-linked fucose residues on the cell surface.

The specific antibody anti-Lex and anti-sLex antibody binding results indicate that the hESC samples contain Galβ4(Fucα3)GlcNAcβ and SAα3Galβ4(Fucα3)GlcNAcβ carbohydrate epitopes on their surface, respectively.

Taken together, in the present experiments the lectins PNA, MAA, and WFA as well as the antibodies anti-Lex and anti-sLex bound specifically to hESC but not to mEF. In contrast, the lectin PSA bound specifically to mEF but not to hESC. This suggests that the glycan epitopes that these reagents recognize have hESC or mEF specific expression patterns. On the other hand, other reagents in the tested reagent panel bound differentially to the two hESC lines FES 22 and FES 30, indicating cell line specific glycosylation of the hESC cell surfaces (Table 22).

Discussion

Venable, A., et al. (2005 BMC Dev. Biol.) have previously described lectin binding profiles of SSEA-4 enriched human embryonic stem cells (hESC) grown on mouse feeder cells. The lectins used were Lycopersicon esculentum (LEA, TL), RCA, Concanavalin A (ConA), WFA, PNA, SNA, Hippeastrum hybrid (HHA, HHL), Vicia villosa (VVA), UEA, Phaseolus vulganis (PHA-L and PHA-E), MAA, LTA (LTL), and Dolichos biflorus (DBA) lectins. In FACS and cytochemistry analysis, four lectins were found to have similar binding percentage as SSEA-4 (LEA, RCA, ConA, and WFA) and in addition two lectins also had high binding percentage (PNA and SNA). Two lectins did not bind to hESCs (DBA and LTA). Six lectins were found to partially bind to hESC (PHA-E, VVA, UEA, PHA-L, MAA, and HHA). The authors suggested that the differential lectin binding specificities can be used to distinguish hESC and differentiated hESC types based on carbohydrate presentation.

Venable et al. (2005) discuss some carbohydrate structures that they claim to have high expression on the surface of pluripotent SSEA-4 hESC (corresponding lectins according to Venable et al. in parenthesis): α-Man (ConA, HHA), Glc (ConA), Galβ3GalNAcβ (PNA), non-reducing terminal Gal (RCA), non-reducing terminal β-GalNAc (RCA), GalNAcβ4Gal (WFA), GlcNAc (LEA), and SAα6GalNAc (SNA). In addition, Venable et al. discuss some carbohydrate structures that they claim to have expression on surface of a proportion of pluripotent SSEA-4 hESC (corresponding lectins according to Venable et al. in parenthesis): Gal (PHA-L, PHA-E, MAA), GalNAc (VVA) and Fuc (UEA). However, based on the monosaccharide specificities oligosaccharide specifificities on the target cannot be known e.g. ConA is not easily assigned to any specific to Glc or Man-structure and our MAA has no specificity to Gal residues, but SAα3-strcutures; it is realized that large differencies exist between often numerous isolectins of a plant species and Venable did not disclose the exact lectins used. Technical problems avoiding exact interpretation is Background section.

In the present experiments, RCA binding was observed on both hESC line FES 22 and mEF, but not on FES 30. This suggests that RCA binding specificity in hESC varies from cell line to another. The present experiments also show other lectins to be expressed on only one out of the two hESC lines (Table 22), suggesting that there is individual variation in binding of some lectins.

Based on LTA not binding to hESC in their experiments, Venable et al. (2005) suggest that on hESC surface there are no non-modified fucose residues that are α-linked to GlcNAc. However, in the present experiments LTA as well as anti-Lex and anti-sLex monoclonal antibodies were found to bind to the hESC line FES 22. The present antibody binding results indicate that FucαGlcNAc epitopes, specifically Galβ4(Fucα3)GlcNAc sequences, are present on hESC surface.

Venable et al. (2005) describe that PNA recognizes in their hESC samples specifically Galβ3GalNAc structures, wherein the GalNAcresidue is β-linked. In the present experiments, PNA was used to recognize carbohydrate structures generally including β-linked galactose residues and without β-linkage requirement for the GalNAc residue.

Venable et al. (2005) describe that SNA recognizes in their hESC samples specifically SAα6GalNAc structures. In the present experiments, SNA was used to recognize α2,6-linked sialic acids in general and its ligands were also found on mEF.

Inhibition of MAA binding by 200 mM lactose in the experiments described by Venable et al. (2005) suggests non-specific binding of their MAA with respect to sialic acids. According to the present experiments, our MAA can recognize α2,3-linked sialic acid residues on hESC surface and differentiate between hESC and mEF.

Example 7
Lectin and Antibody Profiling of Human Mesenchymal Stem Cells

Experimental Procedures

Cell samples. Bone marrow derived human mesenchymal stem cell lines (MSC) were generated and cultured in proliferation medium as described above.

FITC-labeled lectins. Fluorescein isotiocyanate (FITC) labelled lectins were purchased from several manufacturers: FITC-GNA, -HHA, -MAA, -PWA, -STA and -LTA were from EY Laboratories (USA); FITC-PSA and -UEA were from Sigma (USA); and FITC-RCA, -PNA and -SNA were from Vector Laboratories (UK). Lectins were used in dilution of 5 μg/10⁵cells in 1% human serum albumin (HSA; FRC Blood Service, Finland) in phosphate buffered saline (PBS).

Flow cytometry. Flow cytometric analysis of lectin binding was used to study the cell surface carbohydrate expression of MSC. 90% confluent MSC layers on passages 9-11 were washed with PBS and harvested into single cell suspensions by 0.25% trypsin-1 mM EDTA solution (Gibco). Detached cells were centrifuged at 600 g for five minutes at room temperature. Cell pellet was washed twice with 1% HSA-PBS, centrifuged at 600 g and resuspended in 1% HSA-PBS. Cells were placed in conical tubes in aliquots of 70000-83000 cells each. Cell aliquots were incubated with one of the FITC labelled lectin for 20 minutes at room temperature. After incubation cells were washed with 1% HSA-PBS, centrifuged and resuspended in 1% HSA-PBS. Untreated cells were used as controls. Lectin binding was detected by flow cytometry (FACSCalibur, Becton Dickinson). Data analysis was made with Windows Multi Document Interface for Flow Cytometry (WinMDI 2.8). Two independent experiments were carried out.

Fluorescence microscopy labeling experiments were conducted as described in the preceding Examples.

Results and Discussion

Table 23 shows the tested FITC-labelled lectins, examples of their target saccharide sequences, and the amount of cells showing positive lectin binding (%) in FACS analysis after mild trypsin treatment. Table 24 shows the tested FITC-labelled lectins, examples of their target saccharide sequences, and the graded lectin binding intensities as described in the Table legend, in fluorescence microscopy of fixed cells grown on microscopy slides. Binding specificities of the used lectins are described in the art and in general the binding of a lectin in the present experiments means that the cells express specific ligands for the lectin on their surface. The examples of some of the specificities discussed below and those marked in the Tables are therefore non-exclusive in nature.

α-linked mannose. Abundant labelling of the cells by both Hippeastrum hybrid (HHA) and Pisum sativum (PSA) lectins suggests that they express mannose, more specifically α-linked mannose residues on their surface glycoconjugates such as N-glycans. Possible α-mannose linkages include α1→2, α1→3, and α1→6. The lower binding of Galanthus nivalis (GNA) lectin suggests that some α-mannose linkages on the cell surface are more prevalent than others.

β-linked galactose. Abundant labelling of the cells by Ricinus communis lectin I (RCA-I) and less intense labelling by peanut lectin (PNA) suggests that the cells express β-linked non-reducing terminal galactose residues on their surface glycoconjugates such as N- and/or O-glycans. More specifically, the intense RCA-I binding suggests that the cells contain high amounts of unsubstituted Galβ epitopes on their surface. The binding of RCA-I was increased by sialidase treatment of the cells before lectin binding, indicating that the ligands of RCA-I on MSC were originally partly covered by sialic acid residues. PNA binding suggests for the presence of another type of unsubstituted Galβ epitopes such as Core 1 O-glycan epitopes on the cell surface. The binding of PNA was also increased by sialidase treatment of the cells before lectin binding, indicating that the ligands of PNA on MSC were originally mostly covered by sialic acid residues. These results suggest that both RCA-I and PNA can be used to assess the amount of their specific ligands on the cell surface of BM MSC, and with or without conjunction with sialidase treatment to assess the sialylation level of their specific epitopes.

Sialic acids. Abundant labelling of the cells by Maackia amurensis (MAA) and less intense labelling by Sambucus nigra (SNA) lectins suggests that the cells express sialic acid residues on their surface glycoconjugates such as N- and/or O-glycans and/or glycolipids. More specifically, the intense MAA binding suggests that the cells contain high amounts of α2,3-linked sialic acid residues on their surface. SNA binding suggests for the presence of also α2,6-linked sialic acid residues on the cell surface, however in lower amounts than α2,3-linked sialic acids. Both of these lectin binding activities could be reduced by sialidase treatment, indicating that the specificities of the lectins in BM MSC are mostly targeted to sialic acids.

Poly-N-acetyllactosamine sequences. Labelling of the cells by Solanum tuberosum (STA) and less intense labelling by pokeweed (PWA) lectins suggests that the cells express poly-N-acetyllactosamine sequences on their surface glycoconjugates such as N- and/or O-glycans and/or glycolipids. Higher intensity labelling with STA than with PWA suggests that most of the cell surface poly-N-acetyllactosamine sequences are linear and not branched or substituted chains.

Fucosylation. Labelling of the cells by Ulex europaeus (UEA) and less intense labelling by Lotus tetragonolobus (LTA) lectins suggests that the cells express fucose residues on their surface glycoconjugates such as N- and/or O-glycans and/or glycolipids. More specifically, the UEA binding suggests that the cells contain α-linked fucose residues, including α1,2-linked fucose residues, on their surface. LTA binding suggests for the presence of also α-linked fucose residues, including α1,3-linked fucose residues on the cell surface, however in lower amounts than UEA ligand fucose residues.

Mannose-binding lectin labelling. Low labelling intensity was also detected with human serum mannose-binding lectin (MBL) coupled to fluorescein label, suggesting that ligands for this innate immunity system component may be expressed on in vitro cultured BM MSC cell surface.

Binding of a NeuGc polymeric probe (Lectinity Ltd., Russia) to non-fixed hESC indicates the presence of NeuGc-specific lectin on the cell surfaces. In contrast, polymeric NeuAc probe did not bind to the cells with same intensity in the present experiments.

The binding of the specific antibodies to hESC indicates the presence of Lex and sialyl-Lewis x epitopes on their surfaces, and binding of NeuGc-specific antibody to hESC indicates the presence of NeuGc epitopes on their surfaces.

Example 8
Lectin and Antibody Profiling of Human Cord Blood Cell Populations

Results and Discussion

FIG. 1 shows the results of FACS analysis of FITC-labelled lectin binding to seven individual cord blood mononuclear cell (CB MNC) preparations (experiments performed as described above). Strong binding was observed in all samples by GNA, HHA, PSA, MAA, STA, and UEA FITC-labelled lectins, indicating the presence of their specific ligand structures on the CB MNC cell surfaces. Also mediocre binding (PWA), variable binding between CB samples (PNA), and low binding (LTA) was observed, indicating that the ligands for these lectins are either variable or more rare on the CB MNC cell surfaces as the lectins above.

Example 9
Analysis of Total N-glycomes of Human Stem Cells and Cell Populations

Experimental Procedures

Cell and glycan samples were prepared as described in the preceding Examples.

Relative proportions of neutral and acidic N-glycan fractions were studied by desialylating isolated acidic glycan fraction with A. ureafaciens sialidase as described in the preceding Examples and then combining the desialylated glycans with neutral glycans isolated from the same sample. Then the combined glycan fractions were analyzed by positive ion mode MALDI-TOF mass spectrometry as described in the preceding Examples. The proportion of sialylated N-glycans of the combined N-glycans was calculated by calculating the percentual decrease in the relative intensity of neutral N-glycans in the combined N-glycan fraction compared to the original neutral N-glycan fraction, according to the equation:

$proportion = \frac{I^{neutral} - I^{combined}}{I^{neutral}} \times 100 %,$

wherein I^neutraland I^combinedcorrespond to the sum of relative intensities of the five high-mannose type N-glycan [M+Na]⁺ ion signals at m/z 1257, 1419, 1581, 1743, and 1905 in the neutral and combined N-glycan fractions, respectively.

Results and Discussion

The relative proportions of acidic N-glycan fractions in studied stem cell types were as follows: in human embryonic stem cells (hESC) approximately 35% (proportion of sialylated and neutral N-glycans is approximately 1:2), in human bone marrow derived mesenchymal stem cells (BM MSC) approximately 19% (proportion of sialylated and neutral N-glycans is approximately 1:4), in osteoblast-differentiated BM MSC approximately 28% (proportion of sialylated and neutral N-glycans is approximately 1:3), and in human cord blood (CB) CD133+ cells approximately 38%

(proportion of sialylated and neutral N-glycans is approximately 2:3).

In conclusion, BM MSC differ from hESC and CB CD133+ cells in that they contain significantly lower amounts of sialylated N-glycans compared to neutral N-glycans. However, after osteoblast differentiation of the BM MSC the proportion of sialylated N-glycans increases.

Example 10
Analysis of the Human Embryonic Stem Cell N-glycome

Experimental Procedures

Human embryonic stem cell lines (hESC). Four Finnish hESC lines, FES 21, FES 22, FES 29, and FES 30, were used in the present study. Generation of the lines has been described (Skottman et al., 2005, and M. M., C. O., T. T., and T. O., manuscript submitted for publication). Two of the analysed cell lines in the present work were initially derived and cultured on mouse embryonic fibroblast feeders, and two on human foreskin fibroblast feeder cells. For the mass spectrometry studies all of the lines were transferred on HFF feeder cells treated with mitomycin-C (1 μg/ml, Sigma-Aldrich, USA) and cultured in serum-free medium (Knockout™ D-MEM; Gibco® Cell culture systems, Invitrogen, UK) supplemented with 2 mM L-Glutamin/Penicillin streptomycin (Sigma-Aldrich), 20% Knockout Serum Replacement (Gibco), 1×non-essential amino acids (Gibco), 0.1 mM β-mercaptoethanol (Gibco), 1×ITS (Sigma-Aldrich) and 4 ng/ml bFGF (Sigma/Invitrogen). To induce the formation of embryoid bodies (EB) the hESC colonies were first allowed to grow for 10-14 days whereafter the colonies were cut in small pieces and transferred on non-adherent Petri dishes to form suspension cultures. The formed EBs were cultured in suspension for the next 10 days in standard culture medium (see above) without bFGF. For further differentiation (into stage 3 differentiated cells) EBs were transferred onto gelatin-coated (Sigma-Aldrich) adherent culture dishes in media consisting of DMEM/F12 mixture (Gibco) supplemented with ITS, Fibronectin (Sigma), L-glutamine and antibiotics. The attached cells were cultured for 10 days whereafter they were harvested. For glycan analysis, the cells were collected mechanically, washed, and stored frozen until the analysis. In FACS analyses 70-90% of cells from mechanically isolated hESC colonies were typically Tra 1-60 and Tra 1-81 positive (not shown). Cells differentiated into embryoid bodies (EB) and further differentiated cells grown out of the EB as monolayers (stage 3 differentiated) were used for comparison against hESC. The differentiation protocol favors the development of neuroepithelial cells while not directing the differentiation into distinct terminally differentiated cell types (Okabe et al., 1996). Stage 3 cultures consisted of a heterogenous population of cells dominated by fibroblastoid and neuronal morphologies.

Glycan isolation. Asparagine-linked glycans were detached from cellular glycoproteins by F. meningosepticum N-glycosidase F digestion (Calbiochem, USA) essentially as described (Nyman et al., 1998). The detached glycans were divided into sialylated and non-sialylated fractions based on the negative charge of sialic acid residues. Cellular contaminations were removed by precipitating the glycans with 80-90% (v/v) aqueous acetone at −20° C. and extracting them with 60% (v/v) ice-cold methanol essentially as described previously (Verostek et al., 2000). The glycans were then passed in water through C₁₈silica resin (BondElut, Varian, USA) and adsorbed to porous graphitized carbon (Carbograph, Alltech, USA) based on previous method (Davies et al., 1993). The carbon column was washed with water, then the neutral glycans were eluted with 25% acetonitrile in water (v/v) and the sialylated glycans with 0.05% (v/v) trifluoroacetic acid in 25% acetonitrile in water (v/v). Both glycan fractions were additionally passed in water through strong cation-exchange resin (Bio-Rad, USA) and C₁₈silica resin (ZipTip, Millipore, USA). The sialylated glycans were further purified by adsorbing them to microcrystalline cellulose in n-butanol:ethanol:water (10:1:2, v/v), washing with the same solvent, and eluting by 50% ethanol:water (v/v). All the above steps were performed on miniaturized chromatography columns and small elution and handling volumes were used. The glycan analysis method was validated by subjecting human cell samples to analysis by five different persons. The results were highly comparable, especially by the terms of detection of individual glycan signals and their relative signal intensities, showing that the reliability of the present methods is suitable for comparing analysis results from different cell types.

Mass spectrometry and data analysis. MALDI-TOF mass spectrometry was performed with a Bruker Ultraflex TOF/TOF instrument (Bruker, Germany) essentially as described (Saarinen et al., 1999). Relative molar abundancies of both neutral and sialylated glycan components can be accurately assigned based on their relative signal intensities in the mass spectra (Naven and Harvey, 1996; Papac et al., 1996; Saarinen et al., 1999; Harvey, 1993). Each step of the mass spectrometric analysis methods were controlled for their reproducibility by mixtures of synthetic glycans or glycan mixtures extracted from human cells. The mass spectrometric raw data was transformed into the present glycan profiles by carefully removing the effect of isotopic pattern overlapping, multiple alkali metal adduct signals, products of elimination of water from the reducing oligosaccharides, and other interfering mass spectrometric signals not arising from the original glycans in the sample. The resulting glycan signals in the presented glycan profiles were normalized to 100% to allow comparison between samples. Quantitative difference between two glycan profiles (%) was calculated according to the equation:

$\begin{matrix} difference = \frac{1}{2} \sum_{i = 1}^{n} \langle p_{i, a} - p_{i, b} \rangle, & (2) \end{matrix}$

wherein p is the relative abundance (%) of glycan signal i in profile a or b, and n is the total number of glycan signals.

Glycosidase analysis. The neutral N-glycan fraction was subjected to digestion with Jack bean α-mannosidase (Canavalia ensiformis; Sigma, USA) essentially as described (Saarinen et al., 1999). The specificity of the enzyme was controlled with glycans isolated from human tissues as well as purified otigosaccharides.

NMR methods. For NMR analysis, larger amounts of hESC were grown on mouse feeder cell (MEF) layers. The purity of the collected hESC sample (about 70%), was lower than in the mass spectrometry samples grown on HFF. However, the same H_5-9N₂glycans were the major neutral N-glycan signals in both MEF and hESC. The isolated glycans were further purified for the analysis by gel filtration high-pressure liquid chromatography in a column of Superdex peptide HR 10/30 (Amersham), with water (neutral glycans) or 50 mM NH₄HCO₃(sialylated glycans) as the eluant at a flow rate of 1 ml/min. The eluant was monitored at 214 nm, and oligosaccharides were quantified against external standards. The amount of N-glycans in NMR analysis was below five nanomoles.

Statistical procedures. Glycan score distributions of all three differentiation stages (hESC, EB, and st.3) were analyzed by the Kruskal-Wallis test. Pairwise comparisons were performed by the 2-tailed Student's t-test with Welch's approximation and 2-tailed Mann-Whitney U test. A p value less than 0.05 was considered significant.

Lectin staining. Fluorescein-labeled lectins were from EY Laboratories (USA) and the stainings were performed essentially after manufacturer's instructions. The specificity of the staining was controlled in parallel experiments by inhibiting lectin binding with specific oligo- and monosaccharides.

Results

Mass Spectrometric Profiling of the hESC N-glycome

In order to generate glycan profiles of hESC, embryonic bodies, and further differentiated cells, a MALDI-TOF mass spectrometry based analysis was performed. We focused on the most common type of protein post-translational modifications, the asparagine-linked glycans (N-glycans), which were enzymatically released from cellular glycoproteins. During glycan isolation and purification, the total N-glycan pool was separated by an ion-exchange step into neutral N-glycans and sialylated N-glycans. These two glycan fractions were then analyzed separately by mass spectrometric profiling (FIG. 12), which yielded a global view of the N-glycan repertoire of the samples. The relative abundances of the observed glycan signals were determined based on their relative signal intensities (Naven and Harvey, 1996; Papac et al., 1996; Saarinen et al., 1999), which allowed quantitative comparison of glycome differences between samples. Over one hundred N-glycan signals were detected from each cell type.

The proposed monosaccharide compositions corresponding to the detected masses of each individual signal in FIG. 12 is indicated by letter code. However, it is important to realize that many of the mass spectrometric signals in the present analyses include multiple isomeric structures and the 100 most abundant signals very likely represent hundreds of different molecules. For example, the common hexoses (H) occurring in human N-glycans include D-mannose, D-galactose, and D-glucose (which all have a residue mass of 162.05 Da), and common N-acetylhexosamines (N) include both N-acetyl-D-glucosamine and N-acetyl-D-galactosamine (203.08 Da); deoxyhexoses (F) are typically L-fucose residues (146.06 Da).

In most of the previous glycomic studies of other mammalian tissues the isolated glycans have been derivatized (permethylated) prior to mass spectrometric profiling (Sutton-Smith et al., 2002; Dell and Morris, 2001; Consortium for Functional Glycomics, http://www.functionalglycomics.org) or chromatographic separation (Callewaert et al., 2004). However, in the present study we chose to directly analyze picomolar quantities of unmodified glycans and increased sensitivity was attained by omitting the derivatization and the subsequent additional purification steps. Further, instead of studying the glycan signals one at a time, we were able to simultaneously study all the glycans present in the unmodified glycomes by nuclear magnetic resonance spectroscopy (NMR) and specific glycosidase enzymes. The present data demonstrate that mass spectrometric profiling can be used in the quantitative analysis of total glycomes, especially to pin-point the major glycosylation differences between related samples.

Overview of the hESC N-glycome: Neutral N-glycans

Neutral N-glycans comprised approximately two thirds of the combined neutral and sialylated N-glycan pools. The 50 most abundant neutral N-glycan signals of the hESC lines are presented in FIG. 12a (grey columns). The similarity of the profiles, which is indicated by the minor variation in the glycan signals, suggest that the four cell lines closely resemble each other. For example, 15 of the 20 most abundant glycan signals were the same in every hESC line. The five most abundant signals comprised 76% of the neutral N-glycans of hESC and dominated the profile.

Sialylated N-glycans

All N-glycan signals in the sialylated N-glycan fraction (FIG. 12b, grey columns) contain sialic acid residues (S: N-acetyl-D-neuraminic acid, or G: N-glycolyl-D-neuraminic acid). The 50 most abundant sialylated N-glycans in the four hESC lines showed more variation between individual cell lines than the neutral N-glycans. However, the four cell lines again resembled each other. The group of five most abundant sialylated N-glycan signals was the same in every cell line: S₁H₅N₄F₁, S₁H₅N₄F₂, S₂H₅N₄F₁, S₁H₅N₄, and S₁H₆N₅F₁(for abbreviations see FIG. 12). The majority (61%, in eight signals) of the sialylated glycan signals contained the H₅N₄core composition and differed only by variable amounts of sialic acid (S or G) and deoxyhexose (F) residues. Similarly, another common core structure was H₆N₅(12%, in seven signals). This highlights the biosynthetic mechanisms leading to the total spectrum of N-glycan structures in cells: N-glycans typically consist of common core structures that are modified by the addition of variable epitopes.

Importantly, we were able to detect N-glycans containing N-glycolylneuraminic acid (G), for example glycans G₁H₅N₄, G₁S₁H₅N₄, and G₂H₅N₄, in the hESC samples. N-glycolylneuraminic acid has previously been reported in hESC as an antigen transferred from culture media containing animal-derived materials (Martin et al., 2005). Accordingly, the serum replacement medium used in the present experiments contained bovine serum proteins.

Variation Between Individual Cell Lines

Although the four hESC lines shared the same overall N-glycan profile, there was cell line specific variation within the profiles. Individual glycan signals unique to each cell line were detected, indicating that every cell line was slightly different from each other with respect to the approximately one hundred most abundant N-glycan structures they synthesized.

In general, the 30 most common N-glycan signals in cach hESC fine accounted for circa 85% of the total detected N-glycans, and represent a useful approximation of the hESC N-glycome. In other words, more than five out of six glycoprotein molecules isolated from any of the present hESC lines would carry such N-glycan structures.

Transformation of the N-Glycome During hESC Differentiation

A major goal of the present study was to identify glycan structures that would be specific to either stem cells or differentiated cells, and could therefore serve as differentiation stage markers. In order to determine whether the hESC N-glycome undergoes changes during differentiation, the N-glycan profiles obtained from hESC, EB, and stage 3 differentiated cells were compared (FIG. 12). The profiles of the differentiated cell types (EB and st.3) were significantly different from the profiles of undifferentiated hESC, indicated by non-overlapping distribution bars in many glycan signals. Further, there were many signals present in both hESC and EB that were not detected in stage 3 differentiated cells. Overall, 10% of the glycan signals present in hESC had disappeared in stage 3 differentiated cells. Simultaneously numerous new signals appeared in EB and stage 3 differentiated cells. Their proportion in EB and stage 3 differentiated cells was 14% and 16%, respectively. The glycan signals that were characteristic for hFSC were typically decreased in the EB and had further decreased or totally disappeared in stage 3 differentiated cells. However, among the most common one hundred glycan signals there were no hESC signals that would not have been expressed in EB, suggesting that the EB N-glycome is an intermediate between hESC and stage 3 differentiated cells.

Taken together, differentiation induced the appearance of new N-glycan types while earlier glycan types disappeared. Further, we found that the major hESC-specific N-glycosylation features were not expressed as discrete glycan signals, but instead as glycan signal groups that were characterized by a specific monosaccharide composition feature (see below). In other words, differentiation of hESC into EB induced the disappearance of not only one but multiple glycan signals with hESC-associated features, and simultaneously also the appearance of glycan signal groups with other features associated with the differentiated cell types.

The N-glycan profiles of the differentiated cells were also quantitatively different from the undifferentiated hESC profiles. A practical way of quantifying the differences between individual glycan profiles is to calculate the sum of the signal intensity differences between two cell profiles (see Methods). According to this method, the EB neutral and sialylated N-glycan profiles had undergone a quantitative change of 14% and 29% from the hESC profiles, respectively. Similarly, the stage 3 differentiated cell neutral and sialylated N-glycan profiles had changed by 15% and 43% from the hESC profiles, respectively. This indicates that upon differentiation of hESC into stage 3 differentiated cells, nearly half of the total sialylated N-glycans present in the cells were transformed into different molecular structures, while significantly smaller proportion of the neutral N-glycan molecules were changed during the differentiation process. Taking into account that the proportion of sialylated to neutral N-glycans in hESC was approximately 1:2, the total N-glycome change was approximately 25% during the transition from hESC to stage 3 differentiated cells. Again, the N-glycan profile of EB appeared to lie between hESC and stage 3 differentiated cells.

The data indicated that the hESC N-glycome consisted of two discrete parts regarding propensity to change during hESC differentiation—a constant part of circa 75% and a changing part of circa 25%. In order to characterize the associated N-glycan structures, and to identify the potential biological roles of the constant and changing parts of the N-glycome, we performed structural analyses of the isolated hESC N-glycan samples.

Structural Analyses of the Major hESC N-glycans: Preliminary Structure Assignment Based on Monosaccharide Compositions

Human N-glycans can be divided into the major biosynthetic groups of high-mannose type, hybrid-type, and complex-type N-glycans. To determine the presence of these N-glycan groups in hESC and their progeny, assignment of probable structures matching the monosaccharide compositions of each individual signal was performed utilizing the established pathways of human N-glycan biosynthesis (Kornfeld and Kornfeld, 1985; Schachter, 1991). Here, the detected N-glycan signals were classified into four N-glycan groups according to the number of N and H residues: 1) high-mannose type and 2) low-mannose type N-glycans, which are both characterized by two N residues (N=2), 3) hybrid-type or monoantennary N-glycans, which are classified by three N residues (N=3), and 4) complex-type N-glycans, which are characterized by four or more N residues (N4) in their proposed monosaccharide compositions. This is an approximation: for example, in addition to complex-type N-glycans also hybrid-type and monoantennary N-glycans may contain more than three N residues.

The data was analyzed quantitatively by calculating the percentage of glycan signals in the total N-glycome belonging to each structure group (Table 25, rows A-E and J-L). The quantitative changes in the structural groups reflect the relative activities of different biosynthetic pathways in each cell type. For example, the proportion of hybrid-type or monoantennary N-glycans was increased when hESC differentiated into EB. In general, the relative proportions of most glycan structure classes remained approximately constant through the hESC differentiation process, which indicated that both hESC and the differentiated cell types were capable of equally sophisticated N-glycosylation. The high proportion of N-glycans classified as low-mannose N-glycans in all the studied cell types was somewhat surprising in the light of earlier published studies of human N-glycosylation. However, previous studies had not explored the total N-glycan profiles of living cells. We have detected significant amounts of low-mannose N-glycans also in other human cells and tissues, and they are not specific to hESC (T. S., A. H., M. B., A. O., J. H., J. N, J. S. et al., unpublished results).

Verification of Structure Assignments by Enzymatic Degradation and Nuclear Magnetic Resonance Spectroscopy

In order to verify the validity of the glycan structure assignments made based on the detected mass and the probable monosaccharide compositions we performed enzymatic degradation and proton nuclear magnetic resonance spectroscopic analyses (¹H-NMR) of selected neutral and sialylated N-glycans.

For the validation of neutral N-glycans we chose glycans with 5-9 hexose (H) and two N-acetylhexosamine (N) residues in their monosaccharide compositions (H₅N₂, H₆N₂, H₇N₂, H₈N₂, and H₉N₂) which were the most abundant N-glycans in all studied cell types (FIG. 12a). The monosaccharide compositions suggested that these glycans were high-mannose type N-glycans (Kornfeld and Kornfeld, 1985). To test this hypothesis, neutral N-glycans from stem cell and differentiated cell samples were treated with α-mannosidase, and analyzed both before and after the enzymatic treatment (data not shown). The glycans in question were degraded and the corresponding signals disappeared from the mass spectra, indicating that they contained α-linked mannose residues.

The neutral N-glycan fraction was further analyzed by nanoscale proton nuclear magnetic resonance spectroscopic analysis (¹H-NMR). In the obtained ¹H-NMR spectrum of the hESC neutral N-glycans signals consistent with high-mannose type N-glycans were detected, supporting the conclusion that they were the major glycan components in the sample.

Both α-mannosidase and NMR experiments indicated that the H_5-9N₂glycan signals corresponded to high-mannose type N-glycans. From the data in FIG. 12a it could be estimated that they constituted half of all the detected glycoprotein N-glycans in hESC. This is in accordance with the established role of high-mannose type N-glycans in human cells (Helenius and Aebi, 2001, 2004). The presence of such constitutively expressed N-glycans also explained why the neutral N-glycan profiles did not change to the same extent as the sialylated N-glycan profiles during differentiation.

For the validation of structure assignments among the sialylated N-glycans we noted that the majority of the sialylated N-glycan signals isolated from hESC were characterized by the N≧4 monosaccharide composition (FIG. 12a), which suggested that they were complex-type N-glycans. In the ¹H-NMR analysis N-glycan backbone signals consistent with biantennary complex-type N-glycans were the major detected signals, in line with the assigment made based on the experimental monosaccharide compositions. The present results indicated that the classification of the glycan signals within the total N-glycome data could be used to construct an approximation of the whole N-glycome. However, such classification should not be applied to the analysis of single N-glycan signals.

Differentiation Stage Associated Structural Glycosylation Features

The glycan signal classification described above indicated changes in the core sequences of N-glycans. The present data also suggested that there were differences in variable epitopes added to the N-glycan core structures i.e. glycan features present in many individual glycan signals. In order to quantify such glycan structural features, the N-glycome data were further classified into glycan signal groups that share similar features in their proposed monosaccharide compositions (Table 25, rows F-I and M-P). As a result, the majority of the differentiation-associated glycan signals in the EB and stage 3 differentiated cell samples fell into different groups than the hESC specific glycans. Glycan signals with complex fucosylation (Table 25, row N) were associated with undifferentiated hESC, whereas glycan signals with potential terminal N-acetylhexosamine (Table 25, rows H and P) were associated with the differentiated cells.

Complex Fucosylation of N-glycans is Characteristic of hESC

Differentiation stage associated changes in the sialylated N-glycan profile were more drastic than in the neutral N-glycan fraction and the group of five most abundant sialylated N-glycan signals was different at every differentiation stage (FIG. 12b). In particular, there was a significant differentiation-associated decrease in the relative amounts of glycans S₁H₅N₄F₂and S₁H₅N₄F₃as well as other glycan signals that contained at least two deoxyhexose residues (F≧2) in their proposed monosaccharide compositions. In contrast, glycan signals such as S₂H₅N₄that contained no F were increased in the differentiated cell types. The results suggested that sialylated N-glycans in undifferentiated hESC were subject to more complex fucosylation than in the differentiated cell types (Table 25, row N).

The most common fucosylation type in human N-glycans is α1,6-fucosylation of the N-glycan core structure. The NMR analysis of the sialylated N-glycan fraction of hESC also revealed α1,6-fucosylation of the N-glycan core as the most abundant type of fucosylation. In the N-glycans containing more than one fucose residue, there must have been other fucose linkages in addition to the α1,6-linkage (Staudacher et al., 1999). The F≧2 structural feature decreased as the cells differentiated, indicating that complex fucosylation was characteristic of undifferentiated hESC.

N-glycans with Terminal N-acetylhexosamine Residues Become more Common with Differentiation

A group of N-glycan signals which increased during differentiation contained equal amounts of N-acetylhexosamine and hexose residues (N═H) in their monosaccharide composition, e.g. S₁H₅N₅F₁. This was consistent with structures containing non-reducing terminal N-acetylhexosamine residues. Usually N-glycan core structures contain more hexose than N-acetylhexosamine residues. However, if complex-type N-glycans contain terminal N-acetylhexosamine residues that are not capped by hexoses, their monosaccharide compositions change to either the N═H or the N>H. EB and stage 3 differentiated cells showed increased amounts of potential terminal N-acetylhexosamine structures, of which the N═H structural feature was increased in both neutral and sialylated N-glycan pools (Table 25, rows I and P), whereas the N>H structural feature was elevated in the neutral N-glycan pool, but decreased in the sialylated N-glycan pool during differentiation (Table 25, rows H and O).

Glycome Profiling can Identify the Differentiation Stage of hESC

The analysis of glycome profiles indicated that the studied hESC lines and differentiated cells had differentiation stage specific N-glycan features. However, the data also demonstrated that N-glycan profiles of the individual hESC lines were different from each other and in particular the hESC line FES 22 was different from the other three stem cell lines (Table 25, rows C and I). To test whether the obtained N-glycan profiles could be used to generate an algorithm that would discriminate between hESC and differentiated cells even taking into account cell line specific variation, an analysis was performed using the data of Table 25. The hESC line FES 29 and embryoid bodies derived from it (EB 29) were selected as the training group for the calculation. The algorithm glycan score (equation 1) was defined as the sum of those structural features that were at least two times greater in FES 29 than in EB 29 (row N in Table 25), from which the sum of the structural feature percentages that were at least two times greater in EB 29 than in FES 29 was subtracted (rows C, I, J, and P in Table 25):

glycan score=N−(C+I+J+P), (1)

wherein the letters refer to the row numbering of Table 25.

The Identified hESC Glycans can be Targeted at the Cell Surface

From a practical perspective stem cell research would be best served by the identification of target structures on cell surface. To investigate whether individual glycan structures we had identified would be accessible to reagents targeting them at the cell surface we performed lectin labelling of two candidate structure types. Lectins are proteins that recognize glycans with specificity to certain glycan structures also in hESC (Venable et al., 2005). To study the localization of glycan components in hESC, stem cell colonies grown on mouse feeder cell layers were labeled in vitro by fluorescein-labelled lectins (FIG. 2). The hESC cell surfaces were clearly labeled by Maackia amurensis agglutinin (MAA) that recognizes structures containing α2,3-linked sialylation, indicating that sialylated glycans are abundant on the hESC cell surface (FIG. 2a). Such glycans would thus be available for recognition by more specific glycan-recognizing reagents such as antibodies. In contrast, the cell surfaces were not labelled by Pisum sativum agglutinin (PSA) that recognizes α-mannosylated glycans (FIG. 2b). However, PSA labelled the cells after permeabilization (data not shown), suggesting that the mannosylated N-glycans in hESC were localized in intracellular cell compartments such as the endoplasmic reticulum (ER) or the Golgi complex (FIG. 2c). Interestingly, the mouse fibroblast cells showed complementary staining patterns, suggesting that these lectin reagents efficiently discriminated between hESC and feeder cells. Together the results suggested that the glycan structures we identified could be utilized to design specific reagents targeting hESC.

Comparative Analysis of the N-glycome

Although the N-glycan profiles of the four hESC lines share a similar overall profile shape, there was cell line specific variation in the N-glycan profiles. Individual glycan signals unique to each cell line were found, indicating that every cell line was slightly different from each other with respect to the approximately one hundred most abundant glycan structures they synthesize. This is represented in 0.34a as Venn diagrams combining all the detected glycan signals from both the neutral and the acidic N-glycan fractions. FES 29 and FES 30 were derived from sibling embryos, but their N-glycan profiles did not resemble each other more than they resembled FES 21 in the Venn diagram. Furthermore, FES 30 that has the karyotype XX did not differ significantly from the three XY hESC lines.

In order to determine whether the hESC N-glycome undergoes changes during differentiation, N-glycan profiles obtained from hESC, EB, and stage 3 differentiated cells were compared (FIG. 12). The N-glycan profiles of the differentiated cell types (EB and st.3) differed significantly from the profiles of undifferentiated hESC, which is indicated by non-overlapping distribution bars in many glycan signals. There were many signals in common between hESC and EB that disappeared in stage 3 differentiated cells. Overall, 17% of the glycan signals present in hESC disappeared in EB, and in stage 3 differentiated cells 58% of the original N-glycan signals disappeared. Simultaneously numerous new signals appeared in EB and stage 3 differentiated cells. Their proportion in EB and stage 3 differentiated cells was 24% and 10%, respectively. This indicates that differentiation induced the appearance of new N-glycan types while earlier glycan types disappeared.

Discussion

In the present study, novel mass spectrometric methods were applied to the first structural analysis of human embryonic stem cell N-glycan profiles. Previously, such investigation of whole cell glycosylation has not been feasible due to the lack of methods with sufficiently high sensitivity to analyze the scarce stem cells. The present method was validated for samples of approximately 100 000 cells and the glycan profiles of the analyzed cell types were consistent throughout multiple samples. The objective in the use of the present method was to provide a global view on the glycome profile, or a “fingerprint” of hESC glycosylation, rather than to present the stem cell glycome in terms of the molecular structures of each glycan component. However, changes observed in the N-glycan profiles provide vast amount of information regarding hESC glycosylation and its changes during differentiation, and allows rational design of detailed structural studies of selected glycan components or glycan groups.

The results indicate that a defined group of N-glycan signals dominate the hESC N-glycome and form a unique stem cell glycan profile. It seems that specific monosaccharide compositions were favored over the possible alternatives by the hESC N-glycan biosynthetic machinery. For example, the fifteen most abundant neutral N-glycan signals and fifteen most abundant sialylated N-glycan signals in hESC together comprised over 85% of the N-glycome. Further, different glycan structures were favored during the differentiation of the cells. This suggests that N-glycan biosynthesis in hESC is a controlled and predetermined process. As hundreds of genes, consisting of up to 1% of the human genome, are involved in glycan biosynthesis (Haltiwanger and Lowe, 2004), a future challenge is to characterize the regulatory processes that control hESC glycosylation during differentiation into specialized cell types.

Based on our results the hESC N-glycome seems to contain both a constant part consisting of “housekeeping glycans”, and a changeable part that was altered when the hESC differentiated (FIG. 12). The constant part seemed to contain mostly high-mannose type and biantennary complex-type N-glycans. Such “housekeeping” glycans may need to be present at all times for the maintenance of basic cellular processes. Significantly, 25% (50% if high-mannose glycans are excluded) of the total N-glycan profile of hESC changed during their differentiation. This indicates that during differentiation hESC dramatically change both their appearance towards their environment and possibly also their own capability to sense and respond to exogenous signals.

Our data show that the differentiation-associated change in the N-glycome was generated by addition of variable epitopes on similar N-glycan core compositions. For example, the present lectin staining experiments demonstrated that sialylated glycans were abundant on the cell surface of hESC, indicating that they are potential targets for development of more specific recognition reagents. In contrast, the constantly expressed mannosylated glycans were found to reside mainly inside the cells. It seems plausible that knowledge of the changing surface glycan epitopes could be utilized as a basis in developing reagents and culture systems that would allow improved identification, selection, manipulation, and culture of hESC and their progeny. We are currently characterizing the stem cell specific glycosylation changes at the level of individual molecular structures.

The specific cellular glycan structures perform their functions mainly by 1) acting as ligands for specific glycan receptors (Kilpatrick, 2002; Zanetta and Vergoten, 2003), 2) functioning as structural elements of the cell (Imperiali and O'Connor, 1999), and 3) modulating the activity of their carrier proteins and lipids (Varki, 1993;). More than half of all proteins are glycosylated. Consequently, a global change in protein-linked glycan biosynthesis can simultaneously modulate the properties of multiple proteins. It is likely that the large changes in N-glycans during hESC differentiation have major influences on a number of cellular signaling cascades and affect in profound fashion biological processes within the cells. Our data may provide insight into the regulation of some of these processes.

The major hESC specific glycosylation feature we identified was the presence of more than one deoxyhexose residue in N-glycans, indicating complex fucosylation. Fucosylation is known to be important in cell adhesion and signalling events (Becker and Lowe, 2003) as well as essential for embryonic development Knock-out of the N-glycan core α1,6-fucosyltransferase gene FUT8 leads to postnatal lethality in mice (Wang et al., 2005), and mice completely deficient in fucosylated glycan biosynthesis do not survive past early embryonic development (Smith et al., 2002). Fucosylation defects in humans cause a disease known as leukocyte adhesion deficiency (LAD; Luhn et al., 2001).

Fucosylated glycans such as the SSEA-1 antigen have previously been associated with both mouse embryonic stem cells (mESC) and human embryonic carcinoma cells (EC; Muramatsu and Muramatsu, 2004), but not with hESC. In addition, structurally related Le^xoligosaecharides are able to inhibit embryonic compaction (Fenderson et al., 1984), suggesting that fucosylated glycans arc directly involved in cell-to-cell contacts during embryonic development The α1,3-fucosyltransferase genes indicated in the synthesis of the embryonic Le^xand SSEA-1 antigens arc FUT4 and FU79 (Nakayama et al., 2001; Kudo et al., 2004). Interestingly, the published gene expression profiles for the same hESC lines as studied here (Skottman et al., 2005) have demonstrated that three human fucosyltransferase genes, FUT1, FUT4, and FUT8 are expressed in hESC, and that FUT1 and FUT4 are overexpressed in hESC when compared to EB. The known specificities of these fucosyltransferases (Mollicone et al., 1995) correlate with our findings of simple fucosylation in EB and complex fucosylation in hESC (FIG. 3). Taken together, although hESC do not express the specific glycolipid antigen recognized by the SSEA-1 antibody, they share with mESC the characteristic feature of complex fucosylation and may have conserved the biological functions of fucosylated glycan epitopes.

New N-glycan forms emerged in EB and stage 3 differentiated cells. These structural features included additional N-acetylhexosamine residues, potentially leading to new N-glycan terminal epitopes. Another differentiation-associated feature was an increase in the molar proportions of hybrid-type or monoantennary N-glycans. Biosynthesis of hybrid-type and complex-type N-glycans has been demonstrated to be biologically significant for embryonic and postnatal development in the mouse (loffe and Stanley, 1994 PNAS; Metzler et al., 1994 EMBO J; Wang et al., 2001 Glycobiology; Akama et al., 2006 PNAS). The preferential expression of complex-type N-glycans in hESC and then the change in the differentiating EB to express more hybrid-type or monoantennary N-glycans may thus be significant for the process of stem cell differentiation.

Human embryonic stem cell lines have previously been demonstrated to have a common genetic stem cell signature that can be identified using gene expression profiling techniques (Skottman et al., 2005; Sato et al., 2003; Abeyta et al., 2004; Bhattacharya et al., 2004). Such signatures have been proposed to be utilized in the characterization of cell lines. The present report provides the first glycomic signatures for hESC. The profile of the expressed N-glycans might be a useful tool for analyzing and classifying the differentiation stage in association with gene and protein expression analyses. Here we demonstrate that the glycan score algorithm was able to reliably differentiate cell samples of separate differentiation stage (FIG. 2). Glycome profiling may be a more sensitive measure of the cell status than any single cell surface marker. Such a method might be especially useful for the quality control of hESC-based cell products. However, further analysis of the hESC glycome may also lead to discovery of novel glycan antigens that could be used as stem cell markers in addition to the commonly used SSEA and Tra glycan antigens.

In conclusion, hESC have a unique glycome which undergoes major changes when the cells differentiate. Information regarding the specific glycome may be utilized in developing reagents for the targeting of these cells and their progeny. Future studies investigating the developmental and molecular regulatory processes resulting in the observed glycan profiles may provide significant insight into mechanisms of human development and regulation of glycosylation.

REFERENCES

Abeyta, M. J., Clark, A. T., Rodriguez, R. T., Bodnar, M. S., Pera, R. A., and Firpo, M. T. (2004). Unique gene expression signatures of independently-derived human embryonic stem cell lines. Hum. Mol. Genet 13, 601-608.

Apweiler, R., Hermjakob, H., and Sharon, N. (1999). On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochem. Biophys. Acta 1473, 4-8.

Badcock, G., Pigott, C., Goepel, J., and Andrews, P. W. (1999). The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res. 59, 4715-4719.

Becker, D. J., and Lowe, J. B. (2003). Fucose: biosynthesis and biological function in mammals. Glycobiology. 13:41R-5R.

Bhattacharya, B., Miura, T., Brandenberger, R., Mejido, J., Luo, Y., Yang, A. X., Joshi, B. H., Ginis, I., Thies, R. S., Amit, M., Lyons, I., Condie, B. G., Itskovitz-Eldor, J., Rao, M. S., and Puri, R. K. (2004). Gene expression in human embryonic stem cell lines: Unique molecular signature. Blood 103, 2956-2964.

Callewacrt, N., Van Vlicrberghe, H., Van Hecke, A., Laroy, W., Delanghe, J., and Contreras, R. (2004). Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 10:429-34.

Carson, D. D., and Lennarz, W. J. (1979). Inhibition of polyisoprenoid and glycoprotein biosynthesis causes abnormal embryonic development. Proc. Natl. Acad. Sci. U.S.A. 76, 5709-5713.

Cooper, D. K. (1998). Xenoantigens and xenoantibodies. Xenotransplantation 5, 6-17.

Davies, M. J., Smith, K. D., Carruthers, R. A., Chai, W., Lawson, A. M., and Hounsell, E. F. (1993). Use of a porous graphitised carbon column for the high-performance liquid chromatography of oligosaecharides, alditols and glycopeptides with subsequent mass spectrometry analysis. J. Chromatogr. 646, 317-326.

Dell, A., and Morris, H. R. (2001). Glycoprotein structure determination by mass spectrometry. Science 291, 2351-2356.

Fenderson, B. A., Zehavi, U., and IIakomori, S. (1984). A multivalent lacto-N-fucopentaose III lysyllysine conjugate decompacts preimplantation mouse embryos, while the free oligosaccharide is ineffective. J. Exp. Med. 160, 1591-1596.

Goldberg, D., Sutton-Smith, M., Paulson, J., and Dell, A. (2005). Automatic annotation of matrix-assisted laser desorption/ionization N-glycan spectra. Proteomics 5, 865-875.

Gooi, H. C., Feizi, T., Kapadia, A., Knowles, B. B., Solter, D., and Evans, M. J. (1981). Stage-specific embryonic antigen involves α1→3 fucosylated type 2 blood group chains. Nature 292, 156-158.

Haltiwanger, R. S., and Lowe, J. B. (2004). Role of glycosylation in development. Annu. Rev. Biochem. 73, 491-537.

Handel, T. M., Johnson, Z., Crown, S. E., Lau, E. K., and Proudfoot, A. E. (2005). Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu. Rev. Biochem. 74:385-410.

Harvey, D. J. (1993). Quantitative aspects of the matrix-assisted laser desorption mass spectrometry of complex oligosaccharides. Rapid Commun. Mass Spectrom. 7, 614-619.

Helenius, A., and Aebi, M. (2001). Intracellular functions of N-linked glycans. Science 291, 2364-2369.

Helenius, A., and Aebi, M. (2004). Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73, 1019-1049.

Homeister, J. W., Thall, A. D., Petryniak, B., Maly, P., Rogers, C. E., Smith, P. L., Kelly, R. J., Gersten, K. M., Askari, S. W., Cheng, G., Smithson, G., Marks, R. M., Misra, A. K., Hindsgaul, O., von Andrian, U. H., and Lowe, J. B. (2001). The α(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity. 15:115-26.

Imperiali, B., and O'Connor, S. E. (1999). Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. Curr. Opin. Chem. Biol. 3, 643-649.

Kannagi, R., Cochran, N. A., Ishigari, F., Hakomori, S., Andrews, P. W., Knowles, B. B., and Solter, D. (1983). Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 2, 2355-2361.

Kilpatrick, D. C. (2002). Animal lectins: A historical introduction and overview. Biochem. Biophys. Acta 1572, 187-197.

Kornfeld, R., and Kornfeld, S. (1985). Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631-664.

Kornfeld, S. (1986). Trafficking of lysosomal enzymes in normal and disease states. J. Clin. Invest. 77:1-6.

Kudo, T., Kaneko, M., Iwasaki, H., Togayachi, A., Nishihara, S., Abe, K., and Narimatsu, H. (2004). Normal embryonic and germ cell development in mice lacking α1,3-fucosyltransferase IX (Fut9) which show disappearance of stage-specific embryonic antigen 1. Mol. Cell. Biol. 24:4221-4228.

Lowe, J. B. (2002). Glycosylation in the control of selectin counter-receptor structure and function. Immunol. Rev. 186:19-36.

Luhn, K., Wild, M. K., Eckhardt, M., Gerardy-Sehahn, R., and Vestweber, D. (2001). The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat. Genet. 28:69-72.

Martin, M. J., Muotri, A., Gage, F., and Varki, A. (2005). Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11, 228-232.

Mollicone, R., Cailleau, A., and Oriol, R. (1995). Molecular genetics of H, Se, Lewis, and other fucosyltransferase genes. Transfusion Clin. Biol. 4:235-242.

Muramatsu, T., and Muramatsu, H. (2004). Carbohydrate antigens expressed on stem cells and early embryonic cells. Glycoconj. J. 21, 41-45.

Nakayama, F., Nishihara, S., Iwasaki, H., Kudo, T., Okubo, R., Kaneko, M., Nakamura, M., Karube, M., Sasaki, K., and Narimatsu, H. (2001). CD15 expression in mature granulocytes is determined by α1,3-fucosyltransferase IX, but in promyelocytes and monocytes by α1,3-fucosyltransferase IV. J. Biol. Chem. 276:16100-16106.

Naven, T. J., and Harvey, D. J. (1996). Effect of structure on the signal strength of oligosaccharides in matrix-assisted laser desorption/ionization mass spectrometry on time-of-flight and magnetic sector instruments. Rapid Commun. Mass Spectrom. 10, 1361-1366.

Nguyen, D. H., Tangvoranuntakul, P., and Varki, A. (2005). Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells J. Immunol. 175, 228-236.

Nyman, T. A., Kallkinen, N., Tölö, H., and Helin, J. (1998). Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon-α2b and interferon-α14c produced by Sendai-virus-induced human peripheral blood leukocytes. Eur. J. Biochem. 253, 485-493.

Okabe, S., Forsberg-Nilsson, K., Spiro, A. C., Segal, M., and McKay, R. D. (1996). Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 59:89-102.

Papac, D. I., Wong, A., and Jones, A. J. (1996). Analysis of acidic oligosaecharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 68, 3215-3223.

Saarinen, J., Welgus, H. G., Flizar, C. A., Kalkkeinen, N., and Helin, J. (1999). N-glycan structures of matrix metalloproteinase-1 derived from human fibroblasts and from HT-1080 fibrosarcoma cells. Eur. J. Biochem. 259, 829-840.

Sato, N., Sanjuan, I. M., Heke, M., Uchida, M., Naef, F., and Brivanlou, A. H. (2003). Molecular signature of human embryonic stem cells and its comparison with the mouse. Dev. Biol. 260, 404-413.

Schachter, H. (1991). The ‘yellow brick road’ to branched complex N-glycans. Glycobiology 1, 453-461.

Schneider, E. G., Nguyen, H. T., and Lennarz, W. J. (1978). The effect of tunicamycin, an inhibitor of protein glycosylation, on embryonic development in the sea urchin. J. Biol. Chem. 253, 2348-2355.

Shriver, Z., Raguram, S., and Sasisekharan, R. (2004). Glycomics: A pathway to a class of new and improved therapeutics. Nat. Rev. Drug Disc. 3, 863-873.

Skottman, H., Mikkola, M., Lundin, K., Olsson, C., Strömberg, A. M., Tuuri, T., Otonkoski, T., Hovatta, O., and Lahesmaa, R. (2005). Gene expression signatures of seven individual human embryonic stem cell lines. Stem cells 23, 1343-1356.

Smith, P. L., Myers, J. T., Rogers, C. E., Zhou, L., Petryniak, B., Becker, D. J., Homeister, J. W., and Lowe, J. B. (2002). Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus. J. Cell Biol. 158:801-815.

Solter, D., and Knowles, B. B. (1978). Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc. Natl. Acad. Sci. U.S.A. 75, 5565-5569.

Staudacher, E., Altmann, F., Wilson, I. B. H., and März, L. (1999). Fucose in N-glycans: From plant to man. Biochim. Biophys. Acta 1473, 216-346.

Sutton-Smith, M., Morris, H. R., Grewal, P. K., Hewitt, J. E., Bittner, R. E., Goldin, E., Schiffmann, R., and Dell, A. (2002). MS screening strategies: Investigating the glycomes of knockout and myodystrophic mice and leukodystrophic human brains. Biochem. Soc. Symp. 69, 105-115.

Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147.

Varki, A. (1993). Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3, 97-130.

Venable, A., Mitalipova, M., Lyons, I., Jones, K., Shin, S., Pierce, M., and Stice, S. (2005). Lectin binding profiles of SSEA-4 enriched, pluripotent human embryonic stem cell surfaces. BMC Dev. Biol. 2005 5, 15.

Verostek, M. F., Lubowski, C., and Trimble, R. B. (2000). Selective organic precipitation/extraction of released N-glycans following large-scale enzymatic deglycosylation of glycoproteins. Anal. Biochem. 278, 111-122.

Wang, X., Inouc, S., Gu, J., Miyoshi, E., Noda, K., Li, W., Mizuno-Horikawa, Y., Nakano, M., Asahi, M., Takahashi, M., Uozumi, N., Ihara, S., Lee, S. H., Ikeda, Y., Yamaguchi, Y., Aze, Y., Tomiyama, Y., Fujii, J., Suzuki, K., Kondo, A., Shapiro, S. D., Lopez-Otin, C., Kuwaki, T., Okabe, M., Honke, K., and Taniguchi, N. (2005). Dysregulation of TGF-β1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 102:15791-15796.

Wobus, A. M., and Boheler, K. R. (2005). Embryonic stem cells: Prospects for developmental biology and cell therapy. Physiol. Rev. 85, 635-678.

Zanetta, J. P., and Vergoten, G. (2003). Lectin domains on cytokines. Adv. Exp. Med. Biol. 535, 107-124.

Example 11
Analysis of Human and Murine Fibroblast Feeder Cells

Murine (mEF) and human (hEF) fibroblast feeder cells were prepared and their N-glycan fractions analyzed as described in the preceding Examples.

Results and Discussion

FIG. 8 shows the major neutral N-glycan fraction glycan signals of hEF and mEF. FIG. 9 shows the glycan grouping of neutral N-glycan fraction glycan signals of hEF and mEF. FIG. 10 shows the glycan grouping of acidic N-glycan fraction glycan signals of hEF and mEF. The mEF and hEF cells differed significantly from each other in their glycan profiles.

The results showed that mEF and hEF cellular N-glycan fractions differ significantly from each other. The differencies include differential proportions of glycan groups, major glycan signals, and the glycan profiles obtained from the cell samples. In addition, the major difference is the presence of Galα3Gal epitopes in the mEF cells, as discussed in the preceding Examples of the present invention.

Example 12
The Glycome or Human Embryonic Stem Cells Reflects their Differentiation Stage
SUMMARY

Complex carbohydrate structures, glycans, are elementary components of glycoproteins, glycolipids, and proteoglycans. These glycoconjugates form a layer of glycans that covers all human cell surfaces and forms the first line of contact towards the cell's environment. Glycan structures called stage specific embryonic antigens (SSEA) are used to assess the undifferentiated stage of embryonic stem cells. However, the whole spectrum of stem cell glycan structures has remained unknown, largely due to lack of suitable analysis technology. We describe the first global study of glycoprotein glycans of human embryonic stem cells, embryoid bodies, and further differentiated cells by MALDI-TOF mass spectrometric profiling. The analysis reveals how certain asparagine-linked glycan structures characteristic to stem cells arc lost during differentiation white new structures emerge in the differentiated cells. The results indicate that human embryonic stem cells have a unique glycome and that their differentiation stage can be identified by glycome analysis. We suggest that knowledge about stem cell specific glycan structures can be used for e.g. purification, manipulation, and quality control of stem cells.

Materials & Methods

Human embryonic stem cell lines. Four Finnish hESC lines, FES 21, FES 22, FES 29, and FES 30 (Skottman et al., 2005. Stem cells 23:1343-56) were used in the present study. These lines are included in the International Stem Cell Initiative (Andrews et al., 2005. Nat. Biotechnol. 23:795-7). The cells were propagated on human foreskin fibroblast (hFF) feeder cells in serum-free medium (Knockout™, Gibco/Invitrogen). In FACS analyses 70-90% of cells from mechanically isolated colonies were typically Tra 1-60 and Tra 1-81 positive (not shown). Cells differentiated into embryoid bodies (EB, stage 2 differentiated) and further differentiated cells grown out of the EB as monolayers (stage 3 differentiated) were used for comparison against hESC. The differentiation protocol favors the development of neuroepithelial cells while not directing the differentiation into distinct terminally differentiated cell types (Okabe et al., 1996. Mech. Dev. 59:89-102). FB derived from FES 30 had less differentiated cell types than the other three EB. Stage 3 cultures consisted of a heterogenous population of cells dominated by fibroblastoid and neuronal morphologies. For the glycome studies the cells were collected mechanically, washed, and stored frozen until analysis.

In a preferred embodiment the invention is directed to the use of data obtained embryoid bodies or ESC-cell line cultivated under conditions favouring neuroepithelial cells for search of specific structures indicating neuroepithelial development, preferably by comparing the material with cell materials comprising neuronal and/or epithelial type cells.

Asparagine-linked glycome profiling. Total asparagine-linked glycan (N-glycan) pool was enzymatically isolated from about 100 000 cells. The total N-glycan pool (picomole quantities) was purified with microscale solid-phase extraction and divided into neutral and sialylated N-glycan fractions. The N-glycan fractions were analyzed by MALDI-TOF mass spectrometry either in positive ion mode for neutral N-glycans or in negative ion mode for sialylated glycans (Saarinen et al., 1999, Eur. J Biochem. 259, 829-840). Over one hundred N-glycan signals were detected from each cell type revealing the surprising complexity of hESC glycosylation. The relative abundances of the observed glycan signals were determined based on relative signal intensities (Harvey, 1993. Rapid Commun. Mass Spectrom. 7:614-9; Papac et al., 1996. Anal. Chem. 68:3215-23).

Results

In the present study, we analyzed the N-glycome profiles of hESC, EB, and st.3 differentiated cells (FIG. 4).

The similarity of the N-glycan profiles within the group of four hESC lines suggested that the obtained N-glycan profiles are a description of the characteristic N-glycome of hESC. Overall, 10% of the 100 most abundant N-glycan signals present in hESC disappeared in st.3 differentiated cells, and 16% of the most abundant signals in st3 differentiated cells were not present in hESC. This indicates that differentiation induced the appearance of new N-glycan types while earlier glycan types disappeared. In quantitative terms, the differences between the glycan profiles of hESC, EB, and st.3 differentiated cells were: hESC vs. EB 19%, hESC vs. st.3 24%, and EB vs. st.3 12%.

The glycome profile data was used to design glycan-specific labeling reagents for hESC. The most interesting glycan types were chosen to study their expression profiles by lectin histochemistry as exemplified in FIG. 5 for the lectins that recognize either α2,3-sialylated (MAA-lectin, FIG. 5A.) binding to the hESC cells or α-mannosylated glycans (PSA-lectin, FIG. 5B.) binding to the surfaces of feeder cells (MEF). The binding of the lectin reagents was inhibited by specific carbohydrate inhibitors, sialylα2-lactose and mannose, respectively (FIGS. 5C. and 5D.). The results are summarized in Table 31.

Table 31 further represent differential recognition feeder and stem cells by two other lectins, Ricinus communis agglutinin (RCA, ricin lectin), known to recognize especially terminal Galβ-structures, especially Galβ4Gle(NAc)-type structures and peanut agglutinin (PNA) reconnizing Gal/GalNAc structures. The cell surface expression of ligand for two other lectin RCA and PNA on hESC cells, but only RCA ligands of feeder cells.

The present results indicate and the invention is directed to the hESC glycans are potential targets for recognition by stem cell specific reagents. The invention is further directed to methods of specific recognition and/or separation of hESC and differentiated cells such as feeder cells by glycan structure specific reagents such as lectins. Human embryonic stem cells have a unique glycome that reflects their differentiation stage. The invention is specifically directed to analysis of cells according to the invention with regard to differentiation stage.

Conclusions

The present data represent the glycome profiling of hESC:

- hESC have a unique N-glycome comprising of over 100 glycan components
- Differentiation induces a major change in the N-glycome and the cell surface molecular landscape of hESC

Utility of hESC glycome data:

- Identification of new stem cell markers for e.g. antibody development
- Quality control of stem cell products
- Identification of hESC differentiation stage
- Control of variation between hESC lines
- Effect of external factors and culture conditions on hESC status

Especially preferred uses of the data are

Use of the hESC glycome for identification of specific cell surface markers characteristic for the pluripotent hESCs.

The invention is directed to further analysis and production of present and analogous glycome data and use of the methods for further identification of novel stem cell specific glycosylation features and form the basis for studies of hESC glycobiology and its eventual applications according to the invention

Example 13
Identification of Specific Glycosylation Signatures from Glycan Profiles in Various Steps of Human Embryonic Stem Cell Differentiation

To identify differentiation stage specific N-glycan signals in sialylated N-glycan profiles of hESC, EB, and stage 3 differentiated cells (see Example 12 above), major signals specific to either the undifferentiated (FIG. 6) or differentiated cells (FIG. 7) were selected based on their relative abundances in the database of the four hESC lines, and the four EB and st.3 cell samples derived from the four hESC lines, respectively. The selected glycan signal groups, from where indifferent glycan signals have been removed, have reduced noise or background and less observation points, but have the resolving power. Such selected signal groups and their patterns in different sample types serve as a signature for the identification of for example 1) undifferentiated hESC (FIG. 6), 2) differentiated cells, preferentially their differentiation stage relative to hESC (FIG. 7), 3) differentiation lineage, such as the neuroectodermally enriched st.3 cells compared to the mixed cell population of EB (e.g. 1799), 4) glycan signals that are specific to hESC (e.g. 2953), 5) glycan signals that are specific to differentiated cells (e.g. 2644), or 6) glycan signals that have individual i.e. cell line specific variation (e.g. 1946 in cell line FES 22, 2133 in cell line FES 29, and 2222 in cell line FES 30). Moreover, glycan signals can be identified that do not change during hESC differentiation, including major glycans that can be considered as housekeeping glycans in hESC and their progeny (e.g. 1257, 1419,1581, 1743, 1905 in FIG. 4.A, and 2076 in FIG. 4.B).

To further analyze the data and to find the major glycan signals associated in given hESC differentiation stage, two variables were calculated for the comparison of glycan signals in the N-glycan profile dataset described above, between two samples:

1. absolute difference A=(S2−S1), and

2. relative difference R=A|S1,

wherein S1 and S2 are relative abundances of a given glycan signal in samples 1 (the four EB samples) and 2 (the four st.3 cell samples), respectively.

When A and R were calculated for the glycan profile datasets of the two cell types, and the glycan signals thereafter sorted according to the values of A and R, the most significant differing glycan signals between the two samples could be identified. Among the fifty most abundant neutral N-glycan signals in the data (FIG. 4.A), the following five signals experienced the highest relative change R in the transition from EB to st.3 differentiated cells in the dataset of four EB and four st3 cell samples: 1825 (R=5.8, corresponding to 6.8-fold increase), 1136 (R=1.4, corresponding to 2.4 fold increase), 1339 (R=0.9, corresponding to 1.9 fold increase), 2142 (R=0.87, corresponding to 87% decrease), and 2174 (R=0.56, corresponding to 56% decrease). Four of these signals corresponded to complex-type structures, indicating that the major differing glycan structures were included in the complex-type glycan group. However, the majority of the other complex-type glycan signals in the dataset were not observed to differ as significantly between the two cell types (i.e. they did not have large values of A and/or R), indicating that the procedure was able to identify st.3 cell and EB associated glycan subgroups within the whole complex-type glycan group. The one signal corresponding to hybrid-type structures (1136) had the highest value of the absolute differences A among all the glycan signals in the neutral N-glycan profiles (A=0.48), indicating that also this signal had significance in the discrimination between the EB and st.3 cell samples in the studied dataset.

EB derived from the hESC line FES 30 were different in their overall N-glycan profiles compared to the other three EB samples (FIG. 4) and had the differentiation-specific glycan score value closer to the hESC samples correlating with the property of EB 30 having less differentiated cell types than the other three EB. This was also seen in distinct glycan signals, e.g. 2222 in FIG. 4B.

Example 14
Influence of Lectins on Stem Cell Proliferation Rate

Experimental Procedures

Lectins (EY laboratories, USA) were passively adsorbed on 48-well plates (Nunclon surface, catalog No 150687, Nunc, Denmark) by overnight incubation in phosphate buffered saline.

Human bone marrow derived mesenechymal stem cells (BM MSC) were cultured in minimum essential α-medium (α-MFM) supplemented with 20 mM HFPES, 10% FCS, penicillin-streptomycin, and 2 mM L-glutamine (all from Gibco) on 48-well plates coated with different lectins. Cells were cultivated in Cell IQ (ChipMan Technologies, Tampere, Finland) at +37° C. with 5% CO₂. Images were taken every 15 minutes. Data were analyzed with Cell IQ Analyzer software by analyzer protocol built by Dr. Ulla Impola (Finnish Red Cross Blood Service, Helsinki, Finland).

Results and Discussion

The growth rates of BM MSC varied on different lectin-coated surfaces compared to each other and uncoated plastic surface (Table 32), indicating that proteins with different glycan binding specificities binding to stem cell surface glycans specifically influence their proliferation rate.

Lectins that had an enhancing effect on BM MSC growth rate included in order of relative efficacy:

GS II (β-GlcNAc)>ECA (LacNAc/β-Gal)>PWA (I-branched poly-LacNAc)>LTA (α1,3-Fuc)>PSA (α-Man),

wherein the preferred oligosaccharide specificities of the lectins are indicated in parenthesis. However, PSA was nearly equal to plastic in the present experiments.

Lectins that had an inhibitory effect on BM MSC growth rate included in order of relative efficacy:

RCA (βGal/LacNAc)>>UEA (α1,2-Fuc)>WFA (β-GalNAc)>STA (linear poly-LacNAc)>NPA (α-Man)>SNA (α2,6-linked sialic acids)=MAA (α2,3-linked sialic acids/(α3′-sialyl LacNAc),

wherein the preferred oligosaccharide specificities of the lectins arc indicated in parenthesis. However, NPA, SNA, and MAA were nearly equal to plastic in the present experiments.

Example 15
Glycosphingolipid Glycans of Human Stem Cells

Experimental Procedures

Samples from MSC, CB MNC, and hESC grown on mouse fibroblast feeder cells were produced as described in the preceding Examples. Neutral and acidic glycosphingolipid fractions were isolated from cells essentially as described (Miller-Podraza et al., 2000). Glycans were detached by Macrobdella decora endoglycoceramidase digestion (Calbiochem, USA) essentially according to manuacturer's instructions, yielding the total glycan oligosaccharide fractions from the samples. The oligosaccharides were purified and analyzed by MALDI-TOF mass spectrometry as described in the preceding Examples for the protein-linked oligosaccharide fractions.

Results and Discussion

Human Embryonic Stem Cells (hESC)

hESC neutral lipid glycans. The analyzed mass spectrometric profile of the hESC glycosphingolipid neutral glycan fraction is shown in FIG. 10.

Structural analysis of the major neutral lipid glycans. The six major glycan signals, together comprising more than 90% of the total glycan signal intensity, corresponded to monosaccharide compositions Hex₃HexNAc₁(730), Hex₃HexNAc₁dHex₁(876), Hex₂HexNAc₁(568), Hex₃HexNAc₂(933), Hex₄HexNAc₁(892), and Hex₄HexNAc₂(1095).

In β1,4-galactosidase digestion, the relative signal intensities of 1095 and 730 were reduced by about 30% and 10%, respectively. This suggests that 730 and 1095 contain minor components with non-reducing terminal β1,4-Gal epitopes, preferably including the structures Galβ4GlcNAcLac and Galβ4GlcNAc[Hex₁HexNAc₁]Lac. The other major components were thus shown to contain other terminal epitopes. Further, the glycan signal Hex₅HexNAc₃(1460) was digested to Hex₃HexNAc₃(1136), indicating that the original signal contained glycan structures containing two β1,4-Gal.

The major glycan signals were not sensitive to α-galactosidase digestion.

In α1,3/4-fucosidase digestion, the signal intensity of 876 was reduced by about 10%, indicating that only a minor proportion of the glycan signal corresponded to glycans with α1,3- or α1,4-linked fucose residue. The major affected signal in the total profile was Hex₃HexNAc₁dHex₂(1022), indicating that it included glycans with either α1,3-Fuc or α1,4-Fuc. 511 was reduced by about 30%, indicating that the signal contained a minor component with α1,2-Fuc, preferentially including Fucα2Galβ4Glc (Fucα2′Lac, 2′-fucosyllactose).

When the α1,3/4-fucosidase reaction product was further digested with α1,2-fucosidase, 876 was completely digested into 730, indicating that the structure of the majority of the signal intensity contained non-reducing terminal α1,2-Fuc, preferably including the structure Fucα2[Hex₁HexNAc₁]Lac, more preferably including Fucα2GalHexNAcLac. Another partly digested glycan signal was Hex₄HexNAc₂dHex₁(1241) that was thus indicated to contain α1,2-Fuc, preferably including the structure Fucα2[Hex₂HexNAc₂]Lac, more preferably including Fucα2Gal[Hex₁HexNAc₂]Lac. 511 was completely digested, indicating that the original signal contained a major component with α1,3/4-Fuc, preferentially including Galβ4(Fucα3)Glc (3-fucosyllactose).

When the α1,3/4-fucosidase and α1,2-fucosidase reaction product was further digested with β1,4-galactosidase, the majority of the newly formed 730 was not digested, i.e. the relative proportion of 568 was not increased compared to β1,4-galactosidase digestion without preceding fucosidase treatments. This indicated that the majority of 876 did not contain β1,4-Gal subterminal to Fuc. Further, 892 was not digested, indicating that it did not contain non-reducing terminal β1,4-Gal.

When the α1,3/4-fucosidase, α1,2-fucosidase, and β1,4-galactosidase reaction product was further digested with β1,3-galactosidase, the signal intensity of 892 was reduced, indicating that it included glycans with terminal β1,3-Gal. The signal intensity of 568 was increased relative to 730, indicating that also 730 included glycans with terminal β1,3-Gal.

The experimental structures of the major hESC glycosphingolipid neutral glycan signals were thus determined (‘>’ indicates the order of preference among the lipid glycan structures of hESC; ‘[ ]’ indicates that the oligosaccharide sequence in brackets may be either branched or unbranched; ‘( )’ indicates a branch in the structure):

730
Hex₃HexNAc₁> Hex₁HexNAc₁Lac > Galβ4GlcNAcLac

876
Hex₃HexNAc₁dHex₁> Fucα2[Hex₁HecNAc₁]Lac >

Fucα2Galβ4GlcNAcLac > Fucα3/4[Hex₁HecNAc₁]Lac

568
Hex₂HexNAc₁> HecNAcLac

933
Hex₃HexNAc₂> [Hex₁HecNAc₂]Lac

892
Hex₄HexNAc₁> [Hex₂HecNAc₁]Lac > Galβ3[Hex₁HecNAc₁]Lac

1095
Hex₄HexNAc₂> [Hex₂HecNAc₂]Lac >

Galβ3HexNAc[Hex₁HecNAc₁]Lac >

Galβ4GlcNAc[Hex₁HecNAc₁]Lac

1460
Hex₅HexNAc₃> [Hex₃HecNAc₃]Lac >

Galβ4GlcNAc(Galβ4GlcNAc)[Hex₁HecNAc₁]Lac

Acidic lipid glycans. The analyzed mass spectrometric profile of the hESC glycosphingolipid sialylated glycan fraction is shown in FIG. 11. The four major glycan signals, together comprising more than 96% of the total glycan signal intensity, corresponded to monosaccharide compositions NeuAc₁Hex₃HexNAc₁(997), NeuAc₁Hex₂HexNAc₁(835), NeuAc₁Hex₄HexNAc₁(1159), and NeuAc₂Hex₃HexNAc₁(1288).

The acidic glycan fraction was subjected to a2,3-sialidase digestion and the resulting neutral and acidic glycan fractions were purified and analyzed separately. In the acidic fraction, signals 1159 and 1288 were digested and 835 was partly digested. In the neutral fraction, signals 730 and 892 were the major appeared signals. These results indicated that: 1159 consisted mainly of glycans with α2,3-NcuAc, 1288 contained at least one α2,3-NcuAc, a major proportion of glycans in 835 contained α2,3-NeuAc, and in the original sample a major proportion of NeuAc_1-2Hex₃HexNAc₁contained solely α2,3-linked NeuAc.

Human Mesenechymal Stem Cells (MSC)

Bone marrow derived (BM) MSC neutral lipid glycans. The analyzed mass spectrometric profile of the BM MSC glycosphingolipid neutral glycan fraction is shown in FIG. 10. The six major glycan signals, together comprising more than 94% of the total glycan signal intensity, corresponded to monosaccharide compositions Hex₃HexNAc₁(730), Hex₂HexNAc₁(568), Hex₂dHex₁(511), Hex₂HexNAc₂dHex₂(1063), Hex₃HexNAc₂dHex₂(1225), and Hex₃HexNAc₂dHex₁(1079). The four most abundant signals (730, 568, 511, and 1063) together comprised more than 75% of the total intensity.

Cord blood derived (CB) MSC neutral lipid glycans. The analyzed mass spectrometric profile of the CB MSC glycosphingolipid neutral glycan fraction is shown in FIG. 10. The ten major glycan signals, together comprising more than 92% of the total glycan signal intensity, corresponded to monosaccharide compositions Hex₂HexNAc₁(568), Hex₃HexNAc₁(730), Hex₄HexNAc₂(1095), Hex₅HexNAc₃(1460), Hex₃HexNAc₂(933), Hex₂dHex₁(511), Hex₂HexNAc₂dHex₂(1063), Hex₄HexNAc₃(1298), Hex₃HexNAc₂dHex₂(1225), and Hex₂HexNAc₂(771). The five most abundant signals (568, 730, 1095, 1460, and 933) together comprised more than 82% of the total intensity.

In β1,4-galactosidase digestion, the relative signal intensities of 1095, 1460, and 730 were reduced by about 90%, 95%, and 20%, respectively. This suggests that CB MSC contained major glycan components with non-reducing terminal β1,4-Gal epitopes, preferably including the structures Galβ4GlcNAcβ[Hex₁HexNAc₁]Lac, Galβ4GlcNAc[Hex₂HexNAc₂]Lac, and GalβGlcNAcLac. Further, the glycan signal Hex₅HexNAc₃(1460) was digested into Hex₄HexNAc₃(1298) and mostly into Hex₃HexNAc₃(1136), indicating that the original signal contained glycan structures containing either one or two β1,4-Gal, and that the majority of the original glycans contained two β1,4-Gal, preferentially including the structure GalβGlcNAc(Galβ4GlcNAc)[Hex₁HexNAc₁]Lac. Similarly, 1095 was digested into Hex₂HexNAc₂(771) in addition to 933, indicating that the original signal contained glycan structures containing either one or two β1,4-Gal, and that the minority of the original glycans contained two β1,4-Gal, preferentially including the structure Galβ4GlcNAc(Galβ4GlcNAc)Lac.

The experimental structures of the major CB MSC glycosphingolipid neutral glycan signals were thus determined (‘>’ indicates the order of preference among the lipid glycan structures of hESC; ‘[ ]’ indicates that the oligosaccharide sequence in brackets may be either branched or unbranched; ‘( )’ indicates a branch in the structure):

568
Hex₂HexNAc₁> HecNAcLac

730
Hex₃HexNAc₁> Hex₁HexNAc₁Lac > Galβ4GlcNAcLac

1095
Hex₄HexNAc₂> [Hex₂HecNAc₂]Lac >

Galβ4GlcNAc[Hex₁HecNAc₁]Lac >

Galβ4GlcNAc(Galβ4GlcNAc)Lac

1460
Hex₅HexNAc₃> [Hex₃HecNAc₃]Lac >

Galβ4GlcNAc[Hex₂HecNAc₂]Lac >

Galβ4GlcNAc(Galβ4GlcNAc)[Hex₁HecNAc₁]Lac

933
Hex₃HexNAc₂> Hex₁HexNAc₂Lac

Sialylated lipid glycans. The analyzed mass spectrometric profile of the hESC glycosphingolipid sialylated glycan fraction is shown in FIG. 11. The five major glycan signals of BM MSC, together comprising more than 96% of the total glycan signal intensity, corresponded to monosaccharide compositions NcuAc₁Hex₂HexNAc₁(835), NeuAc₁Hex₁HexNAc₁dHex₁(819), NeuAc₁Hex₃HexNAc₁(997), NeuAc₁Hex₃HexNAc₁dHex, (1143), and NeuAc₂Hex₁HexNAc₂dHex₁(1313). The six major glycan signals of CB MSC, together comprising more than 92% of the total glycan signal intensity, corresponded to monosaccharide compositions NcuAc₁Hex₂HexNAc₁(835), NeuAc₁Hex₃HexNAc₁(997), NeuAc₂Hex₂(905), NeuAc₁Hex₄HexNAc₂(1362), NeuAc₁Hex₅HexNAc₃(1727), and NeuAc₂Hex₂HexNAc₁(1126).

Human Cord Blood Mononuclear Cells (CB MNC)

CB MNC neutral lipid glycans. The analyzed mass spectrometric profile of the CB MNC glycosphingolipid neutral glycan fraction is shown in FIG. 10. The five major glycan signals, together comprising more than 91% of the total glycan signal intensity, corresponded to monosaccharide compositions Hex₃HexNAc₁(730), Hex₂HexNAc₁(568), Hex₃HexNAc₁dHex₁(876), Hex₄HexNAc₂(1095), and Hex₄HexNAc₂dHex₁(1241).

In β1,4-galactosidase digestion, the relative signal intensities of 730 and 1095 were reduced by about 50% and 90%, respectively. This suggests that the signals contained major components with non-reducing terminal β1,4-Gal epitopes, preferably including the structures Galβ4GlcNAcβLac and Galβ4GlcNAcβ[Hex₁HexNAc₁]Lac. Further, the glycan signal Hex₅HexNAc₃(1460) was digested to Hex₄HexNAc₃(1298) and Hex₃HexNAc₃(1136), indicating that the original signal contained glycan structures containing either one or two β1,4Gal.

The experimental structures of the major CB MNC glycosphingolipid neutral glycan signals were thus determined (‘>’ indicates the order of preference among the lipid glycan structures of hESC; ‘[ ]’ indicates that the oligosaccharide sequence in brackets may be either branched or unbranched; ‘( )’ indicates a branch in the structure):

730
Hex₃HexNAc₁> Hex₁HexNAc₁Lac > Galβ4GlcNAcLac

568
Hex₂HexNAc₁> HecNAcLac

876
Hex₃HexNAc₁dHex₁> [Hex₁HecNAc₁dHex₁]Lac >

Fuc[Hex₁HecNAc₁]Lac

1095
Hex₄HexNAc₂> [Hex₂HecNAc₂]Lac >

Galβ4GlcNAc[Hex₁HecNAc₁]Lac

1241
Hex₄HexNAc₂dHex₁> [Hex₂HecNAc₂dHex₁]Lac >

Fuc[Hex₂HecNAc₂]Lac

1460
Hex₅HexNAc₃> [Hex₃HecNAc₃]Lac >

Galβ4GlcNAc[Hex₂HecNAc₂]Lac >

Galβ4GlcNAc(Galβ4GlcNAc)[Hex₁HecNAc₁]Lac

Sialylated lipid glycans. The analyzed mass spectrometric profile of the CB MNC glycosphingolipid sialylated glycan fraction is shown in FIG. 11. The three major glycan signals of CB MNC, together comprising more than 96% of the total glycan signal intensity, corresponded to monosaccharide compositions NeuAc₁Hex₃HexNAc₁(997), NeuAc₁Hex₄HexNAc₂(1362), and NeuAc₁Hex₅HexNAc₃(1727).

Overview of Human Stem Cell Glycosphingolipid Glycan Profiles

The neutral glycan fractions of all the present sample types altogether comprised 45 glycan signals. The proposed monosaccharide compositions of the signals were composed of 2-7 Hex, 0-5 HexNAc, and 0-4 dHex. Glycan signals were detected at monoisotopic m/z values between 511 and 2263 (for [M+Na]⁺ ion).

Major neutral glycan signals common to all the sample types were 730, 568, 1095, and 933, corresponding to the glycan structure groups Hex_0-1HexNAc₁Lac (568 or 730) and Hex_1-2HexNAc₂Lac (933 or 1095), of which the former glycans were more abundant and the latter less abundant. A general formula of these common glycans is Hex_mHexNAc_nLac, wherein m is either n or n-1, and n is either 1 or 2.

Neutral Glycolipid Profiles of Human Stem Cell Types:

Glycan signals typical to hESC preferentially include 876 and 892 (especially compared to MSC); the former preferentially corresponds to FucHexHexNAcLac, wherein α1,2-Fuc is preferential to α1,3/4-Fuc, and the latter preferentially corresponds to Hex₂HexNAc₁Lac, and more preferentially to Galβ3[Hex₁HexNAc₁]Lac; the glycan core composition Hex₄HexNAc₁was especially characteristic of hESC compared to other human stem cell types, in addition to fucosylation and more preferentially α1,2-linked fucosylation.

Glycan signals typical to both CB and BM MSC preferentially include 771, 1063, 1225; more preferentially including compositions dHex_0/2Hex_0-1HexNAc₂Lac.

Glycan signals typical to especially BM MSC preferentially include 511 and fucosylated structures, preferentially multifucosylated structures.

Glycan signals typical to especially CB MSC preferentially include 1460 and 1298, as well as large neutral glycolipids, especially Hex_2-3HexNAc₃Lac. In addition, low fucosylation and/or high expression of terminal β1,4-Gal was typical to especially CB MSC.

Glycan signals typical to CB MNC preferentially include compositions dHex_0-1[HexHexNAc]_1-2Lac, more preferentially high relative amounts of 730 compared to other signals; and fucosylated structures; and glycan profiles with less variability and/or complexity than other stem cell types.

The acidic glycan fractions of all the present sample types altogether comprised 38 glycan signals. The proposed monosaccharide compositions of the signals were composed of 0-2 NeuAc, 2-9 Hex, 0-6 HexNAc, 0-3 dHex, and/or 0-1 sulphate or phosphate esters. Glycan signals were detected at monoisotopic m/z values between 786 and 2781 (for [M−H]⁻ ion).

The acidic glycosphingolipid glycans of CB MNC were mainly composed of NeuAc₁Hex_n+2HexNAc_n, wherein 1≦n≦3, indicating that their structures were NeuAc₁[HexHexNAc]_1-3Lac.

Terminal glycan epitopes that were demonstrated in the present experiments in stem cell glycosphingolipid glycans include:

Gal

Galβ4Glc (Lac)

Galβ4GlcNAc (LacNAc type 2)

Galβ3

Non-reducing terminal HexNAc

Fuc

α1,2-Fuc

α1,3-Fuc

Fucα2Gal

Fucα2Galβ4GlcNAc (H type 2)

Fucα2Galβ4Glc (2′-fucosyllactose)

Fucα3GlcNAc

Galβ4(Fucα3)GlcNAc (Lex)

Fucα3Glc

Galβ4(Fucα3)Glc (3-fucosyllactose)

Neu5Ac

Neu5Acα2,3

Neu5Acα2,6

Development-related glycan epitope expression. According to the present invention, the glycosphingolipid glycan composition Hex₄HexNAc₁preferentially corresponds to (iso)globo structures. The glycan sequence of the SSEA-3 glycolipid antigen has been determined to be Galβ3GalNAcβ3Galα4Galβ4Glc, which corresponds to the glycan signal Hex₄HexNAc₁(892) detected in the present experiments only in hESC. Similarly, the glycan sequence of the SSEA-4 glycolipid antigen has been determined to be NeuAcα3Galβ3GalNAcβ3Galα4Galβ4Glc, which corresponds to the glycan signal NeuAc₁Hex₄HexNAc₁(1159) detected in the present experiments only in hESC. Consistent with the present glycan structure analyses, the hESC samples were determined to be SSEA-3 and SSEA-4 positive by monoclonal antibody staining as described in the preceding Examples. In contrast to mouse ES cells, hESC do not express the SSEA-1 antigen; consistent with this we found only low expression levels of α1,3/4-fucosylated neutral glycolipid glycans. In contrast, we were able to show that the major fucosylated structures of hESC glycosphingolipid glycans contain α1,2-Fuc, which is a molecular level explanation to the mouse-human difference in SSEA-1 reactivity.

Example 16
Lectin Based Selection of CB MNC Cell Populations

The FACS experiments with fluorescein-labeled lectins and CB MNC were performed essentially similarly to Example 7. Double stainings were performed with CD34 specific monoclonal antibody (Jaatinen et al., 2006) with complementary fluorescent dye. Erythroblast depletion from CD MNC fraction was performed by anti-glycophorin A (GlyA) monoclonal antibody negative selection.

Results and Discussion

Compared to the CB MNC fraction, GlyA depleted CB MNC showed decreased staining in FACS with the following lectins (the decrease in % in parenthesis): PWA (48%), LTA (59%), UEA (34%), STA, MAA, and PNA (all latter three less than 23%); indicating that GlyA depletion increased the resolving power of the lectins in cell sorting.

In FACS double staining with both fluorescein-labeled lectins and anti-CD34 antibody, the following lectins colocalized with CD34+ cells: STA (3/3 samples), HHA (3/3 samples), PSA (3/3 samples), RCA (3/3 samples), and partly also NPA (2/3 samples). In contrast, the following lectins did not colocalize with CD34+ cells: GNA (3/3 samples) and PWA (3/3 samples), and partly also LTA (2/3 samples), WFA (2/3 samples), and GS-II (2/3 samples).

Taken together with the results of Example 8, the present results indicate that lectins can enrich CD34+ cells from CB MNC by both negative and positive selection, for example:

- 1) GNA binds to about 70% of CB MNC but not to CD34+ cells, leading to about 3× enrichment in negative selection of CB MNC in CD34+ cell isolation.
- 2) STA binds to about 50% of CB MNC and also to CD34+ cells, leading to about 2× enrichment in positive selection of CB MNC in CD34+ cell isolation.
- 3) UEA binds to about 50% of CB MNC and also to CD34+ cells, leading to about 2× enrichment in positive selection of CB MNC in CD34+ cell isolation.

Example 17
Galectin Gene Expression Profiles of Stem Cells

Experimental Procedures

Gene expression analysis of CB CD133+ cells has been described (Jaatinen et al., 2006) and the present analysis was performed essentially similarly. The galectins whose gene expression profile was analyzed included (corresponding Affymetrix codes in parenthesis): Galectin-1 (201105_at), galectin-2 (208450_at), galectin-3 (208949_s_at), galectin-4 (204272_at), galectin-6 (200923_at), galectin-7 (206400_at), galectin-8 (208933_s_at), galectin-9 (203236_s_at), galectin-10 (206207_at), galectin-13 (220158_at).

Results and Discussion

In CB CD133+ versus CD133−, as well as CD34+ versus CD34− CB MNC cells, the galectin gene expression profile was as follows: Overall, galectins 1, 2, 3, 6, 8, 9, and 10 showed gene expression in both CD34+/CD133+ cells. Galectins 1, 2, and 3 were downregulated in both CD34+/CD133+ cells with respect to CD34−/CD133− cells, and in addition galectin 10 was downregulated in CD133+ cells with respect to CD133− cells. In contrast, in both CD34+/CD133+ cells galectin 8 was upregulated with respect to CD34−/CD133− cells.

In hESC versus EB samples, the galectin gene expression profile was as follows: Overall, galectins 1, 3, 6, 8, and 13 showed gene expression in hESC. Galectin 3 was clearly downregulated with respect to EB, and in addition galectin 13 was downregulated in 2 out of 4 hESC lines. In contrast, galectin 1 was clearly upregulated in all hESC lines.

The results indicate that both CB CD34+/CD133+ stem cell populations and hESC have an interesting and distinct galectin expression profiles, leading to different galectin ligand affinity profiles (Hirabayashi et al., 2002). The results further correlate with the glycan analysis results showing abundant galectin ligand expression in these stem cells, especially non-reducing terminal β-Gal and type II LacNAc, poly-LacNAc, β1,6-branched poly-LacNAc, and complex-type N-glycan expression.

Example 18
Immunohistochemical Staining of Stem Cells

Immunohistochemical Studies of Stem Cells (GF Series of Stainings)

After rinsing with PBS the sections were incubated in 3% highly purified BSA in PBS for 30 minutes at RT to block nonspecific binding sites. Primary antibodies (GF279, 288, 287, 284, 285, 283,286,290 and 289) were diluted (1:10) in PBS containing 1% BSA-PBS and incubated 1 hour at RT. After rinsing three times with PBS, the sections were incubated with biotinylated rabbit anti-mouse, secondary antibody (Zymed Laboratories, San Francisco, Calif., USA) in PBS for 30 minutes at RT, rinsed in PBS and incubated with peroxidase conjugated streptavidin (Zymed Laboratories) diluted in PBS. The sections were finally developed with AEC substrate (3-amino-9-ethyl carbazole; Lab Vision Corporation, Fremont, Calif., USA). After rinsing with water counterstaining was performed with Mayer's hemalum solution.

Antibodies used in the immunostainings. See also Table 22 for results.

Producer code
Manufact
Clone
Specificity
Code
Target stucture(s)
Host/isotype

MAB-S206 (Globo-H)
Glycotope
A69-A/E8
Globo-H
GF288
Fucα2Galβ3GalNAcβ3GalαLacCer
mouse/IgM

MAB-S201 CD174
Glycotope
A70-C/C8
CD174
GF289
Fucα2Galβ4(Fucα3)GlcNAc
mouse/IgM

(Lewis y)

(Lewis y)

MAB-S204 H type 2
Glycotope
A51-B/A6
H type 2
GF290
Fucα2Galβ4GlcNAc
mouse/IgA

DM3122: 0.1 mg
Acris
2-25LE
Lewis b
GF283
Fucα2Galβ3(Fucα4)GlcNAc
mouse/IgG

(Lewis b)

DM3015: 0.15 mg
Acris
B393
H Type 2
GF284
Fucα2Galβ4GlcNAc
mouse/IgM

DM3014: 0.15 mg
Acris
B389
H Type 2,
GF285
Fucα2Galβ4GlcNAc,
mouse/IgG1

Le b, Ley

Fucα2Galβ3(Fucα4)GlcNAc,

Fucα2Galβ4(Fucα3)GLcNAc

BM258P: 0.2 mg
Acris
BRIC 231
H Type 2
GF286
Fucα2Galβ4GlcNAc
mouse/IgG1

ab3355 (blood group
Abcam
17-206
H type 1
GF287
Fucα2Galβ3GlcNAc
mouse/IgG3

antigen H1)

ab3352 (pLN)
Abcam
K21
Lewis c
GF279
Galβ3GlcNAcβ(3Lac)
mouse/IgM

Gb3GN

Example 19
Glycosidase Profiling of Cord Blood Mononuclear cell N-Glycans

Experimental Procedures

Exoglycosidase digestions. Neutral N-glycan fractions were isolated from cord blood mononuclear cell populations as described above. Exoglycosidase reactions were performed essentially after manufacturers' instructions and as described in (Saarinen et al., 1999). The different reactions were; α-Man: α-mannosidase from Jack beans (C. ensiformis; Sigma, USA); β1,4-Gal: β1,4-galactosidase from S. pneumoniae (recombinant in E. coli; Calbiochem, USA); β1,3-Gal: recombinant β1,3-galactosidase (Calbiochem, USA); β-GlcNAc: β-glucosaminidase from S. pneumoniae (Calbiochem, USA); α2,3-SA: α2,3-sialidase from S. pneumoniae (Calbiochem, USA). The analytical reactions were carefully controlled for specificity with synthetic oligosaccharides in parallel control reactions that were analyzed by MALDI-TOF mass spectrometry. The sialic acid linkage specificity of α2,3-SA was controlled with synthetic oligosaccharides in parallel control reactions, and it was confirmed that in the reaction conditions the enzyme hydrolyzed α2,3-linked but not α2,6-linked sialic acids. The analysis was performed by MALDI-TOF mass spectrometry as described in the preceding examples. Digestion results were analyzed by comparing glycan profiles before and after the reaction.

RESULTS Glycosidase profiling of neutral N-glycans. Neutral N-glycan fractions from affinity-purified CD34+, CD34−, CD133+, CD133−, Lin+, and Lin− cell samples from cord blood mononuclear cells were isolated as described above. The glycan samples were subjected to parallel glycosidase digestions as described under Experimental procedures. Profiling results are summarized in Table 3 (CD34+ and CD34− cells), Table 4 (CD133+ and CD133− cells), and Table 5 (Lin− and Lin+ cells). The present results show that several neutral N-glycan signals are individually sensitive towards all the exoglycosidases, indicating that in all the cell types several neutral N-glycans contain specific substrate glycan structures in their non-reducing termini. The results also show clear differences between the cell types in both the sensitivity of individual glycan signals towards each enzyme and also profile-wide differences between cell types, as detailed in the Tables cited above.

Glycosidase profiling of sialylated N-glycans. Sialylated N-glycan fractions from affinity-purified CD133+ and CD133− cell samples from cord blood mononuclear cells were isolated as described above. The glycan samples were subjected to parallel glycosidase digestions as described under Experimental procedures. Profiling results by α2,3-sialidase are shown in Table 6. The results show significant differences between the glycan profiles of the analyzed cell types in the sialylated and neutral glycan fractions resulting in the reaction. The present results show that differences are seen in multiple signals in a profile-wide fashion. Also individual signals differ between cell types, as discussed below.

Cord blood CD133⁺ and CD133⁻ cell N-glycans are differentially α2,3-sialylated. Sialylated N-glycans from cord blood CD133⁺ and CD133⁻ cells were treated with c2,3-sialidase, after which the resulting glycans were divided into sialylated and non-sialylated fractions, as described under Experimental procedures. Both α2,3-sialidase resistant and sensitive sialylated N-glycans were observed, i.e. after the sialidase treatment sialylated glycans were observed in the sialylated N-glycan fraction and desialylated glycans were observed in the neutral N-glycan fraction. The results indicate that cord blood CD133⁺ and CD133⁻ cells are differentially α2,3-sialylated. For example, after α2,3-sialidase treatment the relative proportions of monosialylated (SA₁) glycan signal at m/z 2076, corresponding to the [M−H]⁻ ion of NeuAc₁Hex₅HexNAc₄dHex₁, and the disialylated (SA₂) glycan signal at m/z 2367, corresponding to the [M−H]⁻ ion of NeuAc₂Hex₅HexNAc₄dHex₁, indicate that α2,3-sialidase resistant disialylated N-glycans are relatively more abundant in CD133⁻ than in CD133⁺ cells, when compared to α2,3-sialidase resistant monosialylated N-glycans. It is concluded that N-glycan α2,3-sialylation in relation to other sialic acid linkages including especially α2,6-sialylation, is more abundant in cord blood CD133⁺ cells than in CD133⁻ cells.

In cord blood CD133⁻ cells, several sialylated N-glycans were observed that were resistant to α2,3-sialidase treatment, i.e. neutral glycans were not observed that would correspond to the desialylated forms of the original sialylated glycans. The results revealing differential α2,3-sialylation of individual N-glycan structures between cord blood CD133⁺ and CD133⁻ cells are presented in Table 6. The present results indicate that N-glycan α2,3-sialylation in relation to other sialic acid linkages is more abundant in cord blood CD133⁺ cells than in CD133⁻ cells.

Sialidase analysis. The sialylated N-glycan fraction isolated from a cord blood mononuclear cell population (CB MNC) was digested with broad-range sialidase as described in the preceding Examples. After the reaction, it was observed by MALDI-TOF mass spectrometry that the vast majority of the sialylated N-glycans were desialylated and transformed into corresponding neutral N-glycans, indicating that they had contained sialic acid residues (NeuAc and/or NeuGc) as suggested by the proposed monosaccharide compositions. Combined glycan profiles of neutral and desialylated (originally sialylated) N-glycan fractions of a CB MNC population was produced. The profiles correspond to total N-glycan profiles isolated from the cell samples (in desialylated form). It is calculated that approximately 25% of the N-glycan signals correspond to high-mannosc type N-glycan monosaccharide compositions, and 28% to low-mannose type N-glycans, 34% to complex-type N-glycans, and 13% to hybrid-type or monoantennary N-glycans monosaccharide compositions.

CONCLUSIONS The present results suggest that 1) the glycosidase profiling method can be used to analyze structural features of individual glycan signals, as well as differences in individual glycans between cell types, 2) different cell types differ from each other with respect to both individual glycan signals' and glycan profiles' susceptibility to glycosidases, and 3) glycosidase profiling can be used as a further means to distinguish different cell types, and in such case the parameters for comparison are both individual signals and profile-wide differences.

Example 20
Enzymatic Modification of Cell Surface Glycan Structures

Experimental Procedures

Enzymatic modifications. Sialyltransferase reaction: Human cord blood mononuclear cells (3×10⁶cells) were modified with 60 mU α2,3-(N)-sialyltransferase (rat, recombinant in S. frugiperda, Calbiochem), 1.6 μmol CMP-Neu5Ac in 50 mM sodium 3-morpholinopropanesulfonic acid (MOPS) buffer pH 7.4, 150 mM NaCl at total volume of 100 μl for up to 12 hours. Fucosyltransferase reaction: Human cord blood mononuclear cells (3×10⁶cells) were modified with 4 mU α1,3-fucosyltransferase VI (human, recombinant in S. frugiperda, Calbiochem), 1 μmol GDP-Fuc in 50 mM MOPS buffer pH 7.2, 150 mM NaCl at total volume of 100 μl for up to 3 hours. Broad-range sialidase reaction: Human cord blood mononuclear cells (3×10⁶cells) were modified with 5 mU sialidase (A. ureafaciens, Glyko, UK) in 50 mM sodium acetate buffer pH 5.5, 150 mM NaCl at total volume of 100 μl for up to 12 hours. α2,3-specific sialidase reaction: Cells were modified with α2,3-sialidase (S. pneumoniae, recombinant in E. coli) in 50 mM sodium acetate buffer pH 5.5, 150 mM NaCl at total volume of 100 μl. α-mannosidase reaction: α-mannosidase was from Jack beans and reaction was performed essentially similarly as with other enzymes described above. Sequential enzymatic modifications: Between sequential reactions cells were pelleted with centrifugation and supernatant was discarded, after which the next modification enzyme in appropriate buffer and substrate solution was applied to the cells as described above. Washing procedure: After modification, cells were washed with phosphate buffered saline.

Glycan analysis. After washing the cells, total cellular glycoproteins were subjected to N-glycosidase digestion, and sialylated and neutral N-glycans isolated and analyzed with mass spectrometry as described above. For O-glycan analysis, the glycoproteins were subjected to reducing alkaline β-elimination essentially as described previously (Nyman et al., 1998), after which sialylated and neutral glycan alditol fractions were isolated and analyzed with mass spectrometry as described above.

Results

Sialidase digestion. Upon broad-range sialidase catalyzed desialylation of living cord blood mononuclear cells, sialylated N-glycan structures as well as O-glycan structures (data not shown) were desialylated, as indicated by increase in relative amounts of corresponding neutral N-glycan structures, for example Hex₆HexNAc₃, Hex₅HexNAc₄dHex_0-2, and Hex₆HexNAc₅dHex_0-1monosaccharide compositions (Table 10). In general, a shift in glycosylation profiles towards glycan structures with less sialic acid residues was observed in sialylated N-glycan analyses upon broad-range sialidase treatment. The shift in glycan profiles of the cells upon the reaction served as an effective means to characterize the reaction results. It is concluded that the resulting modified cells contained less sialic acid residues and more terminal galactose residues at their surface after the reaction.

α2,3-specific sialidase digestion. Similarly, upon α2,3-specific sialidase catalyzed desialylation of living mononuclear cells, sialylated N-glycan structures were desialylated, as indicated by increase in relative amounts of corresponding neutral N-glycan structures (data not shown). In general, a shift in glycosylation profiles towards glycan structures with loss sialic acid residues was observed in sialylated N-glycan analyses upon α2,3-specific sialidase treatment. The shift in glycan profiles of the cells upon the reaction served as an effective means to characterize the reaction results. It is concluded that the resulting modified cells contained less α2,3-linked sialic acid residues and more terminal galactose residues at their surface after the reaction.

Sialyltransferase reaction. Upon α2,3-sialyltransferase catalyzed sialylation of living cord blood mononuclear cells, numerous neutral (Table 10) and sialylated N-glycan (Table 9) structures as well as O-glycan structures (data not shown) were sialylated, as indicated by decrease in relative amounts of neutral N-glycan structures (Hex₅HexNAc₄dHex_0-3and Hex₆HexNAc₅dHex_0-2monosaccharide compositions in Table 10) and increase in the corresponding sialylated structures (for example the NeuAc₂Hex₅HexNAc₄dHex₁glycan in Table 9). In general, a shift in glycosylation profiles towards glycan structures with more sialic acid residues was observed both in N-glycan and O-glycan analyses. It is concluded that the resulting modified cells contained more α2,3-linked sialic acid residues and less terminal galactose residues at their surface after the reaction.

Fucosyltransferase reaction. Upon α1,3-fucosyltransferase catalyzed fucosylation of living cord blood mononuclear cells, numerous neutral (Table 10) and sialylated N-glycan structures as well as O-glycan structures (see below) were fucosylated, as indicated by decrease in relative amounts of nonfucosylated glycan structures (without dHex in the proposed monosaccharide compositions) and increase in the corresponding fucosylated structures (with n_dHex>0 in the proposed monosaccharide compositions). For example, before fucosylation O-glycan alditol signals at m/z 773, corresponding to the [M+Na]⁺ ion of Hex₂HexNAc₂alditol, and at m/z 919, corresponding to the [M+Na]⁺ ion of Hex₂HexNAc₂dHex₁alditol, were observed in approximate relative proportions 9:1, respectively (data not shown). After fucosylation, the approximate relative proportions of the signals were 3:1, indicating that significant fucosylation of neutral O-glycans had occurred. Some fucosylated N-glycan structures were even observed after the reaction that had not been observed in the original cells, for example neutral N-glycans with proposed structures Hex₆HexNAc₅dHex₁and Hex₆HexNAc₅dHex₂(Table 10), indicating that in α1,3-fucosyltransferase reaction the cell surface of living cells can be modified with increased amounts or extraordinary structure types of fucosylated glycans, especially terminal Lewis x epitopes in protein-linked N-glycans as well as in O-glycans.

Sialidase digestion followed by sialyltransferase reaction. Cord blood mononuclear cells were subjected to broad-range sialidase reaction, after which α2,3-sialyltransferase and CMP-Neu5Ac were added to the same reaction, as described under Experimental procedures. The effects of this reaction sequence were observable on the N-glycan profiles. The sialylated N-glycan profile was also analyzed between the reaction steps, and the result clearly indicated that sialic acids were first removed from the sialylated N-glycans (indicated for example by appearance of increased amounts of neutral N-glycans), and then replaced by α2,3-linked sialic acid residues (indicated for example by disappearance of the newly formed neutral N-glycans; data not shown). It is concluded that the resulting modified cells contained more α2,3-linked sialic acid residues after the reaction.

Sialyltransferase reaction followed by fucosyltransferase reaction. Cord blood mononuclear cells were subjected to α2,3-sialyltransferase reaction, after which α1,3-fucosyltransferase and GDP-fucose were added to the same reaction, as described under Experimental procedures. The effects of this reaction sequence were observable on the sialylated N-glycan profiles of the cells. The results show that a major part of the glycan signals (examples in Tables 9 and 110) have undergone changes in their relative intensities, indicating that a major part of the sialylated N-glycans present in the cells were substrates of the enzymes. It was also clear that the combination of the enzymatic reaction steps resulted in different result than either one of the reaction steps alone.

Different from the α1,3-fucosyltransferase reaction described above, sialylation before fucosylation apparently sialylated the neutral fucosyltransferase acceptor glycan structures present on cord blood mononuclear cell surfaces, resulting in no detectable formation of the neutral fucosylated N-glycan structures that had emerged after α1,3-fucosyltransferase reaction alone (discussed above; Table 10).

α-mannosidase reaction. α-mannosidase reaction of whole cells showed a minor reduction of glycan signals including those indicated to contain α-mannose residues in the preceding examples.

Glycosyltransferase-derived glycan structures. We detected that glycosylated glycosyltransferase enzymes can contaminate cells in modification reactions. For example, when cells were incubated with recombinant fucosyltransferase or sialyltransferase enzymes produced in S. frugiperda cells, N-glycosidase and mass spectrometric analysis of cellular and/or cell-associated glycoproteins resulted in detection of an abundant neutral N-glycan signal at m/z 1079, corresponding to [M+Na]⁺ ion of Hex₃HexNAc₂dHex₁glycan component (calc. m/z 1079.38). Typically, in recombinant glycosyltransferase treated cells, this glycan signal was more abundant than or at least comparable to the cells' own glycan signals, indicating that insect-derived glycoconjugates are a very potent contaminant associated with recombinant glycan-modified enzymes produced in insect cells. Moreover, this glycan contamination persisted even after washing of the cells, indicating that the insect-type glycoconjugate corresponding to or associated with the glycosyltransferase enzymes has affinity towards cells or has tendency to resist washing from cells. To confirm the origin of the glycan signal, we analyzed glycan contents of commercial recombinant fucosyltransferase and sialyltransferase enzyme preparations and found that the m/z 1079 glycan signal was a major N-glycan signal associated with these enzymes. Corresponding N-glycan structures, e.g. Manα3(Manα6)Manβ4GlcNAc(Fucα3/6)GlcNAc(β-N-Asn), have been described previously from glycoproteins produced in S. frugiperda cells (Staudacher et al., 1992; Kretzchmar et al., 1994; Kubelka et al., 1994; Altmann et al., 1999). As described in the literature, these glycan structures, as well as other glycan structures potentially contaminating cells treated with recombinant or purified enzymes, especially insect-derived products, are potentially immunogenic in humans and/or otherwise harmful to the use of the modified cells. It is concluded that glycan-modifying enzymes must be carefully selected for modification of human cells, especially for clinical use, not to contain immunogenic glycan epitopes, non-human glycan structures, and/or other glycan structures potentially having unwanted biological effects.

Example 21
Proton NMR Analysis of Human Embryonic Stem Cell N-Glycan Fractions

Experimental Procedures

N-glycans were isolated from human embryonic stem cell (hESC) line (25 million cells) and fractionated into neutral and acidic N-glycan fractions as described above. The final purification prior to NMR analysis was performed by gel filtration high-performance liquid chromatography (HPLC) on a Superdex Peptide HR10/300 column in water or 50 mM ammonium bicarbonate for the neutral and acidic fractions, respectively. Fractions were collected and MALDI-TOF mass spectra were recorded from each fraction as described above (data not shown). All fractions containing N-glycans were pooled and prepared for the NMR experiment. The yields of neutral and acidic glycans were 4.0 and 6.6 nmol, respectively. Prior to NMR analysis the purified glycome fractions were repeatedly dissolved in 99.996% deuterium oxide and dried to omit H₂O and to exchange sample protons. The ¹H-NMR spectra at 800 MHz were recorded using a cryo-probe for enhanced sensitivity. Chemical shifts are expressed in parts per million (ppm) by reference to internal standard acetone (2.225 ppm).

Results and Discussion

Neutral N-glycan fraction. The identified signals in the neutral N-glycan spectrum are described in Table 11. The identified signals were consistent with N-glycan structures, more specifically high-mannose type N-glycan structures such as the structures A-D in FIG. 26 that have the proposed monosaccharide compositions Man_7-9GlcNAc₂. In the mass spectrum recorded from the pooled neutral N-glycan fraction, the signals with the Hex_7-9HexNAc₂composition together accounted for more than a half of the total signal intensity, which is consistent with the NMR result that these signals were the major glycans in the sample. The NMR spectrum contained the characteristic signals of the glycan structures A-D (Fu et al., 1994; Hård et al., 1991) and the significant signals in the NMR spectrum can be explained by the following glycan structure combinations: A+D, B+C, A+B+D, A+C+D, B+C+D, and A+B+C+D.

Neutral N-glycan core sequences. The identified N-glycan core structure common to all the identified glycan structures in the NMR spectrum includes the following glycan sequences: the internal core sequences Manβ4GlcNAc, Manα3Manβ4GlcNAc, Manα6Manβ4GlcNAc, and Manα3(Manα6)Manβ4GlcNAc, and the reducing terminal glycan core sequences GlcNAcβ4GlcNAc, Manα4GlcNAcβ4GlcNAc, Manα3Manβ4GlcNAcβ4GlcNAc, Manα6Manβ4GlcNAcβ4GlcNAc, and Manα3(Manα6)Manβ4GlcNAcβ4GlcNAc. The N-glycans in the sample were liberated by N-glycosidase F enzyme indicating that the reducing terminal core sequences were β-N-linked to asparagine residues in the original sample glycoproteins. Other glycan core structures could not be identified in the spectrum.

Neutral N-glycan antennae. In the identified structures A-D, the common reducing terminal N-glycan core sequence Manα3(Manα6)Manβ4GlcNAc4GlcNAc is further elongated by the following antennae: Manα2Manα2 or Manα2 to the α3-linked Man; and/or Manα2Manα3, Manα2Manα6, Manα3, and/or Manα6 to the α6-linked Man. Other glycan antennae could not be identified in the spectrum.

Acidic N-glycan fraction. The identified signals in the acidic N-glycan spectrum are described in Table 12. The identified signals were consistent with N-glycan structures, more specifically complex type N-glycan structures such as the reference structures A-E in FIG. 27 (Hård et al., 1992; Helin et al., 1995). In the mass spectrum recorded from the pooled acidic N-glycan fraction, the signals containing exactly five hexoses and four N-acetylhexosamines in their proposed composition i.e. containing the Hex₅HexNAc₄structural feature (like structures B-E) together accounted for approximately 45% of the total signal intensity, which is consistent with the NMR result that the corresponding glycans were the major glycans in the sample. The NMR spectrum contained the characteristic signals of the structures A-E, and the significant signals in the NMR spectrum can be explained by the structural components of these reference structures.

Acidic N-glycan core sequences. The identified N-glycan core structure common to all the identified glycan structures in the NMR spectrum includes the following glycan sequences: the reducing terminal glycan core sequences GlcNAcβ4(±Fucα6)GlcNAc, Manβ4GlcNAcβ4(±Fucα6)GlcNAc, Manα3Manβ4GlcNAcβ4(±Fucα6)GlcNAc, Manα6Manβ4GlcNAcβ4(±Fucα6)GlcNAc, and Manα3(Manα6)Manβ4GlcNAcβ4(±Fucα6)GlcNAc, wherein ±Fucα6 indicates the site of N-glycan core fucosylation. The N-glycans in the sample were liberated by N-glycosidase F enzyme indicating that the reducing terminal core sequences were β-N-linked to asparagine residues in the original sample glycoproteins. Other glycan core structures could not be identified in the spectrum.

Acidic N-glycan antennae. In the reference structures A-D, the reducing terminal N-glycan core sequences are further elongated by the following antennae, which were also identified in the recorded spectrum: Neu5Acα3Galβ4GlcNAcβ2, Neu5Acα6Galβ4GlcNAcβ2, Galβ4GlcNAcβ2, and/or Galα3Galβ4GlcNAcβ2 to either α3-linked Man or α6-linked Man. The identified antennae in the NMR spectrum include the internal glycan sequence GlcNAc β-linked or more specifically β2-linked to the N-glycan core structure. Other glycan antennae could not be identified in the spectrum, indicating that these antennae were the most abundant antenna structures in the sample.

Galα3Gal sequences. In the mass spectrum recorded from the pooled acidic N-glycan fraction, the signals corresponding to glycan structures containing the Hex₆HexNAc₄composition feature together accounted for about 16% of the total signal intensity, which is consistent with the NMR result that these signals correspond to major glycans in the sample.

Comparison of NMR profiling and mass spectrometric profiling results. As described above, the ¹H-NMR spectra were consistent with the mass spectra recorded from the hESC samples and support the quantitative and structural assignments made based on the mass spectrometric profiles in the preceding Examples.

NMR REFERENCES

Fu D., Chen L. and O'Neill R. A. (1994) Carbohydr. Res. 261, 173-186

Helin J., Maaheimo H., Seppo A., Keane A. and Renkonen O. (1995) Carbohydr. Res. 266, 191-209

Hård K., Mekking A., Kamerling J. P., Dacremont G. A. A. and Vliegenthart J. F. G. (1991) Glycoconjugate J. 8, 17-28

Hård K., Van Zadelhoff G., Moonen P., Kamerling J. P. and Vliegenthart J. F. G. (1992) Eur. J. Biochem. 209, 895-915

Example 22
Exoglycosidase Analysis of Human Embryonic Stem Cells

Experimental Procedures

hESC and differentiated cell samples. The human embryonic stem cell (hESC) and embryoid body (EB) samples were prepared from hESC line FES 29 (Skottman et al., 2005) essentially as described in the preceding Examples, however in the present Example the hESCs were propagated on murine fibroblast feeder cells (mEF) and the hESC samples contained some mEF cells.

Exoglycosidase digestions were performed essentially as described (Saarinen et al., 1999) and as described in the preceding Examples. The enzymes used were α-mannosidase and β-hexosaminidase from Jack beans (C. ensiformis, Sigma, USA), β-glucosaminidase and β1,4-galactosidase from S. pneumoniae (rec. in E. coli, Calbiochem, USA), α2,3-sialidase from S. pneumoniae (Glyko, UK), α1,3/4-fucosidase from Xanthomonas sp. (Calbiochem, USA), α1,2-fucosidase from X. manihotis (Glyko), β1,3-galactosidase (rec. in E. coli, Calbiochem), and α2,3/6/8/9-sialidase from A. ureafaciens (Glyko). The specific activities of the enzymes were controlled in parallel reactions with purified oligosaccharides or oligosaccharide mixtures, and analyzed similarly as the analytic reactions. The changes in the exoglycosidase digestion result Tables are relative changes in the recorded mass spectra and they do not reflect absolute changes in the glycan profiles resulting from glycosidase treatments.

Results and Discussion

hESC. Neutral and acidic N-glycan fractions were isolated from hESC grown on both murine and human fibroblast feeder cells as described in the preceding Examples. The results of parallel exoglycosidase digestions of the neutral (Tables 13 and 14) and acidic (Table 15) glycan fractions are discussed below. In the following chapters, the glycan signals are referred to by their proposed monosaccharide compositions according to the Tables of the present invention and the corresponding m/z values can be read from the Tables.

α-mannosidase sensitive structures. All the glycan signals that showed decrease upon α-mannosidase digestion of the neutral N-glycan fraction (Tables 13 and 14) are indicated to correspond to glycans that contain terminal α-mannose residues. The present results indicate that the majority of the neutral N-glycans of hESC contain terminal α-mannose residues. On the other hand, increased signals correspond to their reaction products. Structure groups that form series of α-mannosylated glycans in the neutral N-glycan fraction as well as individual α-mannosylated glycans are discussed below in detail.

The Hex_1-9HexNAc₁glycan series was digested so that Hex_3-9HexNAc₁were digested and transformed into Hex₁HexNAc₁(data not shown), indicating that they had contained terminal α-mannose residues. Because they were transformed into Hex₁HexNAc₁, their experimental structures were (Manα)_1-8Hex₁HexNAc₁.

The Hex_1-12HexNAc₂glycan series was digested so that Hex_3-12HexNAc₂were digested and transformed into Hex_1-7HexNAc₂and especially into Hex₁HexNAc₂that had not existed before the reaction and was the major reaction product. This indicates that 1) glycans Hex_3-12HexNAc₂include glycans containing terminal α-mannose residues, 2) glycans Hex_1-7HexNAc₂could be formed from larger α-mannosylated glycans, and 3) majority of the glycans Hex_3-12HexNAc₂were transformed into newly formed Hex₁HexNAc₂and therefore had the experimental structures (Manα)_nHex₁HexNAc₂, wherein n≧1. The fact that the α-mannosidase reaction was only partially completed for many of the signals suggests that also other glycan components are included in the the Hex_1-12HexNAc₂glycan series. In particular, the Hex_10-12HexNAc₂components contain 1-3 hexose residues more than the largest typical mammalian high-mannose type N-glycan, suggesting that they contains glucosylated structures including (Glcα)_1-3Hex₈HexNAc₂, preferentially α2- and/or α3-linked Glc and even more preferentially present in the glucosylated N-glycans Glcα3→Man₉GlcNAc₂, Glcα2Glcα3→Man₉GlcNAc₂, and/or Glcα2Glcα2Glcα3→Man₉GlcNAc₂. The corresponding glucosylated fragments were observed after the α-mannosidase digestion, preferentially corresponding to Glc_1-3Man₄GlcNAc₂(Hex_5-7HexNAc₂).

The Hex_1-6HexNAc₁dHex₁glycan series was digested so that Hex_3-9HexNAc₁dHex₁were digested and transformed into Hex₁HexNAc₁dHex₁, indicating that they had contained terminal α-mannose residues and their experimental structures were (Manα)_2-5Hex₁HexNAc₁dHex₁. Hex₁HexNAc₁dHex₁appeared as a new signal indicating that glycans with structures (Manα)_nHex₁HexNAc₁dHex₁, wherein n≧1, had existed in the sample.

The Hex_2-7HexNAc₃glycan series was digested so that Hex_5-7HexNAc₃were digested and transformed into other glycans in the series, indicating that they had contained terminal α-mannose residues. Hex₂HexNAc₃appeared as a new signal indicating that glycans with structures (Manα)_nHex₂HexNAc₃, wherein n≧1, had existed in the sample.

The Hex_2-7HexNAc₃dHex₁glycan series was digested so that Hex_5-7HexNAc₃dHex₁were digested and transformed into other glycans in the series, indicating that they had contained terminal α-mannose residues. Hex₂HexNAc₃dHex₁was increased significantly indicating that glycans with structures (Manα)_nHex₂HexNAc₃dHex₁, wherein n≧1, had existed in the sample.

Hex₃HexNAc₃dHex₂appeared as a new signal indicating that glycans with structures (Manα)_nHex₃HexNAc₃dHex₂, wherein n≧1, had existed in the sample.

β-glucosaminidase sensitive structures. The Hex₃HexNAc_2-5and Hex₃HexNAc_2-5dHex₁glycan series were digested so that Hex_3-5HexNAc₁dHex_0-1were digested and transformed into Hex₃HexNAc₂dHex_0-1, indicating that they had contained terminal β-GlcNAc residues and their experimental structures were (GlcNAcβ→)_1-3Hex₃HexNAc₂and (GlcNAcβ→)_1-3Hex₃HexNAc₂dHex₁, respectively.

Hex₄HexNAc₄, Hex₄HexNAc₄dHex₁, Hex₄HexNAc₄dHex₂, and Hex₅HexNAc₅dHex₁were also digested indicating they contained structures including (GlcNAcβ→)Hex₄HexNAc₃, (GlcNAcβ→)Hex₄HexNAc₃dHex₁, (GlcNAcβ→)Hex₄HexNAc₃dHex₂, and (GlcNAcβ→)Hex₅HexNAc₄dHex₁, respectively.

Hex₄HexNAc₅dHex₁and Hex₄HexNAc₅dHex₂were digested by β-glucosaminidase and indicated to contain two β-GlcNAc residues each. In contrast, Hex₄HexNAc₅was not digested with β-glucosaminidase.

β-hexosaminidase sensitive structures. The Hex₄HexNAc₅glycan signal was sensitive to β-hexosaminidase but not to β-glucosaminidase indicating that it corresponded to glycan structures containing terminal β-N-acetylhexosamine residues other than β-GlcNAc, preferentially β-GalNAc. Upon β-hexosaminidase digestion, the signal was transformed into Hex₄HexNAc₃indicating that the enzyme liberated two HexNAc residues from the corresponding glycan structures.

β1,4-galactosidase sensitive structures. Glycan signals that were sensitive to β1,4-galactosidase comprised a major proportion of hESC glycans, indicating that β1,4-linked galactose is a common terminal epitope in hESC neutral N-glycans.

Hex₅HexNAc₄and Hex₅HexNAc₄dHex₁were digested into Hex₃HexNAc₄and Hex₃HexNAc₄dHex₁indicating they had the structures (Galβ4GlcNAcβ→)₂Hex₃HexNAc₂and (Galβ4GlcNAcβ→)₂Hex₃HexNAc₂dHex₁, respectively. In contrast, Hex₅HexNAc₄dHex₂was digested into Hex₄HexNAc₄dHex₂indicating that it had the structure (Galβ4GlcNAcβ→)Hex₄HexNAc₃dHex₂, and Hex₅HexNAc₄dHex₃was not digested at all. Taken together, in hESC, hexose residues are protected by deoxyhexose residues from the action of β1,4-galactosidase in the N-glycan structures. Such dHex-protected structures containing β1,4-linked galactose include Galβ4(Fucα3)GlcNAc and Fucα2Galβ4GlcNAc.

Hex₄HexNAc₅that also included a β-hexosaminidase sensitive component was digested by β1,4-galactosidase. Taken together, the results suggest that the Hex₄HexNAc₅glycan signal includes glycan structures including Galβ4GlcNAc(GalNAcβHexNAcβ)Hex₃HexNAc₂.

β1,3-galactosidase sensitive structures. Because only few structures in hESC neutral N-glycan fraction were sensitive to the action of β1,3-galactosidase, the majority of terminal galactose residues appear to be β1,4-linked.

Glycosidase resistant structures. In the present experiments, Hex₄HexNAc₃, Hex₄HexNAc₃dHex₂, and Hex₅HexNAc₅were resistant to the tested exoglycosidases. The second monosaccharide composition contains more than one deoxyhexose residues suggesting that it is protected from glycosidase digestions by d&ex residues such as α2-, α3-, or α4-linked fucose residues, preferentially present in Fucα2Gal, Fucα3GlcNAc, and/or Fucα4GlcNAc epitopes.

The compiled neutral N-glycan fraction glycan structures based on the exoglycosidase digestions of hESC are presented in Table 16.

Acidic N-glycan fraction. The acidic N-glycan fraction of hESC grown on mEF cell layers were characterized by parallel α2,3-sialidase and A. ureafaciens sialidase treatments as well as sequential digestions with α1,3/4-fucosidase and α1,2-fucosidase. The results from these reactions as analyzed by MALDI-TOF mass spectrometry are described in Table 15. The results suggest that multiple N-glycan components in the hESC sample contain the specific glycan substrates for these enzymes, namely α2,3-linked and other sialic acid residues, and both α1,2- and α1,3/4-linked fucose residues. Some glycan signals showed the presence of many of these epitopes, such as the glycan signal at m/z 2222 (corresponding to NeuAc₁Hex₅HexNAc₄dHex₂) that was suggested to contain all these epitopes, preferentially in multiple glycan structures. The compiled acidic N-glycan fraction glycan structures based on the exoglycosidase digestions of hESC are presented in Table 34.

EB. Differentiation specific changes between embryoid bodies (EB; FES 29 st 2 in Table 13) and hESC (FES 29 st 1 in Table 13) were reflected in their neutral N-glycan fraction exoglycosidase digestion profiles, as described in Table 13. Differential exoglycosidase digestion results were observed in glycan signals including m/z 1688, 1704, 1793, 1866, 1955, 1971, 2012, 2028, 2142, 2158, and 2320, corresponding to different neutral N-glycan fraction glycan profiles.

mEF. By comparison of Table 35 and Table 13, murine feeder cell (mEF) specific neutral N-glycan fraction glycan components were identified and they are listed in Table 36. These glycan components are characterized by additional hexose residues compared to hESC or hEF specific structures according to the present invention. The exoglycosidase experiments also suggest that β1,4-linked galactose epitopes are protected from β1,4-galactosidase digestion by any additional hexose residues in the monosaccharide compositions. Taken together with the NMR analysis results of the present invention, the additional hexose residues are suggested to be α-linked galactose residues, more specifically including Galα3Gal epitopes in the N-glycan antennae, as described in Table 36.

Example 23
Exoglycosidase Analysis of Human Mesenchymal Stem Cells

The changes in the exoglycosidase digestion result Tables are relative changes in the recorded mass spectra and they do not reflect absolute changes in the glycan profiles resulting from glycosidase treatments. The experimental procedures are described in the preceding Example.

Results

Undifferentiated BM MSC

Neutral and acidic N-glycan fractions were isolated from BM MSC as described. The results of parallel exoglycosidase digestions of the neutral (Table 17) and acidic (data not shown) glycan fractions are discussed below. In the following chapters, the glycan signals are referred to by their proposed monosaccharide compositions according to the Tables of the present invention and the corresponding m/z values can be read from the Tables.

α-mannosidase sensitive structures. All the glycan signals that showed decrease upon α-mannosidase digestion of the neutral N-glycan fraction (Table 17) are indicated to correspond to glycans that contain terminal α-mannose residues. The present results indicate that the majority of the neutral N-glycans of BM MSC contain terminal α-mannose residues. On the other hand, increased signals correspond to their reaction products. Structure groups that form series of α-mannosylated glycans in the neutral N-glycan fraction as well as individual α-mannosylated glycans are discussed below in detail.

The Hex_1-10HexNAc₂glycan series was digested so that Hex_4-10HexNAc₂were digested and transformed into Hex_1-4HexNAc₂and especially into Hex₁HexNAc₂that had not existed before the reaction and was the major reaction product. This indicates that 1) glycans Hex_1-10HexNAc₂include glycans containing terminal α-mannose residues, 2) glycans Hex_1-4HexNAc₂could be formed from larger α-mannosylated glycans, and 3) majority of the glycans Hex_4-10HexNAc₂were transformed into newly formed Hex₁HexNAc₂and therefore had the experimental structures (Manα)_nHex₁HexNAc₂, wherein n≧1. The fact that the α-mannosidase reaction was only partially completed for many of the signals suggests that also other glycan components are included in the the Hex_1-10HexNAc₂glycan series. In particular, the Hex₁₀HexNAc₂component contains one hexose residue more than the largest typical mammalian high-mannose type N-glycan, suggesting that it contains glucosylated structures including (Glcα→)Hex₈HexNAc₂, preferentially α3-linked Glc and even more preferentially present in the glucosylated N-glycan (Glcα3)Man₉GlcNAc₂.

The Hex_2-7HexNAc₃glycan series was digested so that Hex_6-7HexNAc₃were digested and transformed into other glycans in the series, indicating that they had contained terminal α-mannose residues. Hex₂HexNAc₃appeared as a new signal indicating that glycans with structures (Manα)_nHex₂HexNAc₃, wherein n≧1, had existed in the sample.

The Hex_2-7HexNAc₃dHex₁glycan series was digested so that Hex_6-7HexNAc₃dHex₁were digested and transformed into other glycans in the series, indicating that they had contained terminal α-mannose residues. Hex₂HexNAc₃dHex₁appeared as a new signal indicating that glycans with structures (Manα)_nHex₂HexNAc₃dHex₁, wherein n≧1, had existed in the sample. Hex₃HexNAc₃dHex₂and Hex₃HexNAc₄appeared as new signals indicating that glycans with structures (Manα)_nHex₃HexNAc₃dHex₂and (Manα)_nHex₃HexNAc₄, respectively, wherein n≧1, had existed in the sample.

β-glucosaminidase sensitive structures. The Hex₃HexNAc_2-5dHex₁glycan series was digested so that Hex_3-9HexNAc₁dHex₁were digested and transformed into Hex₁HexNAc₁dHex₁, indicating that they had contained terminal α-mannose residues and their experimental structures were (Manα)_2-5Hex₁HexNAc₁dHex₁. Hex₁HexNAc₁dHex₁appeared as a new signal indicating that glycans with structures (Manα)_nHex₁HexNAc₁dHex₁, wherein n≧1, had existed in the sample. However, Hex₃HexNAc₆dHex₁was not digested indicating that it contained other terminal HexNAc residues than β-linked GlcNAc residues.

Hex₂HexNAc₃and Hex₂HexNAc₃dHex₁were digested into Hex₂HexNAc₂and Hex₂HexNAc₂dHex₁indicating they had the structures (GlcNAcβ→)Hex₂HexNAc₂and (GlcNAcβ→)Hex₂HexNAc₂dHex₁, respectively.

Hex₄HexNAc₄dHex₁, Hex₄HexNAc₄dHex₂, Hex₄HexNAc₅dHex₂, and Hex₅HexNAc₅dHex₁were also digested indicating they contained structures including (GlcNAcβ→)Hex₄HexNAc₃dHex₁, (GlcNAc⊖→)Hex₄HexNAc₃dHex₂, (GlcNAcβ→)Hex₄HexNAc₄dHex₂, and (GlcNAcβ→)Hex₅HexNAc₄dHex₁, respectively.

β1,4-galactosidase sensitive structures. Glycan signals that were sensitive to β1,4-galactosidase comprised a major proportion of BM MSC glycans, indicating that β1,4-linked galactose is a common terminal epitope in BM MSC neutral N-glycans.

Hex₅HexNAc₄and Hex₅HexNAc₄dHex₁were digested into Hex₃HexNAc₄and Hex₃HexNAc₄dHex₁indicating they had the structures (Galβ4GlcNAcβ→)₂Hex₃HexNAc₂and (Galβ4GlcNAcβ→)₂Hex₃HexNAc₂dHex₁, respectively. In contrast, Hex₅HexNAc₄dHex₂was digested into Hex₄HexNAc₄dHex₂indicating that it had the structure (Galβ4GlcNAcβ→)Hex₄HexNAc₃dHex₂, respectively, and Hex₅HexNAc₄dHex₃was not digested at all. Taken together, in BM MSC, n-1 hexose residues are protected by deoxyhexose residues from the action of β1,4-galactosidase in the N-glycan structures Hex₅HexNAc4dHex_n, wherein 0≦n≦3. Such dHex-protected structures containing β1,4-linked galactose include Galβ4(Fucα3)GlcNAc and Fucα2Galβ4GlcNAc.

Similarly, Hex₆HexNAc₅, Rex₅HexNAc₅dHex₁, Hex₆HexNAc₅, and Hex₅HexNAc₅dHex₁were digested into Hex₃HexNAc₅, Hex₃HexNAc₅dHex₁, and Hex₃HexNAc₆dHex₁indicating they had the structures (Galβ4GlcNAcβ→)₃Hex₃HexNAc₂, (Galβ4GlcNAcβ→)₂Hex₃HexNAc₃dHex₁, and (Galβ4GlcNAc⊖→)₃Hex₃HexNAc₃dHex₁, respectively. In contrast, Hex₄HexNAc₅dHex₂, Hex₅HexNAc₅dHex₃, Hex₆HexNAc₅dHex₂, and Hex₆HexNAc₅dHex₃were not digested, indicating that hexose residues in these structures were protected by deoxyhexose residues. Such dHex-protected structures containing β1,4-linked galactose include Galβ4(Fucα3)GlcNAc and Fucα2Galβ4GlcNAc. However, Hex₄HexNAc₅dHex₃was digested indicating that it contained one or more terminal β1,4-linked galactose residues.

Hex₇HexNAc₃, Hex₆HexNAc₃dHex₁, Hex₆HexNAc₃, and Hex₅HexNAc₃dHex₁were digested into products including Hex₅HexNAc₃and Hex₄HexNAc₃dHex₁, indicating they had the structures (Galβ4GlcNAcβ→)Hex_5-6HexNAc₂and (Galβ4GlcNAcβ→)Hex_4-5HexNAc₃dHex₁, respectively. The relative amounts of Hex₃HexNAc₃, and Hex₃HexNAc₃dHex₁were increased indicating that they were products of (Galβ4GlcNAcβ→)Hex₃HexNAc₂and (Galβ4GlcNAcβ→)Hex₃HexNAc₂dHex₁, respectively.

β1,3-galactosidase sensitive structures. Because only few structures in BM MSC neutral N-glycan fraction are sensitive to the action of β1,3-galactosidase, the majority of terminal galactose residues appear to be β1,4-linked. The glycan signals corresponding to β1,3-galactosidase sensitive glycans include Hex₅HexNAc₅dHex₁and Hex₄HexNAc₅dHex₃.

Glycosidase resistant structures. In the present experiments, Hex₂HexNAc₃dHex₂, Hex₄HexNAc₃dHex₂, and Hex₁₁HexNAc₂were resistant to the tested exoglycosidases. The first two proposed monosaccharide compositions contain more than one deoxyhexose residues suggesting that they are protected from glycosidase digestions by the second dHex residues such as α2-, α3-, or α4-linked fucose residues, preferentially present in Fucα2Gal, Fucα3GlcNAc, and/or Fucα4GlcNAc epitopes. The last proposed monosaccharide composition contains two hexose residues more than the largest typical mammalian high-mannose type N-glycan, suggesting that it contains glucosylated structures including (Glcα→)₂Hex₉HexNAc₂, preferentially α2- and/or α3-linked Glc and even more preferentially present in the diglucosylated N-glycan (GlcαGlcα→)Man₉GlcNAc₂.

The compiled neutral N-glycan fraction glycan structures based on the exoglycosidase digestions of BM MSC are presented in Table 18.

Osteoblast-Differentiated BM MSC

The analysis of osteoblast differentiated BM MSC are presented in Table 19, allowing comparison of differentiation specific changes in CB MSC. The exoglycosidase profiles produced for BM MSC and osteoblast differentiated BM MSC are characteristic for the two cell types. For example, signals at m/z 1339, 1784, and 2466 are digested differentially in the two experiments. Specifically, the presence of β1,3-galactosidase sensitive neutral N-glycan signals in osteoblast differentiated BM MSC indicate that the differentiated cells contain more β1,3-linked galactose residues than the undifferentiated cells.

The sialidase analysis performed for the acidic N-glycan fraction of BM MSC supported the proposed monosaccharide compositions based on sialylated (NeuAc or NeuGc containing) N-glycans in the acidic N-glycan fraction.

Analysis of CB MSC Neutral Glycan Fraction by Exoglycosidases

The results of the analysis by β1,4-galactosidase and β-glucosaminidase are presented in Table 20. The results suggest that also in CB MSC neutral N-glycans containing non-reducing terminal β1,4-linked galactose residues are abundant, and they suggest the presence of characteristic non-reducing terminal epitopes for most of the observed glycan signals. The analysis of adipocyte differentiated CB MSC are presented in Table 21, allowing comparison of differentiation specific changes in CB MSC, similarly as described above for BM MSC. The sialidase analysis performed for the acidic N-glycan fraction of CB MSC supported the proposed monosaccharide compositions based on sialylated (NeuAc or NeuGc containing) N-glycans in the acidic N-glycan fraction.

Example 24
Gene Expression and Glycome Profiling of Human Embryonic Stem Cells

Results and Discussion

Obtaining of the gene expression data from the hESC lines FES 21, 22, 29, and 30 has been described (Skottman et al., 2005) and the present data was produced essentially similarity. The results of the gene expression profiling analysis with regard to a selection of potentially glycan-processing and accessory enzymes are presented in Table 26, where gene expression is both qualitatively determined as being present (P) or absent (A) and quantitatively measured in comparison to embryoid bodies (EB) derived from the same cell lines.

Fucosyltransferase expression levels. Three fucosyltransferase transcripts were detected in hESC: FUT1 (α1,2-fucosyltransferase; increased in all FES cell lines), FUT4 (α1,3-fucosyltransferase IV; increased in all FES cell lines), and FUT8 (N-glycan core α1,6-fucosyltransferase).

Hexosaminyltransferase expression levels. The following transcripts in the selection of Table 26 were detected in hESC: MGAT3, MGAT2 (increased in three FES cell lines), MGAT1, GNT4b, β3GlcNAc-T5, β3GlcNAc-T7, β3GlcNAc-T4 (present in two FES cell lines), β6GlcNAcT (increased in one FES cell line), iβ3GlcNAcT, globosideT, and α4GlcNAcT (present in two FES cell lines).

Other gene expression levels. The following transcripts in the selection of Table 26 were detected in hESC: AER1 (increased in all FES cell lines), AGO61, β3GALT3, MAN1C1, and LGALS3.

Example 25

Isolation of Subset Expressing Glycan Structures of Formula (I) on Human Embryonic Stem Cells

Cell Culture and Passaging

FES hESC lines with normal karyotypes are obtained and grown as described in Mikkola et al. (2006; Distinct differentiation characteristics of individual human embryonic stem cell lines, BMC Dev Biol. 2006; 6: 40).

Human ESCs are maintained on mitotically inactivated primary mouse embryonic fibroblasts (MEF) feeder layers for routine maintenance. Cells are grown in tissue culture treated dishes (Corning Incorporated). Cells are passaged every 6 days using either a pretreatment with 10 mg/ml collagenase 5 minutes or manual dissection with a fire pulled Pasteur pipette.

Immunocytochemistry is performed on routinely maintained adherent hESC colonies, and flow cytometry is performed using routinely maintained hESC colonies that are stained for antibodies, lectins or glycosidases of the present invention.

Enrichment of Glycan Structure of Formula (1) Expressing Stem Cells

The FACS analysis is performed essentially as described in Venable et al. (2005) but living cells are used instead and FACSAria™ cell sorter (BD).

Human ESCs are harvested into single cell suspensions using collagenase and cell dissociation solution (Sigma). Then, cells are placed in sterile tube in aliquots 106 cells each and stained with one of the GF antibody in 1:100 solution. Cells are washed 3 times with PBS and then stained with secondary antibodies (antigoat mouse IgG or IgM FITC conjugated). Unstained FES used as control. The FITC positive cells are collected into cell culture media (in +4° C.) (according to BD instructions).

Then, cells are placed on MEF or HHF feeder layers and monitored for clonal or cell lineage. To check the undifferentiation stage, the gene expression of sorted cells are analyzed with real-time PCR.

Alternatively, FACS enriched cells are let to spontaneously differentiate on gelatin. Immunohistochemistry is performed with various tissue specific antibodies as described in Mikkola et al. (2006) or analyzed with PCR.

Example 26
Evaluation of Glycan Classes and Epitopes in Stem Cells

Experimental Procedures

Human embryonic stem cells (hESC), human bone marrow derived (BM) and cord blood derived (CB) mesenchymal stem cells (MSC), and human cord blood mononuclear cells (CB MNC) were produced as described in the preceding Examples. Glycosphingolipid glycans were isolated from glycolipid fractions isolated from these cells by endoglycoceramidase digestion; O-glycans were isolated by non-reductive alkaline β-elimination with concentrated ammonia in saturated ammonium carbonate; all glycan fractions were isolated with miniaturized solid-phase extraction steps; glycans were analyzed by MALDI-TOF mass spectrometry; terminal glycan epitopes were analyzed by specific exoglycosidase enzymatic digestions combined with analysis by mass spectrometry; the analysis steps were performed as described in the present invention.

Results and Discussion

Mass spectrometric profiles providing relative quantitative information about glycan signals and specific exoglycosidase digestions, together with antibody, lectin, and biochemical characterization of the cell types as described above, was used to further characterize different stem cell types and differentiated cell types. Tables 37 and 38 describe examples of combinatiorial characterization of glycan types associated with each cell type. Analysis of glycolipid and/or O-glycan structures and classes in addition to N-glycan structures and classes yielded a more complete characterization of the cell types, revealed further differences between cell types, and provided more glycan epitopes and classes associated with each cell type. In conclusion, combination of analysis of different glycan types and epitopes was useful in analysis and identification of cell types.

Example 27
Characterization of Stem Cell Glycosphingolipid Glycans

Glycans were isolated from hESC glycosphingolipid fraction by endoglycoceramidase digestion, purified, and permethylated according to the methods described in the present invention. Mass spectrometric fragmentation of permethylated glycans was performed using Bruker Ultraflex TOF/TOF instrument essentially after manufacturer's instructions. In the following, all fragments are sodiated unless otherwise indicated. Naming of fragments is according to Domon and Costello, 1998 (Glycoconj. J. 5, 397-409).

Glycosphingolipid Glycans of hESC

Based on the resulting fragment ions, 1130.6 (mother), 912.5 (Y₄), 708.1 (C₃), 667.0 (Y₃), 485.8 (B₂), 462.8 (Y₂), 258.7 (Y₁), a major glycan included in Hex₄HexNAc₁composition had the following linear sequence: Hex-HexNAc-Hex-Hex-Hex. Fragment C₃suggests that corresponding glycans include structures with 3-substitution of the second Hex from the reducing end, indicative of isoglobo-type structure.

Based on the resulting fragment ions, 926.5 (mother), 718 (unknown), 690.6 (B₃), 667.5 (Y₃), 486.2 (B₂), 463.2 (Y₂), 282.1 (B₁), 259.1 (Y₁), 227.0 (B₂/Y₃or Y₂/B₃), a major glycan included in Hex₃HexNAc₁composition had the following linear sequence: HexNAc-Hex-Hex-Hex, indicative of globo-type structure.

Based on the resulting fragment ions, 1100.6 (mother), 912.6 (Y₄), 708.2 (Y₃), 690.3 (Z₃), 660.2 (B₃),462 (Y₂), 432.9 (C₂), 415 (B₂), a major glycan included in Hex₃HexNAc₁dHex₁composition had the following linear sequence: dHex-Hex-HexNAc-Hex-Hex. Fragments Z₃and C₂suggest that corresponding glycans include structures with 3-substitution of HexNAc, indicative of lacto-type structure.

Based on the resulting fragment ions, 1304.6 (mother), 666.9 (Y₃), 660.2 (B₂) 432.6 (C₂), a major glycan included in Hex₄HexNAc₁dHex₁composition had the following linear sequence: dHex-Hex-HexNAc-Hex-Hex-Hex. Fragment C₂suggests that corresponding glycans include structures with 3-substitution of HexNAc.

Similarly, fragmentation analysis of sialylated glycosphingolipid glycans indicated ganglio-type structures including branched sequence Hex-HexNAc-(NeuAc-)Hex-Hex, wherein the branch is indicated by brackets.

TABLE 1

Neutral N-glycan grouping of cord blood cell populations, cord blood mononuclear

cells (CB MNC), and peripheral blood mononuclear cells (PB MNC).

Neutral N-glycan Grouping:
CD

CD
CD

CB
PB

Composition
Glycan Grouping
34+
CD 34−
133+
133−
LIN−
LIN+
MNC
MNC

General N-glycan grouping:

Hex_5-12HexNAc₂
high-mannose
56.3
52.9
67.0
55.1
58.9
61.2
65.4
62.7

Hex_1-4HexNAc₂dHex_0-1
low-mannose
33.1
35.5
25.6
32.8
21.1
24.5
26.5
29.6

n_HexNAc= 3 and n_Hex≧ 2
hybrid/monoant.
5.5
6.4
2.4
5.6
8.6
5.5
4.3
3.7

n_HexNAc≧ 4 and n_Hex≧ 2
complex
4.3
4.8
4.5
5.9
11.0
8.0
3.1
3.3

Other types
—
0.8
0.4
0.6
0.7
0.5
0.7
0.7
0.7

Complex/hybrid/monoantennary N-glycan grouping:

n_dHex≧ 1
fucosylated
67.8
70.6
81.2
66.4
49.0
66.8
58.8
56.4

n_dHex≧ 2
α2/3/4-linked Fuc
18.8
21.3
0.5
11.5
0
5.4
12.2
4.9

n_HexNAc> n_Hex≧ 2
terminal HexNAc
21.3
18.3
50.8
32.1
38.7
34.2
22.7
26.9

n_HexNAc= n_Hex≧ 5
bisecting GlcNAc
0
0
0.8
0.8
0.4
2.0
0.4
0

Complex N-glycan grouping:

n_HexNAc≧ 5 and n_Hex≧ 6
large N-glycans
1.8
6.0
0
2.5
0
4.0
3.8
2.4

TABLE 2

Sialylated N-glycan grouping of cord blood cell populations,

cord blood mononuclear cells (CB MNC), and peripheral

blood mononuclear cells (PB MNC).

Sialylated N-glycan Grouping:
CD
CD
CB

Composition
Glycan Grouping
133+
133−
MNC

General N-glycan grouping:

n_HexNAc= 3 and n_Hex≧ 5
hybrid
5.7
3.2
7.7

n_HexNAc= 3 and n_Hex= 3 or 4
monoantennary
12.1
7.5
11.6

n_HexNAc≧ 4 and n_Hex≧ 3
complex
76.5
82.6
75.8

Other types
—
5.8
6.8
5.0

Complex/hybrid/monoantennary N-glycan grouping:

n_dHex≧ 1
fucosylated
62.3
70.0
67.7

n_dHex≧ 2
α2/3/4-linked Fuc
13.3
14.9
13.3

n_HexNAc> n_Hex≧ 3
terminal HexNAc
0.6
0.1
0.6

n_HexNAc= n_Hex≧ 5
bisecting GlcNAc
3.4
4.9
6.3

Complex N-glycan grouping:

n_HexNAc≧ 5 and n_Hex≧ 6
large N-glycans
13.6
34.2
24.1

Sialylation degree SD_HexNAc=
75
78
72

n_NeuAc/Gc:(n_HexNAc− 2)

TABLE 3

Exoglycosidase profiling of cord blood CD34+ and CD34− cell neutral N-glycan

fraction. α-Man, β1,4-Gal, β1,3-Gal, and β-GlcNAc refer to specific

exoglycosidase enzymes as described in the text. Code for profiling results,

when compared to the profile before the reaction;

α-Man
β1,4-Gal
β1,3-Gal
β-GlcNAc

Proposed composition
m/z
CD 34+
CD 34−
CD 34+
CD 34−
CD 34+
CD 34−
CD 34+
CD 34−

Hex2HexNAc
568

−−
+++
+++
+++
+++

HexHexNAc2
609
+++
+++

+++

+++

Hex3HexNAc
730

−−−
−−

−

HexHexNAc2dHex
755
+++
++
−
−
−
−−

Hex2HexNAc2
771
++
−−
−−
−−
−−
−−
−−

Hex4HexNAc
892
−−−
−−−
−

−

Hex2HexNAc2dHex
917
−−
−−
−−

−−
−−
−−

Hex3HexNAc2
933
−−−
−−
−
−−
−−
−−

HexHexNAc3dHex
958

+++

Hex2HexNAc3
974

+++

+++

Hex5HexNAc
1054
−−−
−−
+

+
−

Hex3HexNAc2dHex
1079
−−
−−

−−
−
−−
+

Hex4HexNAc2
1095
−−−
−−−

Hex2HexNAc3dHex
1120

+

+

Hex3HexNAc3
1136
−−−

−
−−−

Hex6HexNAc
1216
−−−
−−

−

−
−

Hex4HexNAc2dHex
1241

−−−

−
−
−
−

Hex5HexNAc2
1257
−−−
−−
+
+
+
+

Hex3HexNAc3dHex
1282
−−−
+

−
−
−−

Hex4HexNAc3
1298
−−−

−−−

−

Hex2HexNAc4dHex
1323

+++

Hex3HexNAc4
1339

+++

+++

Hex7HexNAc
1378

−−−
+

+

Hex5HexNAc2dHex
1403

−−−

+++

Hex6HexNAc2
1419
−−−
−−
++
++
++
++
++

Hex3HexNAc3dHex2
1428
−−−
++

+++

+++

Hex4HexNAc3dHex
1444
−−−

−
−−

−−
+

Hex5HexNAc3
1460
−−−
−
+++

+++

−−−

Hex3HexNAc4dHex
1485
−

+

−−−

Hex4HexNAc4
1501
−−−

−−−

−−−
−−−

Hex8HexNAc
1540
−−−
−−−
−−−
+++
−−−
+++
−−−

Hex3HexNAc5
1542

+++

+++

+++

Hex6HexNAc2dHex
1565

+++

Hex7HexNAc2
1581
−−−
−−

++
++
++
++

Hex4HexNAc3dHex2
1590
−−−

−−−
−

−
+

Hex5HexNAc3dHex
1606

−−−
−−−
+++

+++
+++

Hex6HexNAc3
1622
−−−
−−−
−−−
−−−

−−−

Hex4HexNAc4dHex
1647
−−−

−
−−−

Hex5HexNAc4
1663
−−−

−−−
−−−
−−−
−−
−−−

Hex3HexNAc5dHex
1688

+++

+++

Hex9HexNAc
1702
−−−
−−−

+++
+++
+++

Hex4HexNAc5
1704

+++

Hex8HexNAc2
1743
−−−
−−−
+++
+
+++
++
++

Hex5HexNAc3dHex2
1752

−−−

+++

+++
+++

Hex6HexNAc3dHex
1768

+++

+++

Hex7HexNAc3
1784
−−−

−−−

Hex4HexNAc4dHex2
1793

−−
+++
−−
+++

Hex5HexNAc4dHex
1809
−−−

−−−
+++
−

Hex6HexNAc4
1825

+++

Hex3HexNAc6dHex
1891

+++

Hex9HexNAc2
1905
−−−
−−−
−

+
++
++

Hex5HexNAc4dHex2
1955
−−−

−−−
−−

−−

Hex10HexNAc2
2067

−−−
−

+++

Hex5HexNAc4dHex3
2101

−
−

−
+++

Hex5HexNAc5dHex2
2158
+++

+++

Hex6HexNAc5dHex
2174

+++

Hex6HexNAc5dHex3
2466

+++

+++: new signal appears;

++: signal is significantly increased;

+: signal is increased;

−: signal is decreased;

−−: signal is significantly decreased;

−−−: signal disappears;

blank: no change.

TABLE 4

Exoglycosidase profiling of cord blood CD133+ and CD133− cell neutral N-glycan

fraction. α-Man, β1,4-Gal, β1,3-Gal, and β-GlcNAc refer to specific

exoglycosidase enzymes as described in the text. Code for profiling results,

when compared to the profile before the reaction;

α-Man
β1,4-Gal
β1,3-Gal
β-GlcNAc

Proposed composition
m/z
CD 133+
CD 133−
CD 133+
CD 133−
CD 133+
CD 133−
CD 133+
CD 133−

Hex2HexNAc
568

+

+

+++

HexHexNAc2
609
+++
++

−−−

Hex3HexNAc
730
−−−
−−−
+++
++
+++
++

++

HexHexNAc2dHex
755
+++
++
−−−

−−−

Hex2HexNAc2
771
+
−−
++
++
+
+

+

Hex4HexNAc
892
−−−
−−−
+
++

++

+

Hex2HexNAc2dHex
917
−−−
−−
++
++
++
+

Hex3HexNAc2
933

−−
+
+
−

+

Hex2HexNAc3
974

+++

Hex5HexNAc
1054
−−−
−−
+
++
+
++

+

Hex3HexNAc2dHex
1079
−−−
−−
++
+
+

++

Hex2HexNAc3dHex
1120
+++
++
++
+
++
+

−−−

Hex3HexNAc3
1136
+++
+

+

−−−

Hex6HexNAc
1216
−−−
−
+

+
+

Hex4HexNAc2dHex
1241
−−−
−−−
+

Hex5HexNAc2
1257
−−
−−
−

Hex3HexNAc3dHex
1282

−−

Hex4HexNAc3
1298
++
+
+

+

Hex3HexNAc4
1339

+++

−−−

Hex7HexNAc
1378
−−−
−−−

−
+++

+

Hex5HexNAc2dHex
1403
−−−
−−−
−−−

−

Hex6HexNAc2
1419
−−
−−
−−
−
−
−−

Hex3HexNAc3dHex2
1428

+++

−

−

Hex4HexNAc3dHex
1444

−
−
−

Hex5HexNAc3
1460
−−−
−
+
+

Hex3HexNAc4dHex
1485
−−

+
+

−

−−−

Hex4HexNAc4
1501

−−−

+++

−−−

Hex8HexNAc
1540
−−−
−−−
−−−

++

Hex3HexNAc5
1542

−−−

+

−

−−−

Hex6HexNAc2dHex
1565

−−−

−−−
+++

Hex7HexNAc2
1581
−−−
−−
−−
−−
−
−−

Hex4HexNAc3dHex2
1590

−−−
−
−
−
−

+

Hex5HexNAc3dHex
1606
−−−
−−−
+

−−−

Hex6HexNAc3
1622
−−−
−−−
−−−
−−

−

Hex4HexNAc4dHex
1647
−−−

−−−
−

−−−

Hex5HexNAc4
1663

−−−
−
−−
−

−

Hex3HexNAc5dHex
1688
−−−
+

−−−

−−−

Hex9HexNAc
1702

+

Hex4HexNAc5
1704
−−−

−−−

Hex8HexNAc2
1743
−−−
−−−
−−
−−
−
−−

Hex5HexNAc3dHex2
1752

−

+++

Hex6HexNAc3dHex
1768

Hex4HexNAc4dHex2
1793

Hex5HexNAc4dHex
1809
−−−

−−−
−−−

−

−

Hex6HexNAc4
1825

−

−−−

Hex5HexNAc5
1866
−−−
−−−

−−−

−−−

Hex3HexNAc6dHex
1891

−−−

Hex9HexNAc2
1905
−−−
−−−
−−
−−
−
−−

Hex6HexNAc3dHex2
1914

−−−

−−−

Hex5HexNAc4dHex2
1955

−−

−

−−−

Hex6HexNAc4dHex
1971

−−−

−−−

−−−

Hex7HexNAc4
1987

−−−

−−−

Hex5HexNAc5dHex
2012

+++

Hex6HexNAc5
2028

−−−

−−−

−−−

Hex10HexNAc2
2067
−−−
−−−
−
−

Hex5HexNAc4dHex3
2101

−
−

−

Hex6HexNAc4dHex2
2117

−−−

−−−
−−−

−−−

Hex7HexNAc4dHex
2133

−−−

Hex6HexNAc5dHex
2174

−−−

−−−

−−−

Hex5HexNAc6dHex
2215

−−−

Hex6HexNAc4dHex3
2263

−−−

−−−

Hex6HexNAc5dHex2
2320

−−−

Hex6HexNAc5dHex3
2466

−−−

+++: new signal appears;

++: signal is significantly increased;

+: signal is increased;

−: signal is decreased;

−−: signal is significantly decreased;

−−−: signal disappears;

blank: no change.

TABLE 5

Exoglycosidase profiling of cord blood Lin+ and Lin− cell neutral N-glycan

fraction.

α-Man
β1,4-Gal
β1,3-Gal
β-GlcNAc

Proposed composition
m/z
LIN+
LIN−
LIN+
LIN−
LIN+
LIN−
LIN+
LIN−

Hex2HexNAc
568
−−−
+++
+

+

−

HexHexNAc2
609
+++
+++

+++

Hex2HexNAcdHex
714

+++

Hex3HexNAc
730
−−−
+++
++
+++
+
+++
+

HexHexNAc2dHex
755
+++
+++
+

+

+++

Hex2HexNAc2
771
+
+
+
+
+

+

Hex4HexNAc
892
−−−
−−−
++
+
++

+
+

Hex2HexNAc2dHex
917
−−
−−−
+
++

−

−

Hex3HexNAc2
933
−

+
+
+
−

+

Hex2HexNAc3
974
+++

Hex5HexNAc
1054
−−
−−−
++

−

−

Hex3HexNAc2dHex
1079
−−
−−−

++

−
++
++

Hex4HexNAc2
1095
−−
−−−

−

Hex2HexNAc3dHex
1120
+++

Hex3HexNAc3
1136
+++
+
+
+

−
+++
−−−

Hex6HexNAc
1216
−
−−−
+

+
+

+

Hex4HexNAc2dHex
1241
−−−
−−−

+

+

−−−

Hex5HexNAc2
1257
−−
−−−

++
−
−
−
+

Hex3HexNAc3dHex
1282
+

−−
−−−

Hex4HexNAc3
1298
+

Hex2HexNAc4dHex
1323

+++

+++

Hex3HexNAc4
1339

−−−
++
+

−−

−−−

Hex7HexNAc
1378
−−−
−−−

+
++

Hex5HexNAc2dHex
1403
−−−
−−−

+

Hex6HexNAc2
1419
−−
−−

−−
−
−
−

Hex3HexNAc3dHex2
1428
+++

−−−

−−−

+++

Hex4HexNAc3dHex
1444

−−−
−
+

+

Hex5HexNAc3
1460

−−−

Hex3HexNAc4dHex
1485

−−
−−−
−−−

Hex4HexNAc4
1501
+
−−−
+
−
−−−
−−
−−−
−−−

Hex8HexNAc
1540
−−−
−−−

−−−
+
++

Hex3HexNAc5
1542
+++

++
+
++
−

Hex6HexNAc2dHex
1565

−−−
−−−

−−−

Hex7HexNAc2
1581
−−
−−−
−−
−−

−

Hex4HexNAc3dHex2
1590

−

+++

Hex5HexNAc3dHex
1606
−−−
−−−
−
−−−

−−−

−−−

Hex2HexNAc4dHex3
1615

+++

Hex6HexNAc3
1622
−−−
−−−
−−−
−−−

Hex4HexNAc4dHex
1647

−−−
−−
−−−

−−−
−−−

Hex5HexNAc4
1663

−−−
−−
−−

−
−
−−

Hex3HexNAc5dHex
1688

−

−−−
−−−

Hex9HexNAc
1702
−−−
−−−

Hex4HexNAc5
1704
+++

−−−

Hex8HexNAc2
1743
−−
−−−
−−
−−

−

Hex5HexNAc3dHex2
1752

−−−

+++

Hex6HexNAc3dHex
1768

−−−

Hex3HexNAc4dHex3
1777

+++

Hex7HexNAc3
1784

−−−

Hex4HexNAc4dHex2
1793
+++

Hex5HexNAc4dHex
1809
+
−−−
−−
−−−

−−

Hex6HexNAc4
1825
+++

−
−−−

−−
+++

Hex4HexNAc5dHex
1850

+++

+++

Hex5HexNAc5
1866
+++

−−−

Hex3HexNAc6dHex
1891

−−−
−

Hex9HexNAc2
1905
−−−
−−−
−−
−−

−

Hex4HexNAc4dHex3
1939

+++

Hex5HexNAc4dHex2
1955

−−−

+++

Hex6HexNAc4dHex
1971

−−−

Hex7HexNAc4
1987

−−−

+++

Hex5HexNAc5dHex
2012
+++

−−−

Hex6HexNAc5
2028

−−−

Hex10HexNAc2
2067
−−−
−−−
−

++
+

Hex5HexNAc4dHex3
2101

+++

Hex8HexNAc4
2149

−−−

Hex6HexNAc5dHex
2174

−−−

−

Hex5HexNAc6dHex
2215

−−−

−−−

Hex11HexNAc2
2229

+++

Hex6HexNAc6
2231

−−−

−−−

Hex6HexNAc5dHex2
2320

−−−

−−−

Hex12HexNAc2
2391

+++

+++
+++

Hex7HexNAc6
2393

−−−

−−−

Hex6HexNAc5dHex3
2466

−−−

−−−

Hex7HexNAc6dHex
2539
+++

TABLE 6

Differential effect of α2,3-sialidase treatment on isolated

sialylated N-glycans from cord blood CD133⁺and

CD133⁻cells. The neutral N-glycan columns show

that neutral N-glycans corresponding to the listed sialylated N-glycans

appear in analysis of CD133⁺cell N-glycans but not

CD133⁻cell N-glycans. Proposed glycan compositions

outside parenthesis are visible in the neutral N-glycan fraction after

α2,3-sialidase digestion of CD133⁺cell sialylated

N-glycans.

Proposed
Sialylated

monosaccharide
N-glycan
Neutral N-glycan

m/z
composition
CD133⁺
CD133⁻
CD133⁺
CD133⁻

1768
(NeuAc₁)Hex₄HexNAc₄
+
+
+
−

2156
(NeuAc₁)-
+
+
+
−

Hex₈HexNAc₂dHex₁/

(NeuAc₁Hex₅Hex-

NAc₄dHex₁SO₃)

2222
(NeuAc₁)-
+
+
+
−

Hex₅HexNAc₄dHex₂

2238
(NeuAc₁Hex₆Hex-
+
+
+
−

NAc₄dHex₁/

(NeuGc₁)-

Hex₅HexNAc₄dHex₂

2254
(NeuAc₁)Hex₇HexNAc₄/
+
+
+
−

(NeuGc₁)-

Hex₆HexNAc₄dHex₁

2368
(NeuAc₁)-
+
+
+
−

Hex₅HexNAc₄dHex₃

2447
(NeuAc₂)-
+
+
+
−

Hex₈HexNAc₂dHex₁/

(NeuAc₂Hex₅Hex-

NAc₄dHex₁SO₃)

2448
(NeuAc₁)
+
+
+
−

Hex₈HexNAc₂dHex₃/

(NeuAc₁Hex₅Hex-

NAc₄dHex₃SO₃)

2513
(NeuAc₂)-
+
+
+
−

Hex₅HexNAc₄dHex₂

2733
(NeuAc₁)-
+
+
+
−

Hex₆HexNAc₅dHex₃

2953
(NeuAc₁)-
+
+
+
−

Hex7HexNAc₆dHex₂

TABLE 7

Proposed neutral N-glycan grouping of the samples;

Neutral N-glycan Grouping:

Composition
Glycan Grouping
hESC 1
hESC 2
hESC 3
hESC 4
EB 3
EB 4
st.3 3
HEF1
HEF2

General N-glycan grouping:

Hex_5-12HexNAc₂
high-mannose
84.4
73.2
80.0
79.0
64.4
79.1
73.6
82.6
77.5

Hex_1-4HexNAc₂dHex_0-1
low-mannose
5.6
10.9
6.8
7.8
11.5
9.2
9.4
7.1
8.0

n_HexNAc= 3 and n_Hex≧ 2
hybrid/monoantennary
3.4
6.7
3.2
3.2
9.0
6.7
6.5
5.4
5.1

n_HexNAc≧ 4 and n_Hex≧ 2
complex
6.2
8.9
10.1
10.0
14.5
5.0
10.3
4.9
9.1

Other types

0.3
0.3
0.0
0.0
0.7
0.0
0.3
0.0
0.2

Complex/hybrid/monoantennary N-glycan grouping:

n_dHex≧ 1
fucosylated
52.3
40.4
65.3
62.4
46.1
27.9
36.9
51.6
56.6

n_dHex≧ 2
α2/3/4-linked Fuc
11.7
1.8
11.7
13.9
6.9
9.9
2.2
0.0
3.4

n_HexNAc> n_Hex≧ 2
terminal HexNAc
9.4
17.4
6.8
6.0
17.7
15.5
18.4
27.2
16.2

n_HexNAc= n_Hex≧ 5
bisecting GlcNAc
0.0
10.2
0.0
0.0
7.8
4.2
9.7
0.0
0.0

Complex N-glycan grouping:

n_HexNAc≧ 5 and n_Hex≧ 6
large N-glycans
11.3
5.4
13.7
8.7
3.3
0.0
4.6
14.1
20.5

hESC, human embryonal stem cell line, lines 1-4,

EB, embryoid bodies derived from hESC lines 3 and 4,

st.3 3, stage 3 differentiated cells from hESC line 3,

HEF human fibroblasts used as feeder cells.

TABLE 8

Proposed sialylated N-glycan grouping of the samples;

Sialylated N-glycan Grouping:

Composition
Glycan Grouping
hESC 2
hESC 3
hESC 4
EB 3
st.3 3
hEF

General N-glycan grouping:

n_HexNAc= 3 and nHex ≧ 5
hybrid
0.0
3.8
4.5
9.6
3.6
3.4

n_HexNAc= 3 and n_Hex= 3 or 4
monoantennary
2.2
2.3
5.5
6.4
2.5
3.6

n_HexNAc≧ 4 and n_Hex≧ 3
complex
97.8
92.6
89.1
79.1
93.9
92.2

Other types
—
0.0
1.3
0.9
4.8
0.0
0.8

Complex/hybrid/monoantennary N-glycan grouping:

n_dHex≧ 1
fucosylated
93.0
72.6
74.6
79.3
85.3
76.2

n_dHex≧ 2
α2/3/4-linked Fuc
33.5
23.0
18.5
10.8
5.2
20.4

n_HexNAc> n_Hex≧ 3
terminal HexNAc
7.8
6.4
5.2
7.7
3.0
0.8

n_HexNAc= n_Hex≧ 5
bisecting GlcNAc
4.3
3.9
2.2
12.5
25.8
1.4

n_NeuGc≧ 1
NeuGc-containing
0.0
6.8
5.6
1.5
0.0
0.0

Complex N-glycan grouping:

n_HexNAc≧ 5 and n_Hex≧ 6
large N-glycans
22.7
18.7
14.9
12.4
26.6
44.5

sialylation degree SD_HexNAc=
51.6
60.4
63.0
60.7
56.6
60.3

n_NeuAc/Gc:(n_HexNAc− 2)

hESC, human embryonal stem cell line, lines 2-4,

EB, embryoid bodies derived from hESC line 3,

st.3 3, stage 3 differentiated cells from hESC line 3,

HEF human fibroblasts used as feeder cells.

TABLE 9

Mass spectrometric analysis results of sialylated N-glycans with

monosaccharide compositions NeuAc_1-2Hex₅HexNAc₄dHex_0-3

in sequential enzymatic modification steps of human cord blood

mononuclear cells. The columns show relative glycan signal

intensities (% of the tabled signals) before the modification

reactions (MNC), after α2,3-sialyltransferase reaction (α2,3SAT),

and after sequential α2,3-sialyltransferase and

α1,3-fucosyltransferase reactions (α2,3SAT + α1,3FucT).

The sum of the glycan signal intensities in each column has been

normalized to 100% for clarity.

calc m/z

Proposed
[M −

α2,3SAT +

monosaccharide composition
H]⁻
MNC
α2,3SAT
α1,3FucT

NeuAcHex5HexNAc4
1930.68
24.64
12.80
13.04

NeuAcHex5HexNAc4dHex
2076.74
39.37
30.11
29.40

NeuAcHex5HexNAc4dHex2
2222.8
4.51
8.60
6.83

NeuAcHex5HexNAc4dHex3
2368.85
3.77
6.34
6.45

NeuAc2Hex5HexNAc4
2221.78
13.20
12.86
17.63

NeuAc2Hex5HexNAc4dHex
2367.83
14.04
29.28
20.71

NeuAc2Hex5HexNAc4dHex2
2513.89
0.47
n.d.
5.94

TABLE 10

Mass spectrometric analysis results of selected neutral N-glycans in enzymatic

modification steps of human cord blood mononuclear cells. The columns

show relative glycan signal intensities (% of the total glycan signals) before

the modification reactions (MNC), after broad-range sialidase reaction

(SA'se), after α2,3-sialyltransferase reaction (α2,3SAT), after α1,3-

fucosyltransferase reaction (α1,3FucT), and after sequential α2,3-

sialyltransferase and α1,3- fucosyltransferase reactions (α2,3SAT + α1,3FucT).

calc m/z

α2,3SAT +

Proposed monosaccharide composition
[M + H]⁺
MNC
SA'ase
α2,3SAT
α1,3FucT
α1,3FucT

Hex5HexNAc2
1257.42
11.94
14.11
14.16
13.54
9.75

Hex3HexNAc4dHex
1485.53
0.76
0.63
0.78
0.90
0.78

Hex6HexNAc3
1622.56
0.61
1.99
0.62
0.51
0.40

Hex5HexNAc4
1663.58
0.44
4.81
0.00
0.06
0.03

Hex5HexNac4dHex
1809.64
0.19
1.43
0.00
0.25
0.00

Hex5HexNac4dHex2
1955.7
0.13
0.22
0.00
0.22
0.00

Hex6HexNAc5
2028.71
0.07
1.14
0.00
0.00
0.00

Hex5HexNAc4dHex3
2101.76
0.12
0.09
0.00
0.22
0.00

Hex6HexNAc5dHex
2174.77
0.00
0.51
0.00
0.14
0.00

Hex6HexNAc5dHex2
2320.83
0.00
0.00
0.00
0.08
0.00

TABLE 11

NMR analysis of hESC neutral N-glycans (hESC sample).

Glycan

hESC sample

residue
linkage
proton
A ppm
B ppm
C ppm
D ppm
ppm

D-GlcNAc

H-1a
5.191
5.187
5.187
5.188
5.188

H-1b
4.690
4.693
4.693
4.695
4.694

NAc
2.042
2.037
2.037
2.038
2.038

β-D-GlcNAc
4
H-1
4.596
4.586
4.586
4.600
4.596

NAc
2.072
2.063
2.063
2.064
2.061¹⁾

β-D-Man
4, 4
H-1
4.775
4.771
4.771
4.780

H-2
4.238
4.234
4.234
4.240
4.234

α-D-Man
6, 4, 4
H-1
4.869
4.870
4.870
4.870
4.869

H-2
4.149
4.149
4.149
4.150
4.153

α-D-Man
6, 6, 4, 4
H-1
5.153
5.151
5.151
5.143
5.148

H-2
4.025
4.021
4.021
4.020
4.023

α-D-Man
2, 6, 6, 4, 4
H-1
5.047
5.042
5.042
5.041
5.042

H-2
4.074
4.069
4.069
4.070
4.069

α-D-Man
3, 6, 4, 4
H-1
5.414
5.085
5.415
5.092
5.408, 5.085

H-2
4.108
4.069
4.099
4.070
4.102, 4.069

α-D-Man
2, 3, 6, 4, 4
H-1
5.047
—
5.042
—
5.042

H-2
4.074
—
4.069
—
4.069

α-D-Man
3, 4, 4
H-1
5.343
5.341
5.341
5.345
5.346, 5.338

H-2
4.108
4.099
4.099
4.120
4.102

α-D-Man
2, 3, 4, 4
H-1
5.317
5.309
5.050
5.055
5.310, 5.057

H-2
4.108
4.099
4.069
4.070
4.102, 4.069

α-D-Man
2, 2, 3, 4, 4
H-1
5.047
5.042
—
—
5.042

H-2
4.074
4.069
—
—
4.069

¹⁾Under HDO.

TABLE 12

NMR analysis of hESC acidic N-glycans (hESC sample).

Glycan

A.
B.
C.
D.
E.
hESC sample

residue
linkage
proton
ppm
ppm
ppm
ppm
ppm
ppm

D-GlcNAc

H-1a
5.180
5.188
5.189
5.181
5.189
5.182/5.188

H-1b
4.692
n.a.¹⁾
4.695
n.a.
4.694
n.a.

NAc
2.038
2.038
2.038
2.039
2.038
2.038

α-L-Fuc
6
H-1a
4.890
—²⁾
—
4.892
—
4.893

H-1b
4.897
—
—
4.900
—
4.893

H-5a
4.098
—
—
4.10
—
Overlap³⁾

H-5b
4.134
—
—
n.a.
—
Overlap

CH3a
1.209
—
—
1.211
—
1.210

CH3b
1.220
—
—
1.223
—
1.219

β-D-GlcNAc
4
H-1a
4.664
4.612
4.614
4.663
4.613
n.a.

H-1b
4.669
4.604
4.606
n.a.
4.604
n.a./4.605

NAc
2.097
2.081
2.081
2.096/
2.084
2.081/2.095

(a/b)

2.093

β-D-Man
4, 4
H-1
4.772
n.a.
n.a.
n.a.
n.a.
n.a

H-2
4.257
4.246
4.253
4.248
4.258
4.256

α-D-Man
6, 4, 4
H-1
4.929
4.928
4.930
4.922
4.948
4.927

H-2
4.111
4.11
4.112
4.11
4.117
Overlap

β-D-GlcpNAc
2, 6, 4, 4
H-1
4.583
4.581
4.582
4.573
4.604
4.579/4.605

NAc
2.048
2.047
2.047
2.043
2.066
2.047/2.069

β-D-Gal
4, 2, 6, 4, 4
H-1
4.544
4.473
4.473
4.550
4.447
4.447/4.472/

4.545

H-3
n.a.
n.a.
n.a.
4.119
n.a.
Overlap

H-4
4.185
n.a.
n.a.
n.a.
n.a.
4.185

α-D-Galp
3, 4, 2, 6, 4, 4
H-1
5.146
—
—
—
—
5.146

α-D-Neup5Ac
3, 4, 2, 6, 4, 4
H-3a
—
—
—
1.800
—
1.802

H-3e
—
—
—
2.758
—
2.756

NAc
—
—
—
2.031
—
2.030

α-D-Neup5Ac
6, 4, 2, 6, 4, 4
H-3a
—
—
—
—
1.719
1.721

H-3e
—
—
—
—
2.673
2.669

NAc
—
—
—
—
2.029
2.030

α-D-Man
3, 4, 4
H-1
5.135
5.118
5.135
5.116
5.133
5.118/5.134

H-2
4.195
4.190
4.196
4.189
4.197
4.195

β-D-GlcpNAc
2, 3, 4, 4
H-1
4.605
4.573
4.606
4.573
4.604
4.579/4.605

NAc
2.069
2.047
2.069
2.048
2.070
2.047/2.069

β-D-Galp
4, 2, 3, 4, 4
H-1
4.445
4.545
4.445
4.544
4.443
4.445/4.545

H-3
n.a.
4.113
n.a.
4.113
n.a.
Overlap

α-D-Neup5Ac
6, 4, 2, 3, 4, 4
H-3a
1.722
—
1.719
—
1.719
1.721

H-3e
2.666
—
2.668
—
2.667
2.669

NAc
2.029
—
2.030
—
2.029
2.030

α-D-Neup5Ac
3, 4, 2, 3, 4, 4
H-3a
—
1.797
—
1.797
—
1.802

H-3e
—
2.756
—
2.758
—
2.756

NAc
—
2.030
—
2.031
—
2.030

¹⁾n.a., not assigned.

²⁾—, not present.

³⁾Overlap, overlapping signals at 4.139-4.088 ppm.

TABLE 13

Exoglycosidase analysis results of hESC line FES 29 grown on mEF.

FES 29

Proposed composition
m/z
α-Man
β-GlcNAc
β-HexNAc
β1,4Gal
β1,3-Gal
α1,3/4-Fac
α1,2-Fac

Hex2HexNAc
568

+++
+++

−++
+++
+−+

HexHexNAc2
609
+++

+++
+++

Hex3HexNAc
730
−−
+
++
++
+

−−

HexHexNAc2dHex
755
+++

Hex2HexNAc2
771
+
+
−−−

+
+
−−

Hex4HexNAc
892
−−−
+
+
−−−
+
+
−−

Hex2HexNAc2dHex
917
−−
+

+
+
−−

Hex3HexNAc2
933
−−
++
+

+
+
−−

Hex2HexNAc3
974
+++

+++
+++
+−+

Hex5HexNAc
1054
−−
+
+
+
+
+
−−

Hex3HexNAc2dHex
1079
−−
++

+
+
+
−−

Hex4HexNAc2
1095
−−

+

+
+
−−

Hex2HexNAc3dHex
1120
++

−

+
−−

Hex3HexNAc3
1136
+
−−
−−

+
++
−−

Hex6HexNAc
1216
−−
+
++
+
+
+
−−

Hex4HexNAc2dHex
1241
−−
+

+

Hex5HexNAc2
1257
−−

Hex3HexNAc3dHex
1282

−
−−

+
+
−−

Hex4HexNAc3
1298
+
++
++
++
+
++
++

Hex3HexNAc4
1339

−−−
−−−
++
++
−−−
−−−

Hex7HexNAc
1378
−−
+
+
+
+
+
−−

Hex5HexNAc2dHex
1403
−−−
+

−−

Hex6HexNAc2
1419
−−
−

−
−
−

Hex3HexNAc3dHex2
1428
+++

+++

Hex4HexNAc3dHex
1444

++
+

+
+

Hex5HexNAc3
1460
−

+
+
−−

Hex3HexNAc4dHex
1485

−−
−−−
+
+

−−

Hex4HexNAc4
1501

−−−
−−−
−−−
+
−−−
−−−

Hex8HexNAc
1540
−−−
+
++
+

+

Hex3HexNAc5
1542
++
−−−
−−−
++
++

−−

Hex6HexNAc2dHex
1565
−−−

−−−

Hex7HexNAc2
1581
−−

−

Hex4HexNAc3dHex2
1590

++
+

Hex5HexNAc3dHex
1606
−
+

+

Hex6HexNAc3
1622
−−

−−
+
+
−−

Hex4HexNAc4dHex
1647

−−
−−−
−−
+
+

Hex5HexNAc4
1663

+

−
+

−−

Hex3HexNAc5dHex
1688

−−−
−−−

+

−−

Hex9HexNAc
1702
−−−
+
++
+
+

Hex4HexNAc5
1704
+
−
−−−
−−−

Hex8HexNAc2
1743
−−−
−

−
−
−

Hex5HexNAc2dHex2
1752
+++

Hex6HexNAc3dHex
1768
−−

−−

Hex7HexNAc3
1784
−−

−−
+

Hex4HexNAc4dHex2
1793

−−−
−−−
−−−
++
−−−

Hex5HexNAc4dHex
1809

−
+
+
−−

Hex6HexNAc4
1825

−−

Hex4HexNAc5dHex
1850

−−−
−−−
−−−

−+

Hex5HexNAc5
1866
+
+

++
++
++

Hex3HexNAc6dHex
1891
+++

+++
+−+

Hex9HexNAc2
1905
−−−
−
−

−
−
−

Hex7HexNAc3dHex
1930

+−+

Hex5HexNAc4dHex2
1955

−

Hex6HexNAc4dHex
1971

−−

Hex7HexNAc4
1987

+

−−

Hex4HexNAc5dHex2
1996

−−−
−−−

−−−

Hex5HexNAc5dHex
2012

−−−
−−−

+

Hex6HexNAc5
2028

−

Hex10HexNAc2
2067
−−−
+

+
+
−−

Hex5HexNAc6
2069
+++

Hex5HexNAc4dHex3
2101

−−

Hex6HexNAc4dHex2
2117
+++

+++

Hex7HexNAc4dHex
2311

Hex4HexNAc5dHex3
2142
+++

−++

+−+

Hex8HexNAc4
2149

+++

Hex5HexNAc5dHex2
2158
+++

+++

Hex6HexNAc5dHex
2174

−−

Hex3HexNAc6dHex3
2183
+++

−++

+−+

Hex7HexNAc5
2190

Hex11HexNAc2
2229
−−−

Hex6HexNAc6
2231
+++

Hex5HexNAc4dHex4
2247
+++

Hex7HexNAc4dHex2
2279
+++

−++

+−+

Hex5HexNAc5dHex3
2304
+++

+++

Hex6HexNAc5dHex2
2320
+++
+++

−++
+++
+−+

Hex7HexNAc5dHex
2336

−

Hex8HexNAc5
2352

−−−

Hex12HexNAc2
2391
−−−

Hex7HexNAc6
2393
+++

+++

Hex7HexNAc4dHex3
2425
+++

+++

Hex6HexNAc5dHex3
2466
+++

+++

Hex8HexNAc5dHex
2498

−−−

Hex9HexNAc5
2514

Hex7HexNAc6dHex
2539
+++

+++
+−+

Hex13HexNAc2
2553

+−+

Hex8HexNAc6
2555

+++
+++

Hex9HexNAc5dHex
2660

Hex7HexNAc6dHex4
2978

−++

Hex8HexNAc6dHex4
3140

−++

+−+

Hex9HexNAc6dHex4
3302

+++
+++
+−+

Hex10HexNAc6dHex4
3464

−++
+++
+−+

Hex11HexNAc6dHex4
3626

−++
+++
+−+

Hex12HexNAc6dHex4
3788

−++

+−+

TABLE 14

Exoglycosidase analysis results of hESC line FES 29 (st 1) grown on hEF and

embryoid bodies (EB, st 2).

FES 29 st 1
FES 29 st 2
FES 29 st 1
FES 29 st 2

Proposed composition
m/z
α-Man
α-Man
β1,4-Gal
β1,4-Gal

HexHexNAc2
609
++
++
−−−
−−

HexHexNAc2dHex
755
+++
+++

Hex2HexNAc2
771
+++
++

Hex4HexNAc
892

−−−

Hex2HexNAc2dHex
917
−−−

−−−

Hex3HexNAc2
933
++
++
+
+

Hex5HexNAc
1054

Hex3HexNAc2dHex
1079
−−−
−−

−

Hex4HexNAc2
1095
−−−
−−
+
+

Hex2HexNAc3dHex
1120

+

Hex3HexNAc3
1136
+
++
++
++

Hex6HexNAc
1216

Hex4HexNAc2dHex
1241
−−−
−−−
−−−

Hex5HexNAc2
1257
−−
−−

Hex3HexNAc3dHex
1282

++
++

Hex4HexNAc3
1298
+
++
+
+

Hex3HexNAc4
1339

+++
+++

Hex7HexNAc
1378
−−−
−−−
−−−

Hex5HexNAc2dHex
1403

−−−

Hex6HexNAc2
1419
−−
−−

Hex3HexNAc3dHex2
1428
+++
+++

Hex4HexNAc3dHex
1444
−
+

+

Hex5HexNAc3
1460

+
+

Hex3HexNAc4dHex
1485

++
++

Hex8HexNAc
1540

−−−

Hex3HexNAc5
1542

+
+++
++

Hex6HexNAc2dHex
1565

−−−

−−−

Hex7HexNAc2
1581
−−
−−

Hex5HexNAc3dHex
1606
−−−

−−−
−

Hex6HexNAc3
1622
−−−
−−
−−−
−−−

Hex4HexNAc4dHex
1647

−

Hex5HexNAc4
1663

−−−
−−−

Hex3HexNAc5dHex
1688
−−−

++
++

Hex9HexNAc
1702

Hex4HexNAc5
1704

+++
−−

Hex8HexNAc2
1743
−−
−−

Hex6HexNAc3dHex
1768

Hex4HexNAc4dHex2
1793

+++

Hex5HexNAc4dHex
1809
−

−−
−−

Hex4HexNAc5dHex
1850

−−−
−−

Hex5HexNAc5
1866

−−−

Hex3HexNAc6dHex
1891

+++

Hex9HexNAc2
1905
−−−
−−−

Hex5HexNAc4dHex2
1955
−

−
−−−

Hex6HexNAc4dHex
1971

−−−

Hex4HexNAc5dHex2
1996
−−−

−−−
−−−

Hex5HexNAc5dHex
2012

−−−

Hex6HexNAc5
2028

−−−

Hex10HexNAc2
2067
−−−
−−−

Hex5HexNAc4dHex3
2101

−

Hex4HexNAc5dHex3
2142

−−−

−−−

Hex5HexNAc5dHex2
2158

−−−

−−−

Hex6HexNAc5dHex
2174

−−−
−−−

Hex11HexNAc2
2229

++
++

Hex6HexNAc5dHex2
2320

−−−

Hex12HexNAc2
2391

+++
++

Hex13HexNAc2
2553

+++
+++

Hex14HexNAc2
2715

+++

TABLE 15

Exoglycosidase digestion analyses of hESC acidic N-glycans (cell line FES 29, grown on mEF).

α3/4Fuc

Proposed composition
m/z
α3SA
α3/4Fuc
→α2Fuc
SA

Hex3HexNAc2SP
989
+
−−−
−−−
−−−

NeuAcHex3HexNAc
997
+++

Hex2HexNAc3SP
1030
+
−−−
−−−
+

Hex4HexNac2SP
1151
+

−−−
+

Hex3HexNAc3SP
1192
++

++
++

NeuAc2Hex2HexNAcdHex
1272

−−−
−−−
−−−

Hex4HexNAc2dHexSP
1297
−−−
−−−
−−−
+

NeuAc2HexHexNAc2dHex
1313
+

−−−
++

Hex3HexNAc3dHexSP
1338
+
−−−
−−−
++

Hex4HexNAc3SP
1354
++
+
++
++

Hex3HexNac4SP
1395
+

+
++

NeuAcHex3HexNAc3
1403

+
−−−

NeuGcHex3HexNAc3
1419

−−−

NeuAc2Hex2HexNAcdHex
1475
+

+
++

Hex4HexNAc3dHexSP
1500
+

+

Hex5HexNAc3dHexSP/NeuAc2HexHexNAc3dHex
1516
+

+

Hex3HexNAc4dHexSP
1541
+

++
++

NeuAcHex3HexNAc3dHex
1549
+
+
+
−−−

Hex4HexNAc4SP
1557
++

+
++

NeuAcHex4HexNAc3
1565
−

+
−−

NeuGcHex4HexNAc3
1581
+

NeuAcHex3HexNAc4
1606
+++

NeuAc2Hex3HexNAc2dHex
1637
+

+

Hex4HexNAc3dHex2SP
1646
+++

Hex5HexNAc3dHexSP
1662
+
−−−
−−−
+

NeuAc2Hex2HexNAc3dHex
1678
+
−

+

NeuAcHex2HexNAc3dHex3
1679

+++

+++

Hex4HexNAc4dHexSP
1703
++

++
++

NeuAcHex4HexNAc3dHex
1711

+
−−

Hex5HexNAc4SP
1719
++

+
++

NeuAcHex5HexNAc3
1727
−
−

−−

NeuGcHex5HexNAc3
1743
−−−

+
+

NeuAcHex3HexNAc4dHex
1752

−−−
−−−

Hex4HexNAc5SP
1760
+
+

++

NeuAcHex4HexNAc4
1768

+
+
−−

Hex7HexNAc2dHexSP
1783

NeuGcHex4HexNAc4
1784
+++
+++
+++
+++

Hex5HexNAc4SP2/NeuAc2Hex4HexNAc2dHex
1799

++
++

Hex6HexNAc3dHexSP
1824
+++

+++

NeuAc2Hex3HexNAc3dHex
1840
+

+

NeuAcHex3HexNAc3dHex3
1841

+++

Hex5HexNAc4dHexSP
1865
++

+
++

NeuAcHex5HexNAc3dHex
1873
−

−
−−−

Hex6HexNAc4SP
1881
++
+
−−−
++

NeuAcHex6HexNAc3
1889
−

−−

Hex4HexNAc5dHexSP
1906
+

+
++

NeuAcHex4HexNAc4dHex
1914
−
+
+
−−

Hex5HexNAc5SP
1922
+++

+++

NeuAcHex5HexNAc4
1930
+
+
+
−−

NeuGcHex5HexNAc4
1946
++

+
++

NeuAcHex3HexNAc5dHex
1955

+
−−−
−−−

NeuAc2Hex5HexNAc2dHex/Hex6HexNAc4(SP)2
1961

+++

NeuAcHex4HexNAc5
1971

+
+

NeuAc2Hex4HexNAc3dHex/Hex8HexNAc3SP
2002
+

−

NeuAcHex4HexNAc3dHex3
2003
−−−
−−−
−−−
−−−

NeuAcHex5HexNAc4SP
2010

−−−
−−−
−−−

Hex5HexNAc4dHex2SP
2011
−−−

−−−
++

NeuAc2Hex5HexNAc3
2018

+++

NeuAcHex5HexNAc3dHex2
2019

+++

Hex6HexNAc4dHexSP
2027
++

+
++

NeuAcHex6HexNAc3dHex
2035
−−−
+
−−−
−−−

NeuAc2Hex3HexNAc4dHex/Hex7HexNAc4SP
2043
+++

+++

NeuAcHex7HexNAc3
2051

−

−−−

Hex4HexNAc5dHex2SP
2052
−−−

−−−
++

Hex5HexNAc5dHexSP
2068
+++
+++

+++

NeuAcHex5HexNAc4dHex
2076

+
−−

NeuGcHex5HexNAc4dHex/NeuAcHex6HexNAc4
2092
−
−
−

NeuGcHex6HexNAc4
2108
−

+

NeuAcHex4HexNAc5dHex
2117

+
+
−

NeuAcHex5HexNAc5
2133

+
++

NeuAcHex5HexNAc4dHexSP/
2156

+

−−−

NeuAcHex8HexNAc2dHex

Hex5HexNAc4dHex3SP
2157

+++

+++

NeuAc2Hex5HexNAc3dHex
2164

−−−

NeuAcHex5HexNAc3dHex3
2165

+++

NeuAcHex9HexNAc2/NeuAcHex6HexNAc4SP/
2172
+++

NeuGcHex5HexNAc4dHexSP

NeuAcHex4HexNAc6
2174
−−−
−−−
−−−
−−−

NeuAc2Hex3HexNAc4dHex2/Hex7HexNAc4dHexSP
2189

−−−

NeuAcHex3HexNAc4dHex4
2190
−−−
−−−
−−−
++

NeuGcNeuAcHex6HexNAc3/
2196

+++
+++

NeuGc2Hex5HexNAc3dHex

Hex4HexNAc5dHexSP
2198
−−−
−−−
−−−

NeuAc2Hex4HexNAc4(SP)2
2219

+++

NeuAc2Hex5HexNAc4
2221
−−

−−

NeuAcHex5HexNAc4dHex2
2222
−
−−
−−−??
−−

Hex6HexNAc5dHexSP
2230
++
−−−
−−−
++

NeuGcNeuAcHex5HexNAc4
2237
+++
+++

NeuGcHex5HexNAc4dHex2/NeuAcHex6HexNAc4dHex
2238
−−
−
−
−−

NeuGc2Hex5HexNAc4
2253
+
++
−−−
−−−

NeuAcHex7HexNAc4/NeuGcHex6HexNAc4dHex
2254
++
−
++
++

NeuAcHex4HexNAc5dHex2
2263

−−−
−−−
−−−

NeuAcHex5HexNAc5dHex
2279

+
+
−

NeuAcHex6HexNAc5
2295

+

NeuAcHex5HexNAc3dHex4/NeuGcHex6HexNAc5
2311
+++

+++

Hex6HexNAc4dHex3SP
2319
−−−
−−−
++
−−−

NeuAc2Hex5HexNAc4dHex
2367
−−

−
−−−

NeuAcHex5HexNAc4dHex3
2368
−−−
−
−−−
−−−

NeuGcNeuAcHex5HexNAc4dHex/
2383
−−

−
−−−

NeuAc2Hex6HexNAc4

NeuGcHex5HexNAc4dHex3/NeuAcHex6HexNAc4dHex2
2384

+++

NeuAc3Hex5HexNAx3SP/NeuAc2Hex5HexNAc4Ac4
2389
−−−
+
+
−−−

NeuAc2Hex5HexNAc3dHexSP
2390

+++

NeuAc2Hex3HexNAc5dHex2
2392

+++

NeuAcHex3HexNAc5dHex4
2393

+++

NeuGc2Hex5HexNAc4dHex
2399
−−−
−−−
−−−
−−−

NeuAc2Hex6HexNAc3dHexSP
2406
−−−
++
−−−
−−−

NeuAc2Hex4HexNAc5dHex
2408
−−−
−−−
−−−
−−−

NeuAcHex5HexNAc5dHex2
2425

+++

NeuAcHex6HexNAc5dHex
2441
+
+
+

NeuAc2Hex5HexNAc4dHexSP/
2447
−−−
−−−
−−−
−−−

NeuAc2Hex8HexNAc2dHex

NeuAcHex5HexNAc4dHex3SP/
2448
−−−
−−−
−−−
−−−

NeuAcHex8HexNAc2dHex3

NeuAcHex3HexNAc6dHex3
2450

+++

NeuAcHex7HexNAc5
2457

++

NeuAc3Hex5HexNAc4
2512
−−−

−−−
−−−

NeuAc2Hex5HexNAc4dHex2
2513
−−−
−−−
−−−
−−−

NeuAcHex6HexNAc5dHexSP
2521
+++

NeuGcNeuAc2Hex5HexNAc4
2528
−−−

−−−
−−−

NeuGcNeuAcHex5HexNAc4dHex2/
2529
−−−
−−−
−−−
−−−

NeuAc2Hex6HexNAc4dHex

NeuGc2NeuAcHex5HexNAc4
2544
−−−
−−−
−−−
−−−

NeuAc2Hex6HexNAc5
2586
−−−
+
−−−
−−−

NeuAcHex6HexNAc5dHex2
2587
−−−

−−−

Hex7HexNAc6dHexSP
2595
+++

+++

NeuAcHex7HexNAc5dHex/NeuGcHex6HexNAc5dHex2
2603

+

NeuAcHex8HexNAc5/NeuGcHex7HexNAc5dHex
2619

−−−

NeuAcHex6HexNAc6dHex
2644
+++

NeuAcHex7HexNAc6
2660

−−−
−−−
+

NeuAc2Hex6HexNAc5dHex
2732
−

−−−

NeuAcHex6HexNAc5dHex3
2733
−−−

−−−
−−−

NeuAc2Hex4HexNAc6dHex2
2758
+++

+++

NeuAcHex8HexNAc5dHex
2765
−

−−

NeuGcHex8HexNAc5dHex/NeuAcHex9HexNAc5
2781

−−−
−−−

NeuAc2Hex5HexNAc4dHex4
2806
++

+++

NeuAcHex7HexNAc6dHex
2807

+++
+++
−−−

NeuAcHex8HexNAc6
2822
+++

+++

NeuAc3Hex6HexNAc5
2878
−−−
−−−
−−−
−−−

NeuGcNeuAc2Hex6HexNAc5
2894
−−−
−−−
−−−
−−−

NeuGcNeuAcHex6HexNAc5dHex2/
2895

+++

NeuAc2Hex7HexNAc5dHex

NeuAc2Hex7HexNAc6
2952

−−−
−−−
−−−

NeuAcHex7HexNAc6dHex2
2953
+++

NeuAc3Hex6HexNAc5dHex
3024
−−−
+
−−−
−−−

NeuAc2Hex7HexNAc6dHex
3098
−−−
−−−
−−−
−−−

NeuAcHex8HexNAc7dHex
3172
+++

¹⁾Code: +++ new signal appeared, ++ highly increased relative signal intensity, ++ increased relative signal intensity, − decreased relative signal intensity, −− greatly decreased relative signal intensity, −−− signal disappeared, blank: no change.

TABLE 16

Preferred

monosaccharide
Terminal
Experimental structures included in the glycan

m/z*
compositions
epitopes
signal according to the invention^§
Group^#

730
Hex3HexNAc
Manα
(Manα→)₂Hex₁HexNAc₁
S

771
Hex2HexNAc2
Manα
Manα→Hex₁HexNAc₂
LO

892
Hex4HexNAc
Manα
(Manα→)₃Hex₁HexNAc₁
S

Galβ4
Galβ4GlcNAc→Hex₃

917
Hex2HexNAc2dHex
Manα
Manα→Hex₁HexNAc₂dHex₁
LO, F

933
Hex3HexNAc2
Manα
(Manα→)₂Hex₁HexNAc₂
LO

1054
Hex5HexNAc
Manα
(Manα→)₄Hex₁HexNAc₁
S

1079
Hex3HexNAc2dHex
Manα
(Manα→)₂Hex₁HexNAc₂dHex₁
LO, F

1095
Hex4HexNAc2
Manα
(Manα→)₃Hex₁HexNAc₂
LO

1120
Hex2HexNAc3dHex
Fucα3/4
Fucα3/4→Hex₂HexNAc₃
HY, F,

N > H

1136
Hex3HexNAc3
GlcNAcβ
GlcNAcβ→Hex₃HexNAc₂
HY,

N═H

1216
Hex6HexNAc
Manα
(Manα→)₅Hex₁HexNAc₁
S

1241
Hex4HexNAc2dHex
Manα
(Manα)₃Hex₁HexNAc₂dHex₁
LO, F

1257
Hex5HexNAc2
Manα
(Manα→)₄Hex₁HexNAc₂
HI

1282
Hex3HexNAc3dHex
GlcNAcβ
GlcNAcβ→Hex₃HexNAc₂dHex₁
HY, F,

N═H

1298
Hex4HexNAc3

HY

1339
Hex3HexNAc4
2 × GlcNAcβ
(GlcNAcβ→)₂Hex₃HexNAc₂
CO,

N > H

1378
Hex7HexNAc
Manα
(Manα→)₆Hex₁HexNAc₁
S

1403
Hex5HexNAc2dHex
Manα
(Manα→)₄Hex₁HexNAc₂dHex₁
HF

1419
Hex6HexNAc2
Manα
(Manα→)₅Hex₁HexNAc₂
HI

1444
Hex4HexNAc3dHex
Manα
Manα→Hex₃HexNAc₃dHex₁
HY, F

1460
Hex5HexNAc3
Manα
Manα→Hex₄HexNAc₃
HY

1485
Hex3HexNAc4dHex
2 × GlcNAcβ
(GlcNAcβ→)₂Hex₃HexNAc₂dHex₁
CO, F,

N > H

1501
Hex4HexNAc4
GlcNAcβ
GlcNAcβ→Hex₄HexNAc₃
CO,

Galβ4
Galβ4GlcNAc→Hex₃HexNAc₃
N═H

1540
Hex8HexNAc
Manα
(Manα→)₇Hex₁HexNAc₁
S

1542
Hex3HexNAc5
3 × GlcNAcβ
(GlcNAcβ→)₃Hex₃HexNAc₂
CO,

N > H

1565
Hex6HexNAc2dHex
Manα
(Manα→)₅Hex₁HexNAc₂dHex₁
HF

1581
Hex7HexNAc2
Manα
(Manα→)₆Hex₁HexNAc₂
HI

1590
Hex4HexNAc3dHex2
Fucα
Fucα→Hex₄HexNAc₃dHex₁
HY, FC

1606
Hex5HexNAc3dHex
Manα
Manα→Hex₄HexNAc₃dHex₁
HY, F

Galβ4
Galβ4GlcNAc→Hex₄HexNAc₂dHex₁

Manα→[Galβ4GlcNAc→]Hex₃HexNAc₂dHex₁

1622
Hex6HexNAc3
Manα
Manα→Hex₅HexNAc₃
HY

Galβ4
Galβ4GlcNAc→Hex₅HexNAc₂

Manα→[Galβ4GlcNAc→]Hex₄HexNAc₂

1647
Hex4HexNAc4dHex
GlcNAcβ
GlcNAcβ→Hex₄HexNAc₃dHex₁
CO, F,

Galβ4
Galβ4GlcNAc→Hex₃HexNAc₃dHex₁
N═H

GlcNAcβ→[Galβ4GlcNAc→]Hex₃HexNAc₂dHex₁

1663
Hex5HexNAc4
2 × Galβ4
(Galβ4GlcNAc→)₂Hex₃HexNAc₂
CO

1688
Hex3HexNAc5dHex
3 × GlcNAcβ
(GlcNAcβ→)₃Hex₃HexNAc₂dHex₁
CO, F,

Manα
Manα→Hex₂HexNAc₅dHex₁
N > H

1702
Hex9HexNAc
Manα
(Manα→)₈Hex₁HexNAc₁
S

1704
Hex4HexNAc5
2 × HexNAcβ
HexNAcβHexNAcβ→Hex₄HexNAc₃dHex₁
CO,

(not
Galβ4GlcNAc→Hex₃HexNAc₄dHex₁
N > H

GlcNAc)
HexNAcβHexNAcβ→[Galβ4GlcNAc→]

Galβ4
Hex₃HexNAc₂dHex₁

1743
Hex8HexNAc2
Manα
(Manα→)₇Hex₁HexNAc₂
HI

1768
Hex6HexNAc3dHex
Manα
Manα→Hex₅HexNAc₃dHex₁
HY, F

1784
Hex7HexNAc3
Manα
Manα→Hex₆HexNAc₃
HY

Galβ4
Galβ4GlcNAc→Hex₆HexNAc₂

Manα→[Galβ4GlcNAc→]Hex₅HexNAc₂

1793
Hex4HexNAc4dHex2
GlcNAcβ
GlcNAcβ→Hex₄HexNAc₃dHex₂
CO, FC,

Galβ4
Galβ4GlcNAc→Hex₃HexNAc₃dHex₂
N═H

Fucα3/4
Fucα3/4→Hex₄HexNAc₄dHex₁

GlcNAcβ→[Galβ4GlcNAc→]Hex₃HexNAc₂dHex₂

GlcNAcβ→[Fucα3/4→]Hex₄HexNAc₃dHex₁

Fucα3/4→[Galβ4GlcNAc→]Hex₃HexNAc₃dHex₁

GlcNAcβ→[Fucα3/4→][Galβ4GlcNAc→]

Hex₄HexNAc₃dHex₁

1809
Hex5HexNAc4dHex
2 × Galβ4
(Galβ4GlcNAc→)₂Hex₃HexNAc₂dHex₁
CO, F

1850
Hex4HexNAc5dHex
2 × GlcNAcβ
(GlcNAcβ→)₂Hex₄HexNAc₃dHex₁
CO, F,

Galβ4
Galβ4GlcNAc→Hex₃HexNAc₄dHex₁
N > H

Galβ4GlcNAc→[GlcNAcβ→]₂Hex₃HexNAc₂dHex₁

1866
Hex5HexNAc5

CO,

N═H

1905
Hex9HexNAc2
Manα
(Manα→)₈Hex₁HexNAc₂
HI

1955
Hex5HexNAc4dHex2
Fucα3/4
Fucα3/4→Hex₅HexNAc₄dHex₁
CO, FC

Galβ4
Galβ4GlcNAc→Hex₄HexNAc₃dHex₂

Galβ4GlcNAc→[Fucα3/4→]Hex₄HexNAc₃dHex₁

1971
Hex6HexNAc4dHex
Galβ4
Galβ4GlcNAc→Hex₅HexNAc₃dHex₁
CO, F

1996
Hex4HexNAc5dHex2
2 × GlcNAcβ
(GlcNAcβ→)₂Hex₄HexNAc₃dHex₂
CO, FC,

Fucα3/4
Fucα3/4→Hex₄HexNAc₅dHex₁
N > H

Galβ4
Galβ4GlcNAc→Hex₃HexNAc₄dHex₂

(GlcNAcβ→)₂[Fucα3/4→]Hex₄HexNAc₃dHex₁

Galβ4GlcNAc→[Fucα3/4→]Hex₃HexNAc₄dHex₁

2012
Hex5HexNAc5dHex
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₄dHex₁
CO, F,

N═H

2028
Hex6HexNAc5
Galβ4
Galβ4GlcNAc→Hex₅HexNAc₄
CO

3 × Galβ4
(Galβ4GlcNAc→)₃Hex₃HexNAc₂

2067
Hex10HexNAc2
Manα
Glc→(Manα→)₈Hex₁HexNAc₂
G

Glc

2101
Hex5HexNAc4dHex3
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₃dHex₃
CO, FC

2174
Hex6HexNAc5dHex
3 × Galβ4
(Galβ4GlcNAc→)₃Hex₃HexNAc₂dHex₁
CO, F

2229
Hex11HexNAc2
Manα
Glc₂→(Manα→)₈Hex₁HexNAc₂
G

Glc

2320
Hex6HexNAc5dHex2
Galβ4
Galβ4GlcNAc→Hex₅HexNAc₄dHex₂
CO, FC

2391
Hex12HexNAc2
Manα
Glc₃→(Manα→)₈Hex₁HexNAc₂
G

Glc

*[M + Na]⁺ion, first isotope.

^§“→” indicates linkage to a monosaccharide in the rest of the structure; “[ ]” indicates branch in the structure.

^#Preferred structure group based on monosaccharide compositions according to the present invention. HI, high-mannose; LO, low-mannose; S, soluble mannosylated; HF, fucosylated high-mannose; G, glucosylated high-mannose; HY, hybrid-type or monoantennary; CO, complex-type; F, fucosylation; FC, complex fucosylation; N═H, terminal HexNAc (HexNAc = Hex); N > H, terminal HexNAc (HexNAc > Hex).

TABLE 17

Proposed composition
m/z
α-Man
β-GlcNAc
β4-Gal
β3-Gal

Hex2HexNAc
568

−−−

HexHexNAc2
609
+++

Hex2HexNAcdHex
714
+++

Hex3HexNAc
730
−−
−−−

HexHexNAc2dHex
755
+++

Hex2HexNAc2
771
++
++

Hex4HexNAc
892
−−−
+

Hex2HexNAc2dHex
917

+

Hex3HexNAc2
933
++
++

Hex2HexNAc3
974
+++

Hex5HexNAc
1054
−−

Hex3HexNAc2dHex
1079
−−
+

Hex4HexNAc2
1095
−
+

Hex2HexNAc3dHex
1120
+++
−−−

Hex3HexNAc3
1136
++
−−
+

Hex2HexNAc2dHex3
1209
−−−
−−−

Hex6HexNAc
1216
−−

Hex4HexNAc2dHex
1241
−−−

Hex5HexNAc2
1257
−−

Hex2HexNAc3dHex2
1266

Hex3HexNAc3dHex
1282
++
−−
+

Hex4HexNAc3
1298
++
−

Hex3HexNAc4
1339
+++

+++

Hex7HexNAc
1378
−−

Hex5HexNAc2dHex
1403
−−−

Hex6HexNAc2
1419
−−
+

Hex3HexNAc3dHex2
1428
+++

Hex4HexNAc3dHex
1444
+
−
+

Hex5HexNAc3
1460
+
−
++

Hex3HexNAc4dHex
1485

−−
++

Hex4HexNAc4
1501
++

Hex8HexNAc
1540
−

Hex3HexNAc5
1542

+++

Hex6HexNAc2dHex
1565
−−−

−−−
−−−

Hex7HexNAc2
1581
−−

Hex4HexNAc3dHex2
1590

Hex5HexNAc3dHex
1606

−−
−−

Hex6HexNAc3
1622
−−
−
−−

Hex4HexNAc4dHex
1647

−−−

Hex5HexNAc4
1663

−−
−−−

Hex3HexNAc5dHex
1688

−−−
++

Hex9HexNAc
1702
−−−
−−−

Hex8HexNAc2
1743
−−
+

Hex6HexNAc3dHex
1768

−−−

Hex7HexNAc3
1784
−−−
−−−
−−−

Hex4HexNAc4dHex2
1793

−−−
++

Hex5HexNAc4dHex
1809

−−
−−−

Hex3HexNAc6dHex
1891

+++

Hex9HexNAc2
1905
−−−
−

Hex5HexNAc4dHex2
1955

−
−−−

Hex6HexNAc4dHex
1971

−−−
−−−

Hex4HexNAc5dHex2
1996

−−−

Hex5HexNAc5dHex
2012

−−−
−−−
−−−

Hex6HexNAc5
2028

−
−−−

Hex10HexNAc2
2067
−−−
−

Hex5HexNAc4dHex3
2101

−−−

Hex4HexNAc5dHex3
2142

−−
−−−

Hex6HexNAc5dHex
2174

−−
−−−

Hex11HexNAc2
2229

Hex5HexNAc5dHex3
2304

−−−

Hex6HexNAc5dHex2
2320

−−−

Hex7HexNAc6
2393

−−−

Hex6HexNAc5dHex3
2466

−−−

Hex7HexNAc6dHex
2539

−−−
−−−

TABLE 18

Preferred

monosaccharide
Terminal
Experimental structures included in the glycan

m/z*
compositions
epitopes
signal according to the invention^§
Group^#

568
Hex2HexNAc
Manα
Manα→Hex₁HexNAc₁
S

730
Hex3HexNAc
Manα
(Manα→)₂Hex₁HexNAc₁
S

GlcNAc
GlcNAc→Hex₃

771
Hex2HexNAc2
Manα
Manα→Hex₁HexNAc₂
LO

892
Hex4HexNAc
Manα
(Manα→)₃Hex₁HexNAc₁
S

917
Hex2HexNAc2dHex
Manα
Manα→Hex₁HexNAc₂dHex₁
LO, F

933
Hex3HexNAc2
Manα
(Manα→)₂Hex₁HexNAc₂
LO

1054
Hex5HexNAc
Manα
(Manα→)₄Hex₁HexNAc₁
S

1079
Hex3HexNAc2dHex
Manα
(Manα→)₂Hex₁HexNAc₂dHex₁
LO, F

1095
Hex4HexNAc2
Manα
(Manα→)₃Hex₁HexNAc₂
LO

1120
Hex2HexNAc3dHex
GlcNAcβ
GlcNAcβ→Hex₂HexNAc₂dHex₁
HY, F,

N > H

1136
Hex3HexNAc3
GlcNAcβ
GlcNAcβ→Hex₃HexNAc₂
HY,

N═H

1209
Hex2HexNAc2dHex3
Manα
Manα→Hex₁HexNAc₂dHex₃
FC,

GlcNAc
GlcNAc→Hex₂HexNAc₁dHex₃
N═H

1216
Hex6HexNAc
Manα
(Manα→)₅Hex₁HexNAc₁
S

1241
Hex4HexNAc2dHex
Manα
(Manα)₃Hex₁HexNAc₂dHex₁
LO, F

1257
Hex5HexNAc2
Manα
(Manα→)₄Hex₁HexNAc₂
HI

1266
Hex2HexNAc3dHex2
Fuc
Fuc→Hex₂HexNAc₃dHex₁
HY, FC

1282
Hex3HexNAc3dHex
GlcNAcβ
GlcNAcβ→Hex₃HexNAc₂dHex₁
HY, F,

N═H

1298
Hex4HexNAc3

HY

1378
Hex7HexNAc
Manα
(Manα→)₆Hex₁HexNAc₁
S

1403
Hex5HexNAc2dHex
Manα
(Manα)₄Hex₁HexNAc₂dHex₁
HF

1419
Hex6HexNAc2
Manα
(Manα→)₅Hex₁HexNAc₂
HI

1444
Hex4HexNAc3dHex
GlcNAcβ
GlcNAcβ→Hex₄HexNAc₂dHex₁
HY, F

1460
Hex5HexNAc3
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₂
HY

1485
Hex3HexNAc4dHex
2 × GlcNAcβ
(GlcNAcβ→)₂Hex₃HexNAc₂dHex₁
CO, F,

N > H

1501
Hex4HexNAc4

CO,

N═H

1540
Hex8HexNAc
Manα
(Manα→)₇Hex₁HexNAc₁
S

1565
Hex6HexNAc2dHex
Manα
(Manα)₅Hex₁HexNAc₂dHex₁
HF

1581
Hex7HexNAc2
Manα
(Manα→)₆Hex₁HexNAc₂
HI

1590
Hex4HexNAc3dHex2
Fucα
Fucα→Hex₄HexNAc₃dHex₁
HY, FC

1606
Hex5HexNAc3dHex
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₂dHex₁
HY, F

Galβ4
Galβ4GlcNAc→Hex₄HexNAc₂dHex₁

1622
Hex6HexNAc3
Manα
Manα→Hex₅HexNAc₃
HY

GlcNAcβ
GlcNAcβ→Hex₆HexNAc₂

Galβ4
Galβ4GlcNAc→Hex₅HexNAc₂

Manα→[GlcNAcβ→]Hex₅HexNAc₂

Manα→[Galβ4GlcNAc→]Hex₄HexNAc₂

1647
Hex4HexNAc4dHex
GlcNAcβ
GlcNAcβ→Hex₄HexNAc₃dHex₁
CO, F,

N═H

1663
Hex5HexNAc4
2 × Galβ4
(Galβ4GlcNAc→)₂Hex₃HexNAc₂
CO

GlcNAcβ
GlcNAcβ→Hex₅HexNAc₃

1688
Hex3HexNAc5dHex
3 × GlcNAcβ
(GlcNAcβ→)₃Hex₃HexNAc₂dHex₁
CO, F,

N > H

1702
Hex9HexNAc
Manα
(Manα→)₈Hex₁HexNAc₁
S

1743
Hex8HexNAc2
Manα
(Manα→)₇Hex₁HexNAc₂
HI

1768
Hex6HexNAc3dHex
Galβ4
Galβ4GlcNAc→Hex₅HexNAc₂dHex₁
HY, F

1784
Hex7HexNAc3
Manα
Manα→Hex₆HexNAc₃
HY

GlcNAcβ
GlcNAcβ→Hex₇HexNAc₂

Galβ4
Galβ4GlcNAc→Hex₆HexNAc₂

Manα→[GlcNAcβ→]Hex₆HexNAc₂

Manα→[Galβ4GlcNAc→]Hex₅HexNAc₂

1793
Hex4HexNAc4dHex2
GlcNAcβ
GlcNAcβ→Hex₄HexNAc₃dHex₂
CO, FC,

Fuc
Fuc→Hex₄HexNAc₄dHex₁
N═H

GlcNAcβ→[Fuc→]Hex₄HexNAc₃dHex₁

1809
Hex5HexNAc4dHex
2 × Galβ4
(Galβ4GlcNAc→)₂Hex₃HexNAc₂dHex₁
CO, F

GlcNAcβ
GlcNAcβ→Hex₅HexNAc₃dHex₁

1891
Hex3HexNAc6dHex

CO, F,

N > H

1905
Hex9HexNAc2
Manα
(Manα→)₈Hex₁HexNAc₂
HI

1955
Hex5HexNAc4dHex2
Galβ4
Galβ4GlcNAc→Hex₄HexNAc₃dHex₂
CO, FC

Fuc
Fuc→Hex₅HexNAc₄dHex₁

Galβ4GlcNAc→[Fuc→]Hex₄HexNAc₃dHex₁

1971
Hex6HexNAc4dHex
GlcNAcβ
GlcNAcβ→Hex₆HexNAc₃dHex₁
CO, F

Galβ4
Galβ4GlcNAc→Hex₅HexNAc₃dHex₁

1996
Hex4HexNAc5dHex2
2 × GlcNAcβ
(GlcNAcβ→)₂Hex₄HexNAc₃dHex₂
CO, FC,

N > H

2012
Hex5HexNAc5dHex
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₄dHex₁
CO, F,

2 × Galβ4
(Galβ4GlcNAc→)₂Hex₃HexNAc₃dHex₁
N═H

Galβ3
Galβ3GlcNAc→Hex₄HexNAc₄dHex₁

(Galβ4GlcNAc→)₂[GlcNAcβ→]Hex₃HexNAc₂dHex₁

2028
Hex6HexNAc5
3 × Galβ4
(Galβ4GlcNAc→)₃Hex₃HexNAc₂
CO

2067
Hex10HexNAc2
Manα
Glc→(Manα→)₈Hex₁HexNAc₂
G

Glc

2101
Hex5HexNAc4dHex3
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₃dHex₃
CO, FC

2142
Hex4HexNAc5dHex3
Galβ4
Galβ4GlcNAc→Hex₃HexNAc₄dHex₃
CO, FC,

N > H

2174
Hex6HexNAc5dHex
GlcNAcβ
GlcNAcβ→Hex₆HexNAc₄dHex₁
CO, F

3 × Galβ4
(Galβ4GlcNAc→)₃Hex₃HexNAc₂dHex₁

2229
Hex11HexNAc2
Glc
Glc₂→(Manα→)₈Hex₁HexNAc₂
G

Manα

2304
Hex5HexNAc5dHex3
GlcNAcβ
GlcNAcβ→Hex₅HexNAc₄dHex₃
CO, FC,

N═H

2320
Hex6HexNAc5dHex2
GlcNAcβ
GlcNAcβ→Hex₆HexNAc₄dHex₂
CO, FC

2393
Hex7HexNAc6
Galβ4
Galβ4GlcNAc→Hex₆HexNAc₅
CO

2466
Hex6HexNAc5dHex3
GlcNAcβ
GlcNAcβ→Hex₆HexNAc₄dHex₃
CO, FC

2539
Hex7HexNAc6dHex
GlcNAcβ
GlcNAcβ→Hex₇HexNAc₅dHex₁
CO, F

4 × Galβ4
(Galβ4GlcNAc→)₄Hex₃HexNAc₂dHex₁

*[M + Na]⁺ion, first isotope.

^§“→” indicates linkage to a monosaccharide in the rest of the structure; “[ ]” indicates branch in the structure.

^#Preferred structure group based on monosaccharide compositions according to the present invention. HI, high-mannose; LO, low-mannose; S, soluble mannosylated; HF, fucosylated high-mannose; G, glucosylated high-mannose; HY, hybrid-type or monoantennary; CO, complex-type; F, fucosylation; FC, complex fucosylation; N═H, terminal HexNAc (HexNAc = Hex); N > H, terminal HexNAc (HexNAc > Hex).

TABLE 19

Proposed composition
m/z
α-Man
β-GlcNAc
β4-Gal
β3-Gal

Hex2HexNAc
568
−−−
−−−

HexHexNAc2
609
+++

−−−

Hex2HexNAcdHex
714
+++

Hex3HexNAc
730
−

HexHexNAc2dHex
755
+++

Hex2HexNAc2
771
++
++
−
−

Hex4HexNAc
892
−−−
−−−

Hex2HexNAc2dHex
917
−
++
−
−

Hex3HexNAc2
933
++
++
−
−

HexHexNAc3dHex
958

Hex2HexNAc3
974
+++

++
−−−

Hex5HexNAc
1054
−−−

Hex3HexNAc2dHex
1079
−−
++
−
−

Hex4HexNAc2
1095
−−
+
−
−

Hex2HexNAc3dHex
1120
+++

+
−−−

Hex3HexNAc3
1136
++
−−−
++
−−

Hex2HexNAc2dHex3
1209
−−−
−−−

Hex6HexNAc
1216
−−−

+++
+++

Hex4HexNAc2dHex
1241
−−−

−

Hex5HexNAc2
1257
−−

Hex3HexNAc3dHex
1282
++
−−−
+
−

Hex4HexNAc3
1298
+++
+
−
−

Hex3HexNAc4
1339

+++
−−−

Hex7HexNAc
1378

+++
+++

Hex5HexNAc2dHex
1403
−−−

−

Hex6HexNAc2
1419
−−
+

Hex3HexNAc3dHex2
1428
+++

Hex4HexNAc3dHex
1444
++

−
−

Hex5HexNAc3
1460
+
−
+
−

Hex3HexNAc4dHex
1485

−−−
++
−

Hex4HexNAc4
1501
+
−−−
−−
−

Hex8HexNAc
1540

−−−
−

Hex3HexNAc5
1542

+++

Hex6HexNAc2dHex
1565
−−−

−−−

Hex7HexNAc2
1581
−−

Hex4HexNAc3dHex2
1590

Hex5HexNAc3dHex
1606

−−
−−
−

Hex6HexNAc3
1622
−−
−−
−−
−

Hex4HexNAc4dHex
1647

−−−

−

Hex5HexNAc4
1663

−
−−

Hex3HexNAc5dHex
1688

−−−
++
−−−

Hex4HexNAc5
1704

+++

Hex8HexNAc2
1743
−−

Hex5HexNAc3dHex2
1752

−−−
−−−

Hex6HexNAc3dHex
1768
−−
−−
−−

Hex7HexNAc3
1784
−

−−−

Hex4HexNAc4dHex2
1793

−−−
++
−−−

Hex5HexNAc4dHex
1809

−−
−−−

Hex6HexNAc4
1825
+++
+++
−−

Hex4HexNAc5dHex
1850

+++

Hex5HexNAc5
1866

−−−
−−−

Hex3HexNAc6dHex
1891

++
−−−

Hex9HexNAc2
1905
−−−

Hex5HexNAc4dHex2
1955

−−−
−−
−

Hex6HexNAc4dHex
1971

−−−
−−−

Hex7HexNAc4
1987

−−−

−−−

Hex4HexNAc5dHex2
1996

−−−
+++

Hex5HexNAc5dHex
2012

−−−
−−

Hex6HexNAc5
2028

−
−−−
−

Hex10HexNAc2
2067
−−−

−

Hex5HexNAc4dHex3
2101

−

Hex6HexNAc4dHex2
2117

−−−
−−−

Hex7HexNAc4dHex
2133

−−−

−−−

Hex4HexNAc5dHex3
2142

−−−
−−−

Hex6HexNAc5dHex
2174

−−
−−−
−

Hex5HexNAc7
2272

+++

Hex5HexNAc5dHex3
2304

−−−
+++

Hex6HexNAc5dHex2
2320

−−−
−−−

Hex7HexNAc6
2393

−−
−−−

Hex6HexNAc5dHex3
2466

−−−
−−−

Hex7HexNAc6dHex
2539

−−−
−−−

Hex8HexNAc7
2758

−−−
−−−

TABLE 20

Proposed composition
m/z
β4-Gal
β-GlcNAc

Hex2HexNAc
568
−
−−−

HexHexNAc2
609
+++

Hex3HexNAc
730

Hex2HexNAc2
771

−−

Hex4HexNAc
892

−−−

Hex2HexNAc2dHex
917

−

Hex3HexNAc2
933

−

Hex2HexNAc3
974
+++

Hex5HexNAc
1054

Hex3HexNAc2dHex
1079

Hex4HexNAc2
1095

Hex2HexNAc3dHex
1120
+++

Hex3HexNAc3
1136
++
−−−

Hex2HexNAc2dHex3
1209
−−−
−−−

Hex6HexNAc
1216

Hex4HexNAc2dHex
1241

Hex5HexNAc2
1257

Hex3HexNAc3dHex
1282
+
−−

Hex4HexNAc3
1298

Hex3HexNAc4
1339
+++

Hex2HexNac2dHex4
1355
+++

Hex7HexNAc
1378

Hex5HexNAc2dHex
1403

Hex6HexNAc2
1419

Hex4HexNAc3dHex
1444
+

Hex5HexNAc3
1460
++
−

Hex3HexNAc4dHex
1485
++
−−−

Hex4HexNAc4
1501
−−
−−−

Hex8HexNAc
1540

Hex3HexNAc5
1542
+++

Hex6HexNAc2dHex
1565

Hex7HexNAc2
1581

Hex4HexNAc3dHex2
1590
+++
+++

Hex5HexNAc3dHex
1606
−

Hex6HexNAc3
1622
−−
−

Hex4HexNAc4dHex
1647

−−−

Hex5HexNAc4
1663
−−−
++

Hex3HexNAc5dHex
1688
++
−−−

Hex9HexNAc
1702
−−−
−−−

Hex4HexNAc5
1704
+++
−−−

Hex8HexNAc2
1743

Hex5HexNAc3dHex2
1752
+++

Hex6HexNAc3dHex
1768
−

Hex7HexNAc3
1784
−−−
−−−

Hex4HexNAc4dHex2
1793
+++

Hex5HexNAc4dHex
1809
−−−
+

Hex4HexNAc5dHex
1850

−−−

Hex3HexNAc6dHex
1891
++
−−−

Hex9HexNAc2
1905

Hex5HexNAc4dHex2
1955
−−−

Hex4HexNAc5dHex2
1996

−−−

Hex5HexNAc5dHex
2012
−−−
−−−

Hex6HexNAc5
2028
−−−

Hex10HexNAc2
2067

Hex5HexNAc4dHex3
2101

+

Hex6HexNAc5dHex
2174
−−−

Hex7HexNAc6
2393
−−−
−−−

Hex7HexNAc6dHex
2539
−−−
−−−

TABLE 21

Proposed composition
m/z
α-Man
β4-Gal
β-GlcNAc

Hex2HexNAc
568
−−−
−
−−−

HexHexNAc2
609
+++
−
−−−

Hex3HexNAc
730
−−
−

HexHexNAc2dHex
755
+++

−−−

Hex2HexNAc2
771
++
−
−−

Hex4HexNAc
892
−−−
−
−−−

Hex2HexNAc2dHex
917
−−
−
−−

Hex3HexNAc2
933
−
−
−−

Hex2HexNAc3
974
++
+
−−−

Hex5HexNAc
1054
−−−

Hex3HexNAc2dHex
1079
−−−
−
−−

Hex4HexNAc2
1095
−−
−
−

Hex2HexNAc3dHex
1120
++
+
−−−

Hex3HexNAc3
1136
+
++
−−

Hex6HexNAc
1216
−−

Hex4HexNAc2dHex
1241
−−−

Hex5HexNAc2
1257
−−−

Hex3HexNAc3dHex
1282

+
−−

Hex4HexNAc3
1298
+

Hex3HexNAc4
1339

++
−−−

Hex7HexNAc
1378
−−−

Hex5HexNAc2dHex
1403
−−−

Hex6HexNAc2
1419
−−

Hex3HexNAc3dHex2
1428
+++

Hex4HexNAc3dHex
1444

Hex5HexNAc3
1460

+

Hex3HexNAc4dHex
1485

++
−−−

Hex4HexNAc4
1501

−−
−−−

Hex8HexNAc
1540
−−−

−−−

Hex3HexNAc5
1542
+
++
−−−

Hex6HexNAc2dHex
1565
−−−

−

Hex7HexNAc2
1581
−−

Hex4HexNAc3dHex2
1590
−−−

++

Hex5HexNAc3dHex
1606
−
−−
+

Hex6HexNAc3
1622
−−
−−
++

Hex4HexNAc4dHex
1647

−−
−−−

Hex5HexNAc4
1663

−−−
+

Hex3HexNAc5dHex
1688

++
−−−

Hex4HexNAc5
1704

+++

Hex8HexNAc2
1743
−−

Hex5HexNAc3dHex2
1752

+++

Hex6HexNAc3dHex
1768
−
−−
+

Hex7HexNAc3
1784
−−−
−−

Hex4HexNAc4dHex2
1793

+
−−−

Hex5HexNAc4dHex
1809

−−−

Hex6HexNAc4
1825
−−−
−
+

Hex4HexNAc5dHex
1850
−−−

−−−

Hex5HexNAc5
1866

−−−
−−−

Hex3HexNAc6dHex
1891
−−−
++
−−−

Hex9HexNAc2
1905
−−−

Hex5HexNAc4dHex2
1955

++

Hex6HexNAc4dHex
1971

−−−
+

Hex7HexNAc4
1987

+++

Hex4HexNAc5dHex2
1996

−−−

Hex5HexNAc5dHex
2012

−−−
−−−

Hex6HexNAc5
2028

−−−

Hex10HexNAc2
2067
−−−

Hex5HexNAc4dHex3
2101

+

Hex6HexNAc5dHex
2174

−−−

Hex6HexNAc6
2231

−−−
−−−

Hex5HexNAc5dHex3
2304

−−−

Hex6HexNAc5dHex2
2320

−−−
−−−

Hex6HexNAc6dHex
2377

−−−
−−−

Hex7HexNAc6
2393

−−−
−−

Hex6HexNAc5dHex3
2466

Hex7HexNAc6dHex
2539

−−−
−−−

Hex8HexNAc6dHex4
3140

−−−
−−−

TABLE 22

See also Example 18.

FES
FES

Reagent
Target
22
30
mEF
% stain

FITC-PSA
α-Man
−
−
+

FITC-RCA
β-Gal (Galβ4GlcNAc)
+
−
+/−

FITC-PNA
β-Gal (Galβ3GalNAc)
+
+
−

FITC-MAA
α2,3-sialyl-LN
+
+
−

FITC-SNA
α2,6-sialyl-LN
+
n.d.
+

FITC-PWA
I-antigen
+
+
n.d.

FITC-STA
i-antigen
+
−
+

FITC-WFA
β-GalNAc
+
+
−

NeuGc-PAA-
NeuGc-lectin
+
+
+

biotin

anti-GM3(Gc)
NeuGcα3Galβ4Glc
+
+
+

mAb

FITC-LTA
α-Fuc
+
−
+

FITC-UEA
α-Fuc
+
−
+

mAb Lex
Lewis^x
+
n.d.
−

mAb sLex
sialyl-Lewis^x
+
n.d.
−

GF 279 Le c
Galβ3GlcNAc

+
−
95-100

GF 283 Le b

+
−
20-35

GF 284 H Type 2

+
−
15-20

GF 285 H Type 2

−
+
95-100

GF 286 H Type 2

+
−
10-20

GF 287 H Type 1

+
−
90-100

GF 288 Globo-H

+
−
20-35

GF 289 Ley

−
+
95-100

GF 290 H Type 2

+
−
20-35

+, specific binding.

−, no specific binding.

n.d., not determined.

% of stain means approximate percentage of cell stained with a binder.

TABLE 23

% of

Lectins
Target
positive cells

FITC-GNA
α-Man
27.8

FITC-HHA
α-Man
95.3

FITC-PSA
α-Man
95.5

FITC-RCA
β-Gal (Galβ4GlcNAc)
94.8

FITC-PNA
β-Gal (Galβ3GalNAc)
31.1

FITC-MAA
α2,3-sialylation
89.9

FITC-SNA
α2,6-sialylation
14.3

FITC-PWA
I-antigen
1.9

FITC-STA
i-antigen
11.9

FITC-LTA
α-Fuc
2.8

FITC-UEA
α-Fuc
8.0

TABLE 24

BM MSC

lectin concentration, μg/ml

Lectin
Target
0.25
0.5
1
2.5
5
10
20
40

FITC-GNA
α-Man
−¹⁾
−
++
++
++
++
++
++

FITC-HHA
α-Man
++
++
+++
+++
+++
+++
+++
+++

FITC-PSA
α-Man
++
++
++
+++
+++
+++
+++
+++

FITC-RCA
β-Gal (Galβ4GlcNAc)
−
−
+/−
+/−
+
+
++
++

FITC-PNA
β-Gal (Galβ3GalNAc)
−
−
−
−
+/−
+/−
+/−
+

FITC-MAA
α2,3-sialylation
−
−
−
+/−
+
++
++
++

FITC-SNA
α2,6-sialylation
−
−
−
−
+/−
+/−
+
+

FITC-PWA
l-antigen
−
−
−
−
−
−
+/−
+/−

FITC-STA
i-antigen
−
−
−
−
−
+/−
+/−
+/−

FITC-LTA
α-Fuc
−
−
−
−
−
−
−
−

FITC-UEA
α-Fuc
−
−
−
+/−
+/−
+
++
++

FITC-MBL
α-Man/β-GlcNAc
−
−
−
−
−
−
+/−
+

¹⁾Grading of staining/labelling: +++ very intense, ++ intense, + low, +/− barely detectable, − not labelled.

TABLE 25

N-glycan structural feature analysis based on proposed monosaccharide

compositions of four hESC lines FES 21, FES 22, FES 29, and FES 30. The numbers refer to

percentage from either neutral (A-E) or acidic (J-L) N-glycan pools, or from subfractions of

hybrid/monoantenary and complex-type N-glycans (N ≧ 3, F-I and M-P). EB 29 and EB 30:

embryoid bodies derived from hESC lines FES 29 and FES 30, respectively; st.3 29: stage 3

differentiated cells derived from hESC line FES 29. H: hexose; N: N-acetylhexosamine; F:

deoxyhexose.

FES 21*
FES 22
FES 29
FES 30
EB
st. 3

Neutral
A
N = 2 and 5 ≦ H ≦ 10
high-mannose type
84^#
73
79
79
73
72

N-glycans
B
N = 2 and 1 ≦ H ≦ 4
low-mannose type
5
11
7
8
12
12

C
N = 3 and H ≧ 2
hybrid/monoantennary
3
7
3
3
5
6

D
N ≧ 4 and H ≧ 3
complex-type
6
9
10
10
8
8

E
other types

2
0
1
0
2
2

N ≧ 3
F
F ≧ 1
fucosylation
8
11
10
10
14
15

G
F ≧ 2
complex fucosylation
1
0
2
2
2
2

H^§
N > H ≧ 2
terminal N (N > H)
1
2
1
1
3
3

I
N = H ≧ 5
terminal N (N = H)
0
2
0
0
1
1

Sialylated
J
N = 3 and H ≧ 3
hybrid/monoantennary
8
2
5
9
13
14

N-glycans
K
N ≧ 4 and H ≧ 3
complex-type
91
98
94
90
83
77

L
other types

1
0
1
1
4
9

N ≧ 3
M
F ≧ 1
fucosylation
85
96
75
78
83
86

N
F ≧ 2
complex fucosylation
24
34
23
19
12
11

O
N > H ≧ 3
terminal N (N > H)
10
8
6
5
10
10

P
N = H ≧ 5
terminal N (N = H)
3
4
4
2
14
20

TABLE 26¹⁾

FES 21
FES 22
FES 29
FES 30
EB²⁾

Affymetrix ID
Gene Bank ID
Gene
Det.³⁾
Ch.⁴⁾
Det.
Ch.
Det.
Ch.
Det.
Ch.
Det.

206109_at
NM_000148.1
FUT1
P
I
P
I
P
I
P
I
A

214088_s_at
AW080549
FUT3
M
NC
A
NC
A
NC
A
NC
A

209892_at
AF305083.1
FUT4
P
I
P
I
P
I
P
I
A

211225_at
U27330
FUT5
A
NC
A
NC
A
NC
A
NC
A

211225_at
U27329.1
FUT5
A
NC
A
NC
A
NC
A
NC
A

210399_x_at
U27336.1
FUT6
A
NC
A
NC
A
NC
A
NC
A

211882_x_at
U27331.1
FUT6(1)
A
NC
A
NC
A
NC
A
NC
A

211885_x_at
U27332.1
FUT6(2)
A
NC
A
NC
A
NC
A
NC
A

211465_x_at
U27335.1
FUT6(minor)
A
NC
A
NC
A
NC
A
NC
A

210506_at
U11282.1
FUT7
A
NC
A
NC
A
NC
A
NC
A

203988_s_at
NM_004480.1
FUT8
P
NC
P
NC
P
NC
P
NC
A

207696_at
NM_006581.1
FUT9
A
NC
A
NC
A
NC
A
NC
A

229203_at
NM_173593
β4GalNAc-T3
A
NC
A
NC
A
NC
A
NC
A

200016_x_at
NM_002409
MGAT3
P
NC
P
D
P
D
P
D
P

208058_s_at
NM_002409.2
MGAT3
A
NC
A
NC
A
NC
A
NC
A

209764_at
AL022312
β4GlcNAcT
A
NC
A
MD
A
MD
A
NC
A

206435_at
NM_001478.2
GALGT
A
NC
A
NC
A
NC
A
NC
A

206720_at
NM_002410.2
MGAT5
A
NC
A
NC
A
NC
A
NC
A

203102_s_at
NM_002408.2
MGAT2
P
I
P
NC
P
I
P
I
P

201126_s_at
NM_002406.2
MGAT1
P
NC
P
NC
P
NC
P
NC
P

219797_at
NM_012214.1
GNT4a
A
NC
P
NC
A
NC
M
NC
A

220189_s_at
NM_014275.1
GNT4b
P
D
P
NC
P
NC
P
NC
P

204856_at
AB049585
β3GlcNAc-T3
A
NC
A
NC
A
NC
A
NC
A

225612_s_at
BE672260
β3GlcNAc-T5
P
D
P
D
P
D
P
D
P

232337_at
XM_091928
β3GlcNAc-T7
P
NC
P
NC
P
NC
P
NC
A

221240_s_at
NM_030765.1
β3GlcNAc-T4
P
NC
A
NC
A
NC
P
NC
A

204856_at
NM_014256.1
β3GnT3
A
NC
A
NC
A
NC
A
NC
A

205505_at
NM_001490.1
β6GlcNAcT
P
I
P
NC
P
NC
A
NC
A

203188_at
NM_006876.1
i β3GlcNAcT
P
D
P
D
P
MD
P
NC
P

211020_at
L19659.1
I β6GlcNAcT
A
NC
M
NC
A
NC
A
NC
A

214504_at
NM_020459.1
A α3GalNAcT
A
NC
A
NC
A
NC
A
NC
A

211812_s_at
AB050856.1
globosideT
P
NC
A
NC
P
NC
P
NC
A

221131_at
NM_016161.1
α4GlcNAcT
M
NC
P
NC
P
NC
M
NC
A

221935_s_at

AER61
P
I
P
I
P
I
P
I
A

225689_at

AGO61
P
NC
P
NC
P
NC
P
NC
P

210571_s_at

CMAH
A
NC
A
NC
A
NC
A
NC
A

205518_s_at

CMAH
A
D
M
NC
A
D
A
NC
P

213355_at

ST3GAL6
A
NC
A
NC
A
NC
A
NC
A

211379_x_at

β3GALT3
P
D
P
D
P
NC
P
D
P

218918_at

MAN1C1
P
NC
P
NC
P
NC
P
NC
P

208450_at

LGALS2
A
NC
A
NC
A
NC
A
NC
A

208949_s_at

LGALS3
P
D
P
D
P
D
P
D
P

¹⁾Data reference: Skottman, H., et al. (2005).

²⁾EB, embryoid bodies used as reference in calculation of fold changes.

³⁾Det. (detection) codes: P, present; A, absent; M, medium.

⁴⁾Ch. (fold change) codes: I, increased; D, decreased; NC, no change.

TABLE 27

Neutral N-glycan structures of feeder cells
proportion, %

proposed composition
proposed structure types
hEF
mEF

Hex_5-13HexNAc₂
high-mannose/glucosylated
76
72

Hex_1-4HexNAc₂dHex_0-1
low-mannose
8
7

n_HexNAc= 3 ja n_Hex≧ 2
hybrid/monoantennary
4
6

n_HexNAc≧ 4 ja n_Hex≧ 2
complex-type
9
11

other types
3
4

n_dHex≧ 1
fucosylation
13
8

n_dHex≧ 2
complex fucosylation
0.5
0.2

n_HexNAc> n_Hex≧ 2
terminal HexNAc, N > H¹⁾
2
2

n_HexNAc= n_Hex≧ 5
terminal HexNAc, N═H
—
0.3

¹⁾N, HexNAc; H, Hex.

TABLE 28

Acidic N-glycan structures of feeder cells
proportion, %

proposed composition
proposed structure types
hEF
mEF

n_HexNAc= 3 ja n_Hex≧ 5
hybrid-type
3
8

n_HexNAc= 3 ja n_Hex= 3-4
monoantennary
4
6

n_HexNAc≧ 4 ja n_Hex≧ 3
complex-type
92
86

muut
—
1
0

n_dHex≧ 1
fucosylation
76
67

n_dHex≧ 2
complex fucosylation
21
4

n_HexNAc> n_Hex≧ 2
terminal HexNAc, N > H¹⁾
1
2

n_HexNAc= n_Hex≧ 5
terminal HexNAc, N═H
1.5
1.5

NeuAc + 16 Da
NeuGc
—
—

+80 Da
sulphate/phosphate ester
1
9

¹⁾N, HexNAc; H, Hex.

TABLE 29

Proposed composition
m/z
hESC
EB
st.3
hEF
mEF
BM MSC
OB
CB MSC
AC
CB MNC
CD 34+
CD 133+
LIN−
CD 8−

Hex_5-9HexNAc₂

(including high-mannose type

N-glycans)

Hex5HexNAc2
1257
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc2
1419
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex7HexNAc2
1581
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex8HexNAc2
1743
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex9HexNAc2
1905
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex_1-4HexNAc₂dHex_0-1

(including low-mannose type

N-glycans)

HexHexNAc2
609
+
+

+
+
+
+

+

+

HexHexNAc2dHex
755

+
+
+
+

+

Hex2HexNAc2
771
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex2HexNAc2dHex
917
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc2
933
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc2dHex
1079
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc2
1095
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc2dHex
1241
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex_10-12HexNAc₂

(including glucosylated high-

mannose type N-glycans)

Hex10HexNAc2
2067
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex11HexNAc2
2229
+
+
+
+
+
+
+
+
+
+

+

Hex12HexNAc2
2391
+
+

+
+
+
+
+
+
+

+

Hex_5-9HexNAc₂dHex₁

(including fucosylated high-

mannose type N-glycans)

Hex5HexNAc2dHex
1403
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc2dHex
1565

+

+

+
+
+
+
+

+
+
+

Hex7HexNAc2dHex
1727

+

Hex_1-9HexNAc₁

(including soluble glycans)

Hex2HexNAc
568

+
+
+
+
+
+

+

Hex3HexNAc
730

+
+
+
+
+
+
+
+
+

Hex4HexNAc
892
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex5HexNAc
1054
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc
1216
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex7HexNAc
1378
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex8HexNAc
1540
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex9HexNAc
1702
+
+
+
+
+
+

+

+
+

+

HexNAc = 3 and Hex ≧ 2

(including hybrid-type and

monoantennary N-glycans)

Hex2HexNAc3
974

+
+
+

Hex2HexNAc3dHex
1120

+

+
+
+
+
+
+
+

+

Hex3HexNAc3
1136
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex2HexNAc3dHex2
1266

+

Hex3HexNAc3dHex
1282
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc3
1298
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc3dHex2
1428

+

+
+
+
+

+

Hex4HexNAc3dHex
1444
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex5HexNAc3
1460
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc3dHex2
1590
+

+
+
+
+
+
+
+

+

Hex5HexNAc3dHex
1606
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc3
1622
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex5HexNAc3dHex2
1752

+
+
+
+

Hex6HexNAc3dHex
1768
+
+

+
+
+
+
+

+

+

Hex7HexNAc3
1784

+
+
+
+
+
+
+

Hex8HexNAc3
1946

+
+

HexNAc ≧ 4 and Hex ≧ 3

(including complex-type N-

glycans)

Hex3HexNAc4
1339

+
+
+
+
+
+
+

+

Hex3HexNAc4dHex
1485
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc4
1501
+

+
+
+
+
+
+

+

+
+

Hex3HexNAc5
1542
+
+
+
+
+

+
+

+

Hex4HexNAc4dHex
1647
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex5HexNAc4
1663
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc5dHex
1688
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAx5
1704
+
+
+
+
+

+
+
+
+

+
+
+

Hex4HexNAc4dHex2
1793
+

+

+
+
+
+
+

+

Hex5HexNAc4dHex
1809
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc4
1825
+

+
+
+
+
+
+
+
+

+
+

Hex4HexNAc5dHex
1850
+
+
+

+

+
+
+

Hex5HexNAc5
1866
+
+
+
+
+
+
+
+
+
+

+
+

Hex3HexNAc6dHex
1891

+
+
+
+

+

Hex5HexNAc4dHex2
1955
+
+

+

+
+
+
+
+
+
+

+

Hex6HexNAc4dHex
1971

+

+
+
+
+
+
+

+

Hex7HexNAc4
1987

+
+
+
+
+
+

+

Hex4HexNAc5dHex2
1996
+
+

+

+
+
+
+

Hex5HexNAc5dHex
2012
+
+
+
+

+
+
+
+

Hex6HexNAc5
2028
+
+
+
+
+
+
+
+
+
+

+

Hex5HexNAc4dHex3
2101
+
+

+

+
+
+
+
+
+
+

+

Hex6HexNAc4dHex2
2117

+
+

Hex7HexNAc4dHex
2133

+
+

+

+

Hex4HexNAc5dHex3
2142
+
+

+
+
+
+

+

Hex8HexNAc4
2149

+
+
+
+

+

Hex5HexNAc5dHex2
2158

+

+
+
+

Hex6HexNAc5dHex
2174
+
+
+
+

+
+
+
+

+

+

Hex7HexNAc5
2190

+
+

Hex6HexNAc6
2231

+

+

Hex7HexNAc4dHex2
2279

+
+

Hex5HexNAc5dHex3
2304

+
+

+

Hex6HexNAc5dHex2
2320
+

+
+
+
+

+

Hex7HexNAc5dHex
2336

+
+

Hex8HexNAc5
2352

+
+

Hex7HexNAc6
2393

+

+
+
+
+

+

Hex7HexNAc4dHex3
2425

+
+

Hex6HexNAc5dHex3
2466

+
+

+

Hex8HexNAc5dHex
2498

+
+

Hex7HexNAc6dHex
2539

+

+
+
+
+

Hex6HexNAc5dHex4
2612

+
+

Hex8HexNAc7
2758

+
+

HexNAc ≧ 3 and dHex ≧ 1

(including fucosylated N-

glycans)

Hex2HexNAc3dHex
1120

+

+
+
+
+
+
+
+

+

Hex2HexNAc3dHex2
1266

+

Hex3HexNAc3dHex
1282
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc3dHex2
1428

+

+
+
+
+

+

Hex4HexNAc3dHex
1444
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc3dHex2
1590
+

+
+
+
+
+
+
+

+

Hex5HexNAc3dHex
1606
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex5HexNAc3dHex2
1752

+
+
+
+

Hex6HexNAc3dHex
1768
+
+

+
+
+
+
+

+

+

Hex3HexNAc4dHex
1485
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc4dHex
1647
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc5dHex
1688
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc4dHex2
1793
+

+

+
+
+
+
+

+

Hex5HexNAc4dHex
1809
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAc5dHex
1850
+
+
+

+

+
+
+

Hex3HexNAc6dHex
1891

+
+
+
+

+

Hex5HexNAc4dHex2
1955
+
+

+

+
+
+
+
+
+
+

+

Hex6HexNAc4dHex
1971

+

+
+
+
+
+
+

+

Hex4HexNAc5dHex2
1996
+
+

+

+
+
+
+

Hex5HexNAc5dHex
2012
+
+
+
+

+
+
+
+

Hex5HexNAc4dHex3
2101
+
+

+

+
+
+
+
+
+
+

+

Hex6HexNAc4dHex2
2117

+
+

Hex7HexNAc4dHex
2133

+
+

+

+

Hex4HexNAc5dHex3
2142
+
+

+
+
+
+

+

Hex5HexNAc5dHex2
2158

+

+
+
+

Hex6HexNAc5dHex
2174
+
+
+
+

+
+
+
+

+

+

Hex7HexNAc4dHex2
2279

+
+

Hex5HexNAc5dHex3
2304

+
+

+

Hex6HexNAc5dHex2
2320
+

+
+
+
+

+

Hex7HexNAc5dHex
2336

+
+

Hex7HexNAc4dHex3
2425

+
+

Hex6HexNAc5dHex3
2466

+
+

+

Hex8HexNAc5dHex
2498

+
+

Hex7HexNAc6dHex
2539

+

+
+
+
+

Hex6HexNAc5dHex4
2612

+
+

HexNAc ≧ 3 and dHex ≧ 2

(including multifucosylated

N-glycans)

Hex2HexNAc3dHex2
1266

+

Hex3HexNAc3dHex2
1428

+

+
+
+
+

+

Hex4HexNAc3dHex2
1590
+

+
+
+
+
+
+
+

+

Hex5HexNAc3dHex2
1752

+
+
+
+

Hex4HexNAc4dHex2
1793
+

+

+
+
+
+
+

+

Hex5HexNAc4dHex2
1955
+
+

+

+
+
+
+
+
+
+

+

Hex4HexNAc5dHex2
1996
+
+

+

+
+
+
+

Hex5HexNAc4dHex3
2101
+
+

+

+
+
+
+
+
+
+

+

Hex6HexNAc4dHex2
2117

+
+

Hex4HexNAc5dHex3
2142
+
+

+
+
+
+

+

Hex5HexNAc5dHex2
2158

+

+
+
+

Hex7HexNAc4dHex2
2279

+
+

Hex5HexNAc5dHex3
2304

+
+

+

Hex6HexNAc5dHex2
2320
+

+
+
+
+

+

Hex7HexNAc4dHex3
2425

+
+

Hex6HexNAc5dHex3
2466

+
+

+

Hex6HexNAc5dHex4
2612

+
+

HexNAc > Hex ≧ 2

(terminal HexNAc, N > H)

Hex2HexNAc3
974

+
+
+

Hex2HexNAc3dHex
1120

+

+
+
+
+
+
+
+

+

Hex2HexNAc3dHex2
1266

+

Hex3HexNAc4
1339

+
+
+
+
+
+
+

+

Hex3HexNAc4dHex
1485
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex3HexNAc5
1542
+
+
+
+
+

+
+

+

Hex3HexNAc5dHex
1688
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex4HexNAx5
1704
+
+
+
+
+

+
+
+
+

+
+
+

Hex4HexNAc5dHex
1850
+
+
+

+

+
+
+

Hex3HexNAc6dHex
1891

+
+
+
+

+

Hex4HexNAc5dHex2
1996
+
+

+

+
+
+
+

Hex4HexNAc5dHex3
2142
+
+

+
+
+
+

+

HexNAc = Hex ≧ 5

(terminal HexNAc, N = H)

Hex5HexNAc5
1866
+
+
+
+
+
+
+
+
+
+

+
+

Hex5HexNAc5dHex
2012
+
+
+
+

+
+
+
+

Hex5HexNAc5dHex2
2158

+

+
+
+

Hex6HexNAc6
2231

+

+

Hex5HexNAc5dHex3
2304

+
+

+

hESC, human embryonic stem cells;

EB, embryoid bodies derived from hESC;

st.3, stage 3 differentiated cells derived from hESC;

hEF, human fibroblast feeder cells;

mEF, murine fibroblast feeder cells;

BM MSC, bone-marrow derived mesenchymal stem cells;

OB, Osteoblast-differentiated cells derived from BM MSC;

CB MSC, cord blood derived mesenchymal stem cells;

AC, adipocyte-differentiated cells derived from CB MSC;

CB MNC, cord blood mononuclear cells;

CD34+, CD133+, LIN−, and CD8−: subpopulations of CB MNC.

TABLE 30

CB

CB
CD
CD

Proposed composition
m/z
hESC
EB
st.3
hEF
mEF
BM MSC
OB
MSC
AC
MNC
34+
133+
LIN−
CD 8−

HexNAc = 3 and Hex ≧ 2

(including hybrid-type and

monoantennary N-glycans)

Hex3HexNAc3dHexSP
1338

+

Hex4HexNAc3SP
1354

+
+

NeuAcHex3HexNAc3
1403

+

+
+
+

+
+
+
+
+
+

NeuGcHex3HexNAc3
1419

+

Hex4HexNAc3dHexSP
1500
+
+

+
+
+
+

+
+
+
+

Hex5HexNAc3SP
1516

+

+
+

+

NeuAcHex3HexNAc3dHex
1549
+
+

+
+
+
+

+
+
+
+
+
+

NeuAcHex3HexNAc3SP2
1563

+
+

NeuAcHex4HexNAc3
1565
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc3
1581

+

+

+

+
+

Hex4HexNAc3dHex2SP
1646

+

+

Hex5HexNAc3dHexSP
1662

+

Hex6HexNAc3SP and/or
1678
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex2HexNAc3dHex

NeuAc2Hex3HexNAc3
1694

+

NeuAcHex3HexNAc3dHexSP2
1709

+
+

NeuAcHex4HexNAc3dHex
1711
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex5HexNAc3 and/or
1727
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc3dHex

NeuGcHex5HexNAc3
1743

+

NeuAcHex4HexNAc3dHexSP
1791

+

+
+
+

+
+

Hex5HexNAc3dHex2SP
1808

+

NeuAc2Hex3HexNAc3dHex
1840
+
+

+

+
+

+

+

NeuAc2Hex4HexNAc3
1856

+

+

NeuAcHex4HexNAc3dHex2
1857

+
+

NeuAcHex5HexNAc3dHex and/or
1873
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc3dHex2

NeuAcHex6HexNAc3
1889
+
+

+
+
+
+
+
+
+
+
+
+
+

Hex8HexNAc3SP and/or
2002
+
+

+
+
+
+
+
+

+

+

NeuAc2Hex4HexNAc3dHex

NeuAcHex4HexNAc3dHex3
2003

+

+

NeuAc2Hex5HexNAc3 and/or
2018

+
+
+
+

+
+
+

NeuGcNeuAcHex4HexNAc3dHex

NeuAcHex5HexNAc3dHex2
2019

+
+
+

NeuGcNeuAcHex5HexNAc3 and/or
2034

+

NeuGc2Hex4HexNAc3dHex

NeuAcHex6HexNAc3dHex
2035

+

+
+
+
+
+
+
+
+
+

NeuGc2Hex5HexNAc3
2050

+

NeuAcHex7HexNAc3
2051

+

+
+

+
+
+

NeuAc2Hex4HexNAc3dHexSP and/or
2082

+
+
+

Hex8HexNAc3SP2

NeuAcHex6HexNAc3dHexSP
2115

+

Hex8HexNAc3dHexSP and/or
2148

+

NeuAc2Hex4HexNAc3dHex2

NeuAcHex8HexNAc3SP and/or
2293

+

NeuAc3Hex4HexNAc3dHex

NeuAc2Hex5HexNAc3dHex2 and/or
2310

+

NeuGcNeuAcHex4HexNAc3dHex3

NeuAc3Hex5HexNAc3SP
2389

+

NeuAc2Hex5HexNAc3dHex2SP
2390
+
+
+
+
+
+

+
+
+
+

NeuAc2Hex6HexNAc3dHexSP
2406

+

+
+

NeuAcHex8HexNAc3dHexSP and/or
2439

+

NeuAc3Hex4HexNAc3dHex2

NeuAcHex9HexNAc3dHex
2521

+

HexNAc ≧ 4 and Hex ≧ 3

(including complex-type N-

glycans)

Hex4HexNAc4SP
1557

+

+

+
+

NeuAcHex3HexNAc4
1606

+

Hex4HexNAc4SP2
1637

+

+

+
+

+
+
+
+

Hex4HexNAc4dHexSP
1703

+

+

+

Hex4HexNAc4SP3 and/or
1717

+

Hex7HexNAc2SP2

Hex5HexNAc4SP
1719

+

+
+
+
+
+

NeuAcHex3HexNAc4dHex
1752

+

NeuAcHex4HexNAc4
1768

+

+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc4
1784

+
+

Hex5HexNAc4SP2 and/or
1799

+

+

+

Hex8HexNAc2SP

NeuAcHex3HexNAc5
1809

+

NeuGcHex3HexNAc5
1825

+
+

Hex5HexNAc4dHexSP
1865
+
+

+
+
+
+
+

+
+
+
+

Hex6HexNAcSP
1881

+

Hex4HexNAc5dHexSP
1906
+
+

NeuAcHex4HexNAc4dHex
1914
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAcHex4HexNAc4SP2
1928

+
+

NeuAcHex5HexNAc4
1930
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuGcHex5HexNAc4
1946
+
+

+

+
+

+
+
+

NeuAcHex4HexNAc5
1971
+
+

+
+

+

+

+

NeuAcHex5HexNAc4Ac
1972

+

Hex5HexNAc5SP2
2002

+
+
+
+
+
+

+

NeuAcHex5HexNAc4SP
2010

+

+

Hex5HexNAc4dHex2SP
2011

+

NeuGcHex5HexNAc4SP
2026

+

Hex6HexNAc4dHexSP
2027

+

+

Hex7HexNAc4SP and/or
2043

+

Hex4HexNAc6SP2 and/or

NeuAc2Hex3HexNAc4dHex

NeuAcHex4HexNAc5SP
2051

+

+
+

+
+

Hex4HexNAc5dHex2SP
2052
+
+

+
+

NeuAc2Hex4HexNAc4
2059

+

+

NeuAcHex4HexNAc4dHex2
2060

+

+
+

+
+
+

NeuAcHex4HexNAc4dHexSP2
2074

+
+

NeuAcHex5HexNAc4dHex
2076
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc4 and/or
2092
+
+

+
+
+
+
+

+
+
+
+
+

NeuGcHex5HexNAc4dHex

NeuAcHex3HexNAc5dHex2 and/or
2101

+

NeuAc2Hex4HexNAc4Ac

NeuGcHex6HexNAc4
2108

+

NeuAcHex4HexNAc5dHex
2117
+
+
+

+

+
+
+
+
+

Hex4HexNAc5dHex2SP2
2132

+

NeuAcHex5HexNAc5
2133
+
+

+
+

+

+
+
+
+
+

NeuAc2Hex4HexNAc4SP
2139

NeuAcHex5HexNAc4dHexSP
2156
+
+

+
+

+
+
+

Hex5HexNAc4dHex3SP
2157

+

Hex6HexNAc5SP2
2164
+
+

+

Hex6HexNAc4dHex2SP and/or
2173

+

Hex3HexNAc6dHex2SP2

NeuAcHex4HexNAc6
2174
+

+
+
+

+
+

NeuAc3Hex3HexNAc4 and/or
2188

+

+

NeuGcHex6HexNAc4SP and/or

NeuAc2NeuGcHex2HexNAc4dHex

NeuAc2Hex3HexNAc4dHex2 and/or
2189

+
+

Hex7HexNAc4dHexSP and/or

Hex4HexNAc6dHexSP2

NeuAc2Hex4HexNAc4dHex
2205

+

NeuAc2Hex4HexNAc4SP2
2219

+

NeuAc2Hex5HexNAc4
2221
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex5HexNAc4dHex2
2222
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc5dHexSP
2230

+

+

+
+

NeuGcNeuAcHex5HexNAc4
2237
+
+

+

+

+
+
+

NeuAcHex6HexNAc4dHex and/or
2238
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuGcHex5HexNAc4dHex2

NeuAc2Hex3HexNAc5dHex and/or
2246

+
+
+
+

Hex7HexNAc5SP

NeuGc2Hex5HexNAc4
2253
+
+

+

+
+
+

NeuAcHex7HexNAc4 and/or
2254
+
+

+
+
+
+
+

+
+
+

NeuGcHex6HexNAc4dHex

NeuAc2Hex4HexNAc5
2262

+

NeuAcHex4HexNAc5dHex2 and/or
2263
+

+

+

NeuAc2Hex5HexNAc4Ac

NeuAcHex5HexNAc5dHex
2279
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex4HexNAc4dHexSP and/or
2285

+

Hex11HexNAc2SP

NeuAcHex6HexNAc5
2295
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex5HexNAc4SP
2301

+

NeuAcHex5HexNAc4dHex2SP
2302

+

NeuAc2Hex5HexNAc4Ac2
2305

+

Hex6HexNAc4dHex3SP and/or
2319

+

+
+

NeuGcNeuAcHex3HexNAc6

NeuAcHex4HexNAc6dHex
2320

+
+

NeuAcHex5HexNAc5dHexAc
2321

+
+

Hex7HexNAc4dHex2SP and/or
2335

+
+

Hex4HexNAc6dHex2SP2

NeuAcHex5HexNAc6
2338

+

+

NeuAc3Hex4HexNac4
2350

+

NeuAc2Hex4HexNAc4dHexSP
2365

+
+
+

NeuAcHex5HexNAc4dHex
2367
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex5HexNAc4dHex3
2368
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc4 and/or
2383
+
+

+
+
+
+

+
+
+

NeuGcNeuAcHex5HexNAc4dHex

NeuAcHex6HexNAc4dHex2 and/or
2384
+
+

+
+

+

+
+

NeuGcHex5HexNAc4dHex3

NeuAc2Hex3HexNAc5dHex2 and/or
2392

+
+

Hex7HexNAc5dHexSP

NeuAcHex3HexNAc5dHex4
2393

+

NeuGc2Hex5HexNAc4dHex
2399

+

+
+

NeuAcHex4HexNAc6dHexSP and/or
2400

+

NeuGcHex6HexNAc4dHex2 and/or

NeuAcHex7HexNAc4dHex

NeuAc2Hex4HexNAc5dHex
2408
+
+

+

NeuAcHex4HexNAc5dHex3 and/or
2409

+

+

NeuAc2Hex5HexNAc4dHexAc

NeuAc2Hex5HexNAc5
2424

+

+
+

+
+

NeuAcHex5HexNAc5dHex2
2425
+
+

+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex
2441
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex5HexNAc4dHexSP
2447

+

+
+

+
+
+
+

NeuAcHex5HexNAc4dHex3SP
2448

+

+
+
+
+

NeuAcHex7HexNAc5 and/or
2457
+

+
+
+
+

NeuGcHex6HexNAc5dHex

NeuGcHex7HexNAc5
2473

+
+

NeuAcHex5HexNAc6dHex
2482

+

NeuAcHex4HexNAc5dHex3SP
2489

+
+

Hex6HexNAc7SP
2490

+

NeuAc3Hex5HexNAc4
2512

+

+
+
+

NeuAc2Hex5HexNAc4dHex2
2513

+
+
+

+
+
+
+

NeuAcHex5HexNAc4dHex4
2514

+

+

NeuAcHex6HexNAc5dHexSP and/or
2521
+
+

+

+

NeuAc3Hex2HexNAc5dHex2

Hex6HexNAc5dHex3SP
2522

+

+

NeuGcNeuAc2Hex5HexNAc4
2528
+
+

+
+
+

NeuAc2Hex6HexNAc4dHex and/or
2529

+

+
+
+

NeuGcNeuAcHex5HexNAc4dHex2

NeuGc2NeuAcHex5HexNAc4
2544
+
+

+

+
+
+

NeuGc2Hex5HexNAc4dHex2 and/or
2545

+
+
+

NeuGcNeuAcHex6HexNAc4dHex

NeuGc3Hex5HexNAc4
2560

+

+
+
+

NeuGc2Hex6HexNAc4dHex
2561

+

NeuAc2Hex5HexNAc5dHex
2570
+
+

+

+
+
+
+
+

NeuAcHex5HexNAc5dHex3
2571

+
+

+

+
+
+
+
+

NeuAc2Hex6HexNAc5
2588

+

+

+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex2
2587
+
+

+

+
+
+
+
+
+
+
+
+

Hex7HexNAc6dHexSP
2595

+

NeuGcNeuAcHex6HexNAc5
2602

+
+
+

NeuAcHex7HexNAc5dHex and/or
2603

+

+
+
+
+

+
+

NeuGcHex6HexNAc5dHex2

NeuAcHex8HexNAc5 and/or
2619

+

+
+

NeuGcHex7HexNAc5dHex

NeuAc2Hex5HexNAc6
2627

+

NeuGcHex8HexNAc5 and/or
2635

+
+

NeuAcHex4HexNAc5dHex4SP

NeuAcHex6HexNAc6dHex
2644

+
+

+
+
+

+
+
+
+
+

NeuAc2Hex5HexNAc4dHex3
2659

+

+

NeuAcHex7HexNAc6
2660
+

+

+
+
+
+
+
+
+

+

NeuGcNeuAc2Hex5HexNAc4dHex
2674

+
+

and/or NeuAc3Hex6HexNAc4

NeuAc2Hex4HexNAc5dHex2SP2
2714

+

+
+
+

NeuAcHex4HexNAc5dHex4SP2 and/or
2715

+
+

NeuAc3Hex5HexNAc5

NeuAc2Hex5HexNAc5dHex2
2716

+

NeuAc2Hex6HexNAc5dHex
2732
+
+
+
+

+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex3
2733
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcNeuAcHex6HexNAc5dHex
2748

+

NeuAcHex8HexNAc5dHex
2765

+

NeuGcHex8HexNAc5dHex and/or
2781

+

NeuAcHex9HexNAc5

NeuAcHex6HexNAc6dHex2
2791

+
+
+
+

Hex6HexNAc6dHex3SP2
2805

+

NeuAcHex7HexNAc6dHex
2807
+
+
+
+

+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc5dHexSP
2812

+

+
+
+
+

NeuAcHex6HexNAc5dHex3SP
2813

+

NeuGcNeuAc3Hex5HexNAc4
2819

+

NeuAc3Hex6HexNAc4dHex and/or
2820

+

NeuGcNeuAc2Hex5HexNAc4dHex2

NeuAc3Hex6HexNAc5
2878
+
+

+
+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc5dHex2
2879
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex4
2880

+

+
+
+
+

NeuGcNeuAc2Hex6HexNAc5
2894

+

+

NeuAc2Hex7HexNAc5dHex and/or
2895

+

+

NeuGcNeuAcHex6HexNAc5dHex2

NeuAc3Hex6HexNAc4dHexSP and/or
2900

+

NeuGcNeuAc2Hex5HexNAc4dHex2SP

NeuGc2Hex6HexNAc5dHex2
2911

+

NeuAc2Hex5HexNAc6dHex2
2920

+

NeuGc3Hex6HexNAc5
2925

+

NeuGcNeuAc2Hex5HexNAc6
2935

+

NeuAc2Hex6HexNAc6dHex and/or
2936

+
+

+

+
+
+
+

NeuGcNeuAcHex5HexNAc6dHex2

NeuAcHex6HexNAc6dHex3
2937

+

+

NeuGc2NeuAcHex5HexNAc6 and/or
2951

+

NeuAc3Hex5HexNAc4dHex3

NeuAc2Hex7HexNAc6
2952

+
+
+
+

+
+

NeuAcHex7HexNAc6dHex2
2953
+

+

+
+
+

+
+

+

Hex8HexNAc7dHexSP
2961

+

NeuAc2Hex4HexNAc7dHex2
2961

+

NeuAcHex7HexNAc7dHex
3010

+

+
+

NeuAc3Hex6HexNAc5dHex
3024
+
+

+

+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc5dHex3
3025
+
+

+

+
+

+
+
+
+
+
+

NeuAcHex8HexNAc7
3026

+
+

+

+
+

+

NeuGc3Hex6HexNAc5dHex and/or
3072

+

NeuGc2NeuAcHex7HexNAc5

NeuAc2Hex6HexNAc6dHex2
3082

+

NeuAc2Hex7HexNAc6dHex
3098
+
+
+
+

+
+
+
+
+
+
+
+
+

NeuAcHex7HexNAc6dHex3
3099
+
+

+

+
+
+
+
+
+
+
+
+

NeuAc3Hex6HexNAc5dHexSP
3104

+

+

NeuAc2Hex6HexNAc5dHex3SP
3105

+
+

NeuAc3Hex6HexNAc5dHex2
3170

+
+

NeuAc2Hex6HexNAc5dHex4
3171

+

+

+
+

+
+

NeuAcHex8HexNAc7dHex
3172
+

+

+
+
+
+
+
+
+
+
+

NeuAc3Hex6HexNAc6dHex
3227

+

+

NeuAc2Hex6HexNAc6dHex3
3228

+

NeuAc3Hex7HexNAc6
3243

+
+

+

NeuAc2Hex7HexNAc6dHex2
3244

+
+

+
+
+

NeuAcHex7HexNAc6dHex4
3245
+

+

+

+
+
+

NeuAc2Hex7HexNAc7dHex
3301

+

NeuAcHex7HexNAc7dHex3
3302

+

NeuAc2Hex8HexNAc7
3317
+

+

+
+

NeuAcHex8HexNAc7dHex2
3318

+

+
+

NeuAc3Hex7HexNAc6dHex
3389

+
+
+
+

+
+
+

NeuAc2Hex7HexNAc6dHex3
3390
+
+

+
+
+
+

+
+
+
+

NeuAcHex7HexNAc6dHex5 and/or
3391

+

+

+

NeuAcHex9HexNAc8

NeuAc2Hex8HexNAc7dHex
3463
+

+

+
+
+
+

+
+

+

NeuAcHex8HexNAc7dHex3
3464

+

+
+

+
+

+

NeuAc2Hex7HexNAc6dHex4
3536

+
+

+
+
+
+

NeuAcHex9HexNAc8dHex
3537

+

+
+
+

+

NeuAc3Hex8HexNAc7
3608
+

+

NeuAc2Hex8HexNac7dHex2
3609

+
+

+

NeuAcHex8HexNac7dHex4
3610
+

+

+
+

NeuAc4Hex7HexNAc6dHex
3680

+

+

+

NeuAc3Hex7HexNAc6dHex3
3681

+

+

+
+

+
+
+

NeuAc2Hex9HexNAc8
3682
+

+
+

NeuAcHex9HexNAc8dHex2
3683

+

+
+

NeuAc3Hex8HexNAc7dHex
3754

+
+
+

+

NeuAc2Hex8HexNAc7dHex3
3755

+

+
+

+
+
+

NeuAcHex10HexNAc9 and/or
3756
+

+
+

+

NeuAcHex8HexNAc7dHex5

NeuAc4Hex6HexNAc8
3778

+

NeuAc3Hex7HexNAc6dHex4
3827

+

+

NeuAc2Hex9HexNAc8dHex
3828

+

+
+

+

NeuAcHex9HexNAc8dHex3
3829

+
+

+
+

NeuAc2Hex8HexNAc7dHex4
3901

+

+

+

NeuAc2Hex9HexNAc8dHex2
3974

+

+

NeuAcHex9HexNAc8dHex4
3975

+
+

NeuAc4Hex8HexNAc7dHex
4045

+

NeuAc3Hex8HexNAc7dHex3
4046

+
+

NeuAc2Hex10HexNAc9 and/or
4047

+

+

NeuAc2Hex8HexNAc7dHex5

NeuAc3Hex9HexNAc8dHex
4119

+

NeuAc2Hex9HexNAc8dHex3
4120

+

HexNAc ≧ 3 and dHex ≧ 1

(including fucosylated N-

glycans)

Hex3HexNAc3dHexSP
1338

+

Hex4HexNAc3dHexSP
1500
+
+

+
+
+
+

+
+
+
+

NeuAcHex3HexNAc3dHex
1549
+
+

+
+
+
+

+
+
+
+
+
+

Hex4HexNAc3dHex2SP
1646

+

+

Hex5HexNAc3dHexSP
1662

+

Hex6HexNAc3SP and/or
1678
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex2HexNAc3dHex

NeuAcHex3HexNAc3dHexSP2
1709

+
+

NeuAcHex4HexNAc3dHex
1711
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex5HexNAc3 and/or
1727
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc3dHex

NeuAcHex4HexNAc3dHexSP
1791

+

+
+
+

+
+

Hex5HexNAc3dHex2SP
1808

+

NeuAc2Hex3HexNAc3dHex
1840
+
+

+

+
+

+

+

NeuAcHex4HexNAc3dHex2
1857

+
+

NeuAcHex5HexNAc3dHex and/or
1873
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc3dHex2

Hex8HexNAc3SP and/or
2002
+
+

+
+
+
+
+
+

+

+

NeuAc2Hex4HexNAc3dHex

NeuAcHex4HexNAc3dHex3
2003

+

+

NeuAc2Hex5HexNAc3 and/or
2018

+
+
+
+

+
+
+

NeuGcNeuAcHex4HexNAc3dHex

NeuAcHex5HexNAc3dHex2
2019

+
+
+

NeuGcNeuAcHex5HexNAc3 and/or
2034

+

NeuGc2Hex4HexNAc3dHex

NeuAcHex6HexNAc3dHex
2035

+

+
+
+
+
+
+
+
+
+

NeuAc2Hex4HexNAc3dHexSP and/or
2082

+
+
+

Hex8HexNAc3SP2

NeuAcHex6HexNAc3dHexSP
2115

+

Hex8HexNAc3dHexSP and/or
2148

+

NeuAc2Hex4HexNAc3dHex2

NeuAcHex8HexNAc3SP and/or
2293

+

NeuAc3Hex4HexNAc3dHex

NeuAc2Hex5HexNAc3dHex2 and/or
2310

+

NeuGcNeuAcHex4HexNAc3dHex3

NeuAc2Hex5HexNAc3dHex2SP
2390
+
+
+
+
+
+

+
+
+
+

NeuAc2Hex6HexNAc3dHexSP
2406

+

+
+

NeuAcHex8HexNAc3dHexSP and/or
2439

+

NeuAc3Hex4HexNAc3dHex2

NeuAcHex9HexNAc3dHex
2521

+

Hex4HexNAc4dHexSP
1703

+

+

+

NeuAcHex3HexNAc4dHex
1752

+

Hex5HexNAc4dHexSP
1865
+
+

+
+
+
+
+

+
+
+
+

Hex4HexNAc5dHexSP
1906
+
+

NeuAcHex4HexNAc4dHex
1914
+
+

+
+
+
+
+
+
+
+
+
+
+

Hex5HexNAc4dHex2SP
2011

+

Hex6HexNAc4dHexSP
2027

+

+

Hex7HexNAc4SP and/or
2043

+

Hex4HexNAc6SP2 and/or

NeuAc2Hex3HexNAc4dHex

Hex4HexNAc5dHex2SP
2052
+
+

+
+

NeuAcHex4HexNAc4dHex2
2060

+

+
+

+
+
+

NeuAcHex4HexNAc4dHexSP2
2074

+
+

NeuAcHex5HexNAc4dHex
2076
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc4 and/or
2092
+
+

+
+
+
+
+

+
+
+
+
+

NeuGcHex5HexNAc4dHex

NeuAcHex3HexNAc5dHex2 and/or
2101

+

NeuAc2Hex4HexNAc4Ac

NeuAcHex4HexNAc5dHex
2117
+
+
+

+

+
+
+
+
+

Hex4HexNAc5dHex2SP2
2132

+

NeuAcHex5HexNAc4dHexSP
2156
+
+

+
+

+
+
+

Hex5HexNAc4dHex3SP
2157

+

Hex6HexNAc4dHex2SP and/or
2173

+

Hex3HexNAc6dHex2SP2

NeuAc3Hex3HexNAc4 and/or
2188

+

+

NeuGcHex6HexNAc4SP and/or

NeuAc2NeuGcHex2HexNAc4dHex

NeuAc2Hex3HexNAc4dHex2 and/or
2189

+
+

Hex7HexNAc4dHexSP and/or

Hex4HexNAc6dHexSP2

NeuAc2Hex4HexNAc4dHex
2205

+

NeuAcHex5HexNAc4dHex2
2222
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Hex6HexNAc5dHexSP
2230

+

+

+
+

NeuAcHex6HexNAc4dHex and/or
2238
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcHex5HexNAc4dHex2

NeuAc2Hex3HexNAc5dHex and/or
2246

+
+
+
+

Hex7HexNAc5SP

NeuAcHex7HexNAc4 and/or
2254
+
+

+
+
+
+
+

+
+
+

NeuGcHex6HexNAc4dHex

NeuAcHex4HexNAc5dHex2 and/or
2263
+

+

+

NeuAc2Hex5HexNAc4Ac

NeuAcHex5HexNAc5dHex
2279
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex4HexNAc4dHexSP and/or
2285

+

Hex11HexNAc2SP

NeuAcHex5HexNAc4dHex2SP
2302

+

Hex6HexNAc4dHex3SP and/or
2319

+

+
+

NeuGcNeuAcHex3HexNAc6

NeuAcHex4HexNAc6dHex
2320

+
+

NeuAcHex5HexNAc5dHexAc
2321

+
+

Hex7HexNAc4dHex2SP and/or
2335

+
+

Hex4HexNAc6dHex2SP2

NeuAc2Hex4HexNAc4dHexSP
2365

+
+
+

NeuAc2Hex5HexNAc4dHex
2367
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex5HexNAc4dHex3
2368
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc4 and/or
2383
+
+

+
+
+
+

+
+
+

NeuGcNeuAcHex5HexNAc4dHex

NeuAcHex6HexNAc4dHex2 and/or
2384
+
+

+
+

+

+
+

NeuGcHex5HexNAc4dHex3

NeuAc2Hex3HexNAc5dHex2 and/or
2392

+
+

Hex7HexNAc5dHexSP

NeuAcHex3HexNAc5dHex4
2393

+

NeuGc2Hex5HexNAc4dHex
2399

+

+
+

NeuAcHex4HexNAc6dHexSP and/or
2400

+

NeuGcHex6HexNAc4dHex2 and/or

NeuAcHex7HexNAc4dHex

NeuAc2Hex4HexNAc5dHex
2408
+
+

+

NeuAcHex4HexNAc5dHex3 and/or
2409

+

+

NeuAc2Hex5HexNAc4dHexAc

NeuAcHex5HexNAc5dHex2
2425
+
+

+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex
2441
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex5HexNAc4dHexSP
2447

+

+
+

+
+
+
+

NeuAcHex5HexNAc4dHex3SP
2448

+

+
+
+
+

NeuAcHex7HexNAc5 and/or
2457
+

+
+
+
+

NeuGcHex6HexNAc5dHex

NeuAcHex5HexNAc6dHex
2482

+

NeuAcHex4HexNAc5dHex3SP
2489

+
+

NeuAc2Hex5HexNAc4dHex2
2513

+
+
+

+
+
+
+

NeuAcHex5HexNAc4dHex4
2514

+

+

NeuAcHex6HexNAc5dHexSP and/or
2521
+
+

+

+

NeuAc3Hex2HexNAc5dHex2

Hex6HexNAc5dHex3SP
2522

+

+

NeuAc2Hex6HexNAc4dHex and/or
2529

+

+
+
+

NeuGcNeuAcHex5HexNAc4dHex2

NeuGc2Hex5HexNAc4dHex2 and/or
2545

+
+
+

NeuGcNeuAcHex6HexNAc4dHex

NeuGc2Hex6HexNAc4dHex
2561

+

NeuAc2Hex5HexNAc5dHex
2570
+
+

+

+
+
+
+
+

NeuAcHex5HexNAc5dHex3
2571

+
+

+

+
+
+
+
+

NeuAcHex6HexNAc5dHex2
2587
+
+

+

+
+
+
+
+
+
+
+
+

Hex7HexNAc6dHexSP
2595

+

NeuAcHex7HexNAc5dHex and/or
2603

+

+
+
+
+

+
+

NeuGcHex6HexNAc5dHex2

NeuAcHex8HexNAc5 and/or
2619

+

+
+

NeuGcHex7HexNAc5dHex

NeuGcHex8HexNAc5 and/or
2635

+
+

NeuAcHex4HexNAc5dHex4SP

NeuAcHex6HexNAc6dHex
2644

+
+

+
+
+

+
+
+
+
+

NeuAc2Hex5HexNAc4dHex3
2659

+

+

NeuGcNeuAc2Hex5HexNAc4dHex
2674

+
+

and/or NeuAc3Hex6HexNAc4

NeuAc2Hex4HexNAc5dHex2SP2
2714

+

+
+
+

NeuAcHex4HexNAc5dHex4SP2 and/or
2715

+
+

NeuAc3Hex5HexNAc5

NeuAc2Hex5HexNAc5dHex2
2716

+

NeuAc2Hex6HexNAc5dHex
2732
+
+
+
+

+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex3
2733
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcNeuAcHex6HexNAc5dHex
2748

+

NeuAcHex8HexNAc5dHex
2765

+

NeuAcHex6HexNAc6dHex2
2791

+
+
+
+

Hex6HexNAc6dHex3SP2
2805

+

NeuAcHex7HexNAc6dHex
2807
+
+
+
+

+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc5dHexSP
2812

+

+
+
+
+

NeuAcHex6HexNAc5dHex3SP
2813

+

NeuAc3Hex6HexNAc4dHex and/or
2820

+

NeuGcNeuAc2Hex5HexNAc4dHex2

NeuAc2Hex6HexNAc5dHex2
2879
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex4
2880

+

+
+
+
+

NeuAc2Hex7HexNAc5dHex and/or
2895

+

+

NeuGcNeuAcHex6HexNAc5dHex2

NeuAc3Hex6HexNAc4dHexSP and/or
2900

+

NeuGcNeuAc2Hex5HexNAc4dHex2SP

NeuGc2Hex6HexNAc5dHex2
2911

+

NeuAc2Hex5HexNAc6dHex2
2920

+

NeuGcNeuAc2Hex5HexNAc6
2935

+

NeuAc2Hex6HexNAc6dHex and/or
2936

+
+

+

+
+
+
+

NeuGcNeuAcHex5HexNAc6dHex2

NeuAcHex6HexNAc6dHex3
2937

+

+

NeuGc2NeuAcHex5HexNAc6 and/or
2951

+

NeuAc3Hex5HexNAc4dHex3

NeuAcHex7HexNAc6dHex2
2953
+

+

+
+
+

+
+

+

Hex8HexNAc7dHexSP
2961

+

NeuAc2Hex4HexNAc7dHex2
2961

+

NeuAcHex7HexNAc7dHex
3010

+

+
+

NeuAc3Hex6HexNAc5dHex
3024
+
+

+

+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc5dHex3
3025
+
+

+

+
+

+
+
+
+
+
+

NeuGc3Hex6HexNAc5dHex and/or
3072

+

NeuGc2NeuAcHex7HexNAc5

NeuAc2Hex6HexNAc6dHex2
3082

+

NeuAc2Hex7HexNAc6dHex
3098
+
+
+
+

+
+
+
+
+
+
+
+
+

NeuAcHex7HexNAc6dHex3
3099
+
+

+

+
+
+
+
+
+
+
+
+

NeuAc3Hex6HexNAc5dHexSP
3104

+

+

NeuAc2Hex6HexNAc5dHex3SP
3105

+
+

NeuAc3Hex6HexNAc5dHex2
3170

+
+

NeuAc2Hex6HexNAc5dHex4
3171

+

+

+
+

+
+

NeuAcHex8HexNAc7dHex
3172
+

+

+
+
+
+
+
+
+
+
+

NeuAc3Hex6HexNAc6dHex
3227

+

+

NeuAc2Hex6HexNAc6dHex3
3228

+

NeuAc2Hex7HexNAc6dHex2
3244

+
+

+
+
+

NeuAcHex7HexNAc6dHex4
3245
+

+

+

+
+
+

NeuAc2Hex7HexNAc7dHex
3301

+

NeuAcHex7HexNAc7dHex3
3302

+

NeuAcHex8HexNAc7dHex2
3318

+

+
+

NeuAc3Hex7HexNAc6dHex
3389

+
+
+
+

+
+
+

NeuAc2Hex7HexNAc6dHex3
3390
+
+

+
+
+
+

+
+
+
+

NeuAcHex7HexNAc6dHex5 and/or
3391

+

+

+

NeuAcHex9HexNAc8

NeuAc2Hex8HexNAc7dHex
3463
+

+

+
+
+
+

+
+

+

NeuAcHex8HexNAc7dHex3
3464

+

+
+

+
+

+

NeuAc2Hex7HexNAc6dHex4
3536

+
+

+
+
+
+

NeuAcHex9HexNAc8dHex
3537

+

+
+
+

+

NeuAc2Hex8HexNAc7dHex2
3609

+
+

+

NeuAcHex8HexNAc7dHex4
3610
+

+

+
+

NeuAc4Hex7HexNAc6dHex
3680

+

+

+

NeuAc3Hex7HexNAc6dHex3
3681

+

+

+
+

+
+
+

NeuAcHex9HexNAc8dHex2
3683

+

+
+

NeuAc3Hex8HexNAc7dHex
3754

+
+
+

+

NeuAc2Hex8HexNAc7dHex3
3755

+

+
+

+
+
+

NeuAcHex10HexNAc9 and/or
3756
+

+
+

+

NeuAcHex8HexNAc7dHex5

NeuAc3Hex7HexNAc6dHex4
3827

+

+

NeuAc2Hex9HexNAc8dHex
3828

+

+
+

+

NeuAcHex9HexNAc8dHex3
3829

+
+

+
+

NeuAc2Hex8HexNAc7dHex4
3901

+

+

+

NeuAc2Hex9HexNAc8dHex2
3974

+

+

NeuAcHex9HexNAc8dHex4
3975

+
+

NeuAc4Hex8HexNAc7dHex
4045

+

NeuAc3Hex8HexNAc7dHex3
4046

+
+

NeuAc2Hex10HexNAc9 and/or
4047

+

+

NeuAc2Hex8HexNAc7dHex5

NeuAc3Hex9HexNAc8dHex
4119

+

NeuAc2Hex9HexNAc8dHex3
4120

+

HexNAc ≧ 3 and dHex ≧ 1

(including multifucosylated N-

glycans)

Hex5HexNAc3dHex2SP
1808

+

NeuAcHex4HexNAc3dHex2
1857

+
+

NeuAcHex5HexNAc3dHex and/or
1873
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuGcHex4HexNAc3dHex2

NeuAcHex4HexNAc3dHex3
2003

+

+

NeuAcHex5HexNAc3dHex2
2019

+
+
+

Hex8HexNAc3dHexSP and/or
2148

+

NeuAc2Hex4HexNAc3dHex2

NeuAc2Hex5HexNAc3dHex2 and/or
2310

+

NeuGcNeuAcHex4HexNAc3dHex3

NeuAc2Hex5HexNAc3dHex2SP
2390
+
+
+
+
+
+

+
+
+
+

NeuAcHex8HexNAc3dHexSP and/or
2439

+

NeuAc3Hex4HexNAc3dHex2

Hex5HexNAc4dHex2SP
2011

+

Hex4HexNAc5dHex2SP
2052
+
+

+
+

NeuAcHex4HexNAc4dHex2
2060

+

+
+

+
+
+

NeuAcHex3HexNAc5dHex2 and/or
2101

+

NeuAc2Hex4HexNAc4Ac

Hex4HexNAc5dHex2SP2
2132

+

Hex5HexNAc4dHex3SP
2157

+

Hex6HexNAc4dHex2SP and/or
2173

+

Hex3HexNAc6dHex2SP2

NeuAcHex5HexNAc4dHex2
2222
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc4dHex and/or
2238
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuGcHex5HexNAc4dHex2

NeuAcHex4HexNAc5dHex2 and/or
2263
+

+

+

NeuAc2Hex5HexNAc4Ac

NeuAcHex5HexNAc4dHex2SP
2302

+

Hex6HexNAc4dHex3SP and/or
2319

+

+
+

NeuGcNeuAcHex3HexNAc6

Hex7HexNAc4dHex2SP and/or
2335

+
+

Hex4HexNAc6dHex2SP2

NeuAcHex5HexNAc4dHex3
2368
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc4dHex2 and/or
2384
+
+

+
+

+

+
+

NeuGcHex5HexNAc4dHex3

NeuAc2Hex3HexNAc5dHex2 and/or
2392

+
+

Hex7HexNAc5dHexSP

NeuAcHex3HexNAc5dHex4
2393

+

NeuAcHex4HexNAc6dHexSP and/or
2400

+

NeuGcHex6HexNAc4dHex2 and/or

NeuAcHex7HexNAc4dHex

NeuAcHex4HexNAc5dHex3 and/or
2409

+

+

NeuAc2Hex5HexNAc4dHexAc

NeuAcHex5HexNAc5dHex2
2425
+
+

+
+
+
+
+
+
+

NeuAcHex5HexNAc4dHex3SP
2448

+

+
+
+
+

NeuAcHex4HexNAc5dHex3SP
2489

+
+

NeuAc2Hex5HexNAc4dHex2
2513

+
+
+

+
+
+
+

NeuAcHex5HexNAc4dHex4
2514

+

+

NeuAcHex6HexNAc5dHexSP and/or
2521
+
+

+

+

NeuAc3Hex2HexNAc5dHex2

NeuAc2Hex6HexNAc4dHex and/or
2529

+

+
+
+

NeuGcNeuAcHex5HexNAc4dHex2

NeuGc2Hex5HexNAc4dHex2 and/or
2545

+
+
+

NeuGcNeuAcHex6HexNAc4dHex

NeuAcHex5HexNAc5dHex3
2571

+
+

+

+
+
+
+
+

NeuAcHex6HexNAc5dHex2
2587
+
+

+

+
+
+
+
+
+
+
+
+

NeuAcHex7HexNAc5dHex and/or
2603

+

+
+
+
+

+
+

NeuGcHex6HexNAc5dHex2

NeuGcHex8HexNAc5 and/or
2635

+
+

NeuAcHex4HexNAc5dHex4SP

NeuAc2Hex5HexNAc4dHex3
2659

+

+

NeuGcNeuAc2Hex5HexNAc4dHex
2674

+
+

and/or NeuAc3Hex6HexNAc4

NeuAc2Hex4HexNAc5dHex2SP2
2714

+

+
+
+

NeuAcHex4HexNAc5dHex4SP2 and/or
2715

+
+

NeuAc3Hex5HexNAc5

NeuAc2Hex5HexNAc5dHex2
2716

+

NeuAcHex6HexNAc5dHex3
2733
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc6dHex2
2791

+
+
+
+

Hex6HexNAc6dHex3SP2
2805

+

NeuAcHex6HexNAc5dHex3SP
2813

+

NeuAc3Hex6HexNAc4dHex and/or
2820

+

NeuGcNeuAc2Hex5HexNAc4dHex2

NeuAc2Hex6HexNAc5dHex2
2879
+
+

+
+
+
+
+
+
+
+
+
+
+

NeuAcHex6HexNAc5dHex4
2880

+

+
+
+
+

NeuAc2Hex7HexNAc5dHex and/or
2895

+

+

NeuGcNeuAcHex6HexNAc5dHex2

NeuAc3Hex6HexNAc4dHexSP and/or
2900

+

NeuGcNeuAc2Hex5HexNAc4dHex2SP

NeuGc2Hex6HexNAc5dHex2
2911

+

NeuAc2Hex5HexNAc6dHex2
2920

+

NeuAc2Hex6HexNAc6dHex and/or
2936

+
+

+

+
+
+
+

NeuGcNeuAcHex5HexNAc6dHex2

NeuAcHex6HexNAc6dHex3
2937

+

+

NeuGc2NeuAcHex5HexNAc6 and/or
2951

+

NeuAc3Hex5HexNAc4dHex3

NeuAcHex7HexNAc6dHex2
2953
+

+

+
+
+

+
+

+

NeuAc2Hex4HexNAc7dHex2
2961

+

NeuAc2Hex6HexNAc5dHex3
3025
+
+

+

+
+

+
+
+
+
+
+

NeuAc2Hex6HexNAc6dHex2
3082

+

NeuAcHex7HexNAc6dHex3
3099
+
+

+

+
+
+
+
+
+
+
+
+

NeuAc2Hex6HexNAc5dHex3SP
3105

+
+

NeuAc3Hex6HexNAc5dHex2
3170

+
+

NeuAc2Hex6HexNAc5dHex4
3171

+

+

+
+

+
+

NeuAc2Hex6HexNAc6dHex3
3228

+

NeuAc2Hex7HexNAc6dHex2
3244

+
+

+
+
+

NeuAcHex7HexNAc6dHex4
3245
+

+

+

+
+
+

NeuAcHex7HexNAc7dHex3
3302

+

NeuAcHex8HexNAc7dHex2
3318

+

+
+

NeuAc2Hex7HexNAc6dHex3
3390
+
+

+
+
+
+

+
+
+
+

NeuAcHex7HexNAc6dHex5 and/or
3391

+

+

+

NeuAcHex9HexNAc8

NeuAcHex8HexNAc7dHex3
3464

+

+
+

+
+

+

NeuAc2Hex7HexNAc6dHex4
3536

+
+

+
+
+
+

NeuAc2Hex8HexNac7dHex2
3609

+
+

+

NeuAcHex8HexNAc7dHex4
3610
+

+

+
+

NeuAc3Hex7HexNAc6dHex3
3681

+

+

+
+

+
+
+

NeuAcHex9HexNAc8dHex2
3683

+

+
+

NeuAc2Hex8HexNAc7dHex3
3755

+

+
+

+
+
+

NeuAcHex10HexNAc9 and/or
3758
+

+
+

+

NeuAcHex8HexNAc7dHex5

NeuAc3Hex7HexNAc6dHex4
3827

+

+

NeuAcHex9HexNAc8dHex3
3829

+
+

+
+

NeuAc2Hex8HexNAc7dHex4
3901

+

+

+

NeuAc2Hex9HexNAc8dHex2
3974

+

+

NeuAcHex9HexNAc8dHex4
3975

+
+

NeuAc3Hex8HexNAc7dHex3
4048

+
+

NeuAc2Hex10HexNAc9 and/or
4047

+

+

NeuAc2Hex8HexNAc7dHex5

NeuAc2Hex9HexNAc8dHex3
4120

+

HexNAc > Hex ≧ 2

(terminal HexNAc, N > H)

NeuAcHex3HexNAc4
1606

+

NeuAcHex3HexNAc4dHex
1752

+

NeuAcHex3HexNac5
1809

+

NeuGcHex3HexNac5
1825

+
+

Hex4HexNAc5dHexSP
1906
+
+

NeuAcHex4HexNAc5
1971
+
+

+
+

+

+

+

Hex7HexNAc4SP and/or
2043

+

Hex4HexNAc6SP2 and/or

NeuAc2Hex3HexNAc4dHex

NeuAcHex4HexNAc5SP
2051

+

+
+

+
+

Hex4HexNAc5dHex2SP
2052
+
+

+
+

NeuAcHex3HexNAc5dHex2 and/or
2101

+

NeuAc2Hex4HexNAc4Ac

NeuAcHex4HexNAc5dHex
2117
+
+
+

+

+
+
+
+
+

Hex4HexNAc5dHex2SP2
2132

+

Hex6HexNAc4dHex2SP and/or
2173

+

Hex3HexNAc6dHex2SP2

NeuAcHex4HexNAc6
2174
+

+
+
+

+
+

NeuAc3Hex3HexNAc4 and/or
2188

+

+

NeuGcHex6HexNAc4SP and/or

NeuAc2NeuGcHex2HexNAc4dHex

NeuAc2Hex3HexNAc4dNex2 and/or
2189

+
+

Hex7HexNAc4dHexSP and/or

Hex4HexNAc6dHexSP2

NeuAc2Hex3HexNAc5dHex and/or
2246

+
+
+
+

Hex7HexNAc5SP

NeuAc2Hex4HexNAc5
2262

+

NeuAcHex4HexNAc5dHex2 and/or
2263
+

+

+

NeuAc2Hex5HexNAc4Ac

Hex6HexNAc4dHex3SP and/or
2319

+

+
+

NeuGcNeuAcHex3HexNAc6

NeuAcHex4HexNAc6dHex
2320

+
+

Hex7HexNAc4dHex2SP and/or
2335

+
+

Hex4HexNAc6dHex2SP2

NeuAcHex5HexNAc6
2336

+

+

NeuAc2Hex3HexNAc5dHex2 and/or
2392

+
+

Hex7HexNAc5dHexSP

NeuAcHex3HexNAc5dHex4
2393

+

NeuAcHex4HexNAc6dHexSP and/or
2400

+

NeuGcHex6HexNAc4dHex2 and/or

NeuAcHex7HexNAc4dHex

NeuAc2Hex4HexNAc5dHex
2408
+
+

+

NeuAcHex4HexNAc5dHex3 and/or
2409

+

+

NeuAc2Hex5HexNAc4dHexAc

NeuAcHex5HexNAc6dHex
2482

+

NeuAcHex4HexNAc5dHex3SP
2489

+
+

Hex6HexNAc7SP
2490

+

NeuAcHex6HexNAc5dHexSP and/or
2521
+
+

+

+

NeuAc3Hex2HexNAc5dHex2

NeuAc2Hex5HexNAc6
2627

+

NeuGcHex8HexNAc5 and/or
2635

+
+

NeuAcHex4HexNAc5dHex4SP

NeuAc2Hex4HexNAc5dHex2SP2
2714

+

+
+
+

NeuAcHex4HexNAc5dHex4SP2 and/or
2715

+
+

NeuAc3Hex5HexNAc5

NeuGcNeuAc2Hex5HexNAc6
2935

+

NeuGc2NeuAcHex5HexNAc6 and/or
2951

+

NeuAc3Hex5HexNAc4dHex3

NeuAc2Hex4HexNAc7dHex2
2961

+

HexNAc = Hex ≧ 5

(terminal HexNAc, N = H)

Hex5HexNAc5SP2
2002

+
+
+
+
+
+

+

NeuAcHex5HexNAc5
2133
+
+

+
+

+

+
+
+
+
+

NeuAcHex5HexNAc5dHex
2279
+
+
+
+
+
+
+
+
+
+
+
+
+
+

NeuAc2Hex5HexNAc5
2424

+

+
+

+
+

NeuAcHex5HexNAc5dHex2
2425
+
+

+
+
+
+
+
+
+
+

NeuAc2Hex5HexNAc5dHex
2570
+
+

+

+
+
+
+
+

NeuAcHex5HexNAc5dHex3
2571

+
+

+

+
+
+
+
+

NeuAcHex6HexNAc6dHex
2644

+
+

+
+
+

+
+
+
+
+

NeuAcHex4HexNAc5dHex4SP2 and/or
2715

+
+

NeuAc3Hex5HexNAc5

NeuAc2Hex5HexNAc5dHex2
2716

+

NeuAcHex6HexNAc6dHex2
2791

+
+
+
+

Hex6HexNAc6dHex3SP2
2805

+

NeuAc2Hex6HexNAc6dHex and/or
2936

+
+

+

+
+
+
+

NeuGcNeuAcHex5HexNAc6dHex2

NeuAcHex6HexNAc6dHex3
2937

+

+

NeuAcHex7HexNAc7dHex
3010

+

+
+

NeuAc3Hex6HexNAc6dHex
3227

+

+

NeuAc2Hex6HexNAc6dHex3
3228

+

NeuAc2Hex7HexNAc7dHex
3301

+

NeuAcHex7HexNAc7dHex3
3302

+

SP ≧ 1

(including sulphated and/or

phosphorylated glycans)

Hex3HexNAc2SP
989

+
+
+

Hex3HexNAc2dHexSP
1135

+
+

Hex4HexNAc2SP
1151

+
+
+
+

+

Hex3HexNAc3SP
1192

+

Hex5HexNAc2SP
1313

+

Hex3HexNAc3dHexSP
1338

+

Hex4HexNAc3SP
1354

+
+

Hex6HexNAc2SP
1475

+

+

+
+

+

+
+
+

Hex4HexNAc3dHexSP
1500
+
+

+
+
+
+

+
+
+
+

Hex5HexNAc3SP
1516

+
+

+

Hex8HexNAc2SP2
1555

+

Hex4HexNAc4SP
1557

+

+

+
+

NeuAcHex3HexNAc3SP2
1563

+
+

Hex4HexNAc4SP2 and/or
1637

+

+
+

+
+
+
+

Hex7HexNAc2SP

Hex4HexNAc3dHex2SP
1646

+

+

Hex5HexNAc3dHexSP
1662

+

Hex6HexNAc3SP
1678
+
+

+
+
+
+
+
+

+
+
+

Hex4HexNAc4dHexSP
1703

+

+

+

NeuAcHex3HexNAc3dHexSP2
1709

+
+

Hex4HexNAc4SP3 and/or
1717

+

Hex7HexNAc2SP2

Hex5HexNAc4SP
1719

+

+
+
+
+
+

Hex7HexNAc2dHexSP
1783

+

NeuAcHex4HexNAc3dHexSP
1791

+

+
+
+

+
+

Hex5HexNAc4SP2 and/or
1799

+

+

Hex8HexNAc2SP

Hex5HexNAc3dHex2SP
1808

+

NeuAc2Hex5HexNAc2 and/or
1815

+

NeuAc2Hex2HexNAc4SP

Hex5HexNAc4dHexSP
1865
+
+

+
+
+
+
+

+
+
+
+

Hex6HexNAc4SP
1881

+

Hex4HexNAc5dHexSP
1906
+
+

NeuAcHex6HexNAc2dHexSP and/or
1912

+

NeuAcHex3HexNAc4dHexSP2

NeuACHex4HexNAc4SP2
1928

+
+

Hex8HexNAc3SP and/or
2002

+
+
+
+
+
+

+

+

Hex5HexNAc5SP2 and/or

NeuAc2Hex4HexNAc3dHex

NeuAcHex5HexNAc4SP
2010

+

+

Hex5HexNAc4dHex2SP
2011

+

NeuGcHex5HexNAc4SP
2026

+

Hex6HexNAc4dHexSP
2027

+

+

Hex7HexNAc4SP and/or
2043

+

Hex4HexNAc6SP2 and/or

NeuAc2Hex3HexNAc4dHex

NeuAcHex7HexNAc3 and/or
2051

+

+
+

+

+
+
+

NeuAcHex4HexNAc5SP

Hex4HexNAc5dHex2SP
2052
+
+

+
+

NeuAcHex4HexNAc4dHexSP2
2074

+
+

NeuAc2Hex4HexNAc3dHexSP and/or
2082

+
+
+

Hex8HexNAc3SP2 and/or

Hex5HexNAc5SP3

NeuAcHex6HexNAc3dHexSP
2115

+

Hex7HexNAc3dHex2SP and/or
2132

+

NeuAc2Hex3HexNAc3dHex3 and/or

Hex4HexNAc5dHex2SP2

Hex8HexNAc3dHexSP and/or
2148

+

NeuAc2Hex4HexNAc3dHex2

NeuAcHex5HexNAc4dHexSP and/or
2156
+
+

+
+

+
+
+

NeuAcHex8HexNAc2dHex

Hex5HexNAc4dHex3SP
2157

+

NeuAc2Hex5HexNAc3dHex and/or
2164
+
+

+

Hex6HexNAc5SP2

NeuAc2Hex4HexNAc4SP2
2219

+

Hex6HexNAc5dHexSP
2230

+

+

+
+

NeuAc2Hex3HexNAc5dHex and/or
2246

+
+
+
+

Hex7HexNAc5SP

NeuAc2Hex4HexNAc4dHexSP and/or
2285

+

Hex11HexNAc2SP

NeuAcHex8HexNAc3SP and/or
2293

+

NeuAc3Hex4HexNAc3dHex

NeuAc2Hex5HexNAc4SP
2301

+

NeuAcHex5HexNAc4dHex2SP
2302

+

Hex6HexNAc4dHex3SP
2319

+

Hex7HexNAc4dHex2SP and/or
2335

+
+

Hex4HexNAc6dHex2SP2

NeuAc2Hex4HexNAc4dHexSP
2365

+
+
+

NeuAc3Hex5HexNAc3SP and/or
2389

+

NeuAc2Hex5HexNAc4Ac4

NeuAc2Hex5HexNAc3dHex2SP
2390
+
+
+
+
+
+

+
+

+

NeuAc2Hex3HexNAc5dHex2 and/or
2392

+
+

Hex7HexNAc5dHexSP

NeuAcHex4HexNAc6dHexSP and/or
2400

+

NeuGcHex6HexNAc4dHex2 and/or

NeuAcHex7HexNAc4dHex

NeuAc2Hex6HexNAc3dHexSP
2406

+

+
+

NeuAcHex8HexNAc3dHexSP and/or
2439

+

NeuAc3Hex4HexNAc3dHex2

NeuAc2Hex5HexNAc4dHexSP and/or
2447

+

+
+

+
+
+
+

NeuAc2Hex8HexNAc2dHex and/or

Hex12HexNAc2SP

NeuAcHex5HexNAc4dHex3SP and/or
2448

+

+
+
+
+

NeuAcHex8HexNAc2dHex3

NeuAcHex7HexNAc3dHex3 and/or
2489

+
+

NeuAcHex4HexNAc5dHex3SP

Hex6HexNAc7SP
2490

+

NeuAcHex6HexNAc5dHexSP and/or
2521
+
+

+

+

NeuAcHex9HexNAc3dHex and/or

NeuAc3Hex2HexNAc5dHex2

Hex6HexNAc5dHex3SP
2522

+

+

Hex7HexNAc6dHexSP
2595

+

NeuGcHex8HexNAc5 and/or
2635

+
+

NeuAcHex4HexNAc5dHex4SP

NeuAc2Hex4HexNAc5dHex2SP2
2714

+

+
+
+

NeuAcHex4HexNAc5dHex4SP2 and/or
2715

+
+

NeuAc3Hex5HexNAc5

NeuAc3Hex5HexNAc4dHex2 and/or
2804

+
+

NeuAcHex6HexNAc6dHexSP2

Hex6HexNAc6dHex3SP2
2805

+

NeuAc2Hex6HexNAc5dHexSP
2812

+

+
+
+
+

NeuAcHex6HexNAc5dHex3SP
2813

+

NeuAc3Hex6HexNAc4dHexSP and/or
2900

+

NeuGcNeuAc2Hex5HexNAc4dHex2SP

NeuAc3Hex6HexNAc5dHexSP
3104

+

+

NeuAc2Hex6HexNAc5dHex3SP
3105

+
+

hESC, human embryonic stem cells;

EB, embryoid bodies derived from hESC;

st.3, stage 3 differentiated cells derived from hESC;

hEF, human fibroblast feeder cells;

mEF, murine fibroblast feeder cells;

BM MSC, bone-marrow derived mesenchymal stem cells;

OB, Osteoblast-differentiated cells derived from BM MSC;

CB MSC, cord blood derived mesenchymal stem cells;

OB, adipocyte-differentiated cells derived from CB MSC;

CB MNC, cord blood mononuclear cells;

CD34+, CD133+, LIN−, and CD8−: subpopulations of CB MNC.

TABLE 31

Comparison of lectin ligand profile in hESCs and MEFs

Lectin
hESC
MEF

PSA
−
+

MAA
+
−

PNA
+
−

RCA
+
+

+ present in cell surface

− not present in cell surface

TABLE 32

Summary of the results of BM MSC grown

on different immobilized lectin surfaces.

Proliferation
Effect vs.

Coating
factor
plastic

plastic
3.8

RCA
1.0
n.g.

PSA
3.9
(+)

LTA
4.0
+

SNA
3.7
(−)

GS II
4.9
+

UEA
2.1
−

ECA
4.4
+

MAA
3.7
(−)

STA
3.1
−

PWA
4.2
+

WFA
2.9
−

NPA
3.6
(−)

Proliferation factor = the number of cells on day 3/the number of cells on day 1.

Triplicates were used in calculations.

Effect vs. plastic: ‘n.g.’ = no growth; ‘−’ = slower growth rate; ‘+’ = faster growth rate than on plastic; ‘( )’ nearly equal to plastic.

TABLE 33

Detected N-linked and soluble glycome structural type distribution in stem cells.

The column ‘All’ includes all CB stem cell populations.

Neutral N-glycan structural features:
hESC
MSC
All

Glycan feature
Proposed structure
Proportion, %
Proportion, %
Proportion, %

Hex_5-10HexNAc₂
High-mannose type/Glc₁
50-90
30-80
30-90

Hex_1-4HexNAc₂dHex_0-1
Low-mannose type
5-20
5-20
5-50

n_HexNAc= 3 ja n_Hex≧ 2
Hybrid-type/Monoantennary
1-20
5-20
1-20

n_HexNAc≧ 4 ja n_Hex≧ 2
Complex-type
1-10
5-40
1-40

Hex_1-9HexNAc₁
Soluble
1-20
1-30
1-30

n_dHex≧ 1
Fucosylation
5-20
10-40
5-40

n_dHex≧ 2
α2/3/4-linked Fuc
0-5
1-5
0-5

n_HexNAc> n_Hex≧ 2
Terminal HexNAc (N > H)
0-20
0-5
0-20

n_HexNAc= n_Hex≧ 5
Terminal HexNAc (N═H)
0-10
0-2
0-10

Acidic N-glycan structural features:
hESC
MSC
all

Glycan feature
Proposed structure
Proportion, %
Proportion, %
Proportion, %

n_HexNAc= 3 ja n_Hex≧ 3
Hybrid-type/Monoantennary
1-25
2-20
1-25

n_HexNAc≧ 4 ja n_Hex≧ 3
Complex-type
70-99
70-95
70-99

n_dHex≧ 1
Fucosylation
60-99
50-80
50-99

n_dHex≧ 2
α2/3/4-linked Fuc
1-40
1-20
1-40

n_HexNAc> n_Hex≧ 2
Terminal HexNAc (N > H)
1-25
0-5
0-25

n_HexNAc= n_Hex≧ 5
Terminal HexNAc (N═H)
1-30
0-5
0-30

+80 Da
Sulphate or phosphate ester
0-50
0-40
0-50

TABLE 34

Terminal

m/z*
Preferred monosaccharide compositions
epitopes
Group^#

989
Hex3HexNAc2SP

SP

1030
Hex2HexNAc3SP

HY, SP,

N > H

1151
Hex4HexNac2SP

SP

1192
Hex3HexNAc3SP

HY, SP

1272
NeuAc2Hex2HexNAcdHex
NeuAcα6/8/9
F

Fucα3/4

1297
Hex4HexNAc2dHexSP

F, SP

1313
NeuAc2HexHexNAc2dHex
Fucα2
F

1338
Hex3HexNAc3dHexSP
Fucα3/4
HY, F,

SP

1354
Hex4HexNAc3SP

HY, SP

1395
Hex3HexNac4SP

CO, SP,

N > H

1403
NeuAcHex3HexNAc3
NeuAcα6/8/9
HY

1419
NeuGcHex3HexNAc3

HY

1475
NeuAc2Hex2HexNAcdHex

F

1500
Hex4HexNAc3dHexSP

HY, F,

SP

1516
Hex5HexNAc3dHexSP/NeuAc2HexHexNAc3dHex

HY, F

(SP)

1541
Hex3HexNAc4dHexSP

CO, F,

SP,

N > H

1549
NeuAcHex3HexNAc3dHex
NeuAcα6/8/9
HY, F

1557
Hex4HexNAc4SP

CO, SP

1565
NeuAcHex4HexNAc3
NeuAcα6/8/9
HY

NeuAcα3

1581
NeuGcHex4HexNAc3

HY

1637
NeuAc2Hex3HexNAc2dHex

F

1662
Hex5HexNAc3dHexSP
Fucα3/4
HY, F,

SP

1678
NeuAc2Hex2HexNAc3dHex
Fucα3/4
HY, F,

N > H

1703
Hex4HexNAc4dHexSP

CO, F,

SP

1711
NeuAcHex4HexNAc3dHex
NeuAcα6/8/9
HY, F

1719
Hex5HexNAc4SP

CO, SP

1727
NeuAcHex5HexNAc3
NeuAcα6/8/9
HY

NeuAcα3

Fucα3/4

1743
NeuGcHex5HexNAc3
NeuGcα3
HY

1752
NeuAcHex3HexNAc4dHex
NeuAcα6/8/9
CO, F,

Fucα2
N > H

1760
Hex4HexNAc5SP

CO, SP,

N > H

1768
NeuAcHex4HexNAc4
NeuAcα6/8/9
CO

1783
Hex7HexNAc2dHexSP

F, SP

1799
Hex5HexNAc4SP2/NeuAc2Hex4HexNAc2dHex

(CO)

(F) (SP)

1840
NeuAc2Hex3HexNAc3dHex

HY, F

1865
Hex5HexNAc4dHexSP

CO, F,

SP

1873
NeuAcHex5HexNAc3dHex
NeuAcα6/8/9
HY, F

NeuAcα3

Fucα2

1881
Hex6HexNAc4SP

CO, SP

1889
NeuAcHex6HexNAc3
NeuAcα6/8/9
HY

NeuAcα3

1906
Hex4HexNAc5dHexSP

CO, F,

SP,

N > H

1914
NeuAcHex4HexNAc4dHex
NeuAcα6/8/9
CO, F

NeuAcα3

1930
NeuAcHex5HexNAc4
NeuAcα6/8/9
CO

1946
NeuGcHex5HexNAc4

CO

1955
NeuAcHex3HexNAc5dHex
NeuAcα6/8/9
CO, F,

Fucα2
N > H

1971
NeuAcHex4HexNAc5

CO,

N > H

2002
NeuAc2Hex4HexNAc3dHex/Hex8HexNAc3SP
Fucα2
HY (F)

(SP)

2003
NeuAcHex4HexNAc3dHex3
NeuAcα3
HY, FC

NeuAcα6/8/9

Fucα3/4

2010
NeuAcHex5HexNAc4SP
NeuAcα6/8/9
CO, SP

Fucα3/4

2011
Hex5HexNAc4dHex2SP
NeuAcα3
CO, FC,

Fucα2
SP

2027
Hex6HexNAc4dHexSP

CO, F,

SP

2035
NeuAcHex6HexNAc3dHex
NeuAcα3
HY, F

NeuAcα6/8/9

Fucα2

2051
NeuAcHex7HexNAc3
NeuAcα6/8/9
HY

Fucα3/4

2052
Hex4HexNAc5dHex2SP
NeuAcα3
SP

Fucα2

2076
NeuAcHex5HexNAc4dHex
NeuAcα6/8/9
CO, F

2092
NeuGcHex5HexNAc4dHex/NeuAcHex6HexNAc4
NeuAcα3
CO (F)

Fucα3/4

2108
NeuGcHex6HexNAc4
NeuGcα3
CO

2117
NeuAcHex4HexNAc5dHex
NeuAcα6/8/9
CO, F

2133
NeuAcHex5HexNAc5

CO,

N═H

2156
NeuAcHex5HexNAc4dHexSP/NeuAcHex8HexNAc2dHex
NeuAcα6/8/9
(CO) F

(SP)

2164
NeuAc2Hex5HexNAc3dHex
Fucα2
HY, F

2174
NeuAcHex4HexNAc6
NeuAcα3
CO,

NeuAcα6/8/9
N > H

Fucα3/4

2189
NeuAc2Hex3HexNAc4dHex2/Hex7HexNAc4dHexSP
Fucα2
CO

F(C)

(SP)

(N > H)

2190
NeuAcHex3HexNAc4dHex4
NeuAcα3
CO, FC,

Fucα3/4
N > H

2198
Hex4HexNAc5dHexSP
NeuAcα3
CO, F,

Fucα3/4
SP,

N > H

2221
NeuAc2Hex5HexNAc4
NeuAcα3
CO

NeuAcα6/8/9

2222
NeuAcHex5HexNAc4dHex2
NeuAcα3
CO, FC

NeuAcα6/8/9

Fucα3/4

Fucα2

2230
Hex6HexNAc5dHexSP
Fucα3/4
CO, F,

SP

2238
NeuGcHex5HexNAc4dHex2/NeuAcHex6HexNAc4dHex
NeuAcα3
CO,

NeuAcα6/8/9
F(C)

Fucα3/4

2253
NeuGc2Hex5HexNAc4
NeuAcα6/8/9
CO

Fucα2

2254
NeuAcHex7HexNAc4/NeuGcHex6HexNAc4dHex
Fucα3/4
CO (F)

2263
NeuAcHex4HexNAc5dHex2
NeuAcα6/8/9
CO, FC,

Fucα3/4
N > H

2279
NeuAcHex5HexNAc5dHex
NeuAcα6/8/9
CO, F,

N═H

2295
NeuAcHex6HexNAc5

CO

2319
Hex6HexNAc4dHex3SP
NeuAcα3
CO, FC,

NeuAcα6/8/9
SP

Fucα3/4

2367
NeuAc2Hex5HexNAc4dHex
NeuAcα6/8/9
CO, F

NeuAcα3

Fucα2

2368
NeuAcHex5HexNAc4dHex3
NeuAcα3
CO, FC

NeuAcα6/8/9

Fucα2

Fucα3/4

2383
NeuGcNeuAcHex5HexNAc4dHex/NeuAc2Hex6HexNAc4
NeuAcα6/8/9
CO (F)

NeuAcα3

Fucα2

2389
NeuAc3Hex5HexNAc3SP
NeuAcα3
HY, SP

NeuAcα6/8/9

2399
NeuGc2Hex5HexNAc4dHex
NeuAcα3
CO, F

NeuAcα6/8/9

Fucα3/4

2406
NeuAc2Hex6HexNAc3dHexSP
NeuAcα3
HY, F,

NeuAcα6/8/9
SP

Fucα2

2408
NeuAc2Hex4HexNAc5dHex
NeuAcα3
CO, F,

NeuAcα6/8/9
N > H

Fucα3/4

2441
NeuAcHex6HexNAc5dHex

CO, F

2447
NeuAc2Hex5HexNAc4dHexSP
NeuAcα3
CO, F,

NeuAcα6/8/9
SP

Fucα3/4

2448
NeuAcHex5HexNAc4dHex3SP
NeuAcα3
CO, FC,

NeuAcα6/8/9
SP

Fucα3/4

2457
NeuAcHex7HexNAc5

CO

2512
NeuAc3Hex5HexNAc4
NeuAcα3
CO

NeuAcα6/8/9

Fucα2

2513
NeuAc2Hex5HexNAc4dHex2
NeuAcα3
CO, FC

NeuAcα6/8/9

Fucα3/4

2528
NeuGcNeuAc2Hex5HexNAc4
NeuAcα3
CO

NeuAcα6/8/9

Fucα2

2529
NeuGcNeuAcHex5HexNAc4dHex2/NeuAc2Hex6HexNAc4dHex
NeuAcα3
CO,

NeuAcα6/8/9
F(C)

Fucα3/4

2544
NeuGc2NeuAcHex5HexNAc4
NeuAcα3
CO

NeuAcα6/8/9

Fucα3/4

2586
NeuAc2Hex6HexNAc5
NeuAcα3
CO

NeuAcα6/8/9

Fucα2

2587
NeuAcHex6HexNAc5dHex2
NeuAcα3
CO, FC

NeuAcα6/8/9

2603
NeuAcHex7HexNAc5dHex/NeuGcHex6HexNAc5dHex2

CO,

F(C)

2619
NeuAcHex8HexNAc5/NeuGcHex7HexNAc5dHex
Fucα2
CO (F)

2660
NeuAcHex7HexNAc6
Fucα3/4
CO

2732
NeuAc2Hex6HexNAc5dHex
NeuAcα6/8/9
CO, F

NeuAcα3

2733
NeuAcHex6HexNAc5dHex3
NeuAcα3
CO, FC

NeuAcα6/8/9

Fucα2

2765
NeuAcHex8HexNAc5dHex
NeuAcα6/8/9
CO, F

NeuAcα3

2781
NeuGcHex8HexNAc5dHex/NeuAcHex9HexNAc5
Fucα3/4
CO (F)

2878
NeuAc3Hex6HexNAc5
NeuAcα3
CO

NeuAcα6/8/9

Fucα3/4

2894
NeuGcNeuAc2Hex6HexNAc5
NeuAcα3
CO

NeuAcα6/8/9

Fucα3/4

2952
NeuAc2Hex7HexNAc6
NeuAcα6/8/9
CO

3024
NeuAc3Hex6HexNAc5dHex
NeuAcα3
CO, F

NeuAcα6/8/9

Fucα2

3098
NeuAc2Hex7HexNAc6dHex
NeuAcα3
CO, F

NeuAcα6/8/9

Fucα3/4

*[M − H]⁻ion, first isotope.

^#Preferred structure group based on monosaccharide compositions according to the present invention. HY, hybrid-type or monoantennary; CO, complex-type; F, fucosylation; FC, complex fucosylation; N═H, terminal HexNAc (HexNAc = Hex); N > H, terminal HexNAc (HexNAc > Hex); SP, sulphate and/or phosphate ester; “( )” indicates that the glycan signal includes also other structure types.

TABLE 35

Detected acidic O-glycan signals from hESC.

Acidic O-glycan reducing oligosaccharides, [M − H]⁻ions

exp.

Proposed structure
calc. m/z
m/z

NeuAc2HexHexNAc
964.33
964.35

SaHex2HexNAc2
1038.36
1038.49

NeuAcHex2HexNAc2dHex
1184.42
1184.5

Hex3HexNAc3SP
1192.36
1192.73

SaHex3HexNAc2
1200.42
1200.43

NeuAc2Hex2HexNAc2/
1329.46
1329.56

NeuGcNeuAcHexHexNAc2dHex

Hex3HexNAc3dHexSP
1338.41
1338.6

SaHex3HexNAc3
1403.49
1403.62

Sa2Hex2HexNAcdHex
1475.52
1475.79

NeuAcHex6HexNAc/NeuAcHex3HexNAc3SP
1483.49
1483.71

SaHex3HexNAc3dHex
1549.55
1549.9

Hex4HexNAc4SP
1557.49
1557.72

SaHex4HexNAc3
1565.55
1565.66

NeuAc2Hex3HexNAc3
1694.59
1694.8

Hex4HexNAc4dHexSP
1703.55
1703.9

SaHex4HexNAc3dHex
1711.61
1711.78

SaHex5HexNAc3
1727.60
1727.96

SaHex4HexNAc4
1768.57
1768.75

SaHex6HexNAc3
1889.65
1889.96

SaHex4HexNAc4dHex
1914.68
1915.04

SaHex5HexNAc4
1930.68
1930.83

SaHex5HexNAc4dHex
2076.74
2076.91

NeuGcHex5HexNAc4dHex/SaHex6HexNAc4
2092.73
2092.86

Sa2Hex5HexNAc4
2221.78
2221.82

SaHex5HexNAc4dHex2
2222.80
2222.93

NeuGcHex5HexNAc4dHex2/SaHex6HexNAc4dHex
2238.79
2238.9

SaHex7HexNAc4/NeuGcHex6HexNAc4dHex
2254.79
2254.88

SaHex5HexNAc4dHex3
2368.85
2368.26

SaHex6HexNAc5dHex
2441.87
2442.23

TABLE 36

Preferred

monosaccharide
Terminal
Experimental structures included in the glycan

m/z*
compositions
epitopes
signal according to the invention^§
Group^#

1825
Hex6HexNAc4
Galβ4
Galβ4GlcNAc→Hex₅HexNAc₃
CO

Galα
Galα3Gal→Hex₄HexNAc₄

Galβ4GlcNAc→[Galα3Gal→]Hex₃HexNAc₃

1987
Hex7HexNAc4
Galα
Galα3Gal→Hex₅HexNAc₄
CO

(Galα3Gal→)₂Hex₃HexNAc₄

2133
Hex7HexNAc4dHex1
Galα
Galα3Gal→Hex₅HexNAc₄dHex₁
CO, F

(Galα3Gal→)₂Hex₃HexNAc₄dHex₁

2190
Hex7HexNAc5
Galα
Galα3Gal→Hex₅HexNAc₅
CO

2336
Hex7HexNAc5dHex
Galβ4
Galβ4GlcNAc→Hex₆HexNAc₄dHex₁
CO, F

Galα
Galα3Gal→Hex₅HexNAc₅dHex₁

Galβ4GlcNAc→[Galα3Gal→]Hex₄HexNAc₄dHex₁

2352
Hex8HexNAc5
Galβ4
Galβ4GlcNAc→Hex₇HexNAc₄
CO

Galα
Galα3Gal→Hex₆HexNAc₅

Galβ4GlcNAc→[Galα3Gal→]Hex₅HexNAc₄

Galβ4GlcNAc→[Galα3Gal→]₂Hex₃HexNAc₄

2498
Hex8HexNAc5dHex
Galβ4
Galβ4GlcNAc→Hex₇HexNAc₄dHex₁
CO, F

Galα
Galα3Gal→Hex₆HexNAc₅dHex₁

Galβ4GlcNAc→[Galα3Gal→]Hex₅HexNAc₄dHex₁

Galβ4GlcNAc→[Galα3Gal→]₂Hex₃HexNAc₄dHex₁

2514
Hex9HexNAc5
Galα
Galα3Gal→Hex₇HexNAc₅
CO

(Galα3Gal→)₂Hex₅HexNAc₅

(Galα3Gal→)₃Hex₃HexNAc₅

2660
Hex9HexNAc5dHex
Galα
Galα3Gal→Hex₇HexNAc₅dHex₁
CO, F

(Galα3Gal→)₂Hex₅HexNAc₅dHex₁

(Galα3Gal→)₃Hex₃HexNAc₅dHex₁

*[M + Na]⁺ion, first isotope.

^§“→” indicates linkage to a monosaccharide in the rest of the structure; “[ ]” indicates branch in the structure.

^#Preferred structure group based on monosaccharide compositions according to the present invention. HI, high-mannose; LO, low-mannose; S, soluble mannosylated; HF, fucosylated high-mannose; G, glucosylated high-mannose; HY, hybrid-type or monoantennary; CO, complex-type; F, fucosylation; FC, complex fucosylation; N═H, terminal HexNAc (HexNAc = Hex); N > H, terminal HexNAc (HexNAc > Hex).

TABLE 37

CB CD34I

BM & CB

Trivial name
Terminal epitope
hESC 1)
EB
st.3
& CD133+
CB MNC
MSC
adipo/osteo

LN type 1, Le^c
Galβ3GlcNAc
N+
2)
+/−
q
N+/−
q

O+
+/−

O+/−

L++

L+

Lea
Galβ3(Fucα4)GlcNAc
L+
+/−
+/−
+/−
+/−
+/−
+/−

H type 1
Fucα2Galβ3GlcNAc
L++
+/−
+/−
+/−
+/−
+/−
+/−

Leb
Fucα2Galβ3(Fucα4)GlcNAc
+
+/−
+/−
+/−
+/−
+/−
+/−

sialyl Le^a
SAα3Galβ3(Fucα4)GlcNAc

+/−
+/−

α3′-sialyl Le^c
SAα3Galβ3GlcNAc

+/−
+/−
+/−
+/−

LN type 2
Galβ4GlcNAc
N++
+
+
N+
N+
N++
N++

O++

O+
O+
O+

L+/−

L+
L++

Le^x
Galβ4(Fucα3)GlcNAc
N++
+/−
+/−
N+
N+/−
+/−
+/−

O+/−

O+
O+

L+/−

L+/−

H type 2
Fucα2Galβ4GlcNAc
N+
+/−
+/−
N+
+/−
+/−
+/−

O+/−

L+/−

Le^y
Fucα2Galβ4(Fucα3)GlcNAc
+
+/−
+/−

sialyl Le^x
SAα3Galβ4(Fucα3)GlcNAc
+
+/−
+/−
+/−
+/−
+/−
+/−

α3′-sialyl LN
SAα3Galβ4GlcNAc
N++
N+
N+
N++
N+
N++
N++

O+

O+
O+
O+

α6′-sialyl LN
SAα6Galβ4GlcNAc
N+
N++
N++
N+
N++
+/−

Core 1
Galβ3GalNAcα
O+
+/−
+/−
O+
O+
O+

H type 3
Fucα2Galβ3GalNAcα
O+
+/−
+/−
+/−
+/−
+/−

sialyl Core 1
SAα3Galβ3GalNAcα
O+

O+
O+
O+

disialyl Core 1
SAα3Galβ3Saα6GalNAcα
O+

O+
O+
O+

type 4 chain
Galβ3GalNAcβ
L+
+/−
+/−
+/−
L+
L+

H type 4
Fucα2Galβ3GalNAcβ
L+
+/−
+/−
+/−
+/−
+/−

α3′-sialyl type 4
SAα3Galβ3GalNAcβ
L++
+/−
+/−
+/−
+/−
+/−

LecdiNAc
GalNAcβ4GlcNAc
N+
+/−
+/−
+/−
+/−
+/−
+/−

Lac
Galβ4Glc
L+
q
q
q
L+
L+

GlcNAcβ
GlcNAcβ
N+/−
q
q
N+
+/−
+/−
q

L+

Tn
GalNAcα
q

q
q
O+

sialyl Tn
SAα6GalNAcα

O+

GalNAcβ
GalNAcβ
L+
q
q
+/−
+/−
N+/−

N+

L+

poly-LN, i
repeats of Galβ4GlcNAcβ3
+
q
q
+
+
++
q

poly-LN, I
Galβ4GlcNAcβ3(Galβ4GlcNAcβ6)Gal
L+
+/−
+/−
+/−
L+
L+
q

1) Stem cell and differentiated cell types are abbreviated as in other parts of the present document; st.3 indicates stage 3 differentiated, preferentially neuronal-type differentiated cells; adipo/osteo indicates cells differentiated into adipocyte or osteoblast direction from MSC.

2) Occurrence of terminal epitopes in glycoconjugates and/or specifically in N-glycans (N), O-glycans (O), and/or glycosphingolipids (L). Code: q, qualitative data; +/−, low expression; +, common; ++, abundant.

TABLE 38

Neutral
Sialylated

glycans
glycans

Class
Definition
hESC
MSC
CB MNC
hESC
MSC
CB MNC

Examples of glycosphingolipid

glycan classification

Lac
n_Hex= 2
1
1
2
1
a)

Ltri
n_Hex= 2 and n_HexNAc= 1
18
33
12
25

L1
n_Hex= 3 and n_HexNAc= 1
46
32
46
56

L2
3 ≦ n_Hex≦ 4 and n_HexNAc= 2
11
15
4
<1

L3+
i + 1 ≦ n_Hex≦ i + 2 and n_HexNAc= i ≧ 3
1
7
3
1

Gb
n_Hex− 4 and n_HexNAc− 1
20
1
1
16

O
other types
23
11
34
1

F
fucosylated, n_dHex≧ 1
43
12
7
1

T
non-reducing terminal HexNAc,
27
47
12
26

n_Hex≦ n_HexNAc+ 1

SA1
monosialylated, n_Neu5Ac= 1

86

SA2
disialylated, n_Neu5Ac= 2

14

SP
sulphated or phosphorylated, +80 Da

<1

Examples of O-linked glycan

classification

O1
n_Hex= 1 and n_HexNAc= 1
a)
a)
43
a)

O2
n_Hex= 2 and n_HexNAc= 2
53

35

O3+
n_Hex= i and n_HexNAc= i ≧ 3
13

13

O
other types
34

9

F
fucosylated, n_dHex≧ 1
1
47
64
5
15
15

T
non-reducing terminal HexNAc,
12
a)
<1
a)

n_Hex≦ n_HexNAc+ 1

SA1
monosialylated, n_Neu5Ac= 1

39

SA2
disialylated, n_Neu5Ac= 2

52

SP
sulphated or phosphorylated, +80 Da
8
21

a) not included in present quantitative analysis.

REFERENCES

Altmann, F., et al (1999) Glycoconj. J. 16:109-23

Harvey, D. J., et al. (1993) Rapid Commun. Mass Spectrom. 7(7):614-9

Hirabayashi, J., et al. (2002) Biochim. Biophys. Acta. 1572:232-54.

Jaatinen, T., et al. (2006) Stem cells. 24:631-41.

Karlsson, H., et al. (2000) Glycobiology 10(12):1291-309

Kretzchmar, E., et al. (1994) Biol. Chem. Hoppe Seyler 375(5):23-7

Kubelka, V., et al. (1994) Arch. Biochem. Biophys. 308(1):148-57

Leskelä, H., et al. (2003) Biochem. Biophys. Res. Commun. 311:1008-13

Miller-Podraza, H., et al. (2000) Glycobiology. 10:975-982

Moore (1999) Trends Cell Biol. 9:441-6

Naven, T. J. & Harvey, D. J. (1996) Rapid Commun. Mass Spectrom. 10(11):1361-6

Nyman, T. A., et al. (1998) Eur. J. Biochem. 253(2):485-93

Papac, D., et al. (1996) Anal. Chem. 68(18):3215-23

Saarinen, J., et al. (1999) Eur. J. Biochem. 259(3):829-40

Skottman, H. et al. (2005) Stem cells

Staudacher, E., et al. (1992) Eur. J. Biochem. 207(3):987-93

Thomson, J. A., et al. (1998) Science 282:1145-7

Venable et al. (2005) BMC Developmental biology.

Number	Date	Country	Kind
20051130	Nov 2005	FI	national
20060452	May 2006	FI	national
20060630	Jun 2006	FI	national
2006/050336	Jul 2006	FI	national

Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (4)

Parent Case Info

PCT Information